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ABSTRACT 
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac muscle disorder worldwide. The 
disease is characterized by extreme variability in the amount of hypertrophy that develops in different patients in 
response to sarcomeric protein-encoding gene mutations. The underlying defect in HCM is altered contractility of 
the sarcomere, primarily due to a defective sarcomere. Although numerous disease-causing genes have been 
identified for HCM, the factors that modify the amount of hypertrophy that develops in a given person are still 
unknown, it can be hypothesized that molecules that affect contractility can act as modifiers of the hypertrophic 
signal, and therefore influence the development of hypertrophy. 
Cardiac contractility is regulated by dynamic phosphorylation of proteins within the sarcomere by kinases such 
as cAMP-activated protein kinase A (PKA). Because speed and energy efficiency of cardiac muscle contraction 
has to be regulated in order to match the body’s needs, PKA is anchored close to its targets by A-kinase 
anchoring proteins (AKAPs) to enable spatio-temporal control of phosphorylation. Cardiac myosin binding 
protein-C (cMyBPC) and cardiac troponin I (cTNI) are HCM-causing sarcomeric proteins which regulate 
contractility in response to PKA phosphorylation. In a previous study, our laboratory identified a 
phosphodiesterase 4D-interacting protein as ligand of the N-terminal of cMyBPC via a yeast-two-hybrid (Y2H) 
cardiac library screen. This protein is also known in the literature as myomegalin (MMGL) isoform 4. 
Because phosphodiesterases and PKA are sometimes anchored by the same anchoring protein (AKAP), we 
hypothesized that MMGL isoform 4 acts as an AKAP by anchoring PKA to the phosphorylatable N-terminal of 
cMyBPC, and tested this by direct protein-protein interaction analyses in a yeast-based system. The MMGL 
cDNA was cloned into a bait vector, which was directly assessed for interaction with two distinct PKA 
regulatory-subunit preys. We further investigated the function of MMGL itself by using the Y2H bait to screen a 
cardiac cDNA library for novel MMGL interactors. All the prey clones identified via these Y2H analyses were 
subsequently sequenced to determine their identity. Based on their identities and subcellular localization, all 
putative Y2H MMGL-prey interactions were further assessed by additional, separate biochemical techniques viz. 
in vivo co-immunoprecipitation and in vivo 3D co-localization. The interactions between MMGL and its known 
PKA-phosphorylatable sarcomeric ligands were also investigated under conditions of β-adrenergic stress, by 
quantitatively measuring levels of co-localization before and upon addition of the β-adrenergic agonist 
isoproterenol. Furthermore, in order to evaluate the role of MMGL in cMyBPC phosphorylation, we assessed the 
expression of the different phosphorylation isoforms of cMyBPC, with and without β-adrenergic stimulation, in 
the context of siRNA-mediated MMGL knockdown. 
We further hypothesized that MMGL and PKA may serve as modifiers of the hypertrophic phenotype. This was 
tested by conducting a single nucleotide polymorphism (SNP) genotyping study of the genes encoding MMGL 
and the regulatory subunits of PKA viz. PDE4DIP, PRKAR1A and PRKAR2A, respectively, and comparing 
genotypic data with clinical phenotypic traits in a family-based association study. A panel of 353 individuals, 
including genetically and clinically affected as well as unaffected HCM individuals, was identified. All these 
individuals were screened for the presence or absence of all three South African HCM founder mutations, and 
blood was collected and DNA extracted. Genotypes at multiple SNPs in each gene were determined by 
subjecting the DNA samples to TaqMan® allelic discrimination technology. Statistical analysis using 
quantitative transmission disequilibrium testing (QTDT) was done in order to establish whether the difference in 
genotype in these three genes might have an effect on HCM phenotype. 
 
Our results showed that MMGL interacted with both PKA regulatory subunits as well as with other cardiac 
proteins that are PKA targets, including the sarcomeric protein cTNI. It was confirmed that two regulatory 
subunits of PKA (PRKAR1A and PRKAR2A), cardiac ankyrin repeat protein (CARP), copper metabolism gene 
MURR1 domain 4 (COMMD4), α-enolase (ENO1), β-enolase (ENO3) and cTNI are novel interactors of 
MMGL. In order to classify a protein as an AKAP, interaction with one of PKA’s regulatory subunits are 
prerequisite; MMGL showed interaction with both, confirming our hypothesis of MMGL being an AKAP, 
moreover, classifying it as a novel dual-specific sarcomeric AKAP. The identities of the AKAPs involved in the 
phosphorylation of cMyBPC and cTNI had been unknown; our results indicate that MMGL is the AKAP 
involved in the phosphorylation of both these PKA targets. 
 
We also showed that quantitatively more interaction occurs between MMGL and its sarcomeric ligands 
cMyBPC and cTNI under β-adrenergic stress. This implicates that under elevated cAMP levels, PKA is 
dynamically recruited by MMGL to the PKA targets cMyBPC and cTNI, presumably to mediate cardiac stress 
responses and leading to increased cardiac contractility. Furthermore, siRNA-mediated knockdown of MMGL 
lead to a reduction of cMyBPC levels under conditions of β-adrenergic stress, indicating that MMGL-assisted 
phosphorylation is requisite for protection of cMyBPC against proteolytic cleavage.  
 
The SNP modifier study indicated that one variant in PDE4DIP (rs1664005) showed strong association with 
numerous clinical hypertrophy traits, including maximal interventricular septum thickness, as well as a number 
of other composite score traits. Two variants in PRKAR1A (rs11651687 and rs3785906) also showed strong 
association with some of these clinical hypertrophy traits. These results therefore suggest that variants in these 
two genes may act as modifiers of the HCM phenotype. 
 
In conclusion, this study ascribes a novel function to MMGL isoform 4: it meets all criteria for classification as 
an AKAP and appears to be involved in the phosphorylation of cMyBPC as well as cTNI; hence MMGL is 
likely to be an important component in the regulation of cardiac contractility, and by extension, in the 
development of hypertrophy. This has further implications for understanding the patho-aetiology of mutations in 
cMyBPC and cTNI, and raises the question of whether MMGL might itself be considered a candidate HCM-
causing factor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OPSOMMING 
Hipertrofiese kardiomiopatie (HKM) is die mees algemeenste oorerflike hartspier siekte wêreldwyd. Die siekte 
word gekenmerk deur die uiterste variasie in die hoeveelheid hipertrofie wat in verskillende pasiënte ontwikkel 
as gevolg van sarkomeriese proteïen-koderende mutasies.  Die onderliggende gebrek in HKM is geaffekteerde 
kontraktiliteit van die sarkomeer, hoofsaaklik as gevolg van ‘n gebrekkige sarkomeer. Alhoewel daar verskeie 
siekte-veroorsakende gene vir HKM geïdentifiseer is, bly die faktore wat die hoeveelheid hipertrofie in ‘n 
gegewe persoon modifiseer, onbekend. Daar kan dus gehipotiseer word dat molekules wat kontraktiliteit 
beïnvloed as modifiseerders van die hipertrofiese sein kan optree, en dus die ontwikkeling van hipertrofie 
beïnvloed.  
Hartspier kontraktiliteit word gereguleer deur die dinamiese fosforilasie van proteïene binne die sarkomeer deur 
kinases soos bv. cAMP-geaktiveerde proteïen kinase A (PKA). Die spoed en energie doeltreffendheid van 
hartspier kontraksie moet gereguleer word om by die liggaam se behoeftes aan te pas; dus word PKA naby sy 
teikens deur A-kinase anker proteïene (AKAPs) geanker om sodoende die beheer van fosforilasie beide in die 
korrekte area sowel as tydsduur te reguleer. Kardiale miosien-bindingsproteïen C (cMyBPC), asook kardiale 
troponien I (cTNI), is beide HKM-veroorsakende sarkomeriese proteïene wat kontraktiliteit beheer deur middel 
van fosforilasie deur PKA. In ‘n vorige studie in ons laboratorium is ‘n fosfodiesterase 4D-interaksie proteïen as 
bindingsgenoot van die N-terminaal van cMyBPC geïdentifiseer deur middel van ‘n gis-twee-hibried (G2H) 
kardiale biblioteek sifting. In die literatuur staan dié proteïen ook bekend as miomegalin (MMGL) isovorm 4. 
Fosfodiesterases en PKA word soms deur dieselfde anker proteïen (AKAP) geanker, dus het ons hipotiseer dat 
MMGL isovorm 4 ook as AKAP kan optree deur PKA aan die fosforileerbare N-terminaal van cMyBPC te 
anker. Die hipotese is getoets deur middel van direkte proteïen-proteïen interaksie analises in ‘n gis-gebaseerde 
sisteem. Die MMGL cDNA was in ‘n jag-plasmied gekloneer, wat toe direk ge-evalueer is vir interaksie met 
twee verskillende PKA regulatoriese-subeenheid prooi-plasmiede. Die funksie van MMGL self is verder 
ondersoek deur die G2H jag-plasmied te gebruik om ‘n kardiale cDNA biblioteek te sif, sodoende om nuwe 
MMGL bindingsgenote te identifiseer. Alle prooi klone wat deur dié G2H analises geïdentifiseer is, was daarna 
onderworpe aan DNA-volgorde bepaling om hul identiteit vas te stel. Afhangende van hul identiteite en 
subsellulêre lokalisering, is alle moontlike G2H MMGL-prooi interaksies verder ge-evalueer deur bykomende, 
afsonderlike biochemiese tegnieke viz. in vivo ko-immunopresipitasie asook in vivo 3D ko-lokalisering. Die 
interaksie tussen MMGL en sy bekende PKA-gefosforileerde sarkomeriese bindingsgenote was ook ondersoek 
onder kondisies van β-adrenergiese stres, deur kwantitatief die vlakke van ko-lokalisering te meet voor en na 
byvoeging van die β-adrenergiese agonis isoproterenol. Om verder die rol van MMGL in cMyBPC fosforilasie 
te ondersoek, het ons die uitdrukking van die verskillende fosforilasie isovorms van cMyBPC, met en sonder β-
adrenergiese stimulasie, in die konteks van siRNA-bemiddelde MMGL uitklop, bepaal. 
Ons het verder hipotiseer dat MMGL en PKA as modifiseerders van die hipertrofiese fenotipe mag dien. Dit is 
getoets deur ‘n enkel nukleotied polimorfisme (SNP) genotiperings studie van die gene wat kodeer vir MMGL 
en die regulatoriese subeenhede van PKA, viz. PDE4DIP, PRKAR1A en PRKAR2A, en daarna dié genotipiese 
data met kliniese fenotipiese data te vergelyk in ‘n familie-gebaseerde assosiasie studie. ‘n Paneel van 353 
individue wat genetiese en klinies geaffekteerde, sowel as ongeaffekteerde HKM individue insluit, was 
geidentifiseerd. Alle individue was ondersoek vir die aanwesigheid of afwesigheid van al drie Suid-Afrikaanse 
HKM stigter mutasies; bloedmonsters is gekollekteer en DNA uitgetrek. Die genotipes van veelvoudige SNPs in 
elke geen was bepaal deur die DNA monsters aan TaqMan® alleliese diskriminasie tegnologie met behulp van 
die ABI TaqMan® Validated SNP Genotyping Assays sisteem te analiseer. Statistiese analises deur middel van 
kwantitatiewe transmissie disekwilibrium toetse (QTDT) was gedoen om te bepaal of die verskil in genotipe in 
hierdie drie gene ‘n effek op HKM fenotipe het.     
Ons resultate het gewys dat MMGL interaksie toon met beide PKA regulatoriese subeenhede, sowel as met 
ander kardiale proteïene wat ook PKA teikens is, insluitende die sarkomeriese proteïen cTNI. Dit is bevestig dat 
die twee regulatoriese subeenhede van PKA (PRKAR1A en PRKAR2A), kardiale ankyrin herhaal proteïen 
(CARP), koper metabolisme geen MURR1 domein 4 (COMMD4), α-enolase (ENO1), β-enolase (ENO3) en 
cTNI almal nuwe bindingsgenote van MMGL is. ‘n Proteïen moet interaksie met een van die regulatoriese 
subeenhede van PKA toon om as AKAP geklassifiseer te word; MMGL het interaksie met beide getoon, wat ons 
hipotese bevestig dat MMGL ‘n AKAP is, asook dat MMGL as ‘n nuwe  dubbel-spesifieke sarkomeriese AKAP 
geklassifiseer kan word. Die identiteite van die AKAPs wat betrokke is in die fosforilasie van cMyBPC en cTNI 
was onbekend tot nou; ons resultate wys dat MMGL die AKAP is wat betrokke is in die fosforilasie van beide 
hierdie PKA teikens. 
Ons wys ook dat daar kwantitatief meer interaksie plaasvind tussen MMGL en sy sarkomeriese bindingsgenote 
cMyBPC en cTNI onder kondisies van β-adrenergiese stres. Dit impliseer dat PKA dinamies verwerf word deur 
MMGL, onder verhoogde vlakke van cAMP, tot by die PKA teikens cMyBPC en cTNI, moontlik om kardiale 
stres-response te bemiddel en dus te lei na verhoogde spierkontraksie. Verder het siRNA-bemiddelde uitklop van 
MMGL gelei na ‘n vermindering van cMyBPC vlakke onder kondisies van β-adrenergiese stres. Dit dui aan dat 
fosforilasie deur middel van MMGL-bystand ‘n voorvereiste is vir beskerming van cMyBPC teen proteolise.  
Die SNP modifiseerder studie het gewys dat een variant in PDE4DIP (rs1664005) sterk assosiasie toon met 
verskeie kliniese hipertrofie kenmerke, insluitende maksimale interventrikulêre septum diktheid, sowel as ander 
van die saamgestelde telling kenmerke. Twee variante in PRKAR1A (rs11651687 en rs3785906) het ook sterk 
assosiasie getoon met verskeie van die kliniese hipertropfie kenmerke. Hierdie resultate dui dus daarop dat 
variante in hierdie twee gene as modifiseerders van die HKM fenotipe mag optree. 
In samevatting skryf hierdie studie ‘n nuwe funksie aan MMGL isovorm 4 toe: dit voldoen aan alle vereistes om 
as AKAP geklassifiseer te word en dit blyk of dit betrokke is in die fosforilasie van cMyBPC en cTNI; dus is 
MMGL waarskynlik ‘n belangrike komponent in die regulasie van hartspier sametrekking, en dus met 
uitbreiding, in die ontwikkeling van hipertrofie. Dit hou verdere implikasies in om die siekte-oorsaak van 
mutasies in cMyBPC en cTNI te verstaan, en stel die vraag of MMGL self as ‘n kandidaat HKM-veroorsakende 
geen kan beskou word. 
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Figure 1.9. Schematic representation of an AKAP. The PKA heterotetramer (yellow) anchors to an AKAP via 
an amphipathic helix. When cAMP binds to the regulatory (R) subunit of PKA, the catalytic (C) subunits are 
activated and released to phosphorylate various nearby substrates. An AKAP may also serve as a scaffold 
protein for various other signaling proteins (A, B and C) (McConnachie et al., 2006)  
 
Figure 1.10.  A representation of the mAKAP complex, showing how PDE4D3 and PKA are tethered to the 
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down the kinase (Donelson Smith et al., 2006) 
 
Figure 1.11. Myomegalin interacts with PDE4D (Verde et al., 2001), and with trisphosphorylated cMyBPC (A. 
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Figure 1.12. MMGL isoform and conserved domain structure in Homo sapiens. Exons not drawn to scale in 
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Figure 2.1. Graphical representative example of the heart showing the 3 levels at which measurements of wall 
thickness were made.  A) Long-axis view of left ventricle, taken at level of mitral valve, papillary muscles as 
well as just above apex (levels indicated by dotted lines). B) An example of a 2D echocardiographic ultrasound 
of the left ventricle. Abbreviations: AV- aortic valve, LA-left atrium, LV-left ventricle, LVOT-left ventricular 
outflow tract, MV- mitral valve, RVOT-right ventricular outflow tract. Taken from 
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Figure 2.2. Overview of TaqMan® allelic discrimination technology. Selective annealing of the TaqMan® 
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Figure 3.1. Activation of nutritional reporter genes by PKA-MMGL interaction during direct protein-protein 
interaction assays. Small-scale Y2H matings between pGBKT7-MMGL and pACT2-PRKAR1A (i) and pACT2-
PRKAR2A (ii) on solid medium lacking Leu, Trp, His and Ade (QDO). Both subunits show interaction with 
MMGL, but that of PRKAR2A with MMGL appears to be stronger than that of PRKAR1A, as judged by the 
number and colour of colonies arising 
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Figure 3.2. Live cell fluorescence imaging of co-localization of MMGL with PRKAR1A and PRKAR2A in 
differentiated H9C2 cardiomyocytes. (i) GFP-tagged PRKAR1A and PRKAR2A (green). (ii) dsRed-tagged 
MMGL (red). (iii) Co-localization of PRKAR1A and PRKAR2A with MMGL (yellow). (iv) Overlay of images 
A-C with Hoechst H-33342 labeling of the nuclei (blue). Magnification: 60X oil immersion before 70% 
reduction 
Figure 3.3. Western blots of in vivo co-immunoprecipitations of PKA regulatory subunits and MMGL. (i) 
Endogenous PRKAR1A and PRKAR2A immunoprecipitate exogenous dsRed-MMGL in lysates of pDs-
Red/MMGL-transfected, differentiated H9C2 cardiomyocytes. Conversely, (ii) PRKAR1A and (iii) PRKAR2A 
also immunoprecipitate exogenous dsRed-MMGL in these lysates. The clear protein G control lanes show that 
these precipitations are not spurious, but are the result of physical association between the relevant proteins. 
Abbreviations: IP-immunoprecipitate; Prot G-protein G control; WB-western blot 
 
Figure 3.4. Linear growth curve of yeast strain AH109 transformed with either non-recombinant pGBKT7 or 
pGBKT7-MMGL bait constructs. The growth rate of the pGBKT7-MMGL bait transformant were compared to 
the non-recombinant pGBKT7 transformant in order to determine whether the bait constructs had toxic effects 
on the AH109 strain. The growth rate was determined by calculating the slope of the curve, and, seeing that the 
slopes were comparable, indicated that the bait construct had no toxic effect on the growth of the host yeast 
strain 
Figure 3.5. Live cell fluorescence imaging of co-localization of MMGL and the putative interactors identified in 
the Y2H library screen in differentiated H9C2 cardiac myocytes. (i) GFP-tagged putative library screen 
interactors (green), as indicated to the left of the row. (ii) dsRed-tagged MMGL in the same cell(s) (red). (iii) 
Co-localization of interactors and MMGL within these cell(s) generated from Z-stack images (yellow). (iv) 
Overlay of images A-C with Hoechst H-33342 labelling of the nuclei (blue). Magnification: 60X oil immersion 
before 70% reduction. The presence of yellow staining in each of the images in Column C indicates that each of 
the respective preys co-localize with MMGL in differentiated H9C2 cardiomyocytes 
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Figure 3.6. Western blots of in vivo co-immunoprecipitations of MMGL and putative interactors. A: 
Endogenous CARP (i), ENO1 (ii), ENO3 (iii) and cTNI (iv) immunoprecipitated exogenous dsRed-/YFP-
MMGL in vivo in lysates of ds-Red-/YFP-MMGL transfected, differentiated H9C2 cardiomyocytes. (v) 
indicates that GFP-COMMD4 immunoprecipitates dsRed-MMGL in differentiated H9C2 cardiomyocytes 
transfected with both GFP-COMMD4 and dsRed-MMGL B: Reciprocal immunoprecipitations indicate that 
dsRed-/YFP-MMGL immunoprecipitated  endogenous CARP (i), ENO1 (ii), ENO3 (iii) and cTNI (iv) in lysates 
of ds-Red-/YFP-MMGL transfected, differentiated H9C2 cardiomyocytes. (v) indicates that dsRed-MMGL 
immunoprecipitates GFP-COMMD4. The dsRed antibody is directed against the dsRed-MMGL fusion protein, 
while the JL-8 antibody is directed against the YFP/GFP fusion proteins. The clear protein G control lanes show 
that these precipitations are not spurious, but are the result of physical association between the relevant proteins. 
Abbreviations: IP-immunoprecipitate; Prot G-protein G control; WB-western blot 
Figure 3.7. Live cell fluorescence imaging showing that co-localization of MMGL isoform 4 and cMyBPC 
increases under adrenergic stress. Each panel represents a single frame of the 25 images that were captured for 
the Z-stack. Each of the first three columns shows a single colour channel, while the image in the last column 
shows an overlay of the four colour channels used. A: Colocalization (yellow) between dsRed-MMGL and GFP-
cMyBPC in the absence (-isopro) and presence (+isopro) of the beta-adrenergic agonist, isoproterenol. Co-
localization levels have increased ten minutes after the addition of isoproterenol. B: Quantification of co-
localization shown in A shows that co-localization increases but does not reach statistical significance 
Figure 3.8. Live cell fluorescence imaging showing that co-localization of MMGL isoform 4 and cTNI 
increases under adrenergic stress. Each panel represents a single frame of the 25 images that were captured for 
the Z-stack. Each of the first three columns shows a single colour channel, while the image in the last column 
shows an overlay of the four colour channels used. A: Colocalization (yellow) between dsRed-MMGL and GFP-
cTNI in the absence (-isopro) and presence (+isopro) of the beta-adrenergic agonist, isoproterenol. Co-
localization levels have increased ten minutes after the addition of isoproterenol. B: Quantification of co-
localization shown in A shows that co-localization increases but does not reach statistical significance 
Figure 3.9. Real-time quantification of PDE4DIP cDNA transcribed from RNA extracted from cells transfected 
with either a non-silencing control or a particular PDE4DIP siRNA. Pde4dip Rn_RGD:708410_3_HP (MMGL 
3) resulted in optimal knockdown of PDE4DIP (80%) 
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Figure 3.10. Effect of knockdown on the level of the different phosphorylated forms of cMyBPC in cells either 
exposed to adrenergic stimulation or not. A: Western blots of 2-dimensional IEF gels showing the expression of 
the four phosphorylation isoforms of GFP-cMyBPC in H9C2 cells (i) under non-stimulated conditions; (ii) under 
adrenergic stimulation, and (iii) under adrenergic stimulation in the absence of MMGL (i.e. with MMGL knock-
down). B: Quantification of cMyBPC isoforms in the autoradiographs of the 2-dimensional IEF gels shown in 
(A), graphing the levels of the four phosphorylation isoforms (0=unphosphorylated; 1=monophosphorylated, 
2=diphosphorylated, 3=trisphosphorylated). (i) Under non-stimulated conditions, levels of the mono- and 
diphosphorylated forms are similar and increased compared to the trisphosphorylated form. (ii) Under adrenergic 
stress, there is a relative increase in the trisphosphorylated form of cMyBPC and reduction of the non-
phosphorylated form. (iii) Upon MMGL knock-down, adrenergic stress leads to a reduction in the levels of all 
cMyBPC phosphorylation forms 
Figure 3.11. Graphical representation of PDE4DIP SNPs with a MAF≥0.2 for the CEU or YRI population 
manually selected to cover the whole gene. SNPs were only considered for selection if validated TaqMan® SNP 
genotyping assays could be obtained. Rs2798880 (green) was excluded from QTDT analysis due to an 
insufficient number of informative individuals 
Figure 3.12. Graphical representation of PRKA SNPs selected to achieve an even spacing of 0.5 LDUs on the 
metric LD map for the HapMap CEU and YRI populations. SNPs were only considered for selection if validated 
TaqMan® SNP genotyping assays could be obtained. Rs3923913 was excluded from QTDT analysis due to an 
insufficient number of informative individuals 
Figure 3.13. Representative genotyping result for TaqMan allelic discrimination. Genotyping results for the 
rs1628172 SNP as a representation of the allelic discrimination plots obtained with the SDS software during end 
point analyses. Allele X=a; Allele Y=g 
Figure 4.1. A model of contraction. See text for details 
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CHAPTER 1: INTRODUCTION 
Life-giving oxygen and nutrients reaches all parts of the body by the continuous circulation of blood pumped by 
the heart. Cardiomyocytes, specialized heart muscle cells adapted to contract and respond swiftly to 
physiological stimuli, maintain this cycle by contracting in response to action potentials, originating from the 
pacemaker of the heart, the sinoatrial node. The rate of action potentials fired by the sinoatrial node is mediated 
by two opposing nerve systems, the sympathetic nervous system, using noradrenaline and adrenaline to increase 
the rate, and the parasympathetic nervous system, releasing acetylcholine to reduce the action potentials fired. 
This stimulus-response coupling ensures that the cardiac output is matched by the body’s physiological needs 
(Scott and Santana, 2010). 
 
On a molecular level, the arrival of hormones and neurotransmitters to cardiomyocyte receptors results in 
numerous signal-tranduction cascades. One of the most prominent cardiac signal-transduction pathways is the G-
protein-coupled receptor pathway, involving effector molecules such as adenylyl cyclase, which regulates the 
production of second messengers (Oldham et al., 2008). Ca
2+
 and cyclic AMP (cAMP) are the two most 
common second messengers in cardiac signaling pathways, acting at defined sites and, through signaling, these 
second messengers control contraction, excitability and gene expression of respective target proteins. 
 
One such target protein that regulates cardiac contractility through the cAMP signaling pathway during times of 
physiological stress is cardiac myosin binding protein C (cMyBPC). Since its discovery in 1973, this still very 
enigmatic protein has been the focus of numerous studies, especially when it became known that mutations in 
the gene encoding for cMyBPC is a leading cause of hypertrophic cardiomyopathy (HCM) (Watkins et al., 1995, 
Bonne et al., 1995).  
 
This chapter will briefly describe HCM and the disease’s association with cMyBPC, followed by an overview of 
cMyBPC itself. A more detailed overview of cAMP signaling and regulation of contractility in the heart will 
follow, as will a summary of previous studies in this laboratory, all of which will provide context for the current 
study. 
 
1.1. HYPERTROPHIC CARDIOMYOPATHY 
1.1.1. HCM – a sarcomeric disease characterized by the extreme variability in the amount of cardiac 
hypertrophy that develops 
Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, affecting one in 
every five hundred people (Maron et al., 1995). This autosomal dominantly inherited disease is the most 
common cause of sudden cardiac death (SCD) in young people (Maron et al., 1996). Myocyte disarray, 
interstitial fibrosis and left ventricular hypertrophy characterize HCM, as shown in Figure 1.1 (Wynne et al., 
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2001). The underlying defect in HCM is altered contractility of the sarcomere, primarily due to a defective 
sarcomere caused by mutations in the genes encoding sarcomeric proteins (Thierfelder et al., 1994).
 
One of the 
hallmarks of HCM is the extreme variability in the amount of cardiac hypertrophy that develops in different 
patients in response to sarcomeric protein-encoding mutations (Moolman et al., 1997, Maron et al., 1987). 
Although numerous disease-causing genes have been identified, the factors that modify the amount of 
hypertrophy that develops in a given person are still unknown (Marian 2002).  
 
 
Figure 1.1. Pathology of hypertrophic cardiomyopathy. A. Post-mortem examination of heart showing left 
ventricular hypertrophy with reduced left ventricular cavity size, as compared to a normal heart. B. 
Histopathology section of HCM heart showing myofibre disarray and interstitial fibrosis, as compared to a non-
diseased section (Chung et al., 2003) 
 
HCM mutations have been described predominantly in the genes encoding β-myosin heavy chain, cardiac 
troponin T, and cardiac myosin binding protein C (cMyBPC) (Crilley et al., 2003). In 2003, a study by Richard 
et al. suggested that mutations in the gene encoding for cMyBPC (MYBPC3) are the most common HCM-
causing mutations. The impact of this gene  had been underestimated primarily due to the fact that the mutations 
in this gene is typically associated with benign phenotypes that do not present clinically, and cases are often 
identified incidentally and/or only at a later age (Richard et al., 2003). It was suggested that mutations in 
MYBPC3 are responsible for a very important clinical subclass of HCM (Watkins et al., 1995). Presently, 
MYBPC3 mutations are considered the second most frequent gene associated with HCM worldwide, with only 
MYH7 (encoding the β-cardiac myosin heavy chain) mutations exceeding MYBPC3 mutations (Barefield and 
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Sadayappan, 2010) Together, these two genes account for 79% of all sarcomeric mutations associated with HCM 
(http://cardiogenomics.med.harvard.edu/genes/gene-list).  
 
Interestingly, some of these mutations are associated with a normal life expectancy, whereas other mutations are 
associated with a high SCD risk (Moolman-Smook et al., 2003). For example, mutations in cardiac troponin T 
generally cause minimal hypertrophy, but a high risk of SCD, whereas some mutations in β-myosin heavy chain 
and cMyBPC cause severe hypertrophy, but patients may still have a long life expectancy (Moolman-Smook et 
al., 2003). However, even within families, individuals carrying the same mutation often present very different 
clinical pictures. Thus, penetrance is variable, and hypertrophy and the risk for SCD are not necessarily 
dependent only on the disease-causing mutation, but appear to be modified by additional environmental or 
genetic factors; these are the reason why some patients, who appear to have a mild phenotype, can suffer lethal 
complications (Crilley et al., 2003).  
 
The mechanism by which HCM-causing mutations result in hypertrophy is not completely clear. In short, it has 
been speculated that the mechanism could involve mutant proteins being incorporated into the sarcomere, 
thereby resulting in a dominant negative effect. Such incorporated “poison peptides” may disrupt normal aspects 
of sarcomeric function (Flavigny et al., 1999, Sato et al., 2003).  Contrasting findings suggest that mutant alleles 
cause haploinsufficiency of sarcomeric proteins by effectively acting as null alleles (see Section 1.1.2) 
(Rottbauer et al., 1997, Van Dijk et al., 2009, Marston et al., 2009).  However, it is clear that altered contractility 
in the sarcomere is the first trigger for the development of hypertrophy. Thus, it could be hypothesized that 
molecules that affect contractility can act as modifiers of the hypertrophic signal, and therefore influence the 
development of hypertrophy. Interestingly, cMyBPC is also one of the primary proteins by which contractility is 
regulated in the cardiac sarcomere.   
 
1.1.2. MYBPC3 – one of the two most commonly implicated genes in HCM 
Since 1995, up to 150 HCM-causing MYBPC3 mutations have been described (Barefield and Sadayappan, 
2010). Seventy percent of these MYBPC3 mutations are predicted to cause truncated proteins, with the C-termini 
lacking myosin and/or titin binding sites (Figure 1.2; for further detail about the structure of cMyBPC, see 
Section 1.2) (Watkins et al., 1995, Bonne et al., 1995, Carrier et al., 1997). These mutations are usually 
associated with incomplete disease penetrance and late onset of disease (Niimura et al., 1998, Moolman et al., 
2000).  
 
Interestingly, early studies indicated that cardiac tissue from affected HCM patients with MYBPC3 mutations did 
not contain mutant peptides or normal levels of cMyBPC, which made it extremely difficult to characterize the 
functional outcome of MYBPC3 mutations (Rottbauer et al., 1997). Several studies have since shown that 
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patients with C-terminal truncation mutations demonstrate a lower level of total cMyBPC than individuals with 
no MYBPC3 mutations, suggesting that haploinsufficiency might be the pathological mechanism (Moolman et 
al., 2000, Van Dijk et al., 2009, Marston et al., 2009). The ubiquitin-proteasome system targets the truncated 
cMyBPC for degradation, which could explain the absence of mutant cMyBPC protein (Sarikas et al., 2005). 
This also provides evidence that the mutant MYBPC3 allele causes haploinsufficiency of cMyBPC in the 
sarcomere by effectively acting as a null allele (Van Dijk et al., 2009). Moreover, the study by Marston et al. 
showed that not only patients with truncation mutations, but also patients with missense MYBPC3 mutations, had 
reduced levels of cMyBPC, which further supports haploinsufficiency as a disease mechanism for MyBPC-
related HCM (Marston et al., 2009). However, contrasting findings have also been reported, suggesting that at 
least some MYBPC3 mutations may have a dominant-negative effect on sarcomere organization due to a poison 
polypeptide effect (Flavigny et al., 1999, Sato et al., 2003). 
 
 
 
Figure 1.2. Schematic representation of cardiac myosin binding protein C (cMyBPC), indicating domains of 
known function and cardiac-specific regions (Moolman-Smook et al., 2002) 
 
In the N-terminal, several mutations, which cause HCM with varying penetrance, have been reported to occur in 
the C1-C2 domains, a region which includes the phosphorylatable MyBPC motif, emphasizing the importance of 
this region (Barefield and Sadayappan, 2010). Two specific mutations have been identified which occur within 
the cardiac-specific LAGGGRRIS sequence within the cMyBPC motif, close to two of the phosphorylation sites; 
this suggested that cMyBPC phosphorylation may be critical to normal function (Richard et al., 2003). 
Moreover, patients exhibiting end-stage heart failure showed decreased cMyBPC phosphorylation at Ser-282 
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(El-Armouche et al, 2007). Furthermore, HCM patients showed diminished cMyBPC phosphorylation levels at 
Ser-282 in both end-stage heart failure and HCM (Jacques et al., 2008).  
 
It is well known that MyBPC forms an integral part of vertebrate striated muscle; however, its precise roles and 
quaternary arrangement in the sarcomere are not yet completely understood, while functional studies of MyBPC 
have been limited because of the highly modular nature of this protein. However, as this protein is one of the 
principle effectors in the regulation of cardiac contractility, it is relevant to briefly place this protein within the 
context of the sarcomere, and to discuss the known functional domains and interactions of this protein that are 
likely to be important for maintenance of sarcomeric structure and regulation of cardiac contractility. Moreover, 
it is relevant to this thesis to discuss cMyBPC phosphorylation and the regulation of cardiac contractility, both in 
health and disease.  
 
1.2. CARDIAC MYOSIN BINDING PROTEIN C (cMyBPC) 
1.2.1. MyBPC is a regulatory protein found in the sarcomere 
The sarcomere is the smallest contractile unit of muscle. It consists of thick and thin filaments, which generate 
force in striated and cardiac muscle. The major protein constituting the thick filaments is myosin, with 
filamentous actin being the major constituent of thin filaments. These two proteins interact together to form a 
molecular motor, generating a contractile force (Vander et al., 2001). Figure 1.3 illustrates a simplified version 
of the sarcomere.  
 
 
Figure 1.3. The sarcomere, the smallest contractile unit of muscle (http://circulatory-
system.org/muscule/im4.gif) 
 
However, the fundamental contractile properties of muscle cannot be generated by actin and myosin alone. A 
system consisting only of actin and myosin lacks the calcium-dependent switch crucial for controlling the 
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transition between the resting and contractile states of muscle. Control is provided by additional regulatory 
proteins of the thick and thin filaments, which are involved in assembly, maintenance of structural integrity, and 
regulation of contractile activity (Flashman et al., 2004). In the thin filament, control is achieved by tropomyosin 
and the three subunits of troponin (TNI), which block the access of the myosin head to its binding site on actin in 
the absence of calcium (Winegrad 1999). The thick filament also contains regulatory proteins viz. myosin 
binding protein C, -H and –X (MyBPC-C, -H, and –X) (Offer et al., 1973). The focus will now turn to cMyBPC, 
because of its above-mentioned role in HCM, as well as its role in sarcomeric structure and regulation of cardiac 
contractility.  
 
Offer et al. identified MyBPC as a novel protein that interacts with myosin, and it is localized to the C zone of 
the A band of the sarcomere, as shown in Figure 1.4 (Offer et al., 1973, Craig et al., 1976). Three isoforms of 
MyBPC exist, viz. fast skeletal, slow skeletal, and cardiac (Weber et al., 1993, Yasuda et al., 1995) and separate 
genes encode the three isoforms, the different isoforms are not produced by alternative splicing. The genes 
encoding the human fast (MYBPC2) and slow skeletal (MYBPC1) isoforms are situated on chromosomes 19 and 
12, respectively (Weber et al., 1993), with the gene encoding for the cardiac isoform (MYBPC3) situated on 
chromosome 11 (Gautel et al., 1995). The two skeletal isoforms can occur together, even in the same sarcomere, 
in some muscle types, but never in the human heart (Reinach et al., 1983). The cardiac isoform is found only in 
the heart (Weber et al., 1993). 
 
 
Figure 1.4. Schematic diagram showing the location of cardiac myosin binding protein C (cMyBPC) in the C-
zone of the sarcomere (Barefield and Sadayappan, 2010) 
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Both the skeletal isoforms consist of ten globular domains (C1-C10) (Figure 1.2); seven of these are 
immunoglobulin (Ig) domains and three are fibronectin (Fn) type III domains, and these domains are always 
arranged in the same order (Okagaki et al., 1993). The MyBPC motif, which is a conserved 105-residue linker 
region, occurs between domains C1 and C2 (Gautel et al., 1995).  
 
The 140kDa cardiac isoform of MyBPC differs from the two skeletal isoforms in three important ways. Firstly, 
cardiac MyBPC (cMyBPC) contains an additional immunoglobulin module with 101 residues at the N terminus 
(C0). Secondly, a 28-residue loop is inserted into the C5 immunoglobulin domain. Thirdly, nine additional 
residues with the amino acid sequence LAGGGRRIS plus three phosphorylation sites occur in the MyBPC motif 
and are unique to cMyBPC (Gautel et al., 1995). Figure 1.2 shows the arrangement of the domains, as well as 
the differences between the skeletal and cardiac isoforms. 
 
1.2.2. The role of MyBPC in thick filament formation and its arrangement in the sarcomere 
Studies showed that MyBPC binds to myosin via interaction with the light meromyosin (LMM) portion of the 
myosin rod, the myosin region that forms the backbone of the thick filament (Moos et al., 1975). All three 
MyBPC isoforms bind LMM via their C-terminal domain C10 (Okagaki et al., 1993), contributing to the 
formation of the thick filament backbone (Figure 1.2). MyBPC also binds to titin, another component of the 
thick filament (Furst et al., 1992), via the C-terminal domains C8 to C10 of MyBPC (Figure 1.2) (Freiburg and 
Gautel, 1996). Titin has a region that also lies in the C zone of the A band, like MyBPC, and which is also made 
up of IgI-like and Fn3 domains; this region consists of a series of eleven 11-domain superrepeats (Labeit et al., 
1992). Trinick proposed that the position that MyBPC attains in the thick filament may be due to the titin Ig 
domains, because MyBPC, like the 11-domain superrepeats of titin, is confined to the C zone (Trinick 1996). It 
was therefore concluded that the interaction between MyBPC, myosin and titin is crucial for attaining the 
ordered arrangement of the sarcomere (Freiburg and Gautel, 1996). The interaction between MyBPC and titin 
alone is actually quite weak, but combining all three molecules, viz. myosin, titin and MyBPC at the MyBPC C-
terminus forms a complex binding which is a surprisingly stable structure. 
 
Given these findings, the question that resulted was: Is MyBPC truly necessary for the formation of filament 
assembly, and if it was not present, what would the effect be? Studies done by co-expressing MyBPC and 
myosin heavy chain (MHC) in mammalian non-muscle cells partly answered the question. Co-expression of 
MyBPC and MHC resulted in the formation of long, compact filaments encircling the nucleus. In the absence of 
MyBPC, dysfunctional, diffuse, spindle-shaped structures formed (Seiler et al., 1996, Welikson and Fischman, 
2002). It was also found that myosin filaments can form in vitro in the absence of MyBPC, but the addition of 
physiological ratios of MyBPC caused the filaments to increase in length with improved structure and filament 
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compactness (Koretz 1979, Davis 1988). Truncated MyBPC expression also yielded results that further led to the 
suggestion that the C10 domain is crucial in filament formation (Welikson and Fischman, 2002).  
Knockout mouse model studies by Harris et al. yielded surprising results in the light of these in vitro studies. 
Homozygous-null mice were still viable, and regular sarcomere striations were seen, including features such as 
the Z line, A band and M line. The striations and Z line, A band and M line were, however, frequently 
misaligned (Harris et al., 2002). In a study by McConnell et al., mice expressing homozygous C-terminal 
truncated cMyBPC incorporated very low levels of the mutant protein into the sarcomere, and had an abnormal, 
yet intact, sarcomere structure (McConnell et al., 1999). However, in both these models, mice developed 
contractile dysfunction and cardiomyopathies after three months, which shows that cMyBPC is not necessary for 
sarcomeric development during embryogenesis and basal cardiac function, but it is essential for proper 
sarcomeric organization and function. On the other hand, heterozygous mice with either C-terminal truncation or 
cMyBPC knockout displayed normal cardiac function together with regular sarcomere organization, and 
survived into adulthood (Harris et al., 2002, McConnell et al., 1999). 
 
Flashman et al. concluded that MyBPC does play a role in the formation of the thick filament and its stability, 
however, it is not essential for sarcomere formation (Flashman et al., 2004), probably as other factors besides 
MyBPC exist that contribute to sarcomere assembly in the native filament. Winegrad noted: “Although MyBPC 
is not necessary for the formation of thick filaments, it is necessary for the formation of normal thick filaments” 
(Winegrad 1999). 
 
There are currently two models that describe the arrangement of cMyBPC at the C-terminus with myosin and 
titin, viz. the collar model and the strut model as shown in Figure 1.5. The collar model proposes that three 
cMyBPC molecules form a trimeric collar around the thick filament, with domains C5-C10 of each molecule 
wrapping around the width of the thick filament backbone in such a way that domains C5-C8 and C7-C10 of 
parallel-arranged, sequential cMyBPC molecules interact (Moolman-Smook et al., 2002, Flashman et al., 2004,   
Flashman et al., 2007). Support for this model came from experiments that revealed interactions between 
domains C5-C8 and domains C7-C10 in cardiac and fast skeletal MyBPC (Moolman-Smook et al., 2002), but 
not slow skeletal MyBPC (Flashman et al., 2008). The strut model proposed that three or more cMyBPC 
molecules are arranged axially along the thick filament as support rods, as was suggested by image analysis of 
electron micrographs (Squire et al., 2003, Zoghbi et al., 2008, Al-Khayat et al., 2009); however the study by Al-
Khayat et al. also found evidence of structures which are not incompatible with the collar model closer to the 
thick filament backbone (Al-Khayat et al., 2009). The arrangement of the N-terminal domains (C0-C4) is not 
predicted by either of the two models, but both models propose that the N-terminal domains extend into the 
interfilamental space where they can reach and interact with the thin filament (Squire et al., 2003, Winegrad 
1999). 
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1.2.3. The effects of sarcomeric protein phosphorylation 
β-adrenergic stimulation results in the phosphorylation of three sarcomeric components, viz. phospholamban, 
troponin I and cMyBPC. The phosphorylation of these proteins is mediated via cyclic adenosine monophosphate 
(cAMP)-dependent protein kinase A (PKA) (Jeacocke and England, 1980, Wolska et al., 2002, Garvey et al., 
1988). In the case of cMyBPC, phosphorylation also takes place via an endogenous calcium/calmodulin kinase 
(CaMK) tightly associated with cMyBPC (Schlender and Bean, 1991); furthermore, it was found that cMyBPC 
is also phosphorylated by protein kinase C (PKC) (Venema and Kuo., 1993) and protein kinase D (PKD) 
(Haworth et al., 2004), although not through the β-adrenergic pathway. Phosphorylation of sarcomeric proteins 
ultimately results in changes in contractile function and cardioprotection (Montgomery et al., 2002). 
 
 
 
Figure 1.5. Two independent models predicting the arrangement of cMyBPC with myosin at the C-terminus. A: 
the collar model (Moolman-Smook et al., 2002) B: the strut model (Squire et al., 2003) see text for details 
 
What happens when phosphorylation of these proteins occur? It was found that in the heart, contractility is 
significantly enhanced by the dynamic phosphorylation of phospholamban, troponin I and cMyBPC (Garvey et 
al., 1988, Gautel et al., 1995). Gautel et al. investigated the importance of PKA-dependent cMyBPC 
phosphorylation, and described the presence of four phosphorylation sites (termed A-D) in the MyBPC motif. 
However, steric constraints from domain C2 causes Ser-360 (site D) to not be phosphorylated, leaving only three 
N-terminal phosphorylation sites at Ser-273 (site A), Ser-282 (site B) and Ser-302 (site C). It was found that 
CaMK could phosphorylate cMyBPC to ~1 mol Pi per molecule, but PKA could phosphorylate the protein to ~3 
mol Pi per molecule (Schlender and Bean, 1991). It appears that site B on the cardiac LAGGGRRIS insertion 
A: B: 
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can be phosphorylated by both PKA and CaMK, hence facilitating the phosphorylation of sites A and C by PKA 
by abolishing steric constraints (McClellan et al., 2001). However, it was found that a critical level of calcium is 
necessary for CaMK-mediated phosphorylation of cMyBPC at site B, before the other sites could be 
phosphorylated. The critical calcium concentration required for this monophosphorylation is less than that 
required for activation of contraction, and thus it is not clear whether cMyBPC is ever unphosphorylated under 
normal physiological circumstances in the sarcomere. However, at activating calcium concentrations, with 
cMyBPC being fully phosphorylated, increased contraction force can be observed (McClellan et al., 2001). The 
skeletal isoforms of MyBPC do not contain the LAGGGRRIS insertion, and are therefore not phosphorylated by 
PKA or CaMK (Lim and Walsh, 1986).   
 
It was also found that, of these three phosphorylation sites, two can be phosphorylated by PKC (Ser-273 and Ser-
302) (Mohamed et al., 1998). A new PKA phosphorylation site was also identified in vitro in murine cMyBPC at 
Ser-307 (Shaffer et al., 2008).  
 
cMyBPC is dephosphorylated in response to cholinergic agonists, eg. acetylcholine, and this process occurs 
predominantly via protein phosphatase 2A (PP2A) (Hartzell and Titus, 1982, Schlender et al., 1987).  
 
How does phosphorylation of cMyBPC lead to increased cardiac contraction? Myosin subfragment-2 (S2) is the 
portion of the rod joining the myosin head to the thick filament backbone, and it was shown in vitro that a weak 
interaction occurs between this myosin region and MyBPC (Starr and Offer, 1978). This binding is mediated by 
domains C1-C2 of MyBPC, which includes the MyBPC motif (Gruen et al., 1999). This interaction was found in 
both cardiac and skeletal isoforms of MyBPC and myosin. However, it was found that the interaction between 
the cardiac isoform and myosin S2 was abolished by phosphorylation of the MyBPC motif and this suggested a 
possible functional, rather than just structural, role for the cardiac isoform (Gruen et al., 1999). It was suggested 
that when cMyBPC is phosphorylated and the S2 binding is abolished, the myosin crossbridges assumes a more 
favourable position for actin binding (Weisberg and Winegrad, 1999). 
 
However, in a much more recent study, it was shown that two binding domains in cMyBPC viz. C1 and the 
MyBPC motif can also bind to actin (Shaffer et al., 2009). The C1 binding occurs irrespective of the 
phosphorylation state of the MyBPC motif, whereas the binding of actin to the motif only occurs during the 
unphosphorylated state. Thus, when the MyBPC motif is phosphorylated, its binding with actin is abolished. It 
has therefore been suggested that in the unphosphorylated state, the MyBPC motif binds to actin, blocking 
myosin head binding and limiting cross-bridge attachment to the thin filament (Shaffer et al., 2009).When the 
motif is phosphorylated, its binding to actin is abolished, rendering actin free to interact with other ligands like 
myosin S1 or S2, myosin light chains or thin filament regulatory proteins. Cross-bridge kinetics will therefore be 
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affected by the position and docking of myosin heads onto the unbound actin (Galinska-Rakoczy et al., 2008, 
Shaffer et al., 2009), and increased cardiac contractility will likely occur, as shown in Figure 1.6. 
 
It can be concluded that cMyBPC N-terminal phosphorylation is mainly regulated by β-adrenergic stimulation 
that activates PKA, and intracellular levels of calcium that activates CaMK. The level of phosphorylation of the 
MyBPC motif then determines the state of interaction between cMyBPC and myosin S2, which affects the 
potential for binding of the myosin heads with actin. Alternatively, the phosphorylation level will determine 
whether actin is freed from binding to the MyBPC motif to interact with myosin. Thus, either way, the 
phosphorylation of cMyBPC acts as a sarcomeric regulator of cardiac contractility. 
 
 
Figure 1.6. Proposed mechanism of how dynamic phosphorylation of the MyBPC motif (indicated as the M 
domain in this figure) may influence cross-bridge kinetics. A: During the unphosphorylated state, the C1 and M 
domain binds to actin. B: Upon phosphorylation of the M domain, the binding between the M domain and actin 
is abolished, and actin is free to bind to myosin, enabling increased cardiac contraction (Shaffer et al., 2009, 
Barefield and Sadayappan, 2010) 
 
1.2.4. cMyBPC phosphorylation is cardioprotective 
The level of cMyBPC phosphorylation decreases during heart failure development, ischemic-reperfusion (I/R) 
injury and pathological hypertrophy (Sadayappan et al., 2005). In cMyBPC- transgenic mice which expressed a 
non-phosphorylatable version of cMyBPC (in which the phosphorylatable serines in N-terminal cMyBPC had 
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been mutated to non-phosphorylatable alanines) on a cMyBPC-null background, depressed cardiac function was 
observed, along with altered sarcomeric structure. It was deduced that the mutant, unphosphorylatable protein 
was unable to rescue the original cMyBPC-null phenotype, causing functional deficits. However, overexpression 
of normal, wild-type cMyBPC on this background rescued the null phenotype. This suggested that 
phosphorylation of cMyBPC is necessary for normal cardiac function (Sadayappan et al., 2005, Sadayappan et 
al., 2006). The importance of phosphorylation was emphasized in similar cMyBPC-null transgenic mice where 
the knock-in cMyBPC was mutated to a constant trisphosphorylated state. These mice developed protection 
against I/R injury together with reduced cellular damage and attained fairly normal cardiac function (Sadayappan 
et al., 2006, Sadayappan et al., 2005).  
 
The dephosphorylation of cMyBPC is associated with degradation by proteases like calpain I (Decker et al., 
2005, Sadayappan et al., 2006). Following I/R injury, the total levels of phosphorylated cMyBPC is reduced, 
especially the trisphosphorylated form, a phenomenon which appears to be caused by increased cleavage of 
unphosphorylated cMyBPC by proteases. This cleavage is coupled to disruption of the thick filament, a reduced 
level of actin-myosin cross-bridges and dysfunctional contractility (Decker et al., 2005, Sadayappan et al., 
2006). This inversely proportional ratio of cMyBPC phosphorylation to proteolytic degradation suggests that 
phosphorylated cMyBPC is protected against proteolytic cleavage, preserving normal cardiac function, whereas 
absence of phosphorylation results in reduced levels of cMyBPC as a result of increased degradation of the 
protein (Decker et al., 2005, Sadayappan et al., 2006) 
 
In summary, the dynamic phosphorylation of the N-terminal of cMyBPC, mainly by β-adrenergic-activated 
PKA, significantly enhances cardiac contraction by causing rearrangement of the myosin crossbridges and thin 
filament structure (Gautel et al., 1995, Levine et al., 2001, Weisberg and Winegrad, 1996) and renders the 
protein resistant to degradation, contributing to a cardioprotective effect (Decker et al., 2005, Sadayappan et al., 
2006). The N-terminal region of the protein appears to be crucial for this role of regulating cardiac contractility, 
together with its structural role. However, PKA activation affects a number of cellular pathways, not only 
cMyBPC, and thus it is relevant to discuss the manner in which particular cellular responses to PKA activation 
are targeted. 
 
1.3. COMPARTMENTALIZATION OF cAMP- SIGNALING PATHWAY EFFECTORS 
1.3.1. Kinases need to be compartmentalized for effective second-messsenger signaling 
As mentioned in the previous section, cardiac contractility is significantly enhanced by the dynamic 
phosphorylation of cMyBPC via cAMP-activated PKA, PKC and CaMK (Garvey et al., 1988, Gautel et al., 
1995). Since these kinases regulate a broad range of cellular responses, their compartmentalization in close 
proximity to their targets, including their sarcomeric targets, would facilitate control over which proteins are 
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phosphorylated in response to signaling via ubiquitous second messengers, such as cAMP, cyclic-guanosine-
monophosphate (cGMP) and Ca
2+
 (Pawson and Scott, 1997, Wong and Scott, 2004). Similarly, co-
compartmentalization of enzymes or proteins that generate or terminate these second messenger metabolites, such as 
the phosphodiesterases which degrade cAMP and cGMP, along with the relevant responsive kinases, helps to 
optimise the precision and speed of response to second messenger signaling (Pawson and Nash, 2000).  
 
Compartmentalization of kinases in general is achieved by either direct docking of the kinase on the target protein, 
or by anchoring the kinase to, or close to, the target via an adaptor protein (Colledge and Scott, 1999). A number of 
adaptor proteins that anchor PKA, PKC, or CaMKs near their particular substrates and away from others have 
been described in various tissues. These anchoring proteins are highly varied in sequence, and are not necessarily 
functionally equivalent. Moreover, in some cases, the same adaptor protein has also been shown to anchor both 
the kinase and the relevant phosphodiesterase, viz. PKA and phosphodiesterase 4D (the latter is responsible for 
hydrolysing the cAMP that activates PKA) close to the PKA target (Dodge et al., 2001). In muscle, such co-
compartmentalization is crucial for maintaining contractility, as was shown by Fink et al.: disruption of A-kinase 
anchoring protein (AKAP)-mediated PKA-anchoring has significant detrimental effects on the contractility of 
cardiomyocytes, which is particularly noticeable upon β-adrenergic stimulation (Fink et al., 2001). Interestingly, 
in the absence of β-adrenergic stimulation, such disruption did not cause significant effects on cardiac 
contractility (Fink et al., 2001). The increase in phosphorylation of particularly cMyBPC and cTNI upon β-
adrenergic stimulation was significantly reduced in cells where AKAP/PKA anchoring were disrupted, 
compared to controls where no disruption took place. The increase in phosphorylation of other phosphorylatable 
proteins such as phospholamban was not affected by this disruption, and it was therefore speculated that an 
unidentified myofibril-associated AKAP might function to anchor PKA to cMyBPC and cTNI (Fink et al., 
2001). 
 
It is therefore important to further investigate the role that adaptor proteins play, especially in cMyBPC 
phosphorylation, because this process is so intricately involved in normal and enhanced levels of cardiac 
contractility.  
 
1.3.2. Scaffolding and adaptor proteins create new signaling pathways 
In complex metazoans, a point is reached where evolution is not driven by the creation of new genes, but by 
shuffling modular protein-protein domains to create new signaling pathways (Bhattacharyya et al., 2006). 
Excellent examples of this strategy are scaffolding and adaptor proteins that play an important role in the 
assembly of multi-protein signaling complexes (Pawson and Scott, 1997, Pawson and Nash, 2000). These 
signaling scaffolds serve as central platforms that integrate, and at the same time, disseminate, multiple cellular 
signals. Signaling scaffolds ensure that enzymes are kept near their relevant targets by sequestering a signaling 
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enzyme to a specific subcellular environment. In this way, scaffolds are an essential means by which a common 
signaling pathway can serve many diverse functions, and play a role in the spatiotemporal resolution of cellular 
signaling (Beene and Scott, 2007). 
 
As mentioned earlier, PKA is a cAMP-dependent kinase and is particularly important in the heart, because 
cAMP signaling regulates calcium dynamics as well as the rate and force of contraction. Several studies over the 
years have, however, demonstrated that not all agonists that lead to an increased cAMP concentration elicit 
similar PKA-mediated responses. This begged the question: How can signaling-specificity be achieved by such a 
broad-action kinase like PKA? (Hayes and Brunton, 1982). It is now known that scaffolding, anchoring and 
adaptor proteins function to direct signaling enzymes to discrete subcellular compartments to maintain localized 
pools of kinase activity (Pawson and Nash, 2000). In the cAMP pathway, AKAPs are responsible for clustering 
PKA into discrete intracellular compartments (Colledge and Scott, 1999). Figure 1.7 shows a representation of 
various cardiac AKAPs throughout the cell that targets PKA to specific compartments. 
 
 
Figure 1.7. An illustration demonstrating cardiac A-kinase anchoring proteins (AKAPs) clustering PKA, and 
sometimes other kinases and enzymes, to discrete subcellular compartments throughout the cell, allowing for 
maintained localized pools of kinase activity (Kapiloff 2002) 
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1.3.3. AKAPs play a role in the dynamics of cAMP gradients 
Imaging studies have shown that cAMP levels are unevenly distributed throughout the cell, within dynamic 
pools (Zaccolo and Pozzan, 2002, Rich et al., 2001). cAMP flux is determined by two enzyme sets: Firstly G-
protein-activated adenylyl cyclases, which synthesize cAMP from adenosine triphosphate (ATP), and secondly 
phosphodiesterases (PDEs) that terminate cAMP signaling by hydrolyzing it to 5’-adenosine monophosphate 
(5’-AMP). When cAMP is synthesized, it diffuses into the cytosol to activate downstream effector proteins such 
as cyclic-nucleotide-gated (CNG) channels, guanine-nucleotide exchange proteins (EPACs) and the serine-
threonine kinase, PKA. In this way, a mechanism is therefore provided whereby extracellular stimuli can 
influence biological processes. After the processes take place, members of the PDE superfamily degrades the 
cAMP to 5’-AMP, thereby terminating the signal. AKAPs target PKA to substrates in the proximity of cAMP 
gradients generated by the counterbalancing actions of adenylyl cyclases and PDEs, and thereby contribute to the 
specificity of cAMP signaling. AKAPs therefore provide a mechanism of cAMP regulation in response to 
external stimuli within specialized subcellular regions and for particular time intervals (Tasken and Aandahl, 
2004, Wong and Scott, 2004).  
 
Some PDEs are also tethered to specific cellular sites via various PDE-binding proteins, thereby also 
contributing to generating local cAMP gradients. Moreover, it was found that some AKAPs can act as anchoring 
protein for PDEs, in addition to anchoring PKA (Dodge et al., 2001, Asirvatham et al., 2004). Anchoring PKA 
and PDEs together via the same AKAP would ensure tight regulation of cAMP signaling, as shown in Figure 
1.8. 
 
Several studies indicated that cAMP, which is freely diffusible, is actually compartmentalized in the heart, and 
therefore ensures localized cardiac cAMP action. Whole-cell patch recordings demonstrated localized activation 
of calcium channels in frog hearts by localized stimulation of β-adrenergic receptors (Jurevicius and 
Fischmeister, 1996).  Zaccolo and Pozzan performed live cell imaging studies which monitored the activation of 
PKA in rat neonatal cardiac myocytes; this study clearly indicated that β-adrenergic stimulation activated a 
specific subpopulation of PKA moieties (Zaccolo and Pozzan, 2002). This localized action is a due to a direct 
association between PKA and AKAPs.  
 
1.3.4. The AKAP/PKA complex 
Protein phosphorylation, achieved by protein kinases, has been proclaimed as a principal means of reversibly 
controlling biochemical events. The kinase superfamily, consisting of ~518 members, participates in all aspects 
of cellular regulation (Manning et al., 2002). Kinase research now focuses on how kinases are organized in 
relation to their effectors and substrates within the three dimensions of the cell, and research has shown that 
AKAPs have emerged as important signal-organizing components for PKA and other kinases (Donelson Smith 
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et al. 2006). The AKAP group of proteins is a structurally diverse group, and is defined by their ability to bind 
and target PKA (Tasken and Aandahl, 2004) Figure 1.9 illustrates a diagram of a prototypic AKAP, which 
anchors PKA, together with other signaling proteins, to a specific targeting domain.  
 
PKA is a heterotetramer that consists of a regulatory (R)-subunit dimer, plus a catalytic (C)-subunit dimer, with 
each R-subunit bound to a C-subunit dimer (Scott 1991). The genes encoding the C-subunits have been 
characterized and are identified as Cα, Cβ and Cγ (Scott 1991). Cα and Cβ are ubiquitously expressed and are 
93% identical. Cγ is only 80% identical to the other subunits and is expressed exclusively in the testis (Beebe 
and Corbin, 1986). For the R-subunits, four genes have been identified viz. RIα, RIIα, RIβ and RIIβ (Scott 
1991). The RIα and RIIα-subunits are the most predominant, and are expressed in most tissues. RIβ and RIIβ are 
expressed mostly in reproductive tissues and in the central nervous system (Scott 1991, Cadd and McKnight., 
1989). 
 
 
Figure 1.8. A simplified diagram of an AKAP signaling complex indicating that, in addition to PKA, an AKAP 
may also bind other cAMP effectors such as EPACs or PDEs. This ensures the appropriate subcellular response 
to cAMP signaling (Scott 2006) 
 
It has been observed that RI associates only with other RI-subunits, and RII only with other RII-subunits (Scott 
1991). The type-I PKA holoenzyme therefore consists of RI-subunits (RIα/RIβ) and is found in the cytosol, 
while the type-II holoenzyme consists of RII-subunits (RIIα/RIIβ) and is particulate bound (Scott 1991). When 
cAMP binds to PKA R subunits, the active C subunit (Cα, Cβ or Cγ) is released to phosphorylate nearby 
substrates (Dell’Acqua and Scott., 1997). Studies using various animal hearts determined that 50% of the cAMP-
dependent protein kinase activity was associated with the particulate fraction i.e. the RII-subunits (Corbin et al., 
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1977). Binding of individual hormones to their receptors also tend to preferentially activate a particular R-
subunit. An example in cardiomyocytes is the activation of PKA-RII, which is particulate bound, by 
isoproterenol, an adrenergic agonist, while prostaglandin E2, a vasodilator and noradrenalin-release inhibitor, 
activates PKA-RI, which is found in the cytosol (Keely 1979, Hayes and Brunton., 1982). Thus, in the cell, PKA 
acts globally through the cytosolic RI, and locally through the particulate bound RII.  
 
The localization of PKA-RII to specific sites in the cell is mediated through the association with AKAPs. Most 
AKAPs that have been characterized bind the RII subunit, although several AKAPs have been reported that 
binds the RI subunit (Angelo and Rubin., 1998). However, the binding affinity of RII for AKAPs is typically 
higher than that of RI, and this allows for subcellular placement of the PKA-RII holoenzyme (Carr et al., 1992, 
Alto et al., 2003). Each AKAP has a distinct binding affinity for RII because of limited sequence conservation of 
the RII binding domain on individual AKAPs (Alto et al., 2003). The binding affinity for RII/AKAP interaction 
further increases with the PKA-induced phosphorylation of the RII-subunit (Zakhary et al., 2000). These binding 
affinities and kinetics become important in heart failure, where β-adrenergic signal desensitization occurs. In 
tissue isolated from failing hearts, RII phosphorylation is decreased and suggests a decrease or redistribution of 
anchored PKA signaling (Zakhary et al., 2000). Dual-specific AKAPs have also been described, e.g. D-AKAP1 
and D-AKAP2; these AKAPs can anchor both types of PKA R-subunit (Huang et al., 1997, Wang et al., 2001); 
it was also shown that some dual-specific AKAPs have a higher binding affinity for RII (Miki and Eddy, 1999).  
 
The N-terminal domain of the PKA R-subunit binds to AKAPs via an amphipathic helix, which is found on most 
AKAPs (Carr et al., 1992), see Figure 1.9. The Ht31 peptide is a partial protein fragment that has been 
developed to interrupt the RII/AKAP interaction. This peptide also contains the amphipathic α-helical region of 
an AKAP, but does not contain a targeting domain, and therefore binds RII with the same nanomolar affinity as 
a full-length AKAP, competing for RII binding, thereby disrupting AKAP/PKA interactions when overexpressed 
(Carr et al., 1992, Rosenmund et al., 1994, Lester and Scott, 1997). 
 
Fink et al. demonstrated that PKA binding to AKAPs in cardiomyocytes was disrupted after adenovirus-
mediated expression of the Ht31 peptide, as described in Section 1.3.1. The results of Fink et al. clearly 
demonstrate that PKA, when anchored to an AKAP, regulates specific, localized phosphorylation events without 
interrupting global cAMP signaling, and leads to normal cardiac contraction (Fink et al., 2001).  
 
Using a genetically encoded PKA-activity reporter known as A-kinase activity reporter (AKAR), Zhang et al. 
demonstrated that the rate of phosphorylation was enhanced three- to four-fold when PKA was bound to the 
same complex as its substrate (Zhang et al., 2001). The results of Zhang et al. provided evidence that the release 
of the PKA C-subunit from an AKAP complex in response to cAMP, would preferentially lead to 
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phosphorylation of a specific, localized pool of substrate (Zhang et al., 2001). Taking the results of Fink and 
Zhang et al. into account, it can clearly be seen that AKAPs play a crucial role in the PKA-mediated 
phosphorylation of specific, localized substrates, and in the case of cardiomyocytes, normal cardiac contractility.  
 
For a protein to be classified as an AKAP, it has to meet four criteria. Firstly, a protein has to interact with the R-
subunit of PKA inside a cell. Secondly, the unique targeting domains that are contained within an AKAP must 
participate in either protein/protein or lipid/protein interactions; this will dictate the subcellular localization of 
the relevant PKA. Thirdly, an AKAP must be able to coordinate multiple signaling pathways by anchoring 
additional signaling enzymes e.g. phosphatases, PDEs and other kinases (Colledge and Scott, 1999, Dodge and 
Scott, 2000). Lastly, an AKAP must be able to form larger, multiprotein units through the interaction with other 
scaffolding or adaptor proteins (Colledge et al., 2000). If a protein meets these four criteria, it can be classified 
as an AKAP, and it will have the ability of functioning as a signal processing unit that can link upstream 
activators with their downstream targets. This allows for specificity of signaling and the integration of multiple 
signaling events (Dodge-Kafka et al., 2006) 
 
 
Figure 1.9. Schematic representation of an AKAP. The PKA heterotetramer (yellow) anchors to an AKAP via 
an amphipathic helix. When cAMP binds to the regulatory (R) subunit of PKA, the catalytic (C) subunits are 
activated and released to phosphorylate various nearby substrates. An AKAP may also serve as a scaffold 
protein for various other signaling proteins (A, B and C) (McConnachie et al., 2006)  
 
1.3.5. AKAP signaling complexes 
The biological role of AKAPs coordinating multiple signaling pathways by anchoring additional signaling 
enzymes became apparent when Coghlan et al. discovered that AKAP79 not only anchored PKA, but also 
protein phosphatase PP2B (Coghlan et al., 1995). Their finding suggested for the first time that signals 
controlling the phosphorylation and dephosphorylation of a substrate can pass through a single AKAP signaling 
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complex. Studies that followed the one by Coghlan et al. showed that AKAP79 also interacts with PKC, creating 
a way of integrating cAMP signals with Ca
2+
 and phospholipid signals at the same subcellular locus (Klauck et 
al., 1996). It then became apparent that AKAPs not only bind PKA, but fulfill the crucial task of acting as 
signaling complexes, by binding other kinases, protein phosphatases as well as other signaling transduction 
enzymes.  
 
As already mentioned, cAMP flux needs to be spatio-temporally controlled, and this requires the concerted 
action of two enzyme classes viz. adenylyl cyclases which synthesize cAMP, and PDEs which hydrolyze cAMP 
into 5’-AMP. Houslay and Adams, as well as Conti et al., identified several proteins that bind PDEs, and target 
them to distinct microenvironments (Houslay and Adams, 2003, Conti et al., 1995). A good example of such 
PDE is PDE4D3. This enzyme is differentially localized via interactions with scaffolding proteins e.g. β-arrestin 
and myomegalin (Perry et al., 2002, Verde et al., 2001). Just as scaffolding proteins anchor PDEs, many AKAPs 
group PKA together with PDEs to stop cAMP signals as they diffuse into the cell (Dodge et al., 2001).  
 
1.3.5.1. Muscle-Selective AKAP illustrates how AKAP signaling complexes modulates contractility 
An important example of an AKAP that functions as part of a multienzyme complex is muscle-selective AKAP 
(mAKAP). mAKAP, with a size of 255-kDa, is localized to the nuclear envelope and sarcoplasmic reticulum 
(SR) in the heart and skeletal muscle, and is also expressed in the brain (Kapiloff et al., 1999). The enzymes that 
form part of the mAKAP complex are involved in the regulation of cardiac function, and include PKA, 
phosphodiesterase 4D3 (PDE4D3), the calcium-activated calcium channel or ryanodine receptor (RyR), 
phosphatases PP2A, PP1 and PP2B, nesprin-1α, the GTP exchange protein Epac and the extracellular signal-
regulated kinase 5 (ERK5) (Dodge et al., 2001, Dodge-Kafka et al., 2005). 
 
The localization of mAKAP to the nuclear envelope and SR has been determined by immunohistochemical 
studies of cardiac tissue (Kapiloff et al., 1999, Ruehr et al., 2004, Marx et al., 2000). mAKAP is targeted to the 
nuclear envelope by the direct association of the spectrin-repeat domain on mAKAP to the nuclear-associated 
Nesprin-1α (Pare et al., 2005). Overexpression of the mAKAP spectrin-repeat domain causes disruption of the 
mAKAP/Nesprin binding. This suggests that the localization of mAKAP to the nuclear envelope is saturable 
(Zhang et al., 2001). It is currently still unclear how mAKAP anchors to the SR, but it is speculated that a direct 
association between mAKAP and the RyR through a conserved leucine zipper motif on the RyR may be 
responsible (Marx et al., 2001). 
 
Dodge et al. found that PDE4D3 co-purified with both mAKAP and the RII subunit of PKA in 
immunoprecipitation studies using rat heart extracts  (Dodge et al., 2001).  They also showed that the PDE4D3 
isoform directly interacts with mAKAP, and that PDE4D3 and mAKAP co-localized at the nuclear membrane of 
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cardiac myocytes (Dodge et al., 2001). On discovering that both PDE4D3 and PKA interact with mAKAP, the 
possibility was raised that this complex might be closely involved with regulating local cAMP concentrations as 
well as mAKAP-associated PKA activity. By inhibiting mAKAP-associated PDE4 activity, the activity of the 
anchored PKA was enhanced, as expected (Dodge et al., 2001). PDE4D3 contains two PKA-phosphorylation 
sites, at Ser13 and Ser54. When Ser54 is phosphorylated, a 2-3 fold enhancement of PDE activity is observed 
(Sette and Conti, 1996). Not surprisingly then, mAKAP-associated PKA phosphorylation of PDE4D3 was found 
to cause a two-fold increase of PDE4D3 activity (Dodge et al., 2001).  
 
From these above-mentioned findings, it was suggested that mAKAP forms a cAMP signaling complex by 
anchoring both PKA and PDE4D3. The complex operates by means of a negative-feedback loop, in which 
PKA’s activity is attenuated by PDE4D3. Under basal conditions, mAKAP-bound PDE4D3 maintains local 
cAMP levels below the threshold value needed to activate mAKAP-anchored PKA. When a hormonal signal, 
e.g. β-adrenergic stimulation, activates adenylyl cyclase via G-coupled protein receptors, the cAMP level 
increases. The increased cAMP level overrides the PDE activity, and causes the C-subunit of PKA to be 
released. This leads to the phosphorylation of the Ser54 site on PDE4D3, which increases the local PDE 
(PDE4D3) activity. The increased PDE activity causes increased cAMP hydrolysis, and so cAMP levels return 
to basal. When basal cAMP levels are reached, the PKA holoenzyme reforms, and the process can start again 
(McConnachie et al., 2006). Figure 1.10 summarizes these findings.  
 
 
Figure 1.10.  A representation of the mAKAP complex, showing how PDE4D3 and PKA are tethered to the 
nuclear membrane via mAKAP, thereby regulating the local cAMP flux. PDE4D3 also acts as a scaffold protein 
for ERK5. PDE4D3 activity will eventually reduce cAMP levels back to basal levels, which in turn will shut 
down the kinase (Donelson Smith et al., 2006). 
 
Interestingly, phosphorylation of the Ser13 site only enhances the affinity of PDE4D3 for mAKAP, but does not 
affect PDE activity. By enhancing the affinity of PDE4D3 for mAKAP, the negative-feedback loop is also 
enhanced (Carlisle Michel et al., 2004). PKA phosphorylation has also been shown to modulate protein-protein 
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interactions within several other AKAP complexes (Tao et al., 2003). The consequences of such type of 
regulation are as follows: In the case of mAKAP, PKA may phosphorylate PDE4D3 at Ser54 and Ser13 in 
response to hormonal stimulation, which means that PDE will be drawn into the AKAP complex with increased 
activity. This will decrease the local cAMP level back to basal levels. Dodge-Kafka et al. speculated that this 
arrangement of PKA and PDE may generate local cAMP fluctuations and pulses of compartmentalized PKA 
activity. These authors therefore determined the dynamics of the negative-feedback loop by using live cell 
imaging techniques to monitor the temporal activation of PKA, by using modified versions of the A-kinase 
activity reporter 2 (AKAR2)-PKA reporter. In addition to PKA activity, the AKAR2-PKA activity reporter is 
sensitive to PDE and can therefore monitor both the activation and termination of PKA signaling (Zhang et al., 
2005). The modified versions of AKAR2-PKA used by Dodge-Kafka et al. could either bind PKA alone 
(AKAR-PKA) or PKA and PDE4D3 (AKAR-PKA-PDE). Cells that expressed the AKAR-PKA reporter showed 
sustained elevation of fluorescence resonance energy transfer (FRET), upon cAMP stimulation. This indicated 
that PKA that was associated with AKAR2 was activated. In cells that expressed the AKAR-PKA-PDE reporter, 
the FRET response was short-lived, most likely due to a drop in cAMP levels because the AKAR-PKA-
associated PDE activity increased (Dodge-Kafka et al., 2005). The interaction of PDE4D3 and PKA to the same 
complex therefore resulted in variable periodical levels of PKA activity, ranging from basal to high and back to 
basal, in cells expressing AKAR-PKA-PDE. This suggested that the co-localization of PKA and PDE is a critical 
component for attenuating PKA signaling. This reporter study of Dodge-Kafka et al. serves as a model for the 
recruitment of PKA and PDE into a single complex to control local cAMP gradients, and demonstrates that 
cAMP compartmentalization by the mAKAP complex controls the timing of PKA activation as well as 
regulating the spatial location of PKA. 
 
Moreover, the study by Dodge-Kafka et al. also revealed that PDE4D3 itself acts as a scaffolding protein, and 
recruits ERK5 to the mAKAP complex. PDE4D3 contains two ERK5-binding domains which mediates direct 
interactions between these two enzymes. Mutated forms of either domain inhibit the association between ERK5 
and the mAKAP complex. ERK5 is similar to PKA in that it also regulates PDE4D3 catalytic activity (Hoffman 
et al., 1999). When Ser579 is phosphorylated by ERK5, cAMP hydrolysis is decreased by 40% (Dodge-Kafka et 
al., 2005). Phosphorylation of PDE4D3 at Ser579 by ERK2 also inhibits PDE activity, and causes an increased 
level of cAMP concentration. The resultant relative increase in cAMP levels, in return, stimulates the release of 
the PKA C-subunit. This demonstrates an alternative feedback system where ERK-signaling pathways lead to 
the inhibition of PDE activity, and consequently, increased cAMP levels (Hoffman et al., 1999). On the other 
hand, these results show that mAKAP can assist in the bi-directional regulation of PKA activity by binding 
PDE4D3, ERK5 and PKA to the same anchoring protein. This is another example of how the mAKAP complex 
dictates local cAMP concentrations. 
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The GTP exchange protein Epac is another cAMP effector that was shown to mediate the cAMP inhibitory 
effect. Epac is also associated with the mAKAP complex via a direct binding to PDE4D3. Epac acts as a guanine 
nucleotide exchange factor for the small G-protein Rap1, and is stimulated by cAMP (Kawasaki et al., 1998). 
When Epac was activated with specific cAMP analogs, ERK5 stimulation was attenuated. This demonstrates, yet 
again, the importance of PDEs as anchoring proteins (Dodge-Kafka et al., 2005). 
 
The theory of compartmentalization suggested that cellular cAMP-mediated events, although reactive to 
different durations and concentrations of cAMP, can still originate from the same microdomain. The mAKAP 
complex illustrates this theory as follows: When a stimulus arrives, and cAMP concentrations are in the 
nanomolar range, PKA is activated. As the stimulus continues, the cAMP concentration reaches the micromolar 
range, causing PDE4D3 and Epac to be sequentially activated (Beavo and Brunton, 2002). When the cAMP 
signal reaches its maximum, PDE4D3 is phosphorylated by PKA and results in the increase of cAMP hydrolysis. 
The resulting decrease of cAMP levels starts to shut off the stimulus, and terminates the actions of PDE4D3 and 
Epac. Lastly, PKA’s activity is attenuated (Sette and Conti, 1996, Hoffmann et al., 1999). This is a perfect 
example where three distinct cAMP-binding proteins co-exist within a complex and thus in a particular 
microdomain, with their own different ranges of activation (Dodge-Kafka et al., 2005). 
 
Tasken et al. suggested that another AKAP, AKAP450 is involved in an analogous function to mAKAP, but at 
centrosomal locations rather than at the nuclear membrane. AKAP450 tethers the enzymes PKA and PDE4D3 as 
well as the phosphatases PP1 and PP2A together to form a signaling complex, just like mAKAP does (Tasken et 
al., 2001). Similarly, Bajpai et al. showed that yet another AKAP, AKAP110, binds the PDE4A isoform to the 
acrosome of spermatozoa, whereas Asirvatham et al. did similar work on AKAP149 and AKAP121, as well the 
Nervy and myeloid translocation gene (MTG) anchoring proteins, and found that these proteins target and bind 
the PDE4A and PDE7A isoforms to various subcellular regions (Bajpai et al., 2006, Asirvatham et al., 2004). 
This illustrates more examples of AKAP-PKA-PDE clusters functioning as signaling units that respond to 
upstream signals deriving from adenylyl cyclase and G-protein-coupled receptor (GPCR) networks. These 
signaling complexes continually change the signaling environment in which cAMP levels are distributed 
unevenly in the cell.  
 
The findings mentioned in this section highlight the central role that AKAPs play in the customized regulation of 
cAMP signaling, and emphasize the pleiotropic nature of the second messenger cAMP (Donelson Smith et al., 
2006). 
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1.3.5.2. The mAKAP complex may play a vital role in cardiac function 
As previously mentioned, the mAKAP complex is localized at both the SR and nuclear envelope. Because this 
large complex is found at both locations, diverse roles are suggested for the complex at these respective locations 
(Dodge-Kafka et al., 2006). The mAKAP complex at the SR location plays a role in calcium dynamics in the 
heart, which is mediated through the regulation of the ryanodine receptor (RyR). A function of mAKAP is to 
link PKA to the RyR so that the RyR can be phosphorylated, and it has been shown that mAKAP-tethered PKA 
phosphorylates both cardiac and skeletal isoforms of the RyR (Kapiloff et al., 1999, Ruehr et al., 2004).When 
the RyR is phosphorylated at Ser2808 via PKA, the probability of an open channel, as well as the sensitivity of 
the RyR to calcium-dependent activation, is increased (Marx et al., 2000). Marx et al. demonstrated that in 
failing hearts, PKA-mediated RyR hyperphosphorylation is observed, which leads to exhaustion of the SR 
calcium stores and an increased diastolic SR calcium leak. The physiological importance of the PKA negative-
feedback loop is verified here, because RyR hyperphosphorylation is attributable to a decreased PDE4D3 level 
(Lehnart et al., 2005). Lehnart et al. also showed that deletion of the PDE4D gene in mice leads to progressive 
cardiomyopathy, as well as cardiac arrhythmias and accelerated heart failure after myocardial infarction. Taking 
these data into consideration, it can clearly be seen that regulation of RyR phosphorylation by the mAKAP 
complex has noteworthy impact on SR calcium dynamics. Moreover, the disruption of cAMP dynamics may 
result in the development of cardiac disease. 
 
The understanding of the function of the mAKAP complex at the nuclear envelope is still unclear, but studies 
suggest that it may play a role in the regulation of cardiac hypertrophy (Dodge-Kafka et al., 2005, Pare et al., 
2005). When mAKAP expression in rat neonatal ventriculocytes was knocked down via RNA interference, the 
ability of prohypertrophic agonists to stimulate an increase in myocyte size and the fetal gene expression 
typically seen in hypertrophy, was blocked. The mechanism that the complex uses to induce hypertrophy is still 
unknown. It was, however, speculated that, by localizing the kinases ERK5 and PKA close to nuclear targets 
such as transcription factors, mAKAP may assist the increase in fetal gene expression essential for hypertrophy 
induction (Dodge-Kafka et al., 2005, Pare et al., 2005). 
 
1.3.5.3. The AKAP Yotiao is also linked to cardiac function 
Long-QT syndrome (LQTS) is an inherited cardiac disease, which is characterized by arrhythmias that often 
leads to sudden cardiac death, normally during increased sympathetic stimulation (Watanabe et al., 2005). 
Mutations in the gene KCNQ1, amongst others, leads to LQTS. This gene encodes the ion channel subunit 
KCNQ1 that occurs in the K
+
 channel (Kassand Moss, 2003). The K
+
 channels are responsible for delayed 
rectifier K
+
 currents (IKS) which shape the duration of cardiac action potentials in response to β-adrenergic 
signaling (Westphal et al., 1999). PKA phosphorylates KCNQ1 at Ser27, which leads to a significant increase in 
channel currents (Marx et al., 2002).  
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Potet et al. found that the K
+
 channel is associated with and is regulated by AKAP-bound PKA, and it was 
determined that Yotiao is the particular AKAP that binds this channel to PKA (Potet et al., 2001, Marx et al., 
2002). Yotiao is a 210-kDa protein and was first found to associate with the N-methyl-D-aspartate receptor in 
neurons. It serves the function of tethering a kinase/phosphatase signaling complex to the ion channel at the N-
methyl-D-aspartate receptor in neurons (Westphal et al., 1999). 
 
Yotiao is the AKAP responsible for tethering both PP1 and PKA to the K
+ 
channel. Although the effect of 
Yotiao-anchored PP1 on KCNQ1 is still unknown, this AKAP-bound phosphatase is the predominant enzyme 
that regulates the K
+ 
ion channel under basal conditions. It limits the effect of PKA until a cAMP increase leads 
to overpowering of the phosphatase action, and hence PKA activation (Westphal et al., 1999). Marx et al. 
showed that the disruption of the K
+
 ion channel association with Yotiao resulted in decreased cAMP 
enhancement of the channel’s activity. KCNQ1 binding to Yotiao is mediated via a conserved leucine zipper 
coiled-coiled motif; Yotiao/K
+
 channel disruption can be caused by a single amino acid mutation (G589D) in 
this leucine zipper coiled-coiled motif. This mutation was found in 508 out of 939 Finnish LQTS patients 
(Fodstad et al., 2004). This clearly suggests that specific PKA anchoring to the K
+
 channel is necessary for 
normal channel function in vivo (Marx et al., 2002), and that lack of such anchoring triggers disease. This 
finding was thus the first genetic evidence proving that PKA targeting to particular sub-cellular regions is 
physiologically essential. The finding also gave considerable weight to the anchoring hypothesis (Dodge-Kafka 
et al., 2006). 
 
1.3.5.4. AKAP-Lbc 
As described in section 1.3.4, the peptide Ht31 interrupts the interaction between an AKAP and the PKA RII 
subunit. The Ht31 peptide is a partial protein fragment, derived from a protein first identified in human thyroid 
that binds the PKA RII subunit with high affinity, competing with full-length AKAPs to bind PKA. Ht31 has 
been widely used as a molecular tool to investigate the molecular mechanisms of PKA anchoring, as well as to 
determine the biological importance that anchored PKA has on physiological proceedings (Carr et al., 1992, 
Rosenmund et al., 1994, Fink et al., 2001). 
 
By performing a database search that exposed similarities between full-length Ht31 and the guanine nucleotide 
exchange factor Lbc, Diviani et al. showed that full-length Ht31 functions as a Rho-selective guanine nucleotide 
exchange factor, revealing the function of full-length Ht31. Full-length Ht31 differs from the partial Ht31 used 
as molecular tool in that it contains, in addition to an amphipathic α helix, a domain that targets it to its 
phosphorylation target (Diviani et al., 2001). Full-length Ht31 proved to be an AKAP and is now known as 
AKAP-Lbc, a large 320-kDa protein. Diviani et al. showed that AKAP-Lbc contains several domains that are 
involved in the activation of the small G-protein RhoA, including consecutive Dbl and Pleckstrin-homology 
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domains. It was also showed that Gα12, which is the upstream activator of Rho, also associates with AKAP-Lbc. 
This suggests that this AKAP may function by coupling G-protein activation with Rho signaling (Diviani et al., 
2001). 
 
Studies by Lang et al. and Ellerbroek et al. have found that PKA has an antagonistic effect on Rho signaling. It 
is now known that PKA, when bound to AKAP-Lbc, decreases the activation of Rho (Lang et al., 1996, 
Ellerbroek et al., 2003). This is mediated by blocking the Rho-guanine nucleotide exchange factor (GEF) 
activity of the scaffolding protein (Diviani et al., 2004, Jin et al., 2004). When Ser1565 on AKAP-Lbc is 
phosphorylated by PKA, the recruitment of the protein 14-3-3 to the complex is stimulated, which inhibits Rho 
activation. To have an inhibitory effect on Rho, PKA must be anchored to the AKAP-Lbc complex, and AKAP-
Lbc must also be oligomerized for 14-3-3 (Diviani et al., 2004, Baisamy et al., 2005). This shows that AKAP-
Lbc is involved in the integration of two effector pathways, coupling cAMP signaling with the small G-protein 
Rho. This allows for coordinated G-protein functional regulation. 
 
Studies have shown that Rho signaling is closely linked with the generation of cardiac hypertrophy. However, 
the physiological role that AKAP-Lbc Rho-GEF activity plays in cardiac function is still unknown. Because Rho 
signaling is involved in hypertrophy induction, it can be speculated that AKAP-Lbc acts as an adaptor protein, 
facilitating G-protein activation of Rho. This may lead to the enhancement cardiotrophic effects of this small G-
protein (Clerk and Sugden, 2000).  
 
A study by Carnegie et al. has shown that the AKAP-Lbc complex also tethers PKC and PKD, and plays an 
important role in the activation of PKD (Carnegie et al., 2004). Activation of PKD by the AKAP-Lbc complex is 
mediated by recruiting both PKD and PKDŋ, which is the upstream activator of PKD. This allows for the linear 
transduction of signals from one kinase to the next, and demonstrates a common way in which scaffolding 
proteins are arranged molecularly (Carnegie et al., 2004, Pawsonand Nash, 2000). When PKA phosphorylates 
Ser2737 on AKAP-Lbc, the release of active PKD into the cytoplasm is mediated by AKAP-Lbc. This 
demonstrates that AKAP-Lbc facilitates specific activation of PKD, as well as amplifying the PKD signal by 
processing multiple PKD enzymes in a short time span (Carnegie et al., 2004). 
 
AKAP-Lbc is yet another example of an AKAP that acts as a multi-enzyme complex, illustrating the importance 
of cyclic nucleotide signaling compartmentalization, and that might well be involved in cardiac function. 
 
1.3.5.5. AKAP15/18 
A low molecular weight (81 amino acids) AKAP has been cloned in two unrelated laboratories, and was named 
AKAP15 or AKAP18 depending on the laboratory (Fraser et al., 1998, Gray et al., 1997) This AKAP is now 
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referred to as AKAP15/18, and is expressed exclusively in the plasma membrane of cardiomyocytes. 
AKAP15/18 is anchored to the plasma membrane by covalently attached lipid moieties, and this molecular 
configuration allows for the regulation of plasma membrane substrates.  
 
The first identified target of AKAP15/18 was the L-type calcium channel, the major voltage-gated calcium 
channel in the heart that is responsible for the action potential’s plateau phase (Bers 2002 , Fraser et al., 1998, 
Gray et al., 1997). Gao et al. showed that AKAP-anchored PKA phosphorylation is accountable for the 
increased probability of an open L-type channel that allows the potentiation of the inward calcium channel (Gao 
et al., 1997). It was determined, through the works of Fraser et al. and Gray et al., that AKAP15/18 is the AKAP 
responsible for facilitating this effect. AKAP15/18-anchored PKA phosphorylates Ser1928 on the α1C-subunit as 
well as on multiple sites on the β2-subunit (Gray et al., 1997, Fraser et al., 1998). The AKAP is anchored to the 
L-type calcium channel via a leucine zipper motif at the C-terminus of the α1C-subunit. Inhibition of the voltage-
dependent potentiation of the channel occurred when a synthetic peptide was introduced that mimics channel 
binding (Hulme et al., 2002). β-adrenergic regulation blockage of the channel was also observed when the 
binding between AKAP15/18 and the L-type calcium channel was disrupted (Hulme et al., 2002, Hulme et al., 
2003). This demonstrates that PKA anchoring to the channel via AKAP15/18 is necessary for specific and rapid 
responses to small, localized cAMP concentrations that are mediated by adrenergic stimulation, in order to 
achieve normal channel functioning.  
 
Protein phosphatase 2B (PP2B) and the β2-adrenergic receptor have been identified as partners in the L-type 
calcium channel complex, although it is not clear whether the interactions are direct or AKAP-mediated 
(Sacchetto et al., 2001). In the brain, direct association of the β2-adrenergic receptor with the channel has been 
shown, and this strongly suggests that the L-type calcium channel, together with the β2-adrenergic receptor, 
PP2B and AKAP15/18 may form a multiprotein complex in the heart (Davare et al., 2001). It is therefore clear 
that AKAP15/18 plays a crucial role in cardiac calcium dynamics, as well as the facilitation of the inotropic 
actions of the β2-adrenergic receptor. 
 
1.3.6. Summary of the relevance of AKAPs 
The main AKAPs already mentioned, viz. mAKAP, Yotiao, AKAP-Lbc and AKAP15/18, all play an important 
role in cardiac function, where they function by coordinating signal transduction complexes. Signal transduction 
is coordinated by the AKAPs via the recruitment of multiple signaling enzymes (the most important being PKA) 
close to their respective substrates. This allows upstream effectors to be joined with specific downstream targets 
within a single signaling complex, allowing specific compartmentalization as well as optimal signaling precision 
and speed. It can therefore be concluded that the most important function of AKAPs is to allow biological signal 
transduction to take place quickly and precisely, amplifying specific responses and maintaining the fidelity of 
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signal transduction networks, with the end-goal of eliciting the appropriate and correctly timed physiological 
response.  
 
Since the discovery of the first AKAPs, viz. MAP2 and AKAP75 in 1982 and 1984, respectively, this family of 
proteins has grown and currently more than 70 members have been identified (Theurkauf and Vallee, 1982, 
Sarkar et al., 1984), 13 of which are found in cardiac tissue (Ruehr et al. 2004). However, although the 
molecular composition of AKAP-bound signal transduction units have been greatly dissected and discovered, the 
understanding of the biological functions that they mediate is still only in its infancy. The next challenge, in 
addition to identifying novel AKAPs, will be the investigation of the specific functional roles of all those 
AKAPs in physiological processes (Carlisle Michel et al., 2002).  
 
1.4. A PREVIOUS STUDY REVEALED A POSSIBLE NEW AKAP  
While investigating the interactions of cMyBPC, our laboratory identified a potential new AKAP. As the 
interactions of the N-terminal region of cMyBPC under its various phosphorylation states appear to be integral to 
the regulatory role of cMyBPC in contractility, a series of yeast-two-hybrid (Y2H) library screens using various 
phosphorylation-mimics of the C1-C2 region of this protein as bait has been performed in our laboratory. In 
particular, to gain further insight into the interactions of the trisphosphorylated form of the N-terminal region of 
cMyBPC, a construct of domains C1-C2 was used as bait in a Y2H cardiac library screen in which the serines in 
the three phosphorylation sites of the MyBPC motif had been replaced by glutamic acids (PPP). As a result of 
this screen, three of 19 putative interactors of PPP were identified as isoform 4 of phosphodiesterase 4D 
interacting protein (PDE4DIP), also known as myomegalin (Verde et al., 2001, A.Ramburan, PhD thesis). The 
same study also identified myomegalin isoform 4 as an interactor of unphosphorylated cMyBPC (A.Ramburan, 
PhD thesis).  
 
As mentioned previously (Section 1.3.5), PDE4D is a phosphodiesterase specifically responsible for hydrolyzing 
cAMP, the second messenger molecule which activates PKA (Beltman et al., 1993). The fact that in some cases, 
an AKAP anchors both PKA and a phosphodiesterase to the PKA-target (Fink et al., 2001), made the finding of 
interaction between cMyBPC, a PKA-target, and an isoform of a phosphodiesterase-interacting protein 
particularly intriguing. Although it is known that myomegalin anchors PDE4D (Verde et al., 2001), it is not 
known whether myomegalin is also an AKAP, nor whether it binds to other PKA-targets. Although a CaMK has 
been found to co-purify with cMyBPC (Gautel et al., 1995, Schlender and Bean, 1991), the mechanism of PKA 
anchoring to cMyBPC has never been described; yet it is plausible that close compartmentalization of PKA to 
the sarcomere would be crucial to regulate phosphorylation of this protein and cTNI in the control of the 
response of cardiac contractility to adrenergic stimulation. Furthermore, it has also been shown that co-
compartmentalization of both PKA and PDE4D is crucial for maintaining contractility in muscle, because the 
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disruption of AKAP-mediated PKA anchoring had detrimental effects on cardiomyocyte contractility following 
adrenergic stimulation (Fink et al., 2001). 
 
The findings related above led us to question whether myomegalin is an AKAP, and if so, whether it targets 
PKA specifically to cMyBPC in cardiomyocytes, or to other PKA-targets as well. Furthermore, because of the 
role of cMyBPC phosphorylation in the regulation of cardiac contractility, and because of the effect of disruption 
of AKAP-mediated PKA on contractility, we speculated that myomegalin may be involved in regulating cardiac 
contractility, as schematically indicated in Figure 1.11. 
 
The focus will now turn to PDE4D, the protein with which myomegalin (also known as phosphodiesterase 4D 
interacting protein/ PDE4DIP) is known to directly interact. A literature study of myomegalin itself will then 
follow. 
 
1.4.1. Myocardial phosphodiesterases 
As mentioned previously (Section 1.3.3), in the heart, two main mechanisms contribute to the increase of the 
local level of cAMP. Firstly, the membrane-bound enzyme adenylyl cyclase stimulates cAMP production by 
converting ATP to cAMP. Secondly, cAMP degradation by myocardial phosphodiesterases is slowed down by 
inhibition through enzymes that eliminate cAMP by its conversion to 5’AMP. Both of these processes result in 
an increase in intracellular cAMP concentration, which stimulates myocardial effects such as increased cardiac 
contraction. In contrast, the function of phosphodiesterases (PDEs) is to hydrolyze cAMP, lowering the 
intracellular concentration. 
 
 
Figure 1.11. Myomegalin interacts with PDE4D (Verde et al., 2001), and with un- and trisphosphorylated 
cMyBPC (A. Ramburan, PhD thesis), opening the possibility that it might act as AKAP anchoring PKA to the 
MyBPC motif. 
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Currently, at least eleven PDE subfamilies are known, which includes 20 genes and approximately 50 enzyme 
isoforms. These isoforms are all identified based on primary amino acid sequence as well as regulatory and 
kinetic properties (Beavo 1995, Conti et al., 1995). PDEs are polypeptides that contain C-terminal catalytic 
domains of approximately 270 amino acid residues. These C-terminal catalytic domains are indistinguishable in 
about 20-25% of the isozymes belonging to different subfamilies. The N-terminal regulatory domains are, 
however, unique in amino acid sequence in each PDE subfamily. This domain contains binding sites for specific 
regulators of isoenzyme activity such as Ca
2+
/calmodulin, cGMP and synthetic PDE inhibitors, plus 
phosphorylation sites that are targeted by protein kinases, as well as membrane-associated domains that anchors 
PDE isoenzymes to particular subcellular compartments (Osadchii 2007). 
 
In human myocardial tissue, four different PDE isoforms are present viz. PDE1, PDE2, PDE3 and PDE4. 
Although most PDE cAMP-hydrolyzing activity (69%) is present in the cytosol, activity has also been found in 
the microsomal fractions (i.e. membrane-bound PDEs attached to sarcolemma, T tubule, mitochondria and 
sarcoplasmic reticulum) and cardiac myocyte nuclei (Ahluwalia et al., 1984, Lugnier et al., 1999). All four 
isoforms were found to be present in the cytosolic fraction, with only PDE3 and PDE4 present in the microsomal 
fraction. Lugnier et al. suggested different subcellular localizations for cardiac microsomal PDE3 and PDE4, 
with PDE3 associated with T tubule and sarcoplasmic reticulum areas, and PDE4 targeted to the sarcolemma 
(Lugnier et al., 1993). 
 
When the N-terminal serine amino acid residues (usually Ser54) in PDEs are phosphorylated by various protein 
kinases, the cAMP-hydrolyzing activity of myocardial PDEs is increased by two to three times (Harrison et al., 
1986, Beltman et al., 1993, Sette and Conti 1996). The aforementioned negative feedback loop (Section 1.3.5.1) 
between cAMP-dependent PKA that activates PDE, which again hydrolyzes cAMP, aims to limit 
subsarcolemmal cAMP accumulation in cardiomyocytes after β-adrenergic stimulation. In a study by Rochais et 
al., cAMP-gated channels was used as cAMP sensors; the study showed that an increase in PDE3 and PDE4 
activity occurs through cAMP-dependent PKA phosphorylation of the PDEs following β-adrenergic stimulation 
or via direct adenylyl cyclase activation by the drug forskolin (Rochais et al., 2004). The study also showed that 
the inhibition of PKA results in an increased β-adrenergic-mediated cAMP accumulation in rat cardiomyocytes. 
This effect is due to the lack of PKA-mediated phosphorylation of PDE3 and PDE4 (Rochais et al., 2004). 
 
1.4.2. Phosphodiesterase 4 (PDE4) 
PDE4 is a cAMP-specific, cGMP-independent isoenzyme, with a cAMP Km value of about 25 times lower than 
cGMP Km values in human ventricular tissue (Reeves et al., 1987). Furthermore, Fougier et al. showed that, in 
rat cardiomyocytes, the value for soluble PDE4 cAMP Vmax was 5 to 10 times higher than cGMP Vmax (Fougier 
et al., 1986). Thus, it is clear that PDE4 has a very high cAMP substrate-specificity. 
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Although 90% of the total cAMP-hydrolyzing activity is provided by the PDE3 and PDE4 isoenzymes (Kostic et 
al., 1997), it is still not agreed upon which of these myocardial enzymes plays the most important role in cAMP 
hydrolysis and therefore, in regulation of cardiac contractility. Recent studies, however, showed that PDE4, 
rather than PDE3, plays a more pivotal role in cardiomyocyte contraction. Specifically, the duration and 
amplitude of the cAMP transient in heart cells was shown to be more efficiently increased by PDE4 inhibitors 
than PDE3 inhibitors, both under resting conditions and after β-adrenergic agonist exposure (Mongillo et al., 
2004, Nikolaev et al., 2006). Moreover, in a study using rat hearts, it was found that the selective PDE4 
inhibitors rolipram and Ro 20-1724 were more effective than IBMX, a non-selective inhibitor of all four PDE 
isoenzymes, in increasing isoproterenol-induced cAMP accumulation in ventricular myocytes (Katano and Endo, 
1992). Furthermore, immunocytochemical studies by Mongillo et al. showed that PDE3A and PDE4D have 
discrete subcellular localizations in rat heart cells. It was found that PDE3A was targeted to internal membranes, 
whereas PDE4D was generally anchored to sarcomeric structures. 
 
The PDE4 subfamily is made up of four genes viz. PDE4A, PDE4B, PDE4C and PDE4D. These genes encode 
eighteen different isoforms of the PDE4 enzyme. In rat cardiac myocytes, PDE4D and PDE4B provide 90% of 
the total cAMP-hydrolyzing activity, while PDE4A and PDE4C only provide 10%. The cAMP-hydrolyzing 
activity of PDE4D is also double that of PDE4B (Kostic et al., 1997).  
 
PDE4 activity is regulated by PKA-mediated phosphorylation. In the case of the splice variant PDE4D3, PKA 
phosphorylation on Ser54 contributes to a considerable increase of the enzyme’s cAMP-hydrolyzing activity. 
Interestingly, PKA-mediated phosphorylation of Ser13 on PDE4D3 promotes binding of the phosphodiesterase 
to mAKAP (Section 1.3.5.1), which, as already mentioned, is a scaffolding and adaptor protein that anchors 
PDE4D to distinct subcellular compartments (Carlisle Michel et al., 2004). Thus, PKA-mediated 
phosphorylation of two different serine sites in the same phosphodiesterase cause two distinct effects, the first 
being increased hydrolysis of cAMP, and the second being facilitation of the binding of the PDE to an anchoring 
protein. This latter effect causes localized PDE activity, and mediates the more rapid attenuation of local 
intracellular cAMP signals, induced by β-adrenergic stimulation. 
 
PDE4D proved to be the most commonly expressed isoenzyme in rat (Richter et al., 2005) and mice (Lehnart et 
al., 2005) myocardial tissue. While Okruhlicova et al. showed that much of PDE4 is localized to the sarcolemma 
of cardiac myocytes in rats (Okruhlicova et al., 1996), the PDE4D isoenzyme is localized to the Z-line of the 
sarcomere (Mongillo et al., 2004). This strongly suggests that PDE4D is involved in the regulation of cardiac 
muscle contraction.  
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Splice variants of PDE4D that occurs in the heart was found to be PDE4D3, PDE4D8 and PDE4D9 (Lehnart et 
al., 2005), with the PDE4D3 splice variant identified as an integral part of the ryanodine receptor 
macromolecular complex in murine and human hearts. Rat myomegalin, which shares domain structure with 
myomegalin isoform 4 (Section 1.4), was shown to interact with PDE4D3 (Verde et al., 2001).  
 
Studies have shown that variants that are derived from the PDE4D gene may be particulate or soluble, depending 
on the amino terminus that is present in the protein (Bolger et al., 1997, Jin et al., 1998). Immunofluorescence 
studies have also shown that PDE4D variants are located in different subcellular compartments. In a study by Jin 
et al., two PDE variants (PDE4D3 and PDE4D4) with long amino termini were found to be co-localized to a 
perinuclear region which corresponds to centrosomal inner or Golgi structures, as well as to the membrane 
cortical region. In contrast, PDE4D2, whose expression is cAMP dependent, is recovered mostly in soluble 
fraction (Jin et al., 1998). PDE4D has also displayed localization in discrete subcellular structures in 
macrophages (Pryzwansky et al., 1998). All of these findings suggested that the subcellular localization of 
PDE4D is delicately controlled, and that this localization may be dynamically regulated during cAMP signaling 
(Verde et al., 2001). 
 
In animal models of cardiac disease, cardiac contractility is significantly attenuated in response to PDE 
inhibitors. This may be related to the fact that PDE inhibitors cause a noteworthy decreased cAMP elevation. 
This results in reduced cAMP-PKA-mediated phosphorylation of the proteins troponin I, phospholamban and 
cMyBPC in failing hearts (Bartel et al., 1996, Gilbert et al., 1995). 
 
As already mentioned in Section 1.3.4, in cardiac myocytes, scaffolding proteins such as myomegalin (Verde et 
al., 2001), mAKAP (Dodge-Kafka et al., 2005) and β-arrestins (Baillie et al., 2003) facilitate targeting of PDEs 
to specific subcellular locations, and hence, compartmentalized cAMP degradation. By targeting PDEs to 
particular subcellular locations and structures, the state of cAMP-dependent activation of local PKA pools can be 
controlled. Modification of the extent of PKA-mediated phosphorylation of various substrate proteins can 
therefore take place. Myomegalin or phosphodiesterase 4D-interacting protein is a scaffolding protein highly 
expressed in heart and skeletal cells. When cardiac cells were double stained with myomegalin-specific and 
PDE4D-specific antibodies, a co-localization was revealed between the two proteins in the sarcoplasmic 
reticulum region as well as the Z region of the sarcomere (Verde et al., 2001). Furthermore, myomegalin was 
identified as a ligand of the un- and trisphosphorylated mimic of cMyBPC, a C-zone sarcomeric protein, in the 
study that led up to the present study, and will now be discussed further. 
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1.4.3. Myomegalin (aka phosphodiesterase 4D interacting protein/PDE4DIP) 
Only recently has it been realized that scaffold proteins play a necessary and often indispensable role in signal 
transduction. Scaffold proteins normally have no enzymatic activity, and function solely by bringing together 
different signaling molecules. Several PDE isoforms have been recovered in the particulate bound fraction of 
homogenates, and some have been immunolocalized to various cellular compartments (Conti et al., 1995, 
Houslay and Adams, 2003), suggesting interactions with scaffolding proteins. 
 
Verde et al. set off to understand the mechanism of PDE4 subcellular targeting (see previous section) by 
identifying proteins that interact with PDE4D variants and anchor it to various organelles. They identified a 
novel protein, called myomegalin, that interacts with PDE4D, thereby targeting PDE4D to particulate structures 
(Verde et al. in 2001). 
 
The official name of this protein in Homo sapiens is phosphodiesterase 4D interacting protein (PDE4DIP), with 
aliases myomegalin (MMGL) and cardiomyopathy-associated protein 2 (CMYA2) 
(http://www.ncbi.nlm.nih.gov/gene/9659). The protein is encoded by the gene PDE4DIP (GeneID 9659) and 
results in five protein isoforms due to alternative splicing, designated MMGL isoforms 1- 5. As mentioned in 
Section 1.4, a previous study identified MMGL isoform 4 as an interactor of un- and trisphosphorylated 
cMyBPC (A. Ramburan, PhD thesis). This isoform encodes a protein of 173 amino acids and is the smallest 
MMGL isoform in humans, and shares a conserved microtubule-associated domain with isoforms 1, 2 and 3, but 
not 5 (http://www.ncbi.nlm.nih.gov/). Figure 1.12 shows the exonic structure and conserved domains of the five 
different MMGL isoforms in relation to each other. 
 
MMGL is expressed predominantly in heart and skeletal muscle cells; however, human MMGL has not been 
extensively studied; most studies to date were done on rat myomegalin, the first ortholog of this protein to be 
found.  
 
Verde et al. found that there are at least four different transcripts of rat myomegalin; it was suggested, after RT-
PCR analyses, that the presence of the four different transcripts is the result of alternative splicing of the mRNA 
derived from the rat Pde4dip gene (Verde et al., 2001). Abundant transcripts of 7.5 - 8 kb were found in the 
heart and skeletal muscle which contained the entire open reading frame (ORF) of rat myomegalin. These 
transcripts were also detected in small amounts in the lung, liver and brain. Two shorter transcripts were also 
detected: a 5.9 kb transcript in the heart, and a 2.5 kb transcript in the testis. Another transcript of about 4.3 kb 
was detected in skeletal muscle only.  
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Figure 1.12. MMGL isoform and conserved domain structure in Homo sapiens. Exons not drawn to scale in 
relation to nucleotide size. Image produced from http://www.ensembl.org and http://www.ncbi.nlm.nih.gov 
 
Full length rat myomegalin consists of 2324 amino acids with a calculated molecular mass of 262 kDa, whereas 
in humans, the biggest isoform, viz. MMGL isoform 1 consists out of 2346 amino acids. This isoform shares 
77% homology with rat myomegalin, including conservation of domains (Verde et al., 2001, 
http://www.ncbi.nlm.nih.gov/BLAST). Using computer-assisted predictions, the secondary structure was found 
to consist mainly of coiled-coil and α-helical domains, as well as a 20% identity to MHC, although no ATP-
binding domain sequences similar to MHC could be identified. Full-length rat myomegalin, which is very 
similar to human MMGL isoform 1, contains a putative leucine zipper at the amino terminus between residues 8 
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and 31, as well as domains that are shared with microtubule-associated proteins, and an uncharged proline rich 
region at the COOH-terminal region. Rat myomegalin also contains a helix-loop-helix domain between amino 
acids 1079 and 1094. This domain is homologous to regions found in a human cytoplasmic linker protein called 
CLIP-170, as well as rat dynein associated polypeptide (DAP)-150. CLIP-170 functions by binding microtubules 
and is involved in the processes of endocytosis and organelle transport, whereas the function of DAP-150 is still 
widely unknown (Pierre et al., 1992, Holzbaur et al., 1991). 
 
It was found that rat myomegalin binds tightly to particulate structures, and immunocytochemistry was used to 
further establish the localization of the protein in transfected COS-7 cells. It was determined that rat myomegalin 
is localized to an inner Golgi/centrosome region, as had also been shown for PDE4D (Jin et al., 1998). 
Furthermore, in skeletal muscle and heart cells, these two proteins were found to co-localize in the same 
myofiber region, viz. either to the Z band region between sarcomeres, or the sarcoplasmic reticulum.  
Interestingly, numerous other cAMP-signal transduction proteins also localized to these regions (i.e. Z region 
and sarcoplasmic reticulum) speculated for rat myomegalin: these proteins include L channels, adenylyl cyclase 
and the regulatory subunit of PKA (Gao et al., 1997, Yang et al., 1998). Verde et al. therefore concluded that it 
is possible for myomegalin, in rats and humans, to function by anchoring PDE4D to a specific site where 
signaling cascades takes place in muscle cells. cAMP-regulated phosphorylations, as well as the control of PKA-
activation state may be mediated through PDE4D localization via myomegalin (Verde et al., 2001). 
 
PDE4D deletion mutagenesis studies further showed that rat myomegalin and PDE4D interact via a domain that 
corresponds to the amino terminus of an upstream conserved region 2 (UCR2) of PDE4D, however the region of 
myomegalin involved in this interaction was not defined. This UCR2 domain of PDE4 consists of a region of α-
helical structure with charges being amphipathically distributed. Myomegalin’s C-terminus also contains α-
helical domains, and this may mediate its interaction with PDEs. However, the UCR2 domain is conserved in all 
forms of PDE4, raising the possibility that other PDE4s could also interact with myomegalin. However, co-
immunoprecipitation studies showed that not all PDE variants interact with myomegalin: although PDE4D1 and 
PDE4D3 interact with myomegalin, PDE4D2 does not (Verde et al., 2001). 
 
It is still unknown whether interaction with myomegalin alters the PDE’s catalytic activity. The N-terminal 
domain of PDE4D is involved in intramolecular interactions and functions as an autoinhibitory domain which 
regulates the catalytic activity of PDE4D, and it has been reported that phosphorylation alters the interaction of 
this PDE4D domain with its N-terminus, at least in PDE4D3 (Lim et al., 1999). It is therefore possible that 
phosphorylation, which involves the N-terminus of PDE4D may affect its ability to bind to myomegalin via this 
domain. Furthermore, studies have indicated that PDE4D3 may translocate when activated by the mitogen 
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activated protein kinase pathway (Liu et al., 1999). It is therefore possible that the PDE4D-myomegalin 
interaction may be a dynamic process, and that, during signaling, translocation may occur (Verde et al., 2001). 
 
Both rat and human myomegalin have an extensive coiled-coil composition, and this makes it very likely that it 
either oligomerizes with itself, or binds to other proteins. Also consistent with this conclusion is the fact that it 
contains a leucine zipper domain, which is known to facilitate protein-protein interactions. Verde et al. therefore 
concluded that myomegalin may interact with other proteins as well, in addition to PDE4D. MMGL isoform 4, 
of particular interest to this study, also contains a leucine zipper domain and has a coiled-coil composition, 
making the possibility of this isoform interacting with other proteins very likely. 
 
In an independent study by Soejima et al., the BodyMap database, a human and mouse gene expression 
database, was used to establish that the gene encoding myomegalin in humans consists of 8 exons within a 
genomic sequence of over 70 kB. They named this gene myomegalin-like (MMGL), and found that it resulted in 
four alternatively spliced transcripts (Soejima et al., 2001). The gene was strongly expressed in skeletal muscle 
and the heart, and with faint expression in the brain and placenta. MMGL was mapped to chromosome position 
1q1 by radiation hybrid mapping as well as FISH with BAC clones, which placed in within dilated 
cardiomyopathy (DCM) candidate loci (Soejima et al., 2001).The study showed that the subcellular localization 
for MMGL-expressed protein is in the cytoplasm and nucleus. A high level of homology (~80%) was showed 
between MMGL and rat myomegalin proteins (Soejima et al., 2001). Interestingly, MMGL isoform 4 consists of 
173 aa and is identical to the first 173 aa of transcript variant 1 described by Soejima et al. Because rat 
myomegalin is predicted to be a cyclic nucleotide phosphodiesterase interacting protein (Verde et al., 2001), it 
was suggested that in humans, MMGL may play a role in PDE signal transduction, as well as cardiac 
development (Soejima et al., 2001). 
 
It is now recognized that human MMGL/PDE4DIP is encoded by PDE4DIP, located on chromosome 1q1, and 
results in five different isoforms due to alternative spicing, as shown in Figure 1.12.  
 
1.5. STUDY HYPOTHESIS AND AIM 
As described in Section 1.4, MMGL isoform 4 was identified as a ligand of the un- and trisphosphorylated 
mimic of cMyBPC, a protein which is one of the two most commonly implicated in HCM when its 
corresponding gene is mutated. As can be concluded from the above literature study on MMGL, not much light 
has been shed on MMGL’s function in the cell. Because of MMGL’s evident interaction with cMyBPC, a 
regulator of sarcomeric contractility, it was important to elucidate the function of this rather unfamiliar protein. 
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The interaction between cMyBPC, a PKA target, and a phosphodiesterase-interacting protein is particularly 
intriguing in light of the fact that in some cases an AKAP anchors both PKA and PDE4D (Dodge-Kafka et al., 
2005). The mechanism of PKA anchoring to cMyBPC has not been elucidated, and although it is known that 
MMGL anchors PDE4D (Verde et al., 2001), it was also not known whether MMGL acts as an AKAP, nor 
whether it binds to other PKA-targets. Moreover, it remained unknown which AKAPs are responsible for the 
phosphorylation of sarcomeric proteins (Dodge-Kafka et al., 2006). Furthermore, it has also been shown that co-
compartmentalization of both PKA and PDE4D is crucial for maintaining contractility in muscle, because the 
disruption of AKAP-mediated PKA anchoring had detrimental effects on cardiomyocyte contractility following 
adrenergic stimulation (Fink et al., 2001). 
 
The findings related above led us to hypothesize that MMGL is an AKAP, and that it might also target PKA to 
other sarcomeric proteins. Furthermore, because of the role of cMyBPC phosphorylation in the regulation of 
cardiac contractility, and because of the effect of disruption of AKAP-mediated PKA on contractility, we 
speculated that MMGL may be involved in regulating cardiac contractility, and as such may influence cardiac 
hypertrophy development.  
 
We therefore proposed to determine whether MMGL isoform 4 acts as an anchoring protein for the regulatory 
subunits of PKA, thereby establishing whether MMGL acts as an AKAP. Secondly, we proposed to discover 
other ligands of MMGL by means of Y2H library screening, and to establish whether these are also known 
PKA-targets. Additionaly, we proposed to investigate the effect of adrenergic stimulation of the binding of 
MMGL to particular sarcomeric proteins, including cMyBPC and other sarcomeric proteins, should they be 
identified. We also aimed to investigate the effect of siRNA-mediated knockdown of MMGL on expression of 
the different phosphorylation isoforms of cMyBPC in the context of adrenergic stimulation. Lastly, because of 
the crucial role of dynamic phosphorylation of cMyBPC in normal cardiac contractility, and the fact that 
mutations in the corresponding gene leads to HCM, we aimed to assess whether variants in the genes encoding 
MMGL and both of the PKA regulatory subunits may act as genetic modifiers of hypertrophy.  
 
1.6. RESULTS FROM THE PRESENT STUDY 
1.6.1. MMGL binds to PKA regulatory subunits 
As the primary characteristic of an AKAP is the ability to bind at least PKA regulatory subunit, we investigated 
the possibility that MMGL functions as an AKAP by using Y2H direct protein-protein interaction assays to 
determine binding between MMGL and the two cardiac-expressed regulatory subunits of PKA. Both regulatory 
subunits (PRKAR1A and PRKAR2A) interacted with MMGL, as assessed by growth and light colour of the 
colonies on quadruple dropout nutritional selection medium, compared to relevant controls. Using in vivo 
colocalization with 3D-fluorescence microscopy, we also demonstrated that MMGL isoform 4 occurs in the 
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same 3D-subcellular region as the two PKA regulatory isoforms in H9C2 cardiomyocytes. To further verify 
physical interaction between MMGL and these PKA isoforms in a cellular context and in the absence of GAL4 
domains, we performed pull-down assays in diffentiated H9C2 cardiomyocytes. As commercial antibodies 
against MMGL/PDE4DIP did not detect isoform 4, which is the smallest isoform of this protein, we used an 
antibody directed against the fluorescent protein dsRed to detect a dsRed-fusion of MMGL isoform 4. In this 
way, endogenous PRKAR1A and PRKAR2A were shown to immunoprecipitate dsRed-MMGL, and vice versa.  
 
1.6.2. MMGL binds to additional PKA targets 
We also further investigated the function of MMGL isoform 4 by using it as Y2H bait to screen a cardiac cDNA 
library in order to identify its additional binding partners. Thirteen in-frame putative MMGL-interactors that 
activated all three nutritional reporter genes in the presence of the MMGL bait, but not in the presence of 
heterologous baits were, identified. Proteins with defined vesicular localizations were not considered of primary 
interest for follow-up in this study; these included the mitochondrial protein COX5A, the proteosome 26S 
subunit and sorting nexin 3. Of the remaining ten putative MMGL interactors, six encoded the sarcomeric 
protein, cardiac troponin I (cTNI). Further support for the validity of these interactions was provided by finding 
that MMGL occurs in the same 3D-subcellular region as all five of the putative interactors identified in the Y2H 
library screen, viz. CARP, COMMD4, ENO1, ENO3 and cTNI, in differentiated cardiomyocytes.  
 
Moreover, in pull-down assays, exogenous fluorescently-tagged MMGL and endogenous ENO1, ENO3, CARP, 
and cTNI reciprocally co-precipitated each other. As COMMD4 had a similar mobility to antibody light chains, 
which interfered with detection of these proteins in Western blots, a GFP-tagged fusion of this protein was 
expressed in H9C2 cells for pull-down assays. In these assays, exogenous GFP-COMMD4 immunoprecipiated 
exogenous dsRed-MMGL, and vice versa. 
 
1.6.3. Colocalization between MMGL and sarcomeric proteins cTNI and cMyBPC increases upon 
adrenergic stress 
cTNI is a known PKA target (Patel et al., 2001), while the remaining four putative interactors were shown to be 
likely PKA targets using Phosphomotif Finder (www.hprd.org/PhosphoMotif_finder); we therefore investigated 
the effect of isoproterenol stimulation of the H9C2 cells on colocalization, using the most frequent, and clearly 
sarcomeric, interactor, viz. cTNI, as example. Treating H9C2 cells transfected with dsRed-MMGL/GFP-cTNI 
with isoproterenol resulted in an increase in 3D colocalization between these two proteins, compared to non-
treated cells. Similar results were obtained with GFP-cMyBPC and dsRed-MMGL colocalization, implicating 
that PKA is dynamically recruited by MMGL to distinct sarcomeric locations to mediate cardiac stress 
responses, leading to increased cardiac contraction. 
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1.6.4. Effect of MMGL knockdown  
In order to evaluate the role of MMGL in cMyBPC phosphorylation, we assessed the expression of the different 
phosphorylation isoforms of cMyBPC, in the presence of adrenergic stimulation, in the context of siRNA-
mediated MMGL knockdown.  
 
Using Western blots of 2-dimensional isoelectric focusing (IEF) gels, we found that similar amounts of the 
mono- and diphosphorylated forms of cMyBPC are expressed in untreated H9C2 cells, while lesser amounts of 
the un- and trisphosphorylated forms, relative to the other isoforms, were present. When these cells were 
exposed to increased CaCl2 and isoproterenol, to activate CaMK and PKA such that maximum phosphorylation 
of the MyBPC-motif is likely (McClellan et al., 2001), the relative amount of the trisphosphorylated form 
increased markedly, while the relative amount of unphosphorylated cMyBPC decreased. However, similar 
adrenergic stimulation in the presence of MMGL knockdown resulted in markedly reduced expression of all 
isoforms. 
 
1.7. SNP MODIFIER GENOTYPING STUDY 
It is observed that in many single gene disorders, particularly autosomal dominant disorders, the phenotype is 
affected by genetic factors other than the causal mutations (Marian 2002). This “genetic background” is often 
referred to as modifier genes. Modifier genes differ between individuals due to polymorphisms in the DNA. The 
modifier genes are neither necessary nor sufficient to cause the disease, but will affect the severity of the final 
phenotype (Alcalai et al., 2008). It can therefore be said that the final phenotype will be the result of interactions 
between the causal mutations, the modifier genes and the environment. (Marian 2002). 
 
In HCM, the primary mutation genotype is clearly not the only reason for the variability of the hypertrophic 
phenotype. Through genotype-phenotype correlations, it is commonly seen that in any given family, individuals 
who carry the same HCM mutations have different amounts of hypertrophy, with some patients severely affected 
(i.e. showed marked ventricular hypertrophy) whereas others are more mildly affected, and yet others showed 
normal gross heart structure (Fananapazir and Epstein, 1994, Epstein et al., 1992, Solomon et al., 1993, Marian 
et al., 1995). These differences in hypertrophy are not consistently explained by differences in other factors 
which can also influence hypertrophy, such as age, sex, blood pressure or sporting activity. In HCM it is now 
recognized that although the hypertrophic phenotype is determined to some extent by the causal mutations, it is 
also markedly influenced by the effect of other modifier genes and the environment (Marian 2002). HCM, 
previously considered as a classic example of a “monogenic” cardiac disorder, is therefore, in a sense, not purely 
monogenic, because its phenotype is affected by the expression of multiple genes (Marian 2001). 
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Concluding from our results that MMGL acts as the AKAP anchoring PKA to the MyBPC motif, which leads to 
phosphorylation of cMyBPC and hence, increased cardiac contractility, we hypothesized that MMGL and the 
two regulatory PKA subunits may be involved in the regulation of cardiac contractility, and that variation in the 
genes which encode these proteins, viz. PDE4DIP, PRKAR1A and PRKAR2A, may influence hypertrophy 
development together with the causal mutations. We therefore assessed SNP variants in the genes encoding for 
MMGL and the two cardiac-expressed regulatory subunits of PKA as modifiers of hypertrophy, because of their 
direct involvement in cMyBPC phosphorylation, and, ultimately, cardiac contractility. 
 
PDE4DIP, PRKAR1A and PRKAR2A were prioritised as candidate hypertrophy modifier genes, based on their 
role in altered sarcomeric contractility. In these three genes, intragenic SNP polymorphisms spread throughout 
the genes were selected for use in association studies in order to capture the spectrum of genetic variation within 
these candidate genes. Informative SNPs deposited in public domain databases (NCBI, Genecards and 
HAPMAP) were selected and prioritised according to high heterozygosity values in the CEU and YRI 
populations, validation status and potential functional significance of the variant. Validated ABI TaqMan® 
genotyping assays were subsequently used to perform high throughput genotyping in three cohorts of 
comprehensively phenotyped South African HCM families in which one of three founder mutations segregate. 
 
Quantitative measures of the hypertrophic phenotype, viz left ventricular mass, maximal interventricular septum 
thickness and maximal posterior wall thickness were then analyzed with a family-based statistical method using 
quantitative transmission disequilibrium testing (QTDT) to assess association of these gene variants with 
hypertrophy development. 
 
It was found that one SNP in PDE4DIP (rs1664005), which was in LD with other SNPs in the study population, 
showed significant association with most of the hypertrophy traits that were analysed. Two SNPs in PRKAR1A 
(rs11651687 and rs3785906) also showed association with some hypertrophy traits. This study therefore 
suggests that PDE4DIP and PRKAR1A may modulate the extent of cardiac hypertrophy, and therefore act as 
modifier genes because of their role in regulation of cardiac contractility. 
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CHAPTER 2:  MATERIALS AND METHODS 
PART ONE: PROTEIN INTERACTION STUDY 
 
2.1. DNA EXTRACTION 
2.1.1. Bacterial plasmid purification using Fermentas Plasmid Preparation kit 
Escherichia coli (E. coli) colonies containing plasmids of interest were picked from the appropriate selection 
plates, and, together with the correct antibiotic, inoculated in 10ml of Luria-Bertani (LB) media (Appendix I) in 
a 50ml polypropylene tube. The culture was subsequently incubated at 37°C shaking at 250rpm overnight in a 
YIH DER model LM-530 shaking incubator (SCILAB Instrument Co. Ltd., Taipei, Taiwan). 
 
Following the incubation period, the culture was centrifuged for 10min at 3000rpm in a Beckman model TJ-6 
centrifuge (Beckman Coulter, Scotland, U.K.), after which the supernatant was discarded. The plasmid DNA 
was subsequently extracted using the Fermentas Plasmid Preparation kit (Fermentas Life Sciences, USA) as per 
manufacturer’s instructions. Afterwards, 3µl of this purified plasmid was resolved on a 1% SB agarose gel 
(Appendix I) for verification (Section 2.3.1). 
 
2.1.2. Bacterial plasmid purification using Wizard® Purefection Midi Plasmid DNA purification kit 
In order to isolate plasmid DNA free of endotoxins, which was subsequently used to transfect H9C2 cells for in 
vivo co-localization (Section 2.17) and in vivo co-immunoprecipitation assays (Section 2.15), the Wizard® 
Purefection Midi Plasmid DNA purification kit (Wizard® Purefection Midi Plasmid DNA purification kit, 
Promega Corp. Madison Wisconsin, USA) was used.  
 
Using 50ml polypropylene tubes, 20µl of a bacterial glycerol stock, of the appropriate vector, was inoculated 
into 10ml LB media (containing the appropriate antibiotic) and incubated at 37°C shaking at 250rpm overnight 
in a YIH DER model LM-530 shaking incubator. Following this incubation period, the cultures were centrifuged 
for 10min at 3000rpm in a Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, U.K.), after which the 
supernatant was discarded and the plasmid DNA extracted using the Wizard® kit, according to the 
manufacturer’s instructions. The DNA was resuspended in 50µl sterile water after extraction and the 
concentration visually determined by resolving an aliquot of the DNA on a 1% SB agarose gel (Appendix I) 
(Section 2.3.1). 
 
2.1.3. Yeast plasmid purification 
Yeast cells containing the plasmid of interest were inoculated in 1ml synthetic dropout (SD) medium containing 
the correct dropout supplement (BD Bioscience, Clontech, Paulo Alto, CA, U.S.A.). The cells were then 
incubated overnight at 30°C in a shaking incubator, shaking at 250rpm. After this inoculation period, 4ml YPDA 
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media (a blend of yeast extract, peptone and dextrose supplemented with adenine) (Appendix I) was added to the 
cell culture. An additional incubation period of 4h at 30°C, shaking at 250rpm, then followed.  Thereafter, the 
cell culture was centrifuged at 3000rpm for 5min in a Beckman model TJ-6 centrifuge (Beckman Coulter, 
Scotland, U.K.) after which the supernatant was discarded by decanting. The pellet was then resuspended in the 
remaining supernatant, and transferred to a 2ml Eppendorf microfuge tube. To the pellet was then added 200µl 
yeast lysis buffer (Appendix I), 200µl PCI and 0.3µg sterile 450-600µm glass beads. The yeast cells were milled 
by vortexing this mixture for 2.5min using a Snijders model 34524 press-to-mix vortex (Snijders Scientific, 
Tilburg, Holland). Centrifugation followed at 14000rpm for 10min at room temperature in an Eppendorf model 
5417C centrifuge (Eppendorf AG, Hamburg, Germany) for phase separation. The aqueous phase was transferred 
to a clean 1.5ml microfuge tube. Purification followed by taking 100µl of the aqueous phase and cleaning it 
using the GFX™ PCR DNA Purification kit (Section 2.1.4). Following purification, the DNA was eluted in 30µl 
sterile water. The eluted product was afterward used to transform DH5α E. coli cells (Section 2.12.1). 
 
2.1.4. DNA purification using the Wizard® Purefection Mini Plasmid DNA purification kit 
The Wizard
®
 Purefection Mini Plasmid DNA purification kit (Wizard
®
 Purefection Mini Plasmid DNA 
purification kit, Promega Corp. Madison Wisconsin, USA)  was used to purify yeast plasmid preparations 
(Section 2.1.3) as well as PCR-amplified DNA products (Section 2.2) according to manufacturer’s instructions. 
The purified products were subsequently used for nucleotide sequencing (Section 2.4) and cloning reactions 
(Section 2.8). 
 
2.2. POLYMERASE CHAIN REACTION  
2.2.1. Oligonucleotide primer design and synthesis 
Oligonucleotide primers were designed using sequence data available from either the Ensembl database 
(http://www.ensembl.org) or the Genbank database (http://www.ncbi.nlm.nih.gov/Entrez). Each set of primer 
sequences were analyzed for self-complimentarity and primer-primer complimentarity, as well as compatibility 
of melting temperatures before synthesis, using DNAMAN™ version 4 software (Lynnion Biosoft Corp©). 
Oligonucleotide primers were synthesized according to standard phosphoramidite methodology at the 
Department of Molecular and Cell Biology, University of Cape Town (UCT), Cape Town, South Africa.  
 
2.2.1.1. Primers for generation of inserts for yeast-two-hybrid cloning 
A primer set was designed to amplify the PDE4DIP cDNA sequence for cloning into the appropriate bait vector, 
containing the appropriate restriction enzyme sites as well as a universal “seat” sequence, to facilitate restriction 
digestion of end fragments. Primers were also designed to amplify the PRKAR1A and PRKAR2A cDNA 
sequences for cloning into the appropriate prey vector, containing restriction enzyme sites as well as universal 
seat sequences. The sequences of the primers used for this part of the study are shown in Table 2.1. 
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Table 2.1. Primer sequences used for generation of inserts for Y2H cloning 
Gene Primer name Primer sequence Ta (°C)  
PDE4DIP MMGL F  ATCGTATCG CATATG ATGTCTAATGGATATCGCAC 51  
 MMGL R  ATCGTATCG GAATTC CTACTTGTCCCTCTGGGC 54  
PRKAR1A R1A F  ATCGTATCG GGATCC ATGGAGTCTGGCAGTACC 52  
 R1A R  ATCGTATCG CTCGAG TCAGACAGACAGTGACAC 45  
PRKAR2A R2A F  ATCGTATCG CCATGG ATGAGCCACATCCAGATC 52  
 R2A R ATCGTATCG GGATCC TGTGGCACACCTACTGCCC 62  
Abbreviations: PDE4DIP, phoshodiesterase 4D interacting protein; PRKAR1A, protein kinase regulatory type I alpha; 
PRKAR2A, protein kinase regulatory type II alpha; Ta, annealing temperature used in PCR; °C, degrees Celcius 
Sequences in black font represents the sequence of the primer that anneals to the DNA in the PCR reaction. The sequence in 
coloured fonts represents sites for cloning: Blue, universal enzyme seat; red, NdeI restriction site; green, EcoRI restriction 
site; orange, BamHI restriction site; pink, XhoI restriction site; brown, NcoI restriction site. 
 
2.2.1.2. Primers for yeast-two-hybrid insert screening 
In order to amplify inserts cloned into Y2H cloning vectors, primers were designed to match vector-specific 
sequences flanking the multiple cloning site (MCS) of pGBKT7 (BD Bioscience, Clontech, Palo Alto, CA, 
U.S.A.) and pACT2 (BD Bioscience, Clontech, Palo Alto, CA, U.S.A.) Y2H cloning vectors. The specific vector 
sequences used in the design of these primers were obtained from the Clontech™ Matchmaker™ vector 
handbook (www.clontech.com). The sequences of these primers are shown in Table 2.2. 
 
Table 2.2. Primer sequences and annealing temperatures used for the amplification of inserts from 
cloning vectors 
Primer name Primer sequence Ta (°C)    
pGBKT7 F TCATCGGAAGAGAGTAG 45    
pGBKT7 R TCACTTTAAAATTTGTATACA 45    
pACT2 F CTATTCGATGATGAAGATACCCCACCAAACC 57    
pACT2 R GTGAACTTGCGGGGTTTTTCAGTATCTACGA 57    
Abbreviations: °C, degrees Celcius; Ta, annealing temperature 
 
2.2.1.3. Primers for generation of inserts for in vivo 3D co-localization cloning 
Primer sets were designed to amplify the ANKRD1, COMMD4, ENO1, ENO3, PRKAR1A and PRKAR2A cDNA 
sequences, respectively, for cloning into the pGFP
2
-C1 fluorescent vector (BD Bioscience, Clontech, Palo Alto, 
CA, U.S.A.). A primer set was also designed to amplify the PDE4DIP cDNA sequence for cloning into the pDs-
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Red-C1 fluorescent cloning vector (BD Bioscience, Clontech, Palo Alto, CA, U.S.A.). All primers were 
designed to contain appropriate restriction enzyme sites, as well as universal seat sequences. The sequences of 
the primers used for this part of the study are shown in Table 2.3. In a previous study done in our laboratory, the 
full-length cDNA sequence of TNNI3 and MYBPC3 was cloned into the pGFP
2
-C1 vector, and these constructs 
were used again for the present study. 
 
2.2.2. PCR conditions 
The following PCR conditions were used to amplify the PDE4DIP cDNA sequence from genomic DNA, as well 
as to amplify the PRKAR1A and PRKAR2A cDNA sequences. The resulting MMGL fragment was subsequently 
cloned into the pGBKT7 Y2H cloning vector as well as the pDs-Red-C1 fluorescent vector, and the PRKA 
fragments were cloned into the pACT2 Y2H cloning vector. 
 
For the amplification of the above-mentioned cDNA sequences, 100ng of normal human genomic DNA was 
used as a template in the reaction performed in a 50µl volume containing 150ng of each primer (Table 2.1 and 
2.3), 1.5µl of an equimolar dNTP (2.5mM of each, dATP, dCTP, dGTP, dTTP) solution, 5µl Taq DNA 
polymerase 10X reaction buffer (Bioline UK Ltd, London, UK), 1.5µl of a 1.5mM MgCl2 solution (Bioline UK 
Ltd, London, UK), 2.5µl DMSO, 1µl Taq DNA polymerase (Bioline UK Ltd, London, UK) and ddH2O to a final 
volume of 50µl. Amplification was performed in a GeneAmp® PCR system 9700 thermal cycler (Perkin-Elmer, 
Applied Biosystems Inc, Foster City CA, U.S.A.) and the conditions are summarized in Table 2.4. 
 
2.2.3. High fidelity PCR 
High fidelity PCR was used to amplify the ANKRD1, COMMD4, ENO1, ENO3, PRKAR1A and PRKAR2A 
cDNA sequences from genomic DNA. The resulting fragments were cloned into the pGFP-C1 fluorescent 
cloning vector. 
 
For amplification, 100ng of normal human genomic DNA was used as a template in the reaction performed in a 
50µl volume containing, 150ng of each primer (Table 2.3), 1.5µl of an equimolar dNTP (2.5mM of each, dATP, 
dCTP, dGTP, dTTP) solution supplied by the manufacturer (TaKaRa Shuzo Co.Ltd, Shiga, Japan), 5µl Ex 
Taq™ Mg2+-containing 10X reaction buffer supplied by the manufacturer (TaKaRa Shuzo Co.Ltd, Shiga, 
Japan), 2U Ex Taq™ (TaKaRa Shuzo Co.Ltd, Shiga, Japan), and ddH2O to a final volume of 50µl. 
Amplification was performed in a GeneAmp® PCR system 9700 thermal cycler (Perkin-Elmer, Applied 
Biosystems Inc, Foster City CA, U.S.A.) and the conditions summarized in Table 2.5. 
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Table 2.3. Primer sequences used for generation of inserts for in vivo 3D co-localization cloning 
Gene Primer 
name 
Primer sequence Ta 
(°C) 
    
ANKRD1 CARP F ATCGTATCG CTCGAG ATGATGGTACTGAAAGTAG 
AGGAACTGG  
62     
 CARP R ATCGTATCG GGATCC TCAGAATGTAGCTATGCGAG 
AGGTC 
62     
COMMD4 COMMD4 
F 
ATCGTATCG CTCGAG ATGAGGTTCCGGTTCTGTGG  61     
 COMMD4 
R 
ATCGTATCG GGATCC TCAGCCCAGG GAGCTCATCAGGG 74     
ENO1 ENO1 F ATCGTATCGGATATCATGTCTATTCTCAAGATCCATGCC 48     
 ENO1 R ATCGTATCGCCGCGGTTGCTTGGCCAAGGGGTTTCTG 48     
ENO3 ENO3 F ATCGTATCG CTCGAG  ATGGCCATGCAGAAAATCTT 
TGCCC  
83     
 ENO3 R ATCGTATCG GGATCC TCACTTGGCCTTCGGGTTAC GG 76     
PDE4DIP dsRed 
MMGL F 
ATCGTATCG GTCGAC ATGTCTAATGGATATCGCAC 51     
 dsRed 
MMGL R 
ATCGTATCG GGATCC CTACTTGTCCCTCTGGGC 54     
PRKAR1A R1A F ATCGTATCG CTCGAG ATGGAGTCTGGCAGTACC 62     
 R1A R ATCGTATCG GGATCC TCAGACAGACAGTGACAG 60     
PRKAR2A R2A F ATCGTATCG CTCGAG ATGAGCCACATCCAGATCCCG 
CCG 
90     
 R2A R ATCGTATCG GGATCC TGTGGCACACCTA CTGCCCGAG 87     
Abbreviations: ANKRD1, ankyrin repeat domain 1; COMMD4, COMM domain containing 4; ENO1, Enolase 1 (alpha) 
ENO3, Enolase 3 (beta, muscle), PDE4DIP, phosphodiesterase 4D interacting protein; PRKAR1A, protein kinase regulatory 
type I alpha; PRKAR2A, protein kinase regulatory type II alpha; Ta, annealing temperature; °C, degrees Celcius. Sequences 
in black font represents the sequence of the primer that anneals to the DNA in the PCR reaction. The sequence in coloured 
fonts represents sites for cloning: Blue, universal enzyme seat; red, XhoI restriction site; green, BamHI restriction site; 
brown, SalI restriction site yellow, EcoRV restriction site; orange, SacII restriction site; purple, BglII restriction site 
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Table 2.4. PCR conditions used to amplify the cDNA sequence of PDE4DIP, PRKAR1A and PRKAR2A 
from genomic DNA 
Primer set [MgCl2] mM TD 
°C 
Time 
sec 
Ta °C Time sec TE °C Time 
Sec 
    
MMGL F/R 1.5 94 30 52 30 72 30     
dsRed-MMGL F/R 1.5 94 30 52 30 72 30     
PRKAR1A F/R 1.5 94 30 46 30 72 120     
PRKAR2A F/R 1.5 94 30 47 30 72 120     
Abbreviations: °C, degrees Celcius; mM, millimolar; sec, seconds; Ta, annealing temperature; TD, denaturing temperature; 
TE, extension temperatute 
 
2.2.4. Bacterial colony PCR 
Bacterial colony PCRs were performed in order to rapidly identify bacterial colonies containing the appropriate 
recombinant plasmid with desired insert. The primers used for generation of inserts for Y2H cloning and vector 
cloning (see Tables 2.1 and 2.3) was then used in conjunction with PCR conditions identical as described in 
Section 2.2.3. An amount of an individual E. coli colony was picked from an agar plate, containing the correct 
selective antibiotic, and used as DNA template, instead of using 100ng of human genomic DNA.  
 
Amplification was performed in a GeneAmp® PCR system 9700 thermal cycler (Perkin-Elmer, Applied 
Biosystems Inc, Foster City CA, U.S.A.). The cycling parameters consisted of a single denaturing cycle of 94°C 
for 5min followed by 30 cycles of 94°C for 30sec, Ta for 30sec and 72°C for 1min. The amplified products were 
subsequently electrophoresed on a 1% agarose gel for verification. 
 
2.3. GEL ELECTROPHORESIS 
2.3.1. Agarose gel electrophoresis 
In the study, agarose gel electrophoresis was used to visualize PCR-amplified fragments or plasmid preparations 
for verification. In order to verify that the PCR amplifications (or plasmid preparations) were successful, the 
products were electrophoresed as follows: 6µl PCR product or plasmid preparation was loaded together with 1µl 
bromophenol blue (Appendix I) loading dye into separate wells of a 1-2% (depending on the size of the product) 
agarose gel. The agarose gel contained 1µg/ml ethidium bromide and 1X SB buffer (Appendix I). A 100bp size 
marker (Promega, Madison WI, U.S.A.) was co-electrophoresed with all amplified PCR products. 
Electrophoresis was performed at 10V/cm for 10min in 1X SB running buffer. After electrophoresis, the DNA 
fragments were visualized on a long wave 3UV trans-illuminator (UVP, Inc. Upland, CA, U.S.A.) and 
photographs were taken using an ITC Polaroid camera and Sony videographic printer (Sony Corporation, 
Shinagawa-ku, Tokyo, Japan). 
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Table 2.5. High fidelity PCR conditions used to amplify the cDNA sequences of the Y2H preys from 
genomic DNA for  cloning into the pGFP-C1 vector for co-localization 
Primer set [MgCl2] 
mM 
TD 
°C 
Time sec Ta °C Time sec TE °C Time 
Sec 
ANKRD 
F/R 
1.5 94 30 62 30 72 30 
COMMD4 
F/R 
1.5 94 30 65 30 72 30 
ENO1 F/R 1.5 94 30  30 72 30 
ENO3 F/R 1.5 94 30 77 30 72 30 
PRKAR1A 
F/R 
1.5 94 30 61 30 72 30 
PRKAR2A 
F/R 
1.5 94 30 88 30 72 30 
Abbreviations: °C, degrees Celcius; mM, millimolar; sec, seconds; Ta, annealing temperature; TD, denaturing temperature; 
TE, extension temperatute 
 
2.3.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to electrophorese protein 
products, derived from in vivo co-immunoprecipitation (Co-IP) reactions (Section 2.15).  
 
For in vivo Co-IPs, the protein products were electrophoresed in 100x80x3mm, 15-20% polyacrylamide gels 
containing 10% SDS (Appendix I). After mixing with 6% SDS loading dye (Appendix I), the samples were 
incubated at 95°C for 5min, and subsequently loaded onto the gels. Electrophoresis followed at 100 V for 1 – 
1.5h in 1X SDS running buffer (Appendix I). Afterwards, the protein samples in the gel were transferred to a 
polyvinylidene fluoride (PVDF) membrane for visualization via Western blotting (Section 2.16). 
 
2.3.3. Transfer of protein from SDS polyacrylamide gels to PVDF membrane 
In order to visualise protein bands of in vivo co-immunoprecipitation assays, western blotting was done by 
transferring the protein samples seperated via SDS-PAGE to a polyvinylidene fluoride (PVDF) membrane (GE 
Healthcare Limited, Amersham Place, Little Chalfont, Buckinghamshire, UK) as follows: Following 
electrophoresis, the gel apparatus was dismantled and the gel rinsed in ddH2O by shaking it for 5min on ice. 
Afterwards, the ddH2O was removed and ice-cold transfer buffer (Appendix I) was added to the gel and the gel 
agitated for 20min. During this period, the PVDF membrane was prepared for transfer by incubating it for 15sec 
in undiluted methanol, followed by a rinse in ddH2O for 5min. After removal of the water, ice-cold transfer 
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buffer was added to the membrane, together with cut pieces of Whatman paper and western blot sponges, and 
shaked for 10min. 
 
The blotting apparatus was then stacked forming a sandwich, with western blot sponges on the outside, followed 
by cut pieces of Whatman paper on the inside, with the gel (on the anode side) and the membrane (on the 
cathode side) in the middle. During stacking, everything was kept soaked with transfer buffer. The sandwiches 
were closed and inserted into the transfer apparatus filled with transfer buffer, together with an ice pack and 
magnet, and placed on a magnetic stirrer and electrophoresed at 100V for 1h. 
 
2.4. AUTOMATED DNA SEQUENCING 
Automated DNA sequencing of cloned inserts was performed at the Core Sequencing Facility of the Department 
of Genetics at the University of Stellenbosch, R.S.A. on an ABI Prism™ 3100 automated sequencer (P.E. 
Applied Biosystems, Forster City, CA, U.S.A.). Vector specific primers (see Table 2.2) as well as primers used 
for the generation of cloning inserts (Tables 2.3 and 2.4) were used for these sequencing reactions. 
 
2.5. DNA SEQUENCING ANALYSIS 
ChromasPro software (Techelysium Pty Lmt, Helensvale, Queensland, Australia) was used for sequence 
analysis. Sequence analysis consisted of verification of the sequence integrity (reading frame and cloning sites) 
of inserts cloned into the respective cloning vectors (Section 2.8), identification of putative interactor prey clones 
isolated during the Y2H library screen (Section 2.14), as well as verification of the integrity of the inserts cloned 
for in vivo co-localisation (Section 2.17) and in vivo co-immunoprecipitation (Section 2.15). The nucleotide 
sequences of the bait and prey inserts as determined by automated sequencing (Section 2.4) were compared to 
the appropriate cDNA and mRNA sequences obtained from the Genbank database 
(www.ncbi.nlm.nih.gov/Entrez) and the Ensembl database (www.ensembl.org). The sequences obtained for the 
Y2H prey constructs through automated sequencing were entered into BLAST and analysed against the Genbank 
database using BLASTN (www.ncbi.nlm.nih.gov/BLAST). To determine whether the prey insert encoded for an 
in-frame protein, the nucleotide sequence of the prey insert sequence in the absence of vector or GAL4 domain 
sequences were translated in DNAMAN and a BLASTP search followed of the translated sequence against 
public protein databases in order to assign identity to them.  
 
2.6. BRADFORD PROTEIN CONCENTRATION DETERMINATION 
The protein concentration of all cell lysates was determined prior to starting in vivo co-immunoprecipitations or 
western blots via Bradford protein concentration determination. In order to calculate a standard curve of protein 
concentrations, 10µl of a dilution range of bovine serum albumin (BSA) standards ranging from 0 – 1000µg/µl 
was loaded into the wells of a luminometer plate, together with cell lysate samples, in duplicate. Two hundred 
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microlitres of Bradford solution (Appendix I) was then added to each standard sample as well as lysate sample. 
A Synergy HT luminometer (BioTek Instruments Inc., Vermont, USA) was then used to determine the protein 
concentration of each well, and the KC4™ v 3.4 program (BioTek Instruments Inc.,Vermont, USA) used to 
calculate and set up the standard curve, as well as each sample’s protein concentration. 
 
2.7. RESTRICTION ENZYME DIGESTION FOR CLONING 
For cloning, the PCR-generated  inserts viz. PDE4DIP, PRKAR1A, PRKAR2A, ANKRD1, COMMD4, ENO1 and 
ENO3 (Section 2.2.2 and 2.2.3) as well as the respective cloning vectors viz. pGBKT7, pACT2, pGFP-C1 and 
pDs-Red were double-digested with their appropriate restriction enzymes (see Tables 2.1 and 2.3), as indicated 
in Table 2.6. The digests were prepared in a 100µl reaction volume as follows: 40µl insert DNA or 20µl 
pGBKT7 vector DNA was mixed with 5µl restriction enzyme, 10µl restriction enzyme buffer D (Promega, 
Madison WI, U.S.A.) and the appropriate volume of ddH2O. These mixtures were then incubated at 37°C for 3h. 
After incubation, the samples were purified using the Wizard® Purefection Mini Plasmid DNA purification kit 
(Wizard® Purefection Mini Plasmid DNA purification kit, Promega Corp. Madison Wisconsin, USA), as 
discussed in Section 2.1.4.  
 
The samples were eluted in 50µl ddH2O and subsequently mixed with 5µl of the second restriction enzyme, 10µl 
restriction buffer H (Promega, Madison WI, U.S.A.) and the appropriate volume of ddH2O. Incubation at 37°C 
for 3h followed, after which the samples were again purified using the Wizard® Purefection Mini Plasmid DNA 
purification kit. To prevent the double-digested vectors from annealing to itself in ligation reactions, it was 
treated with calf intestinal alkaline phosphatase (CIP) (Section 2.8.3) prior to  ligation reactions. The double-
digested inserts were not CIP treated and used directly in ligation reactions. 
 
2.8. GENERATION OF CONSTRUCTS 
2.8.1 Generation of Y2H constructs 
The Y2H bait-insert was cloned into the pGBKT7 bait-vector (Appendix IV) and, after automated sequencing to 
verify integrity of the sequence and conservation of the GAL4 DNA-BD reading frame, transformed into the 
yeast strain AH109. This construct (pGBKT7-MMGL:AH109) was used to screen a CLONTECH 
MATCHMAKER™ pre-transformed cardiac cDNA library, comprised of cardiac cDNAs cloned into the 
pACT2 prey-vector (Appendix IV) and transformed into the yeast strain Y187. 
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Table 2.6. Restriction enzymes used to digest cDNA inserts and vectors subsequently used in Y2H, 
colocalization and in vivo co-immunoprecipitation analyses 
cDNA insert Vector Restriction enzymes Application 
PDE4DIP pGBKT7(1), pDs-Red-
C1(2) 
NdeI, EcoRI (1) SalI, 
BamHI (2) 
Y2H analysis (1), 
colocalization, in vivo co-
immunoprecipitation (2) 
PRKAR1A pACT2 (1), pGFP-C1 (2) XhoI, BamHI Y2H analysis (1), 
colocalization (2) 
PRKAR2A pACT2 (1), pGFP-C1 (2)  NcoI, BamHI (1), XhoI, 
BamHI (2) 
Y2H analysis (1), 
colocalization (2) 
ANKRD1 pGFP-C1 XhoI, BamHI colocalization 
COMMD4 pGFP-C1 XhoI, BamHI colocalization, in vivo co-
immunoprecipitation 
ENO1 pGFP-C1 EcoRV, SacII colocalization 
ENO3 pGFP-C1 XhoI, BamHI colocalization 
 
The Y2H prey-inserts viz. PRKAR1A and PRKAR2A, were cloned into the pACT2 prey-vector and, after 
automated sequencing to verify integrity of the sequence and conservation of the GAL4 DNA-AD reading 
frame, transformed into the yeast strain Y187. These constructs (pACT2-R1A:Y187 and pACT2-R2A:Y187) 
were used to perform a direct Y2H protein-protein interaction test on pGBKT7-MMGL:AH109.  
 
2.8.2. Generation of co-localization and in vivo co-immunoprecipitation constructs 
For in vivo co-localisation, the PCR fragments representing ANKRD1, COMMD4, ENO1, ENO3, PRKAR1A and 
PRKAR2A were cloned into the pGFP
2
-C1 fluorescent vector and the integrity of the insert sequence and reading 
frame verified by automated sequencing (Section 2.4). The PCR fragment representing PDE4DIP was cloned 
into the pDs-Red-C1 fluorescent vector and subjected to the same verifications as the prey sequences, and was 
used in subsequent colocalization and in vivo co-immunoprecipitation experiments. TNNI3 and MYBPC3 cloned 
into the pGFP
2
-C1 vector was already available in our laboratory, and used again for this study.   
 
2.8.3. Alkaline phosphatase treatment of vector 
The ends of the linearised plasmid were CIP-treated to remove phosphate groups. This prevents the linearised 
vector from re-circularising by self-ligation (Section 2.7). Alkaline phosphatase treatment was accomplished by 
mixing 50µl of the digested vector with 1µl CIP (Promega, Madison WI, USA), 10µl CIP buffer (Promega, 
Madison WI, USA) and 38µl ddH2O. Incubation of the sample then followed at 37°C for 30 min, after which 
another 2µl CIP was added and the mixture incubated for a further 30 min. After this, 2µl 0.5M EDTA was 
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added to the mixture and the sample incubated at 65°C for 20 min to inactivate the enzyme. The vector was then 
purified by using the Wizard® Purefection Mini Plasmid DNA purification kit (Wizard® Purefection Mini 
Plasmid DNA purification kit, Promega Corp. Madison Wisconsin, USA) (Section 2.1.4). 
 
2.8.4 DNA ligation 
DNA ligations were performed in order to generate the various constructs described in Sections 2.8.1 and 2.8.2. 
For ligation, 2µl of the double-digested insert (Section 2.7) was added to 1µl of CIP-treated, double-digested 
vector (Sections 2.8.1 and 2.8.3). To this mixture, 5µl 2X T4 DNA ligase buffer (Promega, Madison WI, USA), 
5U T4 DNA ligase (Promega, Madison WI, U.S.A.) and ddH2O to a final volume of 10µl, was added. The 
sample was then incubated at 4°C overnight. After this incubation period, 5µl of the sample was transformed 
into the bacterial strain DH5α (Section 2.12.1) and plated onto appropriate selective LB agar plates. Following 
overnight incubation at 37°C, successful ligation reactions were confirmed by bacterial colony PCRs (Section 
2.2.4). 
 
2.9. BACTERIAL STRAINS, YEAST STRAINS AND CELL LINES 
2.9.1. Bacterial strains 
To facilitate selection and purification of vector constructs, ligation reactions were transformed into the E.coli 
DH5α strain. The transformed colonies were then selected on the basis of their ability to grow on LB agar plates 
(Appendix I) containing selection antibiotics. Recombinant plasmids were thereafter identified by colony PCR 
(Section 2.2.4). When selecting for pGBKT7 or pDs-Red-C1, kanamycin was used as selection antibiotic, 
whereas ampicillin was used when selecting for pACT2 and zeocin was used when selecting for pGFP
2
-C1.  
 
2.9.2. Yeast strains 
The pGBKT7 bait construct was transformed into the yeast strain AH109, and the pACT2 prey constructs were 
transformed into the yeast strain Y187. The clones present in the pre-transformed CLONTECH cDNA library 
used in the Y2H library screen had been transformed into the yeast strain Y187 by the manufacturer. Details of 
yeast phenotypes are given in Appendix III. 
 
2.9.3. Cell lines 
Suitable combinations of vectors were co-transfected into the rat atrial myocyte cell line H9C2 for the in vivo 3D 
co-localization (Section 2.17) assays. For in vivo co-immunoprecipitations, the pDs-Red-MMGL construct 
(Section 2.8.2) was also transfected into the H9C2 cell line. 
 
 
 
57 
 
2.10. GENERATION OF E.coli DH5α COMPETENT CELLS 
An amount (50µl) of an E.coli DH5α frozen (-80°C) glycerol stock was inoculated in 10ml LB media (Appendix 
I) and incubated overnight at 37°C at 200rpm in a YIH DER model LM-530 shaking incubator. After the 
inoculation period, a 1ml aliquot of the culture was added to 200ml LB media contained in a 2 L Erlenmeyer 
flask. Incubation of this culture at room temperature, while shaking at 200rpm, then followed for an overnight 
period, until the culture reached a mid log phase (OD600=0.6). Shaking took place on a Labcon orbital shaker 
(Labcon Pty Ltd Maraisburg, R.S.A.). When the culture reached the mid-log phase, it was decanted into 4X 
50ml polypropylene tubes and centrifuged at 3000rpm for 15min at 4°C in a Multitex centrifuge (MSE 
instruments, England). After discarding the supernatant, the pellet was resuspended in 4ml ice-cold CAP buffer 
(Appendix I). The suspended cells were then transferred to 1.5ml microfuge tubes in 500µl aliquots. Storage at -
80°C of the cells followed until needed. 
 
2.11. CULTURING OF CELL LINES 
2.11.1 Culture of cells from frozen stocks 
2.11.1.1 Thawing the cells 
Rattus norvegicus (rat) cardiac (atrial) myocytes, H9C2, were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). Thawing of the frozen stock was done by rapidly immersing the vials 
in a 37°C water bath for 10min. Immediately after thawing, the outside of the vials were sterilized with 70% 
ethanol. 
 
2.11.1.2 Removing Dimethyl sulphoxide (DMSO) from stocks and culturing cells 
It is necessary to remove DMSO from the frozen stock in order to ensure maximum viability of the cells upon 
plating. The DMSO was removed as follows: 1ml of complete growth media (Appendix I), pre-heated to 37°C, 
was added to the frozen stock and mixed by gentle pipetting. Afterwards, this mixture was transferred to a 12ml 
Greiner tube (Greiner Bio-one, Frickenhausen, Germany) and another 5ml of growth media was added. 
Centrifugation at 1000rpm followed for 3min using a Sorval® GLC-4 General Laboratory centrifuge 
(Separations Scientific, Johannesburg, RSA) after which the supernatant was removed. The pellet was 
subsequently resuspended in another 5ml of growth media and centrifugation repeated at 1000rpm for 3min. 
Afterwards, the cells were resuspended in 10ml growth media and transferred into a T25 culture flask. The cells 
were distributed evenly over the growth surface of the flask by swirling the flask gently, and incubated at 37°C 
in a Farma-thermosteri-cycle 5% carbon dioxide humidified incubator (Farma International, Miami, Florida, 
USA). 
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2.11.1.3 Splitting of cell cultures 
Splitting of pre-confluent cultures (approximately 70-80% confluency) was done every 2-4 days, by removing 
the growth media from the flask, after which washing with sterile phosphate buffered saline (PBS) containing no 
calcium or magnesium (Cambrex, Walkersville, MD, USA) followed. In order to loosen the cells from the 
growth surface of the flask, 2ml of trypsin (Highveld Biological, Lyndhurst, RSA) was added. After 5min, 5ml 
growth media was added and the cells gently resuspended, after which it was transferred to a 12ml Greiner tube 
and pelleted by centrifugation at 1000rpm for 3min in a Sorval® GLC-4 General Laboratory centrifuge. After 
centrifuging, the cells were resuspended in 10ml growth media and transferred to 4 flasks each containing 10ml 
growth media.  
 
2.11.2. Cell lysis 
Both untransfected as well as transfected H9C2 cell lysates were used in subsequent in vivo co-
immunoprecipitation and Western blot analyses (Section 2.15 and 2.16). Lysis of cells was accomplished as 
follows: Cells were scraped off the bottom of 6-well plates or 135mm petri dishes (depending on the amount of 
cells cultured) using a cell scraper, and, in the case of 6-well plates, the cells from three wells containing 
similarly transfected cells pooled together in a 50 ml polypropylene tube to obtain sufficient cells for subsequent 
assays. The samples were centrifuged for 10min at 3000rpm in a Beckman model TJ-6 centrifuge (Beckman 
Coulter, Scotland, U.K.) after which the supernatant was discarded, leaving a small amount of media behind. 
The samples were transferred to 1.5ml microcentrifuge tubes; 200µl of PBS (Appendix I) was added and mixed 
with the samples. Centrifugation for 1min at 3000rpm followed in an Eppendorf model 5417 C centrifuge 
(Eppendorf, Germany), after which the supernatant was discarded. Two hundred microlitres of passive lysis 
buffer (Appendix I) was then added and the samples incubated on ice for 30min. Centrifugation at 4°C for 10min 
at 14000rpm followed, after which the supernatant was transferred and frozen at -80°C until required. 
 
2.12. TRANSFORMATIONS AND TRANSFECTION OF PLASMIDS INTO PROKARYOTIC AND 
EUKARYOTIC CELLS 
2.12.1. Bacterial plasmid transformation 
The appropriate aliquot of competent E.coli DH5α cells was removed from a -80°C freezer and thawed on ice for 
20-30min. After thawing, 1µl plasmid preparation (Section 2.1.4) or 3-5µl of the ligation reaction (Section 2.8.4) 
was added to the competent E.coli DH5α cells. Incubation on ice followed for 20min. Transformation was then 
performed by placing the mixture in a Lasec 102 circulating water bath at 42°C for exactly 45sec (Lasec 
Laboratory and Scientific Company Pty Ltd, Cape Town, R.S.A.). The sample was then incubated at room 
temperature for 2min after which 1ml LB media was added to the mixture and the sample incubated for 1h at 
37°C, shaking at 200rpm in a YIH DER model LM-530 shaking incubator. Following incubation, 200µl of the 
sample was plated onto LB agar plates containing the appropriate selection antibiotic (Appendix I). The 
59 
 
remaining transformation mixture was then centrifuged for 1min at 14000rpm in an Eppendorf model 5417C 
centrifuge (Eppendorf AG, Hamburg, Germany) and the supernatant was discarded. The pellet was then 
resuspended in 200µl LB media and also plated on LB agar plates containing the appropriate antibiotic. The 
plates were inverted and incubated for 16h at 37°C in a model 329 stationary CO2 incubator (Former Scientific, 
Marieta, Ohio, U.S.A.) 
 
2.12.2. Yeast plasmid transformation 
Yeast strains to be transformed were streaked from frozen glycerol stocks onto YPDA agar plates (Appendix I) 
and incubated at 30°C for 2-3 days in a Sanyo MIR262 stationary ventilated incubator (Sanyo Electronic 
Company, Ora-Gun, Japan). After the incubation period, a volume representing 20-50µl yeast cells was picked 
and resuspended in 1ml sterile ddH2O in a sterile 2ml tube. The cells were then centrifuged at 13000rpm for 
30sec in a Beckman Microfuge Lite (Beckman Instruments Inc., CA, U.S.A.) to form a pellet. The supernatant 
was discarded and the pellet was resuspended in 1ml 100 mM lithium acetate (LiAc) and incubated for 5min at 
30°C in a MIR262 stationary ventilated incubator. The cells were pelleted again by centrifugation at 13000rpm 
for 30sec after which all the LiAc was removed from the tube. After removal of the LiAc, the following was 
added to the pellet in this order: 240 µl of 50% polyethylene glycol (PEG), 36µl 1M LiAc, 25µl of 2 mg/ml heat 
denatured and snap-cooled sonicated herring sperm DNA (Promega, Madison WI, U.S.A.), 10-20µl plasmid 
preparation and ddH2O, to a final volume of 350µl. The sample was then vortexed by using a Snijders model 
34524 press-to-mix vortex (Snijders Scientific, Tilburg, Holland) for at least 1min and incubated at 42°C for 20-
30min in a Lasec 102 circulating water bath (Lasec Laboratory and Scientific Company Pty Ltd, Cape Town, 
R.S.A.). After the incubation period, the cells were pelleted by centrifugation at 13000rpm for 1min, after which 
all the supernatant was removed. Resuspension of the pellet in 250µl sterile Millipore ddH2O followed, and 
150µl of this resuspension was then plated onto the appropriate selection plates (Appendix I). The plates were 
incubated inverted at 30°C for 2-5 days in a Sanyo MIR262 stationary ventilated incubator (Sanyo Electronic 
Company, Ora-Gun, Japan). 
 
2.12.3. Transfection of H9C2 cells for use in co-localization and in vivo co-immunoprecipitation assays 
For the co-localization assays, approximately 20000-30000 cells/well were seeded in complete growth medium, 
DMEM
10%FBS+1%PS
, (Lonza, Walkersville, MD, USA) in borosilicate coverglass chambers (Nunc, New York, 
USA) and incubated at 37°C in a Farma-thermosteri-cycle 5% carbon dioxide humified incubator. To determine 
the confluency level, the cells were visualized after 48h using a Nikon TMS light microscope (housed at the 
Department of Physiology, University of Stellenbosch). Once the cells reached approximately 70-80% 
confluency, transfection was performed. For each transfection, 100µl serum-free medium (DMEM
1%PS
) (Lonza, 
Walkersville, MD, USA) was aliquoted into sterile 1.5ml microcentrifuge tubes and 6µl of Genejuice® 
(Novagen, Madison, WI, USA) added to the tube. Vortexing of the mixture followed using a Snijders model 
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34524 press-to-mix vortex after which the mixture was incubated at room temperature for 5min. One microgram 
of vector DNA (pGFP
2
-C1:pDs-Red-C1 1:1) (Table 2.8) was then added to the mixture and mixed by gentle 
pipetting. Incubation of this Genejuice/DNA/medium mixture followed at room temperature for 30mins. 
Afterwards, the mixture was added drop-wise to the cells in the growth media while the chambers were carefully 
rocked back and forth in order to distribute the drops evenly across the chamber surface. The cells were then 
incubated at 37°C in a Farma-thermosteri-cycle 5% carbon dioxide humified incubator for 48h. Afterwards, the 
cells were differentiated into cardiac myotubes (Section 2.12.4).  
 
For in vivo co-immunoprecipitation assays, cells were cotransfected with the appropriate vector construct 
combinations in the same manner and conditions as described above, except for seeding approximately 1x10
4
 
cells in 135mm petri dishes to yield larger protein concentrations. For each transfection, 1152µl serum-free 
DMEM was aliquoted into sterile 2 ml microcentrifuge tubes together with 26µl Genejuice® and vortexed, 
followed by a 5min incubation at room temperature. After incubation, 8.64µg vector DNA (pDs-Red-C1:pGFP 
1:1) was added and mixed by gentle pipetting, followed by incubation at room temperature for 15min. Drop-wise 
addition of this mixture to the cells in DMEM
10%FBS+1%PS 
 followed. Following the 48h incubation period at 37°C, 
cells were lysed (Section 2.11.2). 
 
2.12.4. Differentiation of transfected H9C2 cells used for in vivo co-localization 
The growth medium was changed 48hrs after transfection in order to differentiate cardiac myocytes into 
myotubes. After the growth media was removed, the cells were washed with sterile PBS (containing no calcium 
or magnesium) and 3µl of differentiating growth medium (DMEM
1%horse serum + 1%PS
) (Lonza, Walkersville, MD, 
USA) was added. Incubation then followed at 37°C in a Farma-thermosteri-cycle 5% carbon dioxide humidified 
incubator for seven days, with the cells being washed again and fresh differentiating media added on day four. 
On day seven, the cells were visualized using an Olympus IX 81 motorised inverted microscope (Olympus, 
Hamburg, Germany) to confirm differentiation. Following this, the cells were photographed for co-localization 
(Section 2.17). 
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Table 2.7. Transfection experiment layout for the in vivo co-localization assay 
Transfection (1:1)* pDs-Red construct pGFP
2
 construct  
Test 1 MMGL ANKRD1  
Test 2 MMGL COMMD4  
Test 3 MMGL ENO1  
Test 4 MMGL ENO3  
Test 5 MMGL PRKAR1A  
Test 6 MMGL PRKAR2A  
Test 7 MMGL TNNI3  
Genejuice® control - -  
Untransfected control - -  
*Ratio to a total of 1µg 
 
2.13. ASSESSMENT OF Y2H CONSTRUCTS 
2.13.1. Phenotypic assessment of yeast strains 
Before transformation, each of the yeast strains used in the Y2H analysis was phenotypically assessed. 
Assessment were achieved by plating strains AH109 and Y187 onto selective agar plates lacking essential amino 
acids, i.e. agar plates SD
-Ade
, SD
-Trp
, SD
-His
, SD
-Leu
, SD
-Ura
 . Non-transformed yeast cells that were able to grow on 
SD
-Ura
 and unable to grow on SD
-Ade
, SD
-Trp
, SD
-His
 and SD
-Leu
 were used for transformation and subsequent Y2H 
analysis. 
 
2.13.2. Toxicity tests of transformed cells 
It was important to establish whether the bait construct (Section 2.8.1) had any noticeable toxic effect on the host 
yeast strain, AH109 (Section 2.9.2), before proceeding with the Y2H assay. To establish if the constructs were 
toxic to the host cells, a growth curve of AH109 transformed with pGBKT7-MMGL was generated and 
afterwards compared to a growth curve of AH109 transformed with non-recombinant pGBKT7. These two 
growth curves were set up in tandem and under the same experimental conditions. 
 
To generate the two growth curves, each of the transformed yeast strains was grown to stationary phase in SD
-W
 
media in a 50ml polypropylene tube at 30°C in a YIH DER model LM-530 shaking incubator shaking at 
200rpm. After this incubation, a 1:10 dilution of each primary culture was made in SD
-W
 and incubated for an 
extra 24h. During this incubation, over a period of 8h, a 1ml aliquot of the culture was taken every 2h and its 
OD600nm was measured. An overnight (24h) reading was also measured. A linearised graph of the log of these 
OD600nm readings versus time was drawn and the slopes of the graphs generated for the recombinant and non-
recombinant transformants were compared. 
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2.13.3. Testing the mating efficiency 
To determine whether the bait construct had any significant effect on the mating efficiency of the AH109 yeast 
cells, small scale yeast matings were performed. The AH109 transformed with pGBKT7-MMGL bait construct 
was mated with the prey host strain, Y187 transformed with the non-recombinant prey vector pACT2 or the 
control prey vector pTD1.1, supplied by the manufacturer (BD Bioscience, Clontech, Palo Alto, CA, U.S.A.). At 
the same time, control matings were also performed in which the yeast strain AH109 transformed with non-
recombinant pGBKT7 or the control pGKT7-53 vector supplied by the manufacturer was mated with the prey 
host strain, Y187 transformed with the non-recombinant prey vectors pACT2 or the pTD1.1 control vector. The 
experiment was performed as follows: 
 
Each of the yeast strains used in the mating efficiency tests was plated onto the appropriate nutritional selection 
plates as follows: AH109 pGBKT7-MMGL, AH109 pGBKT7 and AH109 pGBKT7-53 on SD
-W
 plates and 
Y187 pACT2 and Y187 pTD1.1 on SD
-L
 plates. Incubation of the plates followed for 2-5 days in a Sanyo 
MIR262 stationary ventilated incubator (Sanyo Electronic Company Ltd, Ora-Gun, Japan). From these plates, a 
single colony was used for each of the test mating experiments. The test matings were performed in 1ml YPDA 
media (Appendix I) in a 2 ml microfuge tube. The matings were incubated overnight at 30°C, shaking at 200rpm 
in a YIH DER model LM-530 shaking incubator. After the incubation period, serial dilutions (1:10, 1:100, 
1:1000 and 1:10000) of the mating cultures were plated onto SD
-L
, SD
-W
 and SD
-L-W
 agar plates. The plates were 
incubated for 4-5 days at 30°C in a Sanyo MIR262 stationary ventilated incubator. Following this period, the 
colonies on each plate were counted and used to calculate the mating efficiency (Appendix II). 
 
2.14. Y2H ANALYSIS 
2.14.1. The cardiac cDNA library 
The library used for the Y2H library screen was a pre-transformed human MATCHMAKER™ cardiac cDNA 
library (BD Bioscience, Clontech, Palo Alto, CA, U.S.A.) consisting of S.cerevisciae Y187 transformed with a 
cardiac cDNA library constructed in pACT2. The library consisted of normal, whole hearts pooled from three 
Caucasian males between the ages of 28 and 47 years. The library was XhoI-(dT)15 primed, and contained 
approximately 3.5x10
6
 independent clones that was inserted into the pACT2 vector between the XhoI and EcoRI 
sites. The library had an average insert size of 2.0kb, with a range of between 0.4 and 4.0kb. 
 
2.14.2. Establishment of bait culture 
An AH109 colony transformed with pGBKT7-MMGL was streaked out on SD
-W
 plates, after which four of the 
resultant colonies were inoculated into four separate 500ml Erlenmeyer flasks containing 50ml SD
-W
 media each. 
Four bait cultures were produced in order to facilitate pooling of the initial cultures, allowing the generation of a 
final bait culture with a titer of at least 1X10
10
. This translated into a 100-fold excess of bait to prey to ensure a 
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high mating efficiency. The four cultures were incubated at 30°C overnight, shaking at 200rpm in a YIH DER 
model LM-530 shaking incubator. After incubation, the cultures were transferred to four separate 50ml 
polypropylene tubes and centrifuged at 3000rpm for 10min at room temperature to pellet the cells in a Beckman 
Microfuge Lite centrifuge (Beckman Instruments Inc., CA, U.S.A.). After centrifugation, the supernatants were 
discarded and the four pellets resuspended together in 50ml SD
-W 
media, followed by transfer of this suspension 
to a single 500ml Erlenmeyer flask. The culture was then incubated for 16h in a YIH DER model LM-530 
shaking incubator, shaking at 200rpm. Following incubation, the titer of the bait culture was estimated by 
measuring the OD600nm of a 1ml aliquot of this culture. Haemocytometric cell count was then used to confirm 
this estimation. 
 
Subsequently, the cells were pelleted again by centrifugation at 3000rpm at room temperature for 10min. 
Discarding of the supernatant followed and the pellet was resuspended in 50ml SD
-W
 media. Aliquots of 10µl of 
this culture were taken for control mating experiments. 
 
2.14.3. Library mating 
An aliquot of 1ml of the pre-transformed cardiac cDNA library was taken from -80°C and thawed at room 
temperature (BD Biosciences, Clontech, Palo Alto, CA, U.S.A.). After thawing, the aliquot was mixed by 
vortexing  using a Snijders model 34524 press-to-mix vortex (Snijders Scientific, Tilburg, Holland). An aliquot 
of 10µl was then transferred to a sterile 1.5ml microfuge tube to be used for library titering. The pGBKT7-
MMGL transformed AH109 pellet (Section 2.8) was then resuspended in 45ml 2X YPDA media (Appendix I) 
supplemented with 10µg/ml kanamycin (Kan) in a 2L Erlenmeyer flask. The remaining 990µl of the library 
culture was then added , after which the mating culture was incubated overnight at 30°C, shaking at 200rpm in a 
YIH DER model LM-530 shaking incubator (SCILAB instrument Co. Ltd, Taipei, Taiwan). 
 
After this overnight incubation period, the entire mating culture was transferred into a sterile 50ml 
polypropylene centrifuge tube. The culture was then centrifuged at 3000rpm for 5min in a Beckman Microfuge 
Lite centrifuge (Beckman Instruments Inc., CA, U.S.A.) to pellet the cells. The supernatant was subsequently 
removed. The Erlenmeyer flask in which the mating was performed was then rinsed twice with 40ml 2X YPDA 
containing 10µg/ml Kan. With each rinsing, the 2X YPDA medium was used to resuspend the cell pellet and the 
cells then re-pelleted by centrifugation for 10min at 3000rpm. After the final centrifugation step, the supernatant 
was removed and the pellet resuspended in 15ml 0.5X YPDA containing 10µg/ml Kan. 
 
To determine mating efficiency, serial dilutions of 100µl aliquots (1:10; 1:100; 1:1000 and 1:10000) of this cell 
suspension were plated onto 90mm SD
-L
, SD
-W
 and SD
-L-W
 agar plates. The rest of the library maiting culture 
was plated directly onto 60 140mm triple dropout (TDO) (media lacking leucine, tryptophan and histidine) 
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(Appendix I) agar plates in 250µl aliquots. The TDO plates were subsequently incubated inverted at 30°C for 2 
weeks in a Sanyo MIR262 stationary ventilated incubator. Growth was monitored and colonies were picked and 
restreaked onto quadruple dropout (QDO) (media lacking leucine, trypthophan, histidine and adenine) plates to 
test for activation of both the HIS3 and ADE2 nutritional reporter genes. Incubation of these plates followed for 
3-6 days at 30°C. Colonies that grew on the QDO plates were picked and plated onto QDO plates containing X-
α-galactose, in order to assess activation of the MEL1 reporter gene, and incubated at 30°C for a further 3-5 
days. 
 
2.14.4. Establishing a library titer 
The serial dilutions plated onto 90 mm SD
-L
, SD
-W
 and SD
-L-W
 agar plates (Section 2.13.3) were incubated for 4 
days in a Sanyo MIR262 stationary ventilated incubator (Sanyo Electronic Company Ltd, Ora-Gun, Japan). 
Colony counts were then performed on the different plates in order to calculate the mating efficiency of the 
library mating and the number of library plasmids screened (Appendix II) 
 
2.14.5. Control matings 
In order to determine whether the recombinant pGBKT7-MMGL:AH109 construct had any negative effects on 
the ability of the transformed AH109 strain to mate with the library strain (Y187), control matings were set up. 
An aliquot of 10µl of pGBKT7-MMGL:AH109 culture and a single test prey colony (yeast strain Y187 
transformed with pTD 1.1 control vector) (BD Biosciences, Clontech, Palo Alto, CA, U.S.A.). were co-
inoculated in 1ml 0.5X YPDA containing 10µg/ml Kan in a 2ml microfuge tube. Incubation of this mixture 
followed at 30°C, with shaking at 200rpm, overnight in a YIH DER model LM-530 shaking incubator (SCILAB 
instrument Co. Ltd. Taipei, Taiwan). After this incubation period, serial dilutions (1:10; 1:100; 1:1000; 1:10000) 
of the mating mixture were plated onto SD
-L
, SD
-W
 and SD
-L-W
 agar plates. These plates were subsequently 
incubated at 30°C for 4 days in a Sanyo MIR262 stationary ventilated incubator (Sanyo Electronic Company 
Ltd, Ora-Gun, Japan). Afterwards, colony counts were performed and the mating efficiency was calculated as 
described in Section 2.14.3. 
 
2.14.6. Detection of activation of nutritional reporter genes 
2.14.6.1. Selection of transformant yeast colonies 
The  pGBKT7-MMGL:AH109 bait construct to be used for the Y2H analysis was plated onto SD
-L
, SD
-W
 and 
SD
-L-W
 agar plates and incubated for 4-6 days at 30°C in a Sanyo MIR262 stationary ventilated incubator (Sanyo 
Electronic Company Ltd, Ora-Gun, Japan). Growth on SD
-W
 plates indicated transformation of the yeast with the 
pGBKT7-MMGL bait plasmid, growth on SD
-L
 plates indicated transformation of the yeast with a prey plasmid 
and growth on SD
-L-W
 plates indicated the presence of both bait and prey plasmids. These transformant yeast 
colonies were subsequently picked and used in direct Y2H screens and a library screen (Section 2.14). 
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2.14.6.2. Selection of diploid yeast colonies containing putative interactor peptides 
Diploid yeast colonies containing both bait and prey plasmids were plated onto TDO plates (Appendix I) as well 
as QDO plates (Appendix I) in order to identify colonies in which an interaction between the bait- and prey-
fusion peptides had taken place. Growth on TDO plates indicated transcriptional activation of the HIS3 
nutritional reporter gene, whereas growth on QDO plates indicated transcriptional activation of both HIS3 and 
the ADE2 reporter genes. The activation of these genes in diploid yeast cells is an indication of interaction 
between bait and prey peptides. 
 
2.14.7. Detection of activation of colourimetric reporter genes via X-α-Galactosidase assay 
X-α-Galactosidase assays were conducted to establish the activation of the MEL1 reporter gene by the specific 
interaction between specific bait and prey peptides. Yeast colonies that had HIS3 and ADE2 activation, as 
determined via their growth on QDO plates, were replicated from QDO plates onto Hybond N
+ 
nylon 
membranes. The membranes were then placed colony-side up onto a QDO plate containing 20mg/ml X-α-Gal 
solution (BD Biosciences, Clontech, Palo Alto, CA, U.S.A.). Incubation followed at 30°C for 3-5 days, after 
which the intensity of the blue colour of the colonies which activated the MEL1 reporter gene, was visually 
assessed.  
 
2.14.8. Rescuing prey plasmids from diploid colonies 
Yeast colonies that grew on QDO and produced blue colour on X-α-galactosidase assays contained putative 
MMGL interactors. In order to further assess the specificity of this putative interaction, as well as to facilitate 
identification of the interactor proteins, the individual preys needed to be isolated from the diploid colonies. 
Plasmid DNA was isolated from each of the diploid cells as described in Section 2.1.3 and then transformed into 
the E.coli strain DH5α as described in Section 2.13.1. The transformants were plated onto LB amp plates which 
allows only for the growth of cells containing the prey constructs. Subsequently, these prey constructs were 
purified from the E.coli (Section 2.1.1) and transformed into the yeast strain Y187. 
 
2.14.9. Interaction specificity test  
Interaction specificity tests were performed to determine whether the interactions detected by the Y2H analysis 
were specific between the pGBKT7-MMGL bait and a particular prey peptide. Each Y187 colonies expressing a 
particular prey peptide was individually mated with the yeast strain AH109 transformed with the pGBKT7-
MMGL construct, AH109 transformed with non-recombinant pGBKT7, AH109 transformed with the pGBKT7-
53 control bait-plasmid, encoding murine p53, supplied by the manufacturer (BD Biosciences, Clontech, Palo 
Alto, CA, U.S.A.) and AH109 transformed with a heterologous bait, encoding a reelin domain from the brain 
protein reeler. After selection for expression of both bait and prey proteins, these diploid clones were streaked 
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out onto TDO and QDO plates to test for activation of nutritional reporter genes. This tested whether the prey-
peptides interacted with the heterologous baits or only with the MMGL bait. 
 
Clones that specifically interacted with the MMGL bait only were considered as putative true interactors. The 
inserts of these putative interactors were subsequently sequenced to determine their identities. 
 
2.14.10 Direct Y2H protein-protein interaction assays 
Small scale yeast matings were performed to determine whether the regulatory subunits of PKA, viz.. 
PRKAR1A and PRKAR2A, interacted directly with MMGL. The pGBKT7-MMGL:AH109 bait construct was 
mated with both pACT2-PRKAR1A:Y187 and -PRKAR2A:Y187 prey constructs as follows: 
 
Each of the yeast strains were plated onto suitable nutritional selection plates (pGBKT7-MMGL:AH109 bait on 
SD
-W
 plates; pACT2-PRKAR1A/R2A:Y187 preys on SD
-L
 plates) and incubated for 2-5 days at 30°C in a Sanyo 
MIR262 stationary ventilated incubator. A single colony from each of these selection plates was used for each 
test mating experiment: a bait and a prey colony were resuspended together to 1ml YPDA media in a 2ml 
microcentrifuge tube. The matings were incubated overnight at 30°C, shaking at 200rpm, in a YIH DER model 
LM-530 shaking incubator. Afterwards, 100µl of the mating cultures were plated onto SD
-L-W 
agar plates and 
incubated for 4-5 days at 30°C in a Sanyo MIR262 stationary ventilated incubator. Following this incubation 
period, the colonies on each plate were plated onto TDO agar plates, and incubated for four days at 30°C. After 
this, the mating mix was transferred to QDO agar plates and incubated at 30°C for seven days. Growth of the 
yeast on the respective plates was assessed on days 4 and 7. 
 
2.15. IN VIVO CO-IMMUNOPRECIPITATION (Co-IP) 
Prior to immunoprecipitation, the appropriate pre-prepared cell lysates (Section 2.11.2) were thawed on ice, and 
the concentration of the lysates determined via a Bradford assay (Section 2.6). The appropriate amount of lysate 
was then transferred to a clean microcentrifuge tube and the volume equalized to 200µl by adding passive lysis 
buffer (PLB) containing protease inhibitors and phenylmethylsulfonyl fluoride (PMSF) (Appendix I), with a 
final protein concentration of 200µg/µl. The lysates were then precleared by adding 20µl of Protein G agarose 
beads (KPL, Gaithersburg, MD, USA) to each sample and incubating it at 4°C on a rotating wheel for 2h. 
Following incubation, the supernatant was collected after centrifugation at 7000rpm for 30sec at room 
temperature. Depending on the optimum amount determined by optimization (Section 2.16), 1-2µg of the 
appropriate primary antibody was then added to each lysate sample, followed by incubation at 4°C on a rotating 
wheel overnight. 
After the overnight incubation period, 60µl of Protein G agarose beads was added to each sample and incubated 
at 4°C on a rotating wheel for 2h. Afterwards, the beads were collected by centrifugation at 7000rpm for 30sec, 
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and the supernatant collected and transferred to separate tubes kept on ice serving as controls in subsequent 
Western blot experiments (Section 2.16). The beads were then washed five times with ice cold PLB containing 
all protease inhibitors by adding PLB to the beads, mixing it, and collecting the beads again via centrifugation at 
7000rpm for 30sec. 
 
Following the washing steps, 40µl of 6X SDS loading dye (Appendix I) was added to each sample and boiled for 
5min at 95°C. Afterwards, the beads were pelleted by centrifugation at 14000rpm for 3min, and the supernatant 
loaded onto a SDS polyacrylamide gel (Section 2.3.2). 
 
2.16. WESTERN BLOTTING 
In order to visualize precipitated protein bands obtained from in vivo co-immunoprecipitation and isoelectric 
focusing (IEF) assays (Section 2.15.2 and 2.18.3), Western blots were done. The ratios of primary and secondary 
antibodies used to detect the various putative interactors of MMGL, as well as the antibody against the pDs-Red-
MMGL and pGFP-MyBPC constructs were first optimized. Together with each Western blot to determine 
protein interactions, a Western blot for β-actin was also done to serve as a control. Table 2.8 shows the 
respective optimal antibody as well as secondary antibody concentration ratios from a 1mg/ml stock determined 
for use in Western blotting. 
 
2.16.1. Membrane blocking 
Following the transfer of proteins from the SDS polyacrylamide gel (Section 2.3.2) onto the PVDF membrane 
(Section 2.3.3), the membranes were removed from the transfer apparatus and rinsed with ddH2O for 5min with 
shaking. The membranes were then blocked with 5% fat free powder milk (Weigh-Less) dissolved in TBST 
(Appendix I) for 1h, with shaking, to eliminate non-specific binding of the antibodies.  
 
2.16.2. Addition of primary antibody 
The PVDF membranes were briefly rinsed twice with TBST (Appendix I) following membrane blocking with 
5% fat free powder milk dissolved in TBST. Afterwards, the appropriate ratio of primary antibody:5% milk in 
TBST (as shown in Table 2.8) was added to each membrane followed by an overnight incubation shaking at 
4°C. Following this incubation period, the membranes were briefly rinsed twice with TBST, followed by 
washing each membrane for 15min shaking in TBST at room temperature, followed by three additional wash 
steps of 5min each, with fresh changes of TBST in between. 
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2.16.3. Addition of secondary antibody 
After all excess primary antibody was washed off the PVDF membrane, the appropriate ratio of secondary 
antibody: 5% milk in TBST (as shown in Table 2.8) was added to each membrane, followed by a 1h incubation 
step shaking at room temperature. Following this incubation period, the membranes were briefly rinsed twice 
with TBST, followed by washing each membrane for 15min shaking in TBST at room temperature, followed by 
three additional wash steps of 5min each, with fresh changes of TBST in between. 
 
2.16.4. Chemiluminescent visualization of membrane proteins using the SuperSignal® West Pico 
Chemiluminescent Substrate kit 
After all excess secondary antibody was removed from the PVDF membrane, the two substrate components of 
the SuperSignal® West Pico Chemiluminescent Substrate kit (Thermo Scientific, Pierce Biotechnology, 
Rockford, IL, USA), viz. the SuperSignal West Pico Luminol/Enhancer solution and the SuperSignal West Pico 
Stable Peroxide solution, was mixed in a 1:1 ratio to prepare the substrate Working Solution. The membrane was 
subsequently incubated for 5min in the Working Solution. After removing excess Working Solution by light 
tapping on a paper towel, the membrane was placed inside an autoradiography cassette and covered with a 
transparent plastic sheath, and exposed to autoradiography film (Eastman Kodak Company, Rochester, New 
York, USA). A glow-in-the-dark sticker was placed in the left hand corner of the cassette next to the membrane 
for orientation. Exposure time varied from 10sec to overnight exposure, depending on the strength of the signal. 
Following sufficient exposure time, the film was processed in a Hyperprocessor™ automatic autoradiography 
film processor (Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Bucks, UK). 
 
2.17. IN VIVO CO-LOCALIZATION 
To assess the proposed protein-protein interactions in a realistic cellular environment, the in vivo co-localization 
assay was the method of choice. The putative interactors were expressed in mammalian cells as fusion proteins 
with different fluorescent tags and were subsequently viewed via fluorescence microscopy at the Central 
Analytical Facility (CAF) (Central Analytical Facility, Department of Physiology, University of Stellenbosch). 
After viewing, the images were processed for co-localization. For this study, the dsRed (red fluorescent protein) 
and GFP (green fluorescent protein) tags were utilized. 
 
2.17.1. Co-localization assay 
H9C2 rat cardiomyocytes were co-transfected with the suitable combination of vectors (Section 2.12.3) and 
afterwards, allowed to differentiate for 7-10 days (Section 2.12.4). Prior to image acquisition, the culture media 
was removed and replaced with culture media containing a 1:200 dilution of the nucleic acid stain Hoechst H-
33342 (Sigma). The purpose of the dye is to stain the nuclear material blue in order for orientation purposes 
during the acquisition of Z-stacked images. Immediately after the addition of the nuclear dye, the cells were 
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photographed using an Olympus IX 81 motorised inverted microscope (Olympus) and afterwards, the CellR 
software was used to perform image analysis. Table 2.9 shows the excitation and emission spectra, as well as 
filter requirements. 
 
Z-stacks were used to co-localize the tagged proteins in three dimensions. Double-labeled images, utilizing the 
co-transfected samples, were obtained at different focal planes; images were processed by the CellR software to 
determine co-localization. Z-stacking was performed by first taking a GFP image at the lowest stack level, and 
then taking a dsRed image at the same level. The camera was then adjusted to the second lowest image and the 
process repeated. This sequence was repeated for each layer until the last image was taken. To determine the 
highest and lowest stack position, the camera was first focused on the nucleus of the cell to be imaged and then 
the image was taken out of focus by moving the objective up (to the top of the cell) and then down (to the 
bottom of the cell). These top and bottom co-ordinates were recorded by the software. A 60X oil immersion 
objective was used to collect image stacks at 0.26µm intervals in the plane. Subsequently, each co-localized 
image was created from the average of 25 frames. 
 
Chambers containing cells co-transfected with pDsRed-MMGL and pGFP-TNNI3 or pGFP-MyBPC were 
treated with 0.1µM isoproterenol and Z-stacks of the same cells taken again after 10min as described above in 
order to monitor changes in co-localization upon β-adrenergic stimulation. 
 
2.18. RNA-INTERFERENCE-MEDIATED PDE4DIP KNOCKDOWN 
To investigate the effect of RNA interference (RNAi) -mediated PDE4DIP knockdown in H9C2 cardiomyocytes 
on cMyBPC phosphorylation, pGFP-cMyBPC (Section 2.2.1.3) was immunoprecipitated from cells with and 
without PDE4DIP knockdown, under different adrenergic-stimulation conditions. These immunoprecipitates 
were then electrophoresed on IEF gels to separate the four phosphorylation states of cMyBPC. Western blots of 
these gels were then probed with the JL-8 antibody (Section 2.16) to detect pGFP-cMyBPC. The relative amount 
of the four phosphorylation states were subsequently compared between cells with and without PDE4DIP 
knockdown, with varying β-adrenergic stimulated conditions. 
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Table 2.8. Antibodies and antibody concentrations optimised for use in in vivo co-immunoprecipitation as 
well as Western blot assays 
Antigen Primary antibody 
and manufacturer 
Optimum ratio Secondary 
antibody 
Optimum ratio 
ANKRD CARP (Santa Cruz 
Biotechnologies) 
1:1000 Donkey anti-goat 1:5000 
β-actin β-actin (Cell 
Signaling 
Technology) 
1:5000 Donkey anti-rabbit 1:5000 
 dsRed Living Colors™ 
DsRed (Clontech) 
1:1000 Goat anti-mouse 1:5000 
ENO1 ENO1 (Abnova) 1:1000  1:5000 
ENO3 ENO3 (Abnova) 1:1000 Goat anti-mouse 1:5000 
PRKAR1A PRKAR1A 
(Abnova) 
 Goat anti-mouse 1:5000 
PRKAR2A PRKAR2A 
(Abnova) 
1:1000 Goat anti-mouse 1:5000 
TNNI3 TNNI3 (Abnova) 1:500 Goat anti-mouse 1:5000 
GFP/YFP Living Colors™ JL-
8 (Clontech) 
1:1000 Goat anti-mouse 1:5000 
 
Table 2.9. Excitation and emission spectra and filter requirements of fluorescent proteins used in in vivo 
co-localization 
Fluorescent protein Excitation Emission Filter set 
Ds-Red 556nm 586nm TxRED 
GFP
2
 395nm 510nm GFP 
Hoechst H-33342
*
 351nm 460nm DAPI 
*Nuclear stain, not a fluorescent protein tag 
 
2.18.1. siRNA preparation, transfection and optimization 
Four different rat siRNAs (Qiagen, Hilden, Germany) designed to achieve knockdown of PDE4DIP were 
optimized to establish which siRNA resulted in optimal knockdown of the targeted gene; the most effective of 
these was used in subsequent knockdown experiments. Table 2.10 summarizes these siRNA sequences as well as 
respective catalog numbers. For optimizing the four PDE4DIP siRNAs, H9C2 cells were cultured until confluent 
(Section 2.11), and subsequently transfected with the appropriate siRNAs. H9C2 cells (2x10
5
 cells) were seeded 
71 
 
in 6-well plates (Costar®, Corning Incorporated, Corning, NY, USA) and cultured till 80% confluent. Stock 
siRNAs of 20µM was prepared prior to transfection by the addition of 250µl siRNA suspension buffer to a 
5nmol synthesis. The tubes were heated at 90°C for 1min, followed by an incubation period of 1h at 37°C. The 
stocks were then either used for subsequent experiments or frozen at -20°C.  
 
Table 2.10. PDE4DIP predicted siRNA sequences from the species, Rat  
Product name siRNA sequences Catalog no. 
Pde4dip_Rn_RGD:708410_1_HP 
siRNA 
Sense: r(CAU UCG AAA GAU ACG UCA A)dTdT 
Antisense: r(UUG ACG UAU CUU UCG AAU G)dTdT 
S102012843 
Pde4dip_Rn_RGD:708410_2_HP 
siRNA 
Sense: r(GCA AGA UAC GAC AAU CCA A)dTdT 
Antisense: r(UUG GAU UGU CGU AUC UUG C)dTdT 
S102012850 
Pde4dip_Rn_RGD:708410_3_HP 
siRNA 
Sense: r(GGU GUU ACG CAG UCG ACU A)dTdT 
Antisense: r(UAG UCG ACU GCG UAA CAC C)dTdT 
S102012857 
Pde4dip_Rn_RGD:708410_4_HP 
siRNA 
Sense: r(CGG GAA CAA CUU AGU UCA A)dTdT 
Antisense: r(UUG AAC UAA GUU GUU CCC G)dTdT 
S102012864 
NCS Sense: UUC UCC GAA CGU GUC ACG UdT 
Antisense: ACG UGA CAC GUU AGA AdTdT 
1022076 
Abbreviations: NCS-non-silencing control; siRNA-small interfering RNA 
 
For siRNA transfection, 12µl of the 20µM siRNA stock was added to 88µl serum free medium followed by 
addition of 7µl HiPerFect® transfection agent (Qiagen, Hilden, Germany) to each tube to achieve a final siRNA 
concentration of 100nM. The samples were incubated at room temperature for 5min to allow the formation of 
complexes during which the culture media in the 6-well plates were replaced with 2.3ml fresh DMEM
10%FBS+1%PS
 
(Lonza, Walkersville, MD, USA). Afterwards, the complexes were added dropwise to each well, and rocked 
gently to enable uniform distribution. The cells were then incubated for 24h at 37°C in a Farma-thermosteri-
cycle 5% carbon dioxide humified incubator. 
 
Total RNA extraction followed after 24h using the RNeasy Plus Mini kit (Qiagen) as per manufacturer’s 
instructions. The effect of siRNA transfection on MMGL mRNA expression using the four different PDE4DIP 
siRNAs was then determined by a 2-step Q-RT-PCR using the Corbett Rotorgene system. cDNA was transcribed 
from the extracted RNA using the Quantitect Reverse Transcription kit (Qiagen) as per manufacturer’s 
instructions. The Quantifast SYBR green PCR kit (Qiagen) was then used to perform a real-time quantification 
of cDNA transcribed from the extracted RNA with or without non-silencing control (NSC) or PDE4DIP 
siRNAs. PDE4DIP levels were quantified with reference to three rodent reference genes (transferring receptor – 
72 
 
TRFR, glyceraldehydes-3-phosphate dehydrogenase – GAPDH and heat shock protein 1β - Hsp1β) selected from 
a panel of 6 commonly used housekeeping genes. 
 
2.18.2. MMGL knockdown  
Rn_RGD:708410_3_HP siRNA (Qiagen) resulted in the lowest PDE4DIP gene expression quantification levels, 
and was used in subsequent experiments. Confluent H9C2 cells were transfected with pGFP-cMyBPC using 
Genejuice® (Novagen)(Section 2.12.3). These cells were then either transfected after 24h with 10nM PDE4DIP 
Rn_RGD:708410_3_HP siRNA using HiPerFect® Transfection Reagent (Qiagen), or no siRNA transfection. 
Treatment with 65mM CaCl2 followed after 24h for 10min, followed by a 0.1µM isoproterenol treatment for 
another 10min, or no treatment. All cells were then lysed (Section 2.11.2) and concentrations determined via 
Bradford assays (Section 2.6), and all volumes equalized to 200µl by adding PLB containing protease inhibitors 
and PMSF with a final concentration of 200µg/µl. A non-denaturing immunoprecipitation of pGFP-cMyBPC 
from the lysate followed using 1µg of the JL-8 antibody (directed against GFP) with the Dynabeads® Protein G 
and DynaMag™-2 system (Invitrogen) as per manufacturer’s instructions. Isoelectric focusing of the GFP-
cMyBPC immunoprecipitates followed to separate the four possible phosphorylated forms of cMyBPC. 
 
2.18.3. Isoelectric focusing 
For the first dimension separation, the pGFP-cMyBPC immunoprecipitates were suspended in ReadyPrep 2-D 
Rehydration buffer 1 (Bio-Rad) containing Bio-lite pH 3-10 buffer (Bio-Rad) to a final volume of 200µl. The 
protein/rehydration buffer mix was then applied to a pH 4-7 (11cm) immobilized pH gradient (IPG) strip (Bio-
Rad). Rehydration of the strip followed for 12h at room temperature. Afterwards, IEF was done under the 
following conditions: 8000V for 20min, 8000V for 2h and 8000V for 40 000 V hours at 21°C (Protean IEF Cell, 
Bio-Rad). Strips were stored at -80°C after IEF until required. 
 
For 2-dimensional gel electrophoresis (2-DE), equilibration of the IPG strips was done by incubating the strips in 
equilibration buffer (0.375M tris-HCl, 6M urea, 20% glycerol, 2%, SDS) containing DTT (Sigma-Aldrich) for 
15min and then in equilibration buffer containing iodoacetamide (Sigma-Aldrich) for 15min shaking at room 
temperature. Following equilibration, the IPG strips were placed on top of a Criterion XT 12% bis-tris precast 
gel (Bio-Rad) and sealed with 0.5% agarose (Bio-Rad). Electrophoresis of the second dimension separation was 
done under constant voltage (200V) for 1-2h in 5% XT-MOPS running buffer (Bio-Rad). Transfer of the gel to a 
nitrocellulose membrane and subsequent western blotting (Sections 2.3.3 and 2.16) with the JL-8 antibody 
followed. 
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PART 2: MODIFIER STUDY 
2.19. STUDY SUBJECTS AND BLOOD COLLECTION 
Approval was granted for the present study by the University of Stellenbosch (US) Ethics Committee 
(N04/03/062). Written informed consent was given by the subjects entered for the study, and blood samples were 
collected from each subject for molecular genetic testing. During the process, 22 consecutively referred index 
cases were identified that carried one of three South African founder mutations i.e. R92W in TNNT2, R403W in 
MYH7 and A797T in MYH7. Moolman-Smook et al. (1999) previously described these mutations within a South 
African population. Pedigree tracing was done for these index individuals and their family members were asked 
to participate in the modifier genotyping study. The families were either of South African Caucasian or of Mixed 
Ancestry descent, as shown in Table 2.11. A panel of 353 individuals including genetically and clinically 
affected as well as unaffected individuals was identified. All these individuals were screened for the presence or 
absence of all three founder mutations. 
 
2.19.1. Clinical evaluation 
Study subjects 18 years or older were used in the present study and were clinically characterized by a 
cardiologist, Dr Miriam Revera of Pavia University, Italy. A two-dimensional (2D) echocardiography was done 
on each subject, with the clinician being unaware of each subject’s mutation status. A 2.5Hz transducer was used 
in standard parasternal long-axis and short-axis, apical four- and two-chamber views using a GE Healthcare 
Vivid7 cardiovascular ultrasound system, and analysis included echocardiographic recordings in M-mode, 2D 
and Doppler blood-flow imaging. Maximal left ventricular wall thickness (mLVWT) was determined at three 
levels viz. mitral valve, papillary muscle and supra-apex level as shown in Figure 2.1. 2D-echocardiographic 
measurements were done in six segments of the left ventricular wall at the mitral valve and papillary muscle 
levels, and in four segments at the smaller supra-apex level. A total of 16 segments were therefore measured. 
 
The six segments measured at the mitral valve and papillary muscle levels consisted of the anterior 
interventricular septum (aIVS), posterior interventricular septum (pIVS) and the anterior wall (AW), lateral wall 
(LW), inferior wall (IW) and posterior wall (PW) of the left ventricle. Evaluation of the supra-apex level of the 
left ventricle consisted of segments IVS, AW, LW and PW as per four chamber view. All variables were 
measured according to the recommendation of the American Society of Echocardiography 
(http://www.asecho.org/guidelines.php). The biplane area-length method was used to measure atrium volumes 
(Schiller et al., 1989). For each subject, covariates of cardiac structure were noted which includes systolic blood 
pressure (BP) (SBP), diastolic BP (DBP), age, sex, body surface area (BSA) and heart rate (HR). 
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Table 2.11. South African HCM-affected families of Caucasian and Mixed Ancestry descent that were 
analysed in the present study 
 Pedigree Ethnic group n Gene Mutation Location 
1 131 Caucasian 25 MYH7 A797T exon 21 
2 101 Caucasian 22 MYH7 A797T exon 21 
3 104 Mixed Ancestry 14 MYH7 A797T exon 21 
4 124 Caucasian 4 MYH7 A797T exon 21 
5 123 Mixed Ancestry 16 MYH7 A797T exon 21 
6 138 Caucasian 32 MYH7 A797T exon 21 
7 145 Mixed Ancestry 4 MYH7 A797T exon 21 
8 147 Mixed Ancestry 10 MYH7 A797T exon 21 
9 158 Caucasian 5 MYH7 A797T exon 21 
10 159 Mixed Ancestry 11 MYH7 A797T exon 21 
11 163 Caucasian 9 MYH7 A797T exon 21 
12 172 Caucasian 8 MYH7 A797T exon 21 
13 106 Mixed Ancestry 69 MYH7 R403W exon 13 
14 134 Mixed Ancestry 9 MYH7 R403W exon 13 
15 157 Mixed Ancestry 4 MYH7 R403W exon 13 
16 100 Mixed Ancestry 43 TNNT2 R92W exon 9 
17 103 Mixed Ancestry 5 TNNT2 R92W exon 9 
18 109 Mixed Ancestry 8 TNNT2 R92W exon 9 
19 139 Mixed Ancestry 41 TNNT2 R92W exon 9 
20 137 Mixed Ancestry 7 TNNT2 R92W exon 9 
21 149 Mixed Ancestry 10 TNNT2 R92W exon 9 
22 173 Mixed Ancestry 2 TNNT2 R92W exon 9 
Abbreviations: n = number of individuals screened for SNPs in the present study includes mutation and non-mutation 
carriers, MYH7 - myosin heavy chain gene 7; TNNT2 - troponin T gene 
 
In order to better describe the extent of hypertrophy in each subject, additional hypertrophy parameters were 
calculated. These parameters included left ventricular mass (LVM). LVM was calculated by using the formula 
for the estimation of LVM from 2-D LV linear dimensions, as recommended by the American Society of 
Echocardiography: 
LVM = 0.8 x (1.04[ (LVIDd + PWTd + SWTd)
3
 – (LVIDd)3 ] + 0.6g 
Additionally, principle component analysis was performed to statistically define composite scores that best 
reflect the variability in left ventricle-wide hypertrophy. Each wall thickness measurement was transformed 
to approximate normality using quantile normalization prior to this analysis (Pilia et al., 2006). 
 
2.20. BLOOD COLLECTION AND DNA EXTRACTION 
2.20.1. Blood collection 
The subjects’ blood was collected in 2x 5ml ethylene-diamine-tetra-acetic acid (EDTA) tubes (Vacutainer, RSA) 
for DNA extraction. Blood was also collected in 1x 10ml heparin tubes (Vacutainer, RSA) to establish 
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permanent lymphoblastoid cell lines using the method described by Neitzel (1986). Blood samples collected 
from subjects at other South African centres were couriered to the research laboratory within 24h of sampling. 
 
 
Figure 2.1. Graphical representative example of the heart showing the 3 levels at which measurements of wall 
thickness were made.  A) Long-axis view of left ventricle, taken at level of mitral valve, papillary muscles as 
well as just above apex (levels indicated by dotted lines). B) An example of a 2D echocardiographic ultrasound 
of the left ventricle. Abbreviations: AV - aortic valve, LA - left atrium, LV - left ventricle, LVOT - left 
ventricular outflow tract, MV - mitral valve, RVOT - right ventricular outflow tract. Taken from 
http://www.med.yale.edu/.../aortic_regurgitation.html with minor modifications by JC Moolman-Smook. 
 
2.20.2. Extraction of nuclei from whole blood 
DNA was extracted from nucleated blood cells according to the method described by Corfield et al. (1993) with 
slight modifications. All DNA extractions, cell transformations and maintenance were performed by Mrs. Ina le 
Roux, with a list of all solutions used for DNA extractions provided in Appendix I. 
 
2.21. BIOINFORMATICS 
2.21.1. Selection of Candidate Genes 
The genes encoding MMGL (PDE4DIP) as well as two regulatory subunits of PKA (PRKAR1A and PRKAR2A) 
were chosen as candidate genes for the modifier study. Variants in these three genes may influence cardiac 
contractility, and hence hypertrophy development, because of the involvement of PKA in the phosphorylation of 
cMyBPC, which plays a crucial role in optimal cardiac contractility and therefore possibly hypertrophy 
(B) (A) 
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development in mutant individuals. Of the four PKA R-subunit genes (PRKAR1A, PRKAR2A, PRKAR1B and 
PRKAR2B), PRKAR1A and PRKAR2A were chosen because PRKAR1A is known to interact with PDE4D 
(Dodge et al., 2001) while it has been shown that PRKAR2A has a high cardiac expression (www.genecards.org). 
Table 2.12 shows the candidate genes chosen for investigation as well as their respective protein functions. 
 
Table 2.12. Candidate genes chosen for SNP variant genotyping study 
Gene Location on 
chromosome 
Size 
(bp) 
Protein function 
PDE4DIP 1q12 1604 Acts as structural/scaffolding protein to localize components of the 
cAMP dependent pathway 
PRKAR1A 17q23 3653 Forms part of the regulatory-subunit dimer of the PKA 
heterodimer, which phosphorylates various substrates 
PRKAR2A 3p21 2381 Forms part of the regulatory-subunit dimer of the PKA 
heterodimer, which phosphorylates various substrates 
Abbreviations: PDE4DIP - phosphodiesterase 4D interacting protein, PRKAR1A - Protein kinase cAMP-dependant 
regulatory, type 1, alpha, PRKAR2A - Protein kinase cAMP-dependant, regulatory, type 2, alpha, cAMP-3’5’-cyclic 
adenosine monophosphate, PKA - protein kinase A, SNP - single nucleotide polymorphism 
 
2.21.2. SNP selection 
Genetic map distance was defined in terms of linkage disequilibrium units (LDUs) by Maniatis et al. (2002). 
According to Maniatis et al., LDUs define a metric coordinate system where locations are additive and distances 
are proportional to the allelic association between markers. Linkage disequilibrium (LD) maps can be efficiently 
used to position markers for population-based disease association studies, and are analogous to genetic maps 
expressed in centi-Morgans (cM) (Collins et al., 2004). 
For PRKAR1A and PRKAR2A, SNPbrowser v 3.5.3 software was used to select SNPs for the present study to 
achieve an even spacing of 0.5 LDUs on the metric LD map for the Central European (CEU) and Yoruba (YRI) 
populations, using default parameters set on the software (De La Vega, 2007). The software utilizes a set of 
metric LD maps constructed from the HapMap NCBI b36 assembly using the LDMAP software (Kuo et al., 
2007). Using the LDMAP software, SNPs that are in perfect LD have zero distance between them, whereas 
SNPs without significant correlation are separated by more than three LDUs (De La Vega et al., 2006).  
 
Only SNPs for which validated TaqMan® SNP genotyping assays were available were chosen. For PDE4DIP, 
such SNPs were selected manually based on a criterion of a minor allele frequency (MAF) of 0.2 or more for the 
CEU or YRI population. By means of its chromosomal position obtained from Genecards, the various SNPs 
were spread out approximately evenly across the gene, aiming to cover more or less the whole gene. A list of 
SNPs chosen for investigation is given in Table 2.13. 
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2.22. TaqMan® SNP GENOTYPING 
Genotypes were deteremined for all the subjects by subjecting the DNA samples to TaqMan® allelic 
discrimination technology using the ABI TaqMan® Validated SNP Genotyping Assays (Applied Biosystems, 
Foster City CA, USA).  
 
Each ABI TaqMan® Validated SNP Genotyping Assay consists of two primers to amplify the sequence of 
interest, as well as two TaqMan® MGB probes for allele detection. Each probe contains a reporter dye at the 5’ 
end of each allele-specific probe (the allele 1 probe contains the VIC reporter dye, and the allele 2 probe contains 
the FAM reporter dye). The probes also contain a minor groove binder (MGB) and a non-fluorescent quencher 
(NFQ) at the 3’ end of each probe. The function of the MGB is to increase the probe’s melting temperature (Tm) 
without increasing the probe length, which results in greater differences in Tm values between matched and 
mismatched probes, giving more accurate allelic discrimination (Kutyavin et al., 2000). Figure 2.2 explains how 
detection is achieved with proven 5’ nuclease chemistry by means of exonuclease cleavage of a 5’ allele-specific 
dye label, generating a permanent assay signal by removing the effect of the 3’ non-fluorescent quencher. 
 
2.22.1. Real-time PCR amplification conditions 
Amplification of each SNP was done by polymerase chain reaction (PCR) in a single reaction tube on a 
thermostable 384-well plate on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems Inc, 
Foster City CA, USA) following manufacturer’s instructions. An EpMotion® liquid handling robot was used to 
dispense the PCR reagents and samples into the 384-well plates (Eppendorf, Hamburg Germany). Each PCR 
reaction consisted of 2.5µl ABI TaqMan® Universal PCR Master Mix, 10ng genomic DNA, 0.25µl ABI 
TaqMan® primer and probe dye mix and 1.25µl Dnase-free sterile filtered water, totaling a 5µl reaction mix. 
Each thermostable 384-well plate consisted of 330 PCR amplifications and 54 non-template controls which 
lacked genomic DNA in the sample, to serve as a test for contamination. Each reaction was subsequently 
subjected to PCR conditions as follows: 2min at 50°C, 10min at 95°C, followed by 40 cycles of 15sec at 92°C 
and 1.5min at 60°C each. 
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Table 2.13. SNPs chosen for investigation as well as the respective TaqMan® assays used for genotyping 
each variant 
Gene SNP ID Chromosome Chromosomal 
position (bp) 
Nucleotide 
change 
ABI TaqMan® 
Assay 
  
PDE4DIP rs1628172 1 143623510 a/g C_42456720_10   
 rs12409452 1 143640607 a/g C_42456764_10   
 rs2798892 1 143643577 a/c C_42456794_10   
 rs2798880 1 143659232 a/g C_42456918_10   
 rs1664005 1 143699625 a/g C_42457524_10   
 rs7516133 1 143726347 c/t C_42457945_10   
 rs771114 1 143745154 c/t C_42458222_10   
 rs7548981 1 143749946 c/g C_42458295_10   
 rs674143 1 143772125 a/g C_42458629_10   
PRKAR2A rs3774628 3 48776844 a/g C_27499285_10   
 rs3923913 3 48817868 c/t C_26008486_10   
 rs9755490 3 48846668 a/c C_26861278_10   
PRKAR1A rs4265886 17 64021487 c/t C_221617_10   
 rs11651687 17 64029901 a/g C_11630616_10   
 rs3785906 17 64035235 a/g C_341301_10   
 rs6958 17 64040373 c/g C_7461387_10   
Abbreviations: PDE4DIP - phosphodiesterase 4D interacting protein, PRKAR1A - Protein kinase cAMP-
dependant,regulatory, type 1, alpha, PRKAR2A - Protein kinase cAMP-dependant,regulatory, type 2, alpha, SNP - single 
nucleotide polymorphism, bp - base pairs 
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Figure 2.2. Overview of TaqMan® allelic discrimination technology. Selective annealing of the TaqMan® 
probes plus exonuclease cleavage of a 5’ allele-specific dye label generates the assay signal, enabling allelic 
discrimination (taken from TaqMan® SNP Genotyping Assays Product Bulletin, Applied Biosystems). 
 
2.22.2. Allelic discrimination 
Allelic discrimination was achieved by running end point detection using ABI Prism 7900HT and Sequence 
Detection System (SDS) 2.3 software (autocaller confidence level 95%). The software allows for reading of 
fluorescence and does automatic allele calling by generating allelic discrimination plots. Subsequently, a text file 
was generated and directly incorporated into a database.  The results obtained were additionaly confirmed by 
visual inspection of the real-time PCR multicomponent analysis plots. 
 
2.23. STATISTICAL ANALYSIS 
The Cyrillic 2.1 (Cherwell Scientific, UK) program was used to enter genotypic and phenotypic data of patients 
onto family trees. This program was then used to export pedigree and genotypic data in MLINK format; this data 
was then collated with the appropriate echocardiographic and covariate data in an Excel spreadsheet, to create a 
pedigree file for statistical analysis.  
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In order to investigate the association between polymorphisms and hypertrophic traits, family-based tests for 
association were used, employing the QTDT (quantitative transmission disequilibrium test) program developed 
by Abecasis et al. (2002). The advantage of using family-based association tests is that it allows tracing of the 
transmission of alleles associated with hypertrophic phenotypes from parent to offspring in multiple generations. 
In order to adjust for various known confounding variables, as well as for specific relatedness between family 
members in estimating the various variance components (viz. environment, polygenic and specific genes), linear 
mixed-effect models were used within the QTDT program. QTDT allows for the assessment of linkage, 
population stratification and association of quantitative traits, depending on the model implemented in the 
program. In this study, after performing a population stratification test, both the orthogonal and total model of 
the QTDT program were used assess particular phenotype-genotype associations. 
 
2.23.1. Descriptive statistics and trait distribution 
Pedstats v. 6.11 (Wigginton and Abecasis, 2005) was used to verify the validation of input files and Mendelian 
inheritance within families. It was also used to test conformance of genotypes with Hardy-Weinberg equilibrium 
(HWE). Graphical summaries were generated of allele and genotype frequencies, as well as the distribution and 
familial correlations of quantitive traits and covariates. Pedstats selected unrelated individuals from families for 
Hardy-Weinberg testing and frequency estimation. 
 
2.23.2. Linkage disequilibrium (LD) determination 
Utilizing the genotype data generated in this study, pairwise LD statistics for the study cohort was generated 
using Haploview v. 4.1 (Barrett et al., 2005). Pairwise LD was analysed in terms of D’ values, and each SNP 
variant was classified as being in strong, uncertain or no LD. The program also enables haplotype analysis by 
constructing haplotypes using a common block definition (Gabriel et al., 2002). In the case of a D’ value 
indicating strong LD, a haplotype block is created. 
 
2.23.3. Quantitative transmission disequilibrium test 
A pedigree and data file was created as specified by the QTDT tutorial 
(http://www.sph.umich.edu/csg/abecasis/QTDT/) for all subsequent analyses of all the quantititive hypertrophic 
traits. Simwalk2 was used to estimate the specific relationship between family members by integrating the 
analyses using identity-by-descent (IBD) probalities (Sobel et al., 2001). The following covariates were also 
included: systolic BP, diastolic BP, age, sex, BSA and HR. The three founder groups (A797T, R403W and 
R92W) were also included to adjust for ancestral relatedness within each founder group and to correct for the 
possible influence of the distinct HCM causal mutation on variability of the hypertrophic phenotype. 
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Two different QTDT models were used viz. the total model and the orthogonal model. The total model allows 
for more statistical power, but does not compensate for population stratification. The orthogonal model is robust 
to population stratification, but has less power as only certain matings are included in the test. A test for 
population stratification was therefore done, and the orthogonal mode used for SNPs where stratification was 
detected, and the total model where no stratification was observed. For the orthogonal model, exact p-values for 
all QTDT significant associations were determined using Monte-Carlo permutation tests (McIntyre et al., 2000). 
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CHAPTER 3: RESULTS 
3.1. INTERACTION OF TRISPHOSPHO-cMyBPC WITH MYOMEGALIN 
As the interactions of the N-terminal region of cMyBPC under its various phosphorylation states appear to be 
integral to the regulatory role of cMyBPC in contracility, a series of Y2H library screens using various 
phosphorylation-mimics of the C1-C2 region of the protein as bait have been  performed in our laboratory. Of 
particular relevance to this study, was the library screen in which a construct of C1-C2 was used in which the 
serines in the three phosphorylation sites of the MyBPC motif had been replaced by glutamic acids (PPP) was 
used as bait to gain further insight into the interactions of the trisphosphorylated form of the N-terminal region of 
cMyBPC (A. Ramburan, PhD thesis).  
During successive rounds of nutritional and colorimetric selection, 19 putative interactors of the 
trisphosphorylated mimic of cMyBPC were identified, which were able to activate the HIS3, ADE2 and MEL1 
reporter genes in the presence of the PPP bait, but not in the presence of heterologous baits. Of these, three in-
frame prey plasmids encoded isoform 4 of PDE4D-interacting protein, also known as myomegalin (MMGL). In 
order to verify that it is the C1-C2 region of cMyBPC that interacts with MMGL, and not the GAL4 regions of 
the Y2H bait protein, and to assess whether trisphosphorylation of the MyBPC motif was crucial to the putative 
interaction, the native C1-C2 as well as a trisphospho-mimic were used in in vitro co-immunoprecipitation 
assays. The results indicated that MMGL interacts with the native as well as the trisphospho-mimic of C1-C2 in 
the absence of the Y2H GAL4 domains (A. Ramburan, PhD thesis). 
This interaction between MMGL and the N-terminal of cMyBPC was intriguing, as the former protein is known 
to anchor PDE4D to particulate structures; PDE4D, in turn, is known to hydrolyze cAMP and thus to attenuate 
PKA-driven phosphorylation (Verde et al., 2001). Furthermore, it has been shown that some adaptor proteins 
can anchor both PKA and PDE4D (Dodge et al., 2001), raising the possibility that MMGL may be anchoring 
PKA to at least cMyBPC in the sarcomere as an AKAP; hence this interaction was prioritized for further 
investigation in the present study. 
 
3.2. MYOMEGALIN BINDS TO PKA REGULATORY SUBUNITS 
3.2.1. Direct Y2H protein-protein interaction assays 
One of the prerequisites for a protein to be classified as an AKAP is the ability to bind to a regulatory subunit of 
PKA (Colledge et al., 1999, Dodge et al., 2000). The possibility that MMGL isoform 4 functions as an AKAP 
was therefore investigated by using direct Y2H protein-protein interaction assays to determine binding between 
MMGL and two regulatory subunits of PKA, viz. PRKAR1A and PRKAR2A. PRKAR1A was prioritized as 
potential subunit based on its known interaction with PDE4D (Dodge et al., 2001), whereas PRKAR2A is highly 
expressed in the heart (www.genecards.org). 
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The PKA regulatory subunits PRKAR1A and PRKAR2A were cloned into the pACT2 vector, which expresses 
the PKA subunits fused to the GAL4 DNA activation domain, and transformed into the yeast strain Y187. 
Subsequently, small scale yeast matings (Section 2.14.10) were performed by mating the PKA regulatory 
subunit clones with pGBKT7-MMGL in AH109, expressing the MMGL isoform 4 fused to the GAL4 DNA 
binding domain. Control matings were also carried out by mating pGBKT7-MMGL with empty pACT2 and 
pACT2-TUSC4, which encodes a heterologous protein viz. tumour suppressor candidate 4.. The interaction 
observed between pGBKT7-MMGL and pACT2-cTNI, one of the strongest bait-prey interactions observed in 
the Y2H library screen (see section 3.3.2.), was used as a positive control to compare PKA-MMGL interaction. 
Positive interaction was observed between both the PKA regulatory subunits and MMGL. However, PRKAR2A 
appeared to show a stronger interaction with MMGL than PRKAR1A, as judged by the number and colour of 
colonies arising as result of activation of nutritional reporter genes by PKA subunit-MMGL interaction, as 
shown in Figure 3.1.  
Figure 3.1. Activation of nutritional reporter genes by PKA-MMGL interaction during direct protein-protein 
interaction assays. Small-scale Y2H matings between pGBKT7-MMGL and pACT2-PRKAR1A (i) and pACT2-
PRKAR2A (ii) on solid medium lacking Leu, Trp, His and Ade (QDO). Both subunits show interaction with 
MMGL, but that of PRKAR2A with MMGL appears to be stronger than that of PRKAR1A, as judged by the 
number and colour of colonies arising. n=2 
3.2.2. Three dimensional in vivo co-localization of MMGL and PKA regulatory subunits 
To assess the interactions of the PKA regulatory subunits with MMGL identified by Y2H in a cellular 
environment, in vivo co-localization, using fluorescence microscopy, was used. In the images presented below 
and in all similar images that follows, a panel represents a single frame of the 25 images that were captured for 
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the Z-stack. In the following figure, images i-iii shows a single colour channel, while image iv shows an overlay 
of the four colour channels used.   
According to the results obtained via this technique, MMGL was shown to exist in the same three dimensional 
subcellular space as both PKA regulatory subunits viz. PRKAR1A and PRKAR2A in H9C2 cardiomyocytes 
(Figure 3.2). This supports the hypothesis that MMGL acts as an AKAP because of its ability to anchor PKA 
regulatory subunits; furthermore, it suggests that MMGL might act as a dual-specific AKAP because of its 
ability to anchor not only one, but two types of PKA regulatory subunits (Colledge and Scott, 1999; Wang et al., 
2001).
 
Figure 3.2. Live cell fluorescence imaging of co-localization of MMGL with PRKAR1A and PRKAR2A in 
differentiated H9C2 cardiomyocytes. (i) GFP-tagged PRKAR1A and PRKAR2A (green). (ii) dsRed-tagged 
MMGL (red). (iii) Co-localization of PRKAR1A and PRKAR2A with MMGL (yellow). (iv) Overlay of images 
A-C with Hoechst H-33342 labeling of the nuclei (blue). Magnification: 60X oil immersion before 70% 
reduction 
3.2.3. In vivo co-immunoprecipitation of MMGL and PKA regulatory isoforms 
To further verify physical interaction between MMGL and these PKA regulatory isoforms in a cellular context 
and in the absence of GAL4 domains, pull-down assays in differentiated H9C2 cardiomyocytes were performed. 
As commercial antibodies against MMGL did not detect isoform 4, which is the smallest isoform of this protein 
and the one identified in the original Y2H screen, an antibody directed against dsRed fluorescent protein was 
used in a pull-down assay to detect a dsRed-fusion of MMGL isoform 4 (dsRed-MMGL) (Section 2.8.2). In this 
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way, endogenous PRKAR1A and PRKAR2A were shown to immunoprecipitate dsRed-MMGL, and vice versa 
(Figure 3.3).  
 
 
 
Figure 3.3. Western blots of in vivo co-immunoprecipitations of PKA regulatory subunits and MMGL. (i) 
Endogenous PRKAR1A and PRKAR2A immunoprecipitate exogenous dsRed-MMGL in lysates of pDs-
Red/MMGL-transfected, differentiated H9C2 cardiomyocytes. Conversely, (ii) PRKAR1A and (iii) PRKAR2A 
also immunoprecipitate exogenous dsRed-MMGL in these lysates. The clear protein G control lanes show that 
these precipitations are not spurious, but are the result of physical association between the relevant proteins. 
Additional lanes in (ii) have been removed for cosmetic effect. Abbreviations: IP-immunoprecipitate; Prot G-
protein G control; WB-western blot 
 
Taken together, the direct protein-protein Y2H assays, the fluorescent co-localization images as well as the pull-
down assays all supports the hypothesis that MMGL acts as an AKAP because of its interactions with both PKA 
regulatory subunits. Moreover, considering that only one such interaction is already sufficient to classify a 
protein as an AKAP, MMGL can therefore be described as a dual-specific AKAP.  
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3.3. MYOMEGALIN BINDS TO ADDITIONAL PKA TARGETS 
The function of MMGL isoform 4 was further investigated by using it as a Y2H bait to screen a pretransformed 
cardiac cDNA library in order to identify any additional binding partners, other than cMyBPC and the PKA 
regulatory isoforms.  
3.3.1. Y2H analysis of MMGL 
3.3.1.1. Sequence analysis of the bait construct 
After the generation of the pGBKT7-MMGL bait construct, DNA sequence analysis was done to verify the 
integrity of the sequence and that the reading frame had been retained. The results of this analysis showed that 
the bait was in the correct reading frame, and that the integrity of the nucleotide sequence had been retained 
throughout the construction process. 
3.3.1.2. Phenotype test 
The transformed yeast strain AH109 containing the bait construct was able to grow on appropriate selection 
media (SD
-W 
and SD
-U
) but unable to grow on selection media lacking other essential amino acids (SD
-A
, SD
-L
, 
SD
-H
) (Section 2.13.1). This confirmed that the phenotype of the AH109 strain was retained after transformation 
with the pGBKT7-MMGL construct. 
3.3.1.3. Toxicity test 
A growth curve (Section 2.13.2) was generated in order to establish whether the pGBKT7-MMGL construct was 
toxic to the yeast strain AH109 in which the growth of the AH109 yeast strain transformed with pGBKT7-
MMGL was compared to the growth of AH109 transformed with non-recombinant pGBKT7. It was concluded 
that the pGBKT7-MMGL construct had no toxic effect on the growth of the AH109 yeast strain, because the 
slope of the linearized test curve proved to be similar to the slope of AH109 transformed with non-recombinant 
pGBKT7 (Figure 3.4). 
3.3.1.4. Mating efficiency of AH109 transformed with pGBKT7-MMGL bait construct 
A small-scale yeast mating (Section 2.13.3) was done in order to determine whether the transformation of the 
pGBKT7-MMGL bait had significantly affected the mating ability of the AH09 host strain. The mating 
efficiency of pGBKT7-MMGL (in host strain AH109) and pACT2 (in host strain Y187) was compared to the 
mating efficiency of pGBKT7-53 and pACT2. The results of this mating efficiency test showed that the 
pGBKT7-MMGL bait construct did not affect the mating efficiency of AH109, seeing that the mating efficiency 
of the MMGL test was higher than the minimum of 2% that is suggested by the manufacturer of the 
MATCHMAKER Y2H system (Table 3.1). 
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Figure 3.4. Linear growth curve of yeast strain AH109 transformed with either non-recombinant pGBKT7 or 
pGBKT7-MMGL bait constructs. The growth rate of the pGBKT7-MMGL bait transformant were compared to 
the non-recombinant pGBKT7 transformant in order to determine whether the bait constructs had toxic effects 
on the AH109 strain. The growth rate was determined by calculating the slope of the curve, and, seeing that the 
slopes were comparable, indicated that the bait construct had no toxic effect on the growth of the host yeast 
strain. 
Table 3.1. Effect of the pGBKT7-MMGL bait construct on AH109 mating efficiency 
Mating tests Mating efficiency (%) 
pGBKT7-53:AH109 x pACT2:Y187 2.33 
pGBKT7-MMGL:AH109 x pACT2:Y187 8.33 
 
3.3.2. Y2H screening of pretransformed cardiac cDNA library with the pGBKT7-MMGL bait 
After meeting the quality control criteria discussed above, the pGBKT7-MMGL bait was used to screen a 
cardiac cDNA library, and it was calculated that approximately 7 x 10
6
 cardiac cDNA clones were screened. 
Judging from the growth of the colonies on TDO plates (Table 3.2), 1130 clones were able to activate the HIS3 
reporter gene. From these 1130 clones, 872 clones were able to activate the ADE2 reporter gene, judged by the 
growth on the QDO plates (Table 3.2). After the X-α-galactosidase assay, a further 612 clones that were unable 
to activate the MEL1 reporter gene were eliminated (Table 3.2). The 260 clones that were able to activate the 
MEL1 reporter gene were grouped into 93 primary clones, and 167 secondary clones, based on colour intensity 
in the X-α-galactosidase assay, as well as robustness of growth on the QDO plates. Heterologous bait matings 
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were subsequently performed on all primary and secondary prey colonies, to assess the specificity of interactions 
of these prey clones in pACT2 with the pGBKT7-MMGL bait (Table 3.3) 
The preys that showed specific interaction with the pGBKT7-MMGL bait in the heterologous bait matings were 
nucleotide sequenced and identity was determined by utilizing online nucleotide and protein sequence databases 
as described in Section 2.5. Only the preys whose nucleotide sequence was in the appropriate reading frame as 
dictated by the upstream GAL4 sequence were considered as putative positive interactors of pGBKT7-MMGL 
and are shown in Table 3.4.  
3.3.3. Y2H library screen in summary 
From the 1130 clones that were able to activate the HIS3 reporter gene, 872 clones were able to activate the 
ADE2 reporter gene. Following this test, a further 612 clones were eliminated which left 260 clones that could 
activate the MEL1 reporter gene, and these 260 clones were subsequently tested for interaction specificity via 
heterologous bait matings. As seen in Table 3.3, only 13 clones passed the stringent bait-specificity 
(heterologous bait mating) test, and were sequenced to determine their identities. Table 3.4 shows the identities 
of these putative interactors. Because we were particularly interested in the role that MMGL may play in the 
phosphorylation of cMyBPC, and hence cardiac contractility, only identified interactors with known roles in this 
particular area of the sarcomere were prioritized for further investigation in the present study. The mitochondrial 
protein COX5A, proteasome 26S subunit and sorting nexin 3 (SNX3) were therefore eliminated as putative 
interactors of myomegalin for the purposes of this study. The putative interactors of myomegalin identified via 
the Y2H library screen were therefore as follows: troponin (cTNI), cardiac ankyrin repeat protein (CARP), 
COMM domain containing 4 (COMMD4), enolase 1 (ENO1) and  enolase 3 (ENO3).  
cTNI is a well-known thin filament protein and was identified six times in the library screen. Moreover, it is a 
known PKA target (Patel et al., 2001), which further supports the hypothesis that MMGL acts as an AKAP. The 
remaining preys had been identified in one or more of the cMyBPC-related library screens, indicating that they 
may well occur in the vicinity of the sarcomere. Using Phosphomotif Finder 
(www.hprd.org/Phosphomotif_finder), the remaining putative interactors were also shown to be likely PKA 
targets. 
 
 
  
91 
 
Table 3.2. Activation of nutritional and colourimetric reporter genes by prey-MMGL interaction. Tabulated are 
a representative subset of the scoring of the 1130 clones that activated the HIS3 reporter gene, 872 clones that 
activated the ADE2 reporter gene and 260 clones that activated the MEL1 reporter gene. 
 
         Clone # 
A 
Growth on TDO 
(HIS3 activation) 
B 
Growth on QDO 
(ADE2 activation) 
C 
X-α-galactosidase assay 
(colour) 
(MEL1 activation) 
1 +++ +++ ++ (medium blue) 
11 ++++ +++ ++ (medium blue) 
76 ++++ ++++ +++ (dark blue) 
163 +++ ++ + (no blue) 
192 +++ +++ +++ (dark blue) 
258 ++++ +++ ++ (medium blue) 
329 +++ + + (light blue) 
495 ++++ ++++ +++ (dark blue) 
550 +++ ++ ++ (no blue) 
618 ++ ++ + (light blue) 
715 ++++ ++++ +++ (dark blue) 
744 ++ + + (no blue) 
885 ++++ +++ ++ (medium blue) 
992 +++ +++ + (light blue) 
1108 ++ ++ + (no blue) 
Colonies in blue font activated HIS3, ADE2 and MEL1 reporter genes. TDO = solid media lacking Leu, Trp and His; QDO 
= solid media lacking Leu, Trp, His and Ade. Growth of colonies on solid media: ++++=very good, +++=good, ++=weak, 
+=very weak, -=no growth  
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Table 3.3 Interaction of the preys with heterologous baits in specificity tests. Tabulated is a representative subset 
of the scoring of the clones that were subjected to heterologous bait mating; all the clones considered as putative 
interactors are highlighted in red 
Clone # pGBKT7-
MMGL 
pGBKT7-53 pGBKT7-C5 Reelin pGBKT7 
11 ++++ + ++++ - + 
24 ++++ ++++ ++++ ++++ ++++ 
73 ++++ + ++++ - + 
128 +++ ++ + - - 
130 ++++ - - - - 
137 +++ - - - - 
148 ++ + - + - 
149 +++ - - + - 
160 +++ + + - - 
192 +++ ++ + - - 
200 ++ - - + - 
203 +++ - - + - 
287 +++ ++++ ++++ + + 
495 +++ ++++ ++++ ++++ ++++ 
583 ++++ ++ ++++ - - 
695 ++++ ++++ ++++ ++++ ++++ 
715 +++ - ++ + - 
Colonies were scored after 7 days on QDO. QDO = solid media lacking Leu, Trp, His and Ade. Growth of colonies on solid 
media: ++++ = very good, +++ = good, ++ = weak, + = very weak, - = no growth
93 
 
Table 3.4 Identification of MMGL putative interactor clones from the Y2H cardiac cDNA library screen.  
Genomic hit 
BLASTN 
 
In-frame protein hit 
 
BLASTP 
Clone # Identity Accession # 
E-value 
Accession # 
E-value 
Size of peptide 
encoded by insert 
(amino acids) 
Cellular 
localisation 
Domains 
128 Homo sapiens 
troponin I type 3 
(cardiac) (TNNI3) 
NM 000363, 0.0 
 
NP 000354.3, 2e-
82 
 
237 
 
Thin filament Troponin 
160 Homo sapiens 
troponin I type 3 
(cardiac) (TNNI3) 
NM 000363, 0.0 
 
NP 000354.3, 2e-
65 
 
263 
 
Thin filament Troponin 
137 Homo sapiens 
troponin I type 3 
(cardiac) (TNNI3) 
NM 000363, 0.0 
 
P 19429, 3e-63 
 
273 Thin filament Troponin 
148 Homo sapiens 
troponin I type 3 
(cardiac) (TNNI3) 
NM 000363, 0.0 
 
P 19429, 1e-62 
 
237 Thin filament Troponin 
149 Homo sapiens 
troponin I type 3 
(cardiac) (TNNI3) 
 
NM 000363, 0.0 P 19429, 5e-42 243 Thin filament Troponin 
200 Homo sapiens 
troponin I type 3 
(cardiac) (TNNI3) 
 
NM 000363, 0.0 P 19429, 3e-55 244 Thin filament Troponin 
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Genomic hit 
BLASTN 
 
In-frame protein hit 
BLASTP 
Clone # Identity Accession # 
E-value 
Accession # 
E-value 
Size of peptide 
encoded by insert 
(amino acids) 
Cellular 
localisation 
Domains 
192 Homo sapiens 
Cardiac ankyrin 
repeat protein 
(CARP) 
NM 014391, 0.0 
 
NP 055206, 2e-
121 
 
383 
 
Cytosol, nucleus Ankyrin repeat 
583 Homo sapiens 
COX5A 
NM 004255, 0.0 
 
NP 004246.1, 8e-
67 
 
204 
 
COX5A Mitochondrion 
715 Homo sapiens 
COMM domain 
containing 4 
(COMMD4) 
NM 017828, 0.0 
 
NP 060298.2, 3e-
97 
 
203 
 
COMMD4 Cytoplasm 
73 Homo sapiens 
proteosome 
(prosome, 
macropain) 26S 
subunit 
NM 002812, 0.0 
 
NP 002803.1, 5e-
113 
 
277 
 
Nin 1 C Cytosol 
130 Homo sapiens 
Enolase 1 (alpha) 
(ENO1) 
NM 001428, 0.0 
 
NP 001419, 4e-
116 
 
280 Enolase Cytoplasm 
203 Homo sapiens 
Enolase 3 (beta, 
muscle) (ENO3) 
NM 053013, 0.0 
 
NP 001967,1, 
0.001 
 
362 None Cytoplasm, 
localised to Z-line 
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Genomic hit 
BLASTN 
 
In-frame protein hit 
 
BLASTP 
Clone # Identity Accession # 
E-value 
Accession # 
E-value 
Size of peptide 
encoded by insert 
(amino acids) 
Cellular 
localisation 
Domains 
11 Homo sapiens 
Sorting nexin 3 
(SNX3) 
NM 003795, 0.0 
 
NP 003786.1, 8e-
62 
 
185 
 
Phox (PX) Cytosol 
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3.3.4. 3D in vivo co-localization of MMGL and putative interactors identified in the Y2H library screen 
To assess the interactions of the putative ligands identified by Y2H with MMGL in a cellular environment, in 
vivo co-localization, using fluorescence microscopy, was used. It was shown that MMGL occurs in the same 
three dimensional subcellular space as all five putative interactors identified in the Y2H library screen viz. 
CARP, COMMD4, ENO1, ENO3 and cTNI (Figure 3.5). No nuclear expression was observed with any of the 
proteins. In the images presented, a panel represents a single frame of the 25 images that were captured for the 
Z-stack. In Figure 3.5, images (i-iii) shows a single colour channel, while image (iv) shows an overlay of the 
four colour channels used.   
3.3.5. In vivo co-immunoprecipitation of MMGL and putative Y2H interactors 
To further verify physical interaction between MMGL and these ligands in a cellular context and in the absence 
of GAL4 domains, pull-down assays in diffentiated H9C2 cardiomyocytes were performed. As commercial 
antibodies against MMGL did not detect isoform 4, which is the smallest isoform of this protein, antibodies 
directed against pDs-Red/pYFP was used to detect dsRed-/YFP-fusions of MMGL isoform 4 (dsRed-
MMGL/YFP-MMGL)  (Section 2.8.2). Exogenous, fluorescently-tagged YFP-MMGL and endogenous CARP 
reciprocally co-precipitated each other (Figure 3.6 i), with dsRed-MMGL reciprocally co-precipitating 
endogenous ENO1, ENO3, and cTNI, as shown in Figure 3.6 (ii-iv). As COMMD4 had a similar mobility to 
antibody light chains, which interfered with detection of the protein in western blots, a GFP-tagged fusion of 
COMMD4 was expressed in H9C2 cells for pull-down assays. Figure 3.6 (v) shows that in the assay, exogenous 
GFP-COMMD4 immunoprecipiated exogenous dsRed-MMGL, and vice versa.  
It is not immediately clear why the dsRed-MMGL fusion protein appeared to have migrated slower during 
electrophoresis, which occurred during repeat experiments under different gel conditions. However, in other 
independent experiments conducted in our laboratory using dsRed fusions of different proteins, the same 
occurrence was observed. 
The results presented thus far therefore strongly suggests that MMGL interacts with both PKA regulatory 
isoforms, as well as with each of the prioritized five putative prey interactors identified in the Y2H screen, in a 
cellular milieu, and in the absence of the GAL4 domains.  
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Figure 3.5. Live cell fluorescence imaging of co-localization of MMGL and the putative interactors identified in 
the Y2H library screen in differentiated H9C2 cardiac myocytes. (i) GFP-tagged putative library screen 
interactors (green), as indicated to the left of the row. (ii) dsRed-tagged MMGL in the same cell(s) (red). (iii) 
Co-localization of interactors and MMGL within these cell(s) generated from Z-stack images (yellow). (iv) 
Overlay of images A-C with Hoechst H-33342 labelling of the nuclei (blue). Magnification: 60X oil immersion 
before 70% reduction. The presence of yellow staining in each of the images in Column C indicates that each of 
the respective preys co-localize with MMGL in differentiated H9C2 cardiomyocytes. 
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Figure 3.6. Western blots of in vivo co-immunoprecipitations of MMGL and putative interactors. A: 
Endogenous CARP (i), ENO1 (ii), ENO3 (iii) and cTNI (iv) immunoprecipitated exogenous dsRed-/YFP-
MMGL in vivo in lysates of ds-Red-/YFP-MMGL transfected, differentiated H9C2 cardiomyocytes. (v) 
indicates that GFP-COMMD4 immunoprecipitates dsRed-MMGL in differentiated H9C2 cardiomyocytes 
transfected with both GFP-COMMD4 and dsRed-MMGL B: Reciprocal immunoprecipitations indicate that 
dsRed-/YFP-MMGL immunoprecipitated  endogenous CARP (i), ENO1 (ii), ENO3 (iii) and cTNI (iv) in lysates 
of ds-Red-/YFP-MMGL transfected, differentiated H9C2 cardiomyocytes. (v) indicates that dsRed-MMGL 
immunoprecipitates GFP-COMMD4. The dsRed antibody is directed against the dsRed-MMGL fusion protein, 
while the JL-8 antibody is directed against the YFP/GFP fusion proteins. The clear protein G control lanes show 
that these precipitations are not spurious, but are the result of physical association between the relevant proteins. 
Additional lanes in (A) have been removed for cosmetic effect. Abbreviations: IP-immunoprecipitate; Prot G-
protein G control; WB-western blot 
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3.4. CO-LOCALIZATION INCREASES BETWEEN MMGL AND PKA TARGETS UPON β-
ADRENERGIC STIMULATION 
As mentioned earlier, cMyBPC and cTNI are known PKA targets (Mohamed et al., 1998; Patel et al., 2001), 
while the remaining five putative interactors were shown to be likely targets using Phosphomotif Finder 
(www.hprd.org/PhosphoMotif_finder), and hence adrenergic stimulation would be expected to affect interaction 
between MMGL and these preys. The effect of adrenergic stimulation on co-localization between MMGL and 
cMyBPC, as well as cTNI, being the most frequent Y2H putative interactor, was therefore investigated.  
 
Z-stacked fluorescent microscopy images showing co-localization of MMGL and cMyBPC as well as cTNI in 
H9C2 cardiomyocytes were obtained, as shown in Figure 3.7 and 3.8. These same cells were then treated with 
0.1µM isoproterenol, a β-adrenergic agonist, and incubated for 10min at 37°C, after which they were imaged 
again. Treating H9C2 cells co-transfected with dsRed-MMGL and either GFP-cMyBPC or GFP-cTNI with 
isoproterenol resulted in an increase in 3D co-localization between the respective protein pairs, as shown in 
Figure 3.7 and 3.8, compared to non-treated cells. This suggests that under adrenergic stimulation, and 
consequential increased intracellular levels of cAMP, PKA is dynamically recruited by MMGL to the PKA 
targets cMyBPC and cTNI, presumably to mediate cardiac stress responses and leading to increased cardiac 
contractility.  
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Figure 3.7. Live cell fluorescence imaging showing that co-localization of MMGL isoform 4 and cMyBPC 
increases under adrenergic stress. Each panel represents a single frame of the 25 images that were captured for 
the Z-stack. Each of the first three columns shows a single colour channel, while the image in the last column 
shows an overlay of the four colour channels used. A: Colocalization (yellow) between dsRed-MMGL and GFP-
cMyBPC in the absence (-isopro) and presence (+isopro) of the beta-adrenergic agonist, isoproterenol. Co-
localization levels have increased ten minutes after the addition of isoproterenol. B: Quantification of co-
localization shown in A shows that co-localization increases but does not reach statistical significance. Data 
presented as mean ±SEM; n=3  
101 
 
 
 
Figure 3.8. Live cell fluorescence imaging showing that co-localization of MMGL isoform 4 and cTNI 
increases under adrenergic stress. Each panel represents a single frame of the 25 images that were captured for 
the Z-stack. Each of the first three columns shows a single colour channel, while the image in the last column 
shows an overlay of the four colour channels used. A: Colocalization (yellow) between dsRed-MMGL and GFP-
cTNI in the absence (-isopro) and presence (+isopro) of the beta-adrenergic agonist, isoproterenol. Co-
localization levels have increased ten minutes after the addition of isoproterenol. B: Quantification of co-
localization shown in A shows that co-localization increases but does not reach statistical significance. Data 
presented as mean ±SEM; n=3 
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3.5. RNAi-MEDIATED MMGL KNOCKDOWN 
3.5.1. Optimizing PDE4DIP siRNAs 
Having accumulated evidence that MMGL isoform 4 acts as an AKAP, the role of MMGL in cMyBPC 
phosphorylation was evaluated by assessing the expression of the different phosphorylation isoforms of 
cMyBPC, with and without adrenergic stimulation in the context of siRNA-mediated MMGL knockdown.  
 
Of four siRNAs tested (Section 2.18.1), Pde4dip Rn_RGD:708410_3_HP siRNA (MMGL 3) (Qiagen, Hilden, 
Germany) was found to provide optimal knockdown of PDE4DIP (80%) in H9C2 cells (Figure 3.9); thus this 
MMGL (MMGL3) siRNA was used in subsequent experiments to silence PDE4DIP gene expression. 
 
 
 
Figure 3.9. Real-time quantification of PDE4DIP cDNA transcribed from RNA extracted from cells transfected 
with either a non-silencing control or a particular PDE4DIP siRNA. Pde4dip Rn_RGD:708410_3_HP (MMGL 
3) resulted in optimal knockdown of PDE4DIP (80%) p = 0.0016. 
3.4.2. Effect of MMGL knockdown 
To assess the effect of MMGL on cMyBPC phosphorylation, MMGL was knocked down by a siRNA approach, 
and the levels of the different cMyBPC phophorylation isoforms compared in lysates of cells that had been 
exposed to adrenergic stimulation via isoproterenol or not. To detect the different phosphorylation forms of 
cMyBPC, 2-dimensional IEF gels were run and western blotted.  
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Results showed that similar amounts of the mono- and diphosphorylated forms of cMyBPC are expressed in 
H9C2 cells not treated with isoproterenol, while lesser amounts of the un- and trisphosphorylated forms, relative 
to the other isoforms, are present (Figure 3.10 i).  
 
When these cells are exposed to increased CaCl2 and isoproterenol, to activate CaMK and PKA such that 
maximum phosphorylation of the MyBPC-motif is likely (McClellan et al., 2001), the relative amount of the 
trisphosphorylated form increases markedly, while the relative amount of unphosphorylated cMyBPC decreases 
(Figure 3.10 ii). However, under adrenergic stimulation, MMGL knockdown results in very low expression of 
all isoforms (Figure 3.10 iii).  
 
 
Figure 3.10. Effect of knockdown on the level of the different phosphorylated forms of cMyBPC in cells either 
exposed to adrenergic stimulation or not. A: Western blots of 2-dimensional IEF gels showing the expression of 
the four phosphorylation isoforms of GFP-cMyBPC in H9C2 cells (i) under non-stimulated conditions; (ii) under 
adrenergic stimulation, and (iii) under adrenergic stimulation in the absence of MMGL (i.e. with MMGL knock-
down). B: Quantification of cMyBPC isoforms in the autoradiographs of the 2-dimensional IEF gels shown in 
(A), graphing the levels of the four phosphorylation isoforms (0=unphosphorylated; 1=monophosphorylated, 
2=diphosphorylated, 3=trisphosphorylated). (i) Under non-stimulated conditions, levels of the mono- and 
diphosphorylated forms are similar and increased compared to the trisphosphorylated form. (ii) Under adrenergic 
stress, there is a relative increase in the trisphosphorylated form of cMyBPC and reduction of the non-
phosphorylated form. (iii) Upon MMGL knock-down, adrenergic stress leads to a reduction in the levels of all 
cMyBPC phosphorylation forms. 
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3.6. MODIFIER STUDY 
As discussed in Chapter 1, myomegalin and the two regulatory subunits of PKA were considered as potential 
modifier genes of the highly variable HCM hypertrophy phenotype. Single nucleotide polymorphisms (SNPs) 
representing variation within these three genes (PDE4DIP, PRKAR1A and PRKAR2A) and a SNP genotyping 
modifier study, comparing clinical HCM traits with the various genotypes obtained for the SNPs in these genes, 
was done with the following results: 
3.6.1. Baseline statistics for the study cohort 
Table 3.5 depicts the baseline clinical characteristics of the study cohort used for the study of PDE4DIP, 
PRKAR1A and PRKAR2A as potential modifiers of hypertrophic cardiomyopathy. The study population is 
stratified into mutation carrier (MC) and non-carrier (NC) groups for the three HCM causal mutations present in 
the cohort. In this population, 127 individuals were identified with HCM causal mutations. 
3.6.2. Prioritising SNPs for investigation 
SNPs were prioritized according to a density-selection strategy, rather than a tag-SNP strategy as the LD 
structure within the study population is not known. Additionally, SNPs were only selected if the SNP could be 
genotyped by means of validated Taqman® SNP genotyping assays. Validated Taqman® SNPs with a minor 
allele frequency (MAF) of 0.2 or more for the CEU or YRI population were selected such that a spread of SNPs 
across the genes was achieved. The CEU population consists of 30 parent-offspring trios with north and western 
European ancestry, whereas the YRI population sample consist of 30 parent-offspring trios from the Yoruba 
population in Ibadan, Nigeria (obtained from Centre d’Etude du Polymorphisme Humain). These two 
populations were deemed the HAPMAP populations closest to the study population. Table 3.6 depicts the MAF 
of each SNP covered in the present study for these two HAPMAP groups. 
The average physical distances between SNPS were 59531, 520025 and 323923kb for the MMGL, PRKAR1A 
and PRKAR2A genes, respectively (Figs 3.11 and 3.12). For PRKAR1A and PRKAR2A, the spacing of these 
SNPs amounted to a spacing of 0.5 linkage disequilibrium units (LDUs) on the metric linkage disequilibrium 
(LD) map for the HapMap CEU and YRI populations.  
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Table 3.5. Basic characteristics of the study cohort stratified into mutation carrier (MC) and non-carrier (NC) 
groups according to HCM mutation status 
 A797T 
 
R92W R403W 
 MC NC MC NC MC NC 
Total: 56 50 41 29 30 21 
Males (%) 32 (57) 27 (54) 18 (44) 11 (38) 19 (63) 8 (38) 
Age 43.5 (14-81) 36.5 (14-68) 37 (14-78) 33 (17-60) 39.5 (18-72) 35 (16-58) 
BSA (m
2
) 1.9 (1.3-2.5) 1.9 (1.5-2.3) 1.7 (1.3-2.2) 1.8 (1.3-2.1) 1.8 (1.3-2.3) 2.0 (1.5-2.3) 
SBP (mm Hg) 120 (100- 
180)  
120 (90-180) 120 (90-200) 120 (90-160) 122.5 (100-
170) 
125 (100-230) 
DBP (mm Hg) 80 (60-100) 80 (60-120) 77.5 (60-100) 80 (60-90) 80 (60-110) 80 (60-110) 
HR (bpm) 65 (44-120) 65 (50-95) 68 (45-110) 70 (45-83) 65 (52-96) 72 (53-90) 
LVM (g) 
200.8 (71.4-
476.6) 
133.3 (61.1- 
272) 
133.7 (48.2-
295.4) 
113.7 (58.4-
246.1) 
173.9 (77.4-
273.8) 
141.9(59.1  -
290.5) 
*Data summarised as median (Q1, Q3); Abbreviations: BSA-body surface area; DBP-diastolic blood pressure; HCM-
hypertrophic cardiomyopathy; HR-heart rate; LVM-left ventricular mass; MC-HCM mutation carrier; NC-non-carrier; SBP-
systolic blood pressure 
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Figure 3.11. Graphical representation of PDE4DIP SNPs with a MAF≥0.2 for the CEU or YRI population 
manually selected to cover the whole gene. SNPs were only considered for selection if validated TaqMan® SNP 
genotyping assays could be obtained. Rs2798880 (green) was excluded from QTDT analysis due to an 
insufficient number of informative individuals 
 
Figure 3.12. Graphical representation of PRKA SNPs selected to achieve an even spacing of 0.5 LDUs on the 
metric LD map for the HapMap CEU and YRI populations. SNPs were only considered for selection if validated 
TaqMan® SNP genotyping assays could be obtained. Rs3923913 was excluded from QTDT analysis due to an 
insufficient number of informative individuals 
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Table 3.6. Minor allele frequencies (MAF) of each SNP covered in the present study in the HapMap CEU and 
YRI population groups 
Abbreviations: a - adenine; c - cytosine; g - guanine; PDE4DIP - phosphodiesterase 4D-interacting protein; PRKAR1A -
Protein kinase cAMP-dependant,regulatory, type 1, alpha, PRKAR2A - Protein kinase cAMP-dependant,regulatory, type 2, 
alpha,; SNP - single nucleotide polymorphism; t - thymine 
 
 MAF 
Gene Chromosome SNP Nucleotide 
change 
CEU YRI 
PDE4DIP 1 rs1628172 a/g 0.22(a) 0.09(a) 
  rs12409452 a/g 0.25(a) 0.06(a) 
  rs2798892 a/c 0.33(a) 0.41(a) 
  rs2798880 a/g 0.5(a/g) 0.5(a/g) 
  rs1664005 a/g 0.331(g) 0 
  rs7516133 c/t 0.212(c) 0.144(c) 
  rs771114 c/t 0 0.358(c) 
  rs7548981 c/g 0.237(g) 0.102(g) 
  rs674143 a/g 0.237(g) 0.102(g) 
PRKAR2A 3 rs3774628 a/g 0.441(g) 0.466(g) 
  rs3923913 c/t 0 0.127(t) 
  rs9755490 a/c 0.433(a) 0.375(a) 
PRKAR1A 7 rs4265886 c/t 0.339(c) 0.2(c) 
  rs11651687 a/g 0.228(a) 0.229(a) 
  rs3785906 a/g 0.25(g) 0.233(g) 
  rs6958 c/g 0.28(c) 0.24(c) 
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3.6.3. Genotyping via Taqman® allelic discrimination 
The Taqman® SNP genotyping PCR amplification runs were all completed successfully and no amplification 
was observed in the non-template controls, eliminating the possibility of amplification due to contamination. All 
results from the end-point analyses were exported to a database for statistical analysis. Figure 3.13 shows the 
genotyping results for the myomegalin SNP rs1628172 as a representation of the allelic discrimination plots 
obtained with the SDS software during end-point analyses. 
 
Figure 3.13. Representative genotyping result for TaqMan allelic discrimination. Genotyping results for the 
rs1628172 SNP as a representation of the allelic discrimination plots obtained with the SDS software during end 
point analyses. Allele X=a; Allele Y=g 
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3.6.4. Statistical analyses 
3.6.4.1. Descriptive statistics 
The statistical program Pedstats was used to determine whether all genotypes were consistent with expected 
Mendelian inheritance patterns. Genotypes that were inconsistent were resolved by re-genotyping. Table 3.7 
shows the exact p-values obtained from an exact Hardy-Weinberg equilibrium (HWE) test among a sample of 
unrelated individuals as determined with Pedstats. The genotype frequencies for all markers were in agreement 
with HWE except rs2798880, which was removed and excluded from further analysis due to an insufficient 
number of informative individuals. 
3.6.4.2. Association and population stratification test 
An additive model of association was used to assess all the SNP markers. For QTDT, Monte-Carlo permutation 
tests were used to calculate exact p-values. P-values of 0.05 and lower were considered as significant. 
To enable association analysis and in order to run QTDT, at least 30 informative matings are required, i.e. 
phenotyped individuals with at least one heterozygous parent. One marker (rs2798880) in PDE4DIP and another 
in PRKAR2A (rs3774628) had an insufficient number of informative individuals, and hence, could not be 
assessed for association using QTDT and were thus excluded from further analysis.  
To assess whether population stratification existed within the study population, a population stratification test 
was carried out using QTDT (Table 3.8). This was necessary, to inform a choice of applying either the total or 
orthogonal model during association analyses. While the total model has more power, it is not robust to 
population stratification. Conversely, the orthogonal model has less power than the total model, because it 
performs within-family association, but compensates for population stratification for the same reason.  
As can be seen from the table, one SNP variant (rs4265886) in PRKAR1A associated with mIVST (p-value of 
0.043) showed stratification, and hence, the orthogonal model was used to calculate association for that 
particular variant. No other population stratification was detected in the samples, and hence, the total model was 
used for all other variants.  
The results of the two QTDT tests can be seen in Table 3.9. Significant association was found between the 
PDE4DIP SNP rs1664005 and all the traits except LVM and mPWT. Significant association was also found 
with two PRKAR1A SNPs (rs11651687 and rs3785906) and the hypertrophy traits mIVST and CWTscore.  
The effect sizes of the G-allele of the PDE4DIP SNP rs1664005 on untransformed, covariate adjusted traits were 
an increase of 1.3mm for mIVST, 3.4mm for Maronscore, 8.1mm for CWTscore and 0.5mm for Comp1. For 
PRKAR1A, the effect size for the A-allele of rs11651687 was an increase of 2.1mm for mIVST, whereas for the 
A-allele of rs3785906, effect sizes were found to be 2.2mm for mIVST and 16.3mm for CWTscore.  
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Table 3.7. Exact Hardy-Weinberg equilibrium p-values calculated for unrelated individuals 
Gene Chromosome Marker HWE exact p-value 
PDE4DIP 1 rs1628172 0.2431 
  rs12409452 0.3021 
  rs2798892 0.0855 
  rs2798880 Not determined 
  rs1664005 0.7316 
  rs7516133 0.0725 
  rs771114 0.7082 
  rs7548981 0.3121 
  rs674143 0.1661 
PRKAR2A 3 rs3774628 0.7542 
  rs3923913 1.0000 
  rs9755490 0.1376 
PRKAR1A 7 rs4265886 1.0000 
  rs11651687 0.2741 
  rs3785906 0.1251 
  rs6958 0.7121 
Abbreviations:  HWE - Hardy-Weinberg equilibrium; PDE4DIP - phosphodiesterase 4D-interacting protein; PRKAR1A -
Protein kinase cAMP-dependant,regulatory, type 1, alpha, PRKAR2A -  Protein kinase cAMP-dependant,regulatory, type 2, 
alpha 
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Table 3.8. Results from the population stratification analysis: p-values for stratification between SNPs in PDE4DIP, PRKAR2A and PRKAR1A and 
hypertrophy traits. Significant p-values are indicated in bold red 
Trait   PDE4DIP PRKAR2A PRKAR1A 
 
rs1628
172 
rs1240
9452 
rs27988
92 
rs16640
05 
rs75161
33 
rs7711
14 
rs75489
81 
rs6741
43 
rs37746
28 
rs97554
90 
rs42658
86 
rs11651
687 
rs37859
06 
rs6958 
LVM 0.549 0.846 0.403 0.872 0.297 0.738 0.672 0.328 0.080 0.750 0.199 0.935 0.989 0.658 
mIVST 0.199 0.126 0.305 0.761 0.706 0.942 0.536 0.163 0.460 0.280 0.043 0.424 0.345 0.278 
mPWT 0.502 0.483 0.476 0.831 0.974 0.564 0.407 0.518 0.337 0.515 0.071 0.436 0.675 0.542 
Maronscore 0.171 0.170 0.274 0.966 0.724 0.824 0.112 0.145 0.317 0.383 0.055 0.760 0.862 0.394 
CWTscore 0.105 0.319 0.893 0.908 0.966 0.512 0.187 0.077 0.160 0.723 0.137 0.481 0.504 0.585 
Comp1 0.157 0.373 0.419 0.723 0.908 0.773 0.169 0.182 0.263 0.450 0.065 0.670 0.637 0.393 
Abbreviations: Comp1 - principle component score; CWTscore - cumulative wall thickness score; LVM - left ventricular mass; Maronscore -  as defined by Spirito and 
Maron (1990); mIVST - maximal interventricular septum thickness; PDE4DIP - phosphodiesterase 4D-interacting protein; mPWT - maximal posterior wall thickness; 
PRKAR1A - Protein kinase cAMP-dependant,regulatory, type 1, alpha, PRKAR2A - Protein kinase cAMP-dependant,regulatory, type 2, alpha  
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Table 3.9. Results from the association analysis using the total model: p-values for association between SNPs in PDE4DIP, PRKAR2A and PRKAR1A 
and hypertrophy traits. Significant p-values are indicated in bold red. **PRKAR1A SNP rs4265886 analysed using the orthogonal model  
Trait PDE4DIP 
 
PRKAR2A PRKAR1A 
 rs1628
172 
rs124094
52 
rs27988
92 
rs16640
05 
rs75161
33 
rs7711
14 
rs75489
81 
rs6741
43 
rs37746
28 
rs97554
90 
rs42658
86 ** 
rs116516
87 
rs3785
906 
rs6958 
LVM 0.504 0.687 0.148 0.061 0.434 0.124 0.767 0.978 0.308 0.631 0.642 0.252 0.126 0.514 
mIVST 0.729 0.737 0.429 0.038 0.366 0.334 0.852 0.379 0.585 0.591 0.523 0.029 0.010 0.438 
mPWT 0.752 0.852 0.890 0.248 0.238 0.523 0.933 0.683 0.925 0.534 0.399 0.721 0.605 0.341 
Maronscore 0.956 0.584 0.642 0.022 0.355 0.177 0.839 0.331 0.151 0.729 0.472 0.191 0.071 0.700 
CWTscore 0.917 0.940 0.281 0.034 0.531 0.093 0.527 0.172 0.248 0.963 0.857 0.118 0.042 0.943 
Comp1 0.643 0.917 0.251 0.028 0.372 0.212 1.000 0.396 0.356 0.918 0.537 0.174 0.062 0.763 
Abbreviations: Comp1 - principle component score; CWTscore - cumulative wall thickness score; LVM - left ventricular mass; Maronscore - as defined by Spirito and 
Maron (1990); mIVST - maximal interventricular septum thickness; PDE4DIP - phosphodiesterase 4D-interacting protein; mPWT - maximal posterior wall thickness; 
PRKAR1A - Protein kinase cAMP-dependant,regulatory, type 1, alpha, PRKAR2A - Protein kinase cAMP-dependant,regulatory, type 2, alpha            
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CHAPTER 4: DISCUSSION 
In the study leading to the current one, the functions of the N-terminal domain of cMyBPC were explored by 
conducting a series of Y2H library screens using constructs mimicking the various phosphorylation states of the 
C1-C2 region. In two of these screens, using the un- and trisphosphorylated mimic of the C1-C2 region as baits, 
MMGL isoform 4 was identified as novel ligand of this region of cMyBPC. The interaction between MMGL 
isoform 4 and the un- and trisphosphorylated mimic of C1-C2 cMyBPC was confirmed by separate, independent 
methods viz. in vitro co-immunoprecipitation and in vivo colocalization (A. Ramburan, PhD thesis).  
After identifying MMGL as an interactor of PDE4D, Verde et al. (2001) described MMGL as a novel 
structural/scaffolding protein that localizes to the sarcomere in cardiac and skeletal muscle. Moreover, because 
MMGL is expressed at high levels in the Z region of the sarcomere in cardiac and skeletal muscle cells, together 
with other cAMP-signal transduction proteins such as adenylyl cyclase, L-channels and PKA regulatory subunits 
(Gao et al., 1997, Yang et al., 1998), Verde et al. speculated that MMGL may act as a scaffolding protein, 
bringing PDE4D in close proximity to these other proteins so that cAMP signal transduction can take place 
(Verde et al., 2001). However, the precise function and interactions of MMGL had not been investigated. 
Considering the results of the previous study performed in our laboratory, which showed that MMGL isoform 4 
interacts with cMyBPC, a known PKA target (Gautel et al., 1995), together with Verde et al.’s findings, we 
hypothesized that MMGL acts not only as scaffolding protein organizing cAMP-signal transduction proteins 
such as PDE4D, but acts as an anchoring protein for PKA, viz. an AKAP, as well, as it has previously been 
shown that some adaptor proteins can anchor both PKA and PDE4D (Dodge et al., 2001). Further support for 
this hypothesis was gained by Fink et al.’s (2001) study showing that appropriate second messenger 
compartmentalization is crucial for normal cardiomyocyte function, because the disruption of AKAP-mediated 
PKA anchoring to cMyBPC and cTNI had detrimental effects on cardiac contractility following β-adrenergic 
stimulation.  
This study thus set out to investigate the functions of MMGL in the context of the sarcomere. The main finding 
of the present study is the description of MMGL as a novel AKAP, anchoring PKA, together with PDE4D, to 
cMyBPC, for the first time delineating a mechanism by which PKA docks to cMyBPC. Not only does MMGL 
anchor PKA to cMyBPC, but also to at least one other sarcomeric protein whose dynamic phosphorylation is 
crucial to the regulation of contractility, viz. cTNI. Our findings thus describe a mechanism whereby the 
precision and speed of second messenger responses in this specialized area of the sarcomere are optimized, 
which is ultimately key to the regulation of cardiac contractility in response to β-adrenergic signaling. 
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4.1. MYOMEGALIN ISOFORM 4 BINDS TWO DISTINCT PKA-REGULATORY SUBUNITS 
In order for a protein to be classified as an AKAP, it has to show interaction with at least one PKA regulatory 
isoform and participate in protein-protein or protein-lipid interactions to dictate the subcellular localization of 
PKA (Colledge and Scott, 1999, Dodge and Scott, 2000). We used Y2H direct protein-protein interaction assays, 
as described in Section 3.2, to determine whether MMGL isoform 4 interacts with either or both of two distinct 
PKA regulatory subunits. The two subunits chosen were PRKAR1A, based on its known interaction with 
MMGL’s other known interactor, viz. PDE4D (Dodge et al., 2001), and PRKAR2A, which has a high cardiac 
expression. The other two regulatory subunits PRKAR1B and PRKAR2B are expressed predominantly in the 
reproductive and central nervous systems (Cadd et al., 1989, Jahnsen et al., 1985), which rendered them 
unsuitable for this cardiovascular-focused study. 
In the Y2H direct protein-protein interaction assay, both PKA regulatory subunits interacted with MMGL, but 
PRKAR2A appeared to show a stronger interaction with MMGL than PRKAR1A, based on robustness of 
activation of nutritional reporter genes by the PKA subunit-MMGL interaction. One of the basic differences 
between the R1 and R2 subunits is that R1 is found mainly in the cytosol, whereas R2 is particulate bound (Scott 
1993); early studies using different types of animal hearts showed that particulate-bound kinase was almost 
exclusively of the R2 isoform (Corbin et al., 1977). Moreover, independent studies found that different types of 
hormones activate different PKA regulatory isoforms, e.g. R2 was activated by isoproterenol, an adrenergic 
agonist, while R1 was activated by prostaglandin E2, a vasodilator and noradrenalin-release inhibitor (Keely 
1977, Keely 1979, Hayes and Brunton, 1982). The R2 subunit also has a higher binding affinity for AKAPs than 
R1, which facilitates sub-cellular placement of R2 in particulate structures (Carr et al., 1992, Alto et al., 2003). 
This, together with R2A’s high cardiac expression levels, could explain why MMGL showed a stronger 
interaction with PRKAR2A than PRKAR1A in a Y2H setting. One could speculate that, if MMGL functions as 
an AKAP binding PKA to cMyBPC, PKA-II would be the predominant kinase responsible for phosphorylating 
cMyBPC under adrenergic stress. This is supported by McConnell et. al.’s finding that cardiomyocyte 
contractility in response to β-adrenergic stimulation is mediated by anchored pools of PKA, and that 
mislocalized PKA, due to Ht31-mediated AKAP inactivation, alters the phosphorylation of several key proteins 
involved in the process of contractility (McConnell et al., 2009, Fink et al., 2001). MMGL, together with other 
AKAPs involved in the phosphorylation of ryanodine receptors, phospholamban, and L-type calcium channels, 
could be mediating cardiac contractility by creating such anchored pools of PKA throughout the sarcomere. 
Interaction of both PKA regulatory subunits with MMGL isoform 4 was verified in a cellular context and in the 
absence of GAL4 domains using 3D in vivo colocalization and in vivo co-immunoprecipitation (pull down) 
assays. This therefore qualifies MMGL isoform 4 as an AKAP, thereby ascribing a novel function to this protein.  
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In addition, the ability of MMGL isoform 4 to bind two different PKA regulatory subunits shows not only that it 
is an AKAP, but that it functions as a dual-specific AKAP (Colledge and Scott, 1999, Wang et al., 2001). The 
PKA-anchoring domain of most conventional R2-anchoring AKAPs is a conserved amphipathic helix of 14-18 
amino acid residues; this region fits into a hydrophobic groove formed by the regulatory subunit dimer (Carr et 
al., 1992, Hausken and Scott, 1996, Newlon et al., 2001). Single amino acid residues in this conserved region 
determine the specificity of R1 vs R2-binding, and it has been shown that point mutations in this area abolish 
dual-specificity of an AKAP, to preferentially binding either R1 or R2. Moreover, some AKAPs, although 
displaying dual-specificity, prefer interaction with R2, with a weaker binding to R1 (Miki and Eddy, 1999). 
More recently it has been shown that dual-specific AKAPs contain an additional R1 binding determinant known 
as the RI Specifier Region (RISR). This region enhances the targeting of PKA-I (Jarnæss et al., 2008). The 
finding that MMGL isoform 4 displays dual-specificity for PKA regulatory subunits might, amongst other 
things, contribute to future studies exploring PKA isoform specificity on cMyBPC phosphorylation. This could 
involve blocking the different PKA subunit binding domains with AKAP inhibiting peptides such as Ht31, 
which disrupts AKAP-R2A binding, and RI-selective anchoring disrupter peptide (RIAD), which disrupts 
AKAP-R1A interactions (Carlson et al., 2006, Carr et al., 1992).  
4.2. MYOMEGALIN BINDS ADDITIONAL PKA TARGETS 
In order to further elucidate the role of MMGL in the sarcomere, and more specifically, the regulation of cardiac 
contractility, more information about its interacting partners were necessary, and hence a Y2H cardiac cDNA 
library screen, using MMGL isoform 4 as bait, was conducted. As described in Section 3.3, a total of 1130 
clones that were able to activate three reporter genes were screened as putative interactors of MMGL isoform 4. 
After the selection for activation of additional nutritional and colourimetric reporter genes, heterologous bait 
mating and bioinformatic analyses, 13 in-frame cDNA clones were prioritized as putative interactors of MMGL 
isoform 4; these encoded cTNI, CARP, COMMD4, ENO1, ENO3, SNX3, COX5A and a proteosome 26S 
subunit. One clone, cTNI, was pulled out multiple times by the MMGL bait, which suggests that this interaction 
is likely to be biologically significant, and less likely to be an artifact of the Y2H system (Parrish et al., 2006).  
4.2.1. Preys excluded from further analysis  
Many clone inserts had significant DNA matches in the NCBI database (http://www.ncbi.nlm.nih.gov) but were 
out of the reading frame dictated by the upstream GAL4 domain, and therefore, when translated, had no 
significant protein matches in the database. This is a common finding when using cDNA libraries derived from 
oligo dT- primed cDNA, which causes only one out of six of all cloned inserts to be in-frame with the 
transcription factor activation domain (van Criekinge and Beyaert, 1999). This is indeed a big limitation of any 
Y2H library screen making use of commercially available libraries. Peptides encoded by such out-of-frame 
constructs were excluded from further analysis because of their physiological irrelevance. 
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Previously, MMGL isoform 4 was identified as a ligand of cMyBPC, which is located in the C-zone of the 
sarcomere, and for the scope of this study, only putative interactors located within the sarcomere were 
considered for further verification. Therefore COX5A, which encodes part of the terminal enzyme of the 
respiratory complex localized in the mitochondrion, was excluded; however, it should be noted that proteins in 
the mitochondria are also PKA targets, which will also require PKA compartementalization by anchoring to 
various AKAPs, and thus this putative interaction may have physiological relevance and should be investigated. 
Furthermore, the proteosome 26S subunit, which is part of a multicatalytic proteinase complex and localized 
throughout eukaryotic cells, was also excluded from further study. SNX3 is a sorting nexin essential for 
endosome-to-Golgi retrieval of proteins and forms part of a retromer complex for protein trafficking (Verges 
2007). MMGL is found in the Golgi area which makes an interaction with SNX3 very plausible, and thus this 
putative interaction is also plausible and should be investigated in future in order to gain more comprehensive 
understanding of the role of MMGL in the cell.  
An obvious question that arises is why cMyBPC and the two PKA regulatory subunits were not identified as 
preys in the Y2H library screen? The absence of cMyBPC as a prey is most likely explained by the known 
absence of cDNAs representing the N-terminals of large proteins in oligo dT-primed libraries. The absence of 
PRKAR1A and PRKAR2A may relate to the stringency of selection during heterologous bait matings during the 
Y2H screen. One of the baits provided as control by the manufacturer of the MATCHMAKER Y2H screening 
system, and used as control in the heterologous bait mating in this study, encodes murine p53, which is a PKA 
target (Adler et al., 1997). MMGL-PRKA interactions would then have been marked as non-specific, due to 
observation of p53-PRKA interactions.   
Seeing that MMGL is characterized as a PDE4D-interacting protein, one would also expect PDE4D to be 
identified as Y2H prey. Although it is known that rat myomegalin interacts with the amino terminus of PDE4D 
in a region corresponding to the upstream conserved region 2 (UCR2) of PDE4D (Verde et al., 2001), it is 
unknown which MMGL domain specifically interacts with PDE4D. MMGL isoform 4 is the smallest of the five 
different MMGL isoform in humans and one possible reason for the absence of PDE4D amongst the identified 
MMGL interactors, is that it might lack the PDE4D binding domain. Future studies should include a direct Y2H 
protein-protein interaction assay to assess this question more directly. 
4.2.2. Preys chosen for further study 
The putative MMGL isoform 4 interactors that localize to the sarcomere, according to literature were subjected 
to further tests to verify these putative interactions in a real cellular environment, and in the absence of the 
GAL4 domains. In vivo 3D co-localization and co-immunoprecipitations verified all interactions between 
MMGL isoform 4 and CARP, COMMD4, ENO1, ENO3 and cTNI. In addition to cTNI, which is a known PKA 
target (Mohamed et al., 1998; Patel et al., 2001), the other interactors were also shown to be likely PKA targets 
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due to the presence of phosphorylatable motifs (www.hrpd.org/PhosphoMotif_finder), supporting our findings of 
MMGL being an AKAP. A discussion of each interactor will now follow, with proposed mechanisms of function 
in the particular region of the sarcomere pertaining to cMyBPC and MMGL. 
4.2.2.1. Cardiac ankyrin repeat protein (CARP) 
CARP, encoded by ANKRD1, is expressed in the heart during embryonic and fetal development. It functions as a 
transcription cofactor, as well as an early differentiation marker of cardiac myogenesis (Jeyaseelan et al., 1997, 
Zou et al., 1997). CARP expression progressively decreases up to adulthood, but is upregulated during end-stage 
heart failure (Zolk et al., 2002). In hypertrophied hearts of mouse models, increased CARP levels have also been 
observed (Ihara et al., 2002, Baudet et al., 2003). This suggests that CARP plays an essential role in cardiac 
muscle functioning, both in health and disease (Arimura et al., 2009).  
CARP has been localized to both the nucleus and the sarcoplasm, which suggested that it is shuttled between 
cellular compartments (Bang et al., 2001). In the sarcomere, CARP binds to the N2A domain of titin as well as 
the N-terminal domain of myopalladin, suggesting that these two proteins act as anchoring proteins for 
sarcomeric CARP (Bang et al., 2001, Miller et al., 2003). CARP’s interaction with titin is mediated through a 
unique sequence in titin’s N2A domain that is located between the Ig repeats Ig80 and 81. It was found that this 
region contains a tyrosine residue-rich motif that is highly conserved in human, murine and avian titins; such a 
region is also present in cMyBPC (Miller et al., 2003).  
The overproduction of CARP during both heart failure and hypertrophy suggests that CARP-upregulation is a 
common feature of the adaptive response of the myocardium to stress (Mikhailov and Torrado 2008). In vivo 
studies have focused on ANKRD1 regulation during various stress conditions including hypertrophy, ischaemia 
and hemodynamic overload. During the cardiomyocyte stress response, CARP levels are elevated and bind 
directly to a variety of proteins. These include titin, which is involved in biochemical stress signaling; 
myopalladin and desmin, both involved in the management of sarcomeric integrity and myofibril orientation; 
YB-1, involved in the prevention of cell senescence and apoptosis; CASQ2, involved in calcium handling; as 
well as MuRF1 and MuRF2, which are involved in stretch signal inhibition and protein quality control 
(Mikhailov and Torrado 2008). All of these CARP-activated pathways lead to an adaptative response of 
cardiomyocytes to stress.  
Arimura et al. (2009) found that mutations in ANKRD1 are associated with HCM. Mutations caused the binding 
of CARP to titin and myopalladin to increase, and reciprocally, HCM-mutations in titin increases the binding of 
titin to CARP. This suggests that the reversible binding of sarcomeric CARP to titin and/or myopalladin is 
involved in the maintenance of cardiac function (Arimura et al., 2009). Moreover, Arimura et al. (2009) found 
an abnormal intranuclear accumulation of mutant CARP proteins in mature myofibrils, and hypothesized, based 
on the fact that the embryonic and fetal gene program of cardiac cytoskeletal proteins is initiated during cardiac 
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remodeling (Swynghedauw and Baillard 2000, Swynghedauw 1999), that nuclear CARP may cause 
embryonic/fetal gene expression in mature myofibrils. This abnormal gene expression, together with abnormal 
recruitment of CARP in cardiomyocytes may be a possible mechanism causing HCM (Arimura et al., 2009). 
To shed light on the functional relevance of  the interaction of CARP, a transcriptional regulator, and MMGL, 
identified in this study as a novel sarcomeric AKAP, some background on CARP’s main interacting partner, viz. 
titin, is necessary. This giant protein, which spans from the Z-disc all the way to the M-band, connecting the 
different sarcomeric regions, acts as a bidirectional molecular spring, enabling the sarcomere to have a long-
range elasticity (Wang et al., 1979, Linke 2008) and determining muscle stiffness. Titin is subjected to rapid 
turnover and to post-translational modification, which provides a mechanism for tuning the elasticity of titin in 
response to changes in the physiological environment. Titin stiffness can be tuned by two mechanisms: isoform 
switching and phosphorylation by PKA and PKG (Kruger and Linke, 2009). 
Titin isoform switching occurs before or around birth, when the compliant (long spring) fetal N2BA isoform is 
replaced by the smaller, less extensible and stiffer N2B isoform (Lahmers et al., 2004, Opitz et al., 2004). N2B 
becomes the dominant isoform in humans after birth, so that in general, fetal/neonatal sarcomeres are much more 
compliant than those in adult myocardium (Warren et al., 2004, Opitz et al., 2005). This increasing titin stiffness 
throughout development benefits the heart by allowing for a faster beating frequency, and elevated end-diastolic 
pressure, stroke volume and LV dimensions (Kruger and Linke, 2009). In adulthood, the four cardiac chambers 
differ in their N2B:N2BA ratios (Granzier and Labeit, 2004). Titin isoform expression is reversed in patients 
undergoing progression to end-stage heart failure, where the myofibrils are more compliant (Nagueh et al., 
2004). This may be an attempt to compensate for the stiffer extracellular matrix that is frequently observed in 
heart failure due to extensive fibrosis (Nagueh et al., 2004, Makarenko et al., 2004). Mechanisms of isoform 
switching include hormonal changes and the activation of the phosphoinositol-3-kinase (PI3K)/PKB pathway 
(Kruger et al., 2008). 
A much more acute, possibly beat-to-beat, mechanism of titin isoform stiffness modulation is through 
phosphorylation, and next to cMyBPC and cTNI, titin is the third major myofilament protein phosphorylated by 
PKA. This post-translational modification promotes a reduction of passive titin stiffness (Kruger and Linke, 
2006, Kruger and Linke, 2009). During the transition to heart failure and in end-stage failing hearts, PKA 
signaling is severely disturbed. Diastolic function is compromised by elevated titin stiffness due to a 
phosphorylation deficit. PKG phosphorylation also reduces passive stiffness, but to a lesser degree than achieved 
by PKA (van Heerebeek et al., 2006, Borbely et al., 2005). PKA and PKG phosphorylate the same titin domain, 
viz. the N2B-unique sequence, situated in the elastic segment. PKG, in addition, phosphorylates two additional 
domains along the spring segment, viz. the Ig-domains I24/25 of the N2B domain, as well as the N2A region 
(Kruger and Linke, 2006, Kruger et al., 2009). Seeing that PKG phosphorylation reduces passive stiffness to a 
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lesser degree than PKA phosphorylation, it was suggested that these additional PKG sites affect protein-protein 
interactions with titin, rather than altering titin stiffness directly (Kruger et al., 2009). 
Interestingly, CARP binds to titin’s PKG-phosphorylated N2A domain (Miller et al., 2003). If phosphorylation 
of titin by PKG affects protein-protein interactions rather than altering titin stiffness directly, as suggested 
(Kruger et al., 2009), phosphorylation of N2A may cause CARP to dissociate from N2A and shuttle back to the 
nucleus to act as a transcriptional regulator (Witt et al., 2005), causing the upregulation of the more compliant 
N2BA isoform required to reduce passive stiffness in periods of mechanical stress. In this way, phosphorylation 
of N2A indirectly, via CARP transcriptional regulation, could reduce titin passive stiffness. 
Experimental evidence exist that CARP is phosphorylated by casein kinase II and PKC (Chu et al., 1995, Scurr 
et al., 2008); however, no formal proof exists of CARP being phosphorylated by PKA. However, our results 
show that MMGL interacts with CARP; by acting as AKAP, MMGL could bring PKA in close proximity to 
phosphorylate CARP’s two putative PKA sites, as predicted by PhosphoMotif Finder 
(www.hprd.org/Phosphomotif_finder). One of the predicted PKA sites is situated in a coiled-coil domain, which 
is known to participate in protein-protein interactions. One could speculate that, should this site be 
phosphorylated by MMGL-bound PKA, the interaction between CARP and the N2A domain of titin might 
weaken, and along with PKG phosphorylation of N2A itself, cause dissociation of CARP form titin, freeing 
CARP to shuttle back to the nucleus to upregulate N2BA transcription. This might constitute an additional 
mechanism of ANKRD1-associated HCM, where mutated CARP might lack these phosphorylation sites, thus 
reducing the ability of CARP to dissociate from N2A to shuttle to the nucleus and cause upregulation of N2BA, 
and explaining the observed increased binding of mutated CARP to titin (Arimura et al., 2009). A mutated PKG 
site on titin might similarly explain the reciprocal increase of titin binding to CARP (Arimura et al., 2009). Of 
course, the same situation might arise if the MMGL binding site on CARP is mutated, which might cause 
decreased or delayed PKA phosphorylation and hence, decreased or delayed dissociation from titin. 
Interestingly, the predicted PKA site is located ten amino acids downstream from a known HCM-causing CARP 
mutation (Pro52Ala) (Arimura et al., 2009), which is situated between a titin-binding domain and the coiled-coil 
domain. This region may constitute CARP’s MMGL-binding domain, and the Pro52Ala mutation might 
therefore disrupt CARP’s ability to interact with MMGL. Without an AKAP in close proximity to the PKA site, 
spatio-temporal control of phosphorylation in this site would be impaired, preventing CARP from dissociating 
form titin, as described above. This may constitute a mechanism whereby the Pro52Ala mutation causes HCM. 
This proposal should be tested in future studies using direct yeast-based protein-protein interaction assays and 
site-directed mutagenesis.   
Rapid phosphorylation and dissociation should be essential in an acute titin stiffness modulation mechanism 
which is considered to be regulated on a “beat-to-beat” basis. Without an appropriate AKAP, such rapid PKA 
signaling would not be possible. This implicates the CARP-MMGL complex as a transmitter of mechanical 
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stress, and implicates MMGL in another HCM-causing mechanism, underscoring the importance of 
phosphorylation in the regulation of myocardial stress-sensing. 
4.2.2.2. α- and β-enolase (ENO1 and ENO3) 
In cells with high intermittent energy-requirement levels, such as muscle cells, ATP is primarily derived from 
glycolysis (Suarez 2003). Enolase is an enzyme involved in one of the terminal steps of glycolysis, catalyzing 
the conversion of 2-phospho-D-glycerate (2-PGA) to 2-phosphoenolpyruvate (PEP). The enolase dimer is 
formed by the combination of two of the three enolase subunits (α, β and γ) that is encoded by three separate 
genes, viz. ENO1, ENO3 and ENO2, respectively (Feo et al., 1990). During embryonic development, the αα 
homodimer accounts for all enolase activity. As development progresses, especially in areas with high energy 
requirements, such as the brain and muscle, the αα isoform is significantly downregulated and replaced by αγ 
and γγ isoforms in the brain, and by αβ and ββ isoforms in muscle (Comi et al., 2001).  
Interestingly, it was found that α-enolase was significantly upregulated in hypertrophic left ventricles of 
spontaneously hypertensive rats (SHR) (Jin et al., 2006), but in the normal myocardium of Wistar-Kyoto (WKY) 
rats, α-enolase levels were very low (Zhu et al., 2009). A possible reason for this could be the switch from a 
relatively hypoxic uterine environment to relatively higher oxygen conditions postnatally, in other words, the 
myocardium is being exposed to a change in oxygen availability. This is accompanied by a change in substrate 
selection (Nau et al., 2002). In particular, the fetal oxidation of glucose and lactate via glycolysis will shift 
towards a bigger reliance on fatty acids as the main fuel of the adult heart; this will result in the downregulation 
of glycolytic α-enolase, and upregulation of fatty acid oxidation enzymes (Zhu et al., 2009). However, in order 
to maintain an energy supply for efficient cardiac function, the hypertrophic heart has an increased demand for 
oxygen and ATP (Stanley et al., 2005, Mizukami et al., 2004), and increased levels of α-enolase will therefore 
accelerate glucose oxidation rates. Upregulated α-enolase therefore seems to play an adaptive role in myocardial 
hypertrophy (Zhu et al., 2009). 
β-enolase, which is the primary enolase expressed in muscle postnatally, was identified as a binding partner of 
MMGL. This enzyme has been shown to localize to the Z-disc and M-line of the sarcomere (Keller et al., 2000), 
and is known to interact with creatine kinase at the M-line (Foucault et al., 2000). β-enolase anchors to the M-
line via an adaptor protein, FHL2, which binds it to titin (Lange et al., 2006). β-enolase has also been identified 
as an interactor of cMyBPC itself (A.Ramburan, PhD thesis). It has been suggested that the recruitment of 
metabolic proteins to sarcomeric regions may provide a structural role; this complex therefore might stabilize the 
particular sarcomeric regions (Clark et al., 2002). Importantly, Lange et al. (2006) also showed that metabolic 
enzyme complexes like this β-enolase complex are common throughout the sarcomere in areas of high energy 
demand. A complex consisting of cMyBPC, MMGL and β-enolase in the C-zone of the sarcomere would 
therefore be advantageous for two main reasons. Firstly, cMyBPC and MMGL are part of a β-adrenergic 
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pathway leading to increased contractility during times of increased cardiac demand, in which case it would be 
advantageous to have β-enolase anchored on site to produce energy via glycolysis. Secondly, the binding 
between MMGL, an adaptor protein, and β-enolase, a metabolic protein, to cMyBPC might stabilize the C-zone 
of the sarcomere, which is desirable seeing that it undergoes sudden changes in motion all the time.  
Identifying α-enolase as an interactor of MMGL is less easily explained, as α-enolase expression is 
downregulated to almost negligible levels after birth under normal circumstances and replaced by β- and αβ-
enolase in muscle (Comi et al., 2001); one would not expect it to be expressed significantly in a normal adult 
cardiac cDNA library. The levels of β-enolase increase as the energy demand of the muscle fibre type increases, 
however, this phenomenon is not observed in α-enolase levels (Keller et al., 2000). However, a few possibilities 
exist: Firstly, the explanation for its presence in the library, which was reportedly constructed from cDNA 
extracted from normal, whole hearts from 3 male Caucasians aged between 28 and 47 years, could be occult 
hypertension in one or more of the donor subjects. The study by Zhu et al. (2009) found upregulation of α-
enolase in hypertrophic hearts of spontaneously hypertensive rats. Hypertension is often overlooked, especially 
in the incipient stages, and does not result in immediate changes in cardiac morphology, hence a donor heart may 
have appeared normal at time of death, even though molecular changes had already begun to take place. Then, 
given the presence of α-enolase in the cDNA library, the observed interaction between MMGL and α-enolase 
may rather reflect a three-way interaction involving the αβ-heterodimer and MMGL (considering that β-enolase 
is also an interactor of MMGL), rather than the α-enolase homodimer. Alternatively, α- and β-enolase share 83% 
homology on amino acid level (www.ncbi.nlm.nih.gov/BLASTP), therefore, the MMGL-binding domain on α-
enolase might be situated in an area of high β-enolase homology. This might implicate that that α-enolase was 
only pulled out as a prey because of the high homology across the β-enolase MMGL-binding site. Given other 
findings in our laboratory, viz. that cMyBPC interacts with β-enolase (A. Ramburan, PhD thesis) and 
COMMD4, which also interacts with MMGL as well as with cMyBPC, interacts with α-enolase (C. Swanepoel, 
PhD thesis), the results of MMGL interacting with β-enolase, and possibly with αβ-enolase, suggests a possible 
complex interaction of the αβ-heterodimer with the ligands MMGL, cMyBPC and COMMD4. MMGL could 
anchor αβ-enolase to cMyBPC in the sarcomere to provide increased energy via glycolysis for β-adrenergic fight 
or flight responses, as already described in this section. However, MMGL could also bind αβ-enolase to one of 
its other ligands identified in this study viz. COMMD4. COMMD4 is implicated in protein trafficking and 
turnover, and functions as an adaptor protein that stabilizes the interaction between cMyBPC and an E3 ligase. 
E3 ligase functions by attaching ubiquitin molecules to cMyBPC to mark it for degradation by the ubiquitin 
proteasome system (UPS), which takes place after cMyBPC has been released from the sarcomere (C. 
Swanepoel, PhD thesis), as will be discussed in Section 4.2.2.3. This protein degradation process requires 
energy, which could be provided by glycolysis through αβ-enolase attached to COMMD4 via MMGL.  
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Both α- and β-enolase contain putative PKA phosphorylation sites, which makes the interaction between these 
glycolytic enzyme dimers and MMGL, an AKAP, plausible. Phosphorylation of these sites could mediate 
protein-protein interactions and/or alter the enzyme’s catalytic properties. Considering the various proteins that 
all seem to interact in one multi-protein complex, a means of regulating these interactions is necessary. β-
adrenergic stimulation might result in phosphorylation of αβ-/β-enolase via MMGL-anchored PKA, which could 
facililtate its binding to cMyBPC (which would also be simultaneously phosphorylated by MMGL-bound PKA) 
to compensate for the increased energy demands required in this part of the sarcomere by anchoring, and 
activating, an energy-producing enzyme on site. Following the β-adrenergic signal, MMGL-bound PDE4D 
would then hydrolyze the remaining cAMP, and the reduced PKA levels might cause dissociation and 
deactivation of αβ-/β-enolase from cMyBPC. αβ-Enolase might bind to COMMD4 in the same phosphorylation-
dependent manner, when energy is required for the degradation of cMyBPC by the UPS after it has been 
released from the sarcomere (see Section 4.2.2.3.).  
4.2.2.3. Copper Metabolism Gene MURR1 Domain 4 (COMMD4) 
The COMM (Copper metabolism gene MURR1) domain-containing family consists of ten members and is found 
in all vertebrates. These proteins are characterized by the presence of a highly conserved and unique C-terminal 
COMM domain and an α-helical rich N-terminal region present in all ten members of the family. The COMM 
domain functions as a critical interface for protein-protein interactions and defines this family of proteins 
(Burstein et al., 2005). However, since this family has only recently been defined, members, including 
COMMD4, have not been extensively studied. COMMD1 has been studied to a greater extent, and will be 
discussed as example to demonstrate the possible functions and roles that COMMD4 plays. COMMD1 functions 
in two distinct cellular activities viz. regulation of the transcription factor NF-κB and control of copper 
metabolism (Burstein et al., 2005).  
NF-κB is a transcription factor and is associated, amongst other things, with cardiac hypertrophy development, 
cell survival and inflammation. All COMMD family members are capable of inhibiting NF-κB transcriptional 
activity (de Bie et al., 2006, Burstein et al., 2005). The termination of the NF-κB response is mediated by 
COMMD1 by its association with a Cullin 2-containing ubiquitin ligase, and it is predicted that other COMMD 
proteins will possibly also associate with ubiquitin ligases to play a role in protein turnover and degradation 
(Burstein et al., 2005). To initiate the progression from hypertrophy to heart failure requires signaling pathways 
that can stimulate NF-κB activation (Li et al., 2004, Gupta et al., 2008); this makes the inhibition of COMMD-
assisted NF-κB inactivation clinically very interesting. 
COMMD1 also interacts with the copper transporter ATP7B, responsible for excreting copper in the bile 
(Burstein et al., 2005). There is a well recognized association of copper deficiency with cardiomyopathy as well 
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as other cardiac diseases (Klevay 2000), and it has been shown that the deterioration in cardiac function and 
morphology can be reversed upon copper repletion (Elsherif et al., 2004).  
Sarikas et al. showed that truncated cMyBPC proteins resulting from mutations in cMyBPC are degraded by the 
UPS system, however, truncated mutant cMyBPC impairs the proteolytic capacity of the UPS by forming 
ubiquinated aggregates, and it was suggested that this impairment could be a mechanism of HCM pathogenesis 
related to frameshift mutations. However, it was not mechanistically clear how truncated cMyBPC causes 
impairment of the UPS (Sarikas et al., 2005). Interestingly, COMMD4 was identified as a ligand of the 
monophosphorylated MyBPC motif (A. Ramburan, PhD thesis). Seeing that COMMD proteins associate with 
ubiquitin ligases, it was speculated that severely truncated cMyBPC, lacking the MyBPC motif, is unable to bind 
to COMMD4. A study in our laboratory concurrent with the present one suggested that COMMD4 acts as an 
adaptor protein that stabilizes the interaction between cMyBPC and the E3 ubiquitin ligase (C. Swanepoel, PhD 
thesis). E3 ligase is essential for the polyubiquitination process by attaching ubiquitin molecules to cMyBPC to 
mark it as a target protein for recognition and degradation by the UPS. At least four attached ubiquitins are 
necessary for recognition of the protein for degradation (Mukhopadhyay and Riezman, 2007); therefore, the 
mutant proteins may pass through the first step of being marked for degradation, but because of the inability of 
COMMD4, together with E3 ligase, to bind to severely truncated cMyBPC, cannot become polyubiquinated. 
This will lead to a buildup of truncated protein and subsequent impairment of the UPS (C. Swanepoel, PhD 
thesis). Other cMyBPC mutations, leading to a less severely truncated protein which still retains the MyBPC 
motif, did not form ubiquinated aggregates (Sarikas et al., 2005). This is congruent with the ability of COMMD4 
to bind to the retained MyBPC motif and complete degradation occurring consequently. 
The UPS degrades abnormal proteins and therefore serves as an essential quality control system in the cell. 
Impairment of this system could be detrimental to cardiomyocytes, because the buildup of proteins that should 
have been removed, such as signaling proteins and transcription regulators could activate transcription and other 
processes that result in hypertrophy (Powell 2006). COMMD4 levels may also rise due to a lack of substrate, 
which may result in increased copper clearing, leading to copper depletion, which also has been implicated in 
cardiomyocyte hypertrophy (Elsherif et al., 2004). 
COMMD4 was identified as ligand of monophosphorylated cMyBPC. Moreover, in the concurrent study on 
COMMD4, the protein was shown to interact with Down syndrome critical region 3 protein (DSCR3), F-box and 
leucine-rich repeat protein 10 (FBXL10) (an E3 ligase subunit) and legumain (LGMN) (C. Swanepoel, PhD 
thesis). These proteins are involved in protein trafficking and degradation. Moreover, COMMD4 also binds to 
SNX3 and ENO1, in addition to cMyBPC; thus, COMMD4 shares three interactors with MMGL. The MMGL-
COMMD4 interaction therefore strongly suggests that a multiprotein complex consisting out of kinases, 
phosphodiesterases, glycolytic enzymes and proteins responsible for intracellular trafficking and degradation are 
anchoring simultaneously to a downstream target viz. cMyBPC. However, it is more likely that this multiprotein 
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complex assembles when cMyBPC has been released from the sarcomere for turnover by the 26S proteasome 
complex, and not within the sarcomere. A large multiprotein complex in the confines of the thick and thin 
filaments might sterically hinder crossbridge formation, especially during β-adrenergic stimulation. MMGL may 
serve as a scaffold stabilizing this cellular machinery in close proximity to ubiquinated cMyBPC thereby 
ensuring optimum precision and timing of cellular responses in the proteasome complex.  
Assembly of such a multiprotein complex involved in intracellular trafficking and degradation would require a 
means of regulating which proteins to bind and at which time (i.e. when cMyBPC is released from the sarcomere 
for turnover). Such regulation could be achieved by phosphorylation. COMMD4 has putative PKA sites, which 
makes it plausible that MMGL, an AKAP, binds to it to bring PKA in close proximity to its target. Members of 
the COMMD protein family rely on protein-protein interactions to exert their functions, and these often involve 
the COMM domain (Burstein et al., 2005). Most of these putative PKA sites are situated in the COMM domain 
of COMMD4, which is used by members of the COMMD protein family to effect protein-protein interactions, 
by means of which they execute their functions. Thus phosphorylation could alter this domain’s interactions with 
its binding partners and so modulate COMMD4 function. It could be speculated that MMGL might therefore not 
only play a role in stabilizing this complex, but also ensure that COMMD4 is phosphorylated by PKA, and 
hence, modulating protein-protein interactions in this complex. Following protein degradation, MMGL-bound 
PDE4D could hydrolyze the cAMP signal, attenuating PKA phosphorylation. Unphoshorylated COMMD4 
might then dissociate from its binding partners, and assembly of the complex may start again upon 
phosphorylation, to initiate cMyBPC turnover and degradation. 
4.2.2.4. Cardiac troponin I (cTNI) 
The troponin complex, together with tropomyosin, forms the calcium-sensitive switch on the thin filament that 
activates contraction. The troponin complex consists of three proteins: the Ca
2+
-binding subunit, troponin C 
(TNC), the tropomyosin-binding subunit, troponin T (TNT) and the inhibitory subunit, troponin I (TNI). These 
subunits are expressed as different isoforms depending on the tissue type, and in the heart, the inhibitory subunit 
is encoded by TNNI3 and known as cardiac (c) TNI. In addition to Ca
2+
, protein-protein interactions in the 
troponin complex are also modulated by cTNI phosphorylation. Human cTNI has primary phosphorylation sites 
at Ser23/Ser24, Ser43/Ser45 and Thr144. Ser23/Ser24 are located in a cardiac-specific N-terminal region, and 
are PKA and PKC substrates, with Ser43/Ser45 and Thr144 being PKC substrates (Noland et al., 1989).  
Numerous excellent reviews are available on the effects of PKA-induced phosphorylation of cTNI and its 
physiological roles (Solaro et al., 2007, Layland et al., 2005, Gomes and Potter, 2004). In short, PKA 
phosphorylation at Ser23/Ser24 of cTNI results in a change in the cardiac-specific N-terminal interactions 
between cTNI and cTNC, reducing Ca
2+
 sensitivity of the latter (Solaro et al., 2008). In particular, 
phosphorylation at Ser23/Ser24 weakens the interactions between cTNI and cTNC, which causes the acidic N-
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terminal of cTNI to bend. The acidic N-terminal subsequently interacts with the inhibitory region of cTNI, which 
results in the weakening of the interaction of the inhibitory region with actin, altering crossbridge reactions 
(Sakthivel et al., 2005). In particular, the desensitization of the myofilament due to PKA-induced cTNI 
phosphorylation, as well as an increase in the rate of Ca
2+
 dissociation from cTnC together causes acceleration of 
relaxation (Abbott et al., 2001, Kentish et al., 2001). Because of this, the crossbridge cycling rate increases and 
unloaded shortening velocity increases, all together contributing to the well-known β-adrenergic-induced 
lusitropy (Zhang et al., 1995, Strang et al., 1994, Herron et al., 2001). 
Animal models are useful in demonstrating the role of PKA-induced cTNI phosphorylation on the lusitropic 
effect of β-adrenergic stimulation. In transgenic mouse models where cTNI was replaced with skeletal TNI, 
which lacks the N-terminal with the phosphorylatable Ser residues, β-agonist-induced lusitropy was significantly 
blunted, PKA-induced increases in unloaded shortening velocity was abolished, and the crossbridge cycling rate 
was decreased (Fentzke et al., 1999, Kentish et al., 2001). This suggested that phosphorylation of the N-terminal 
of cTNI is crucial for these physiological effects to take place. Mice which expressed mutant cTNI where the Ser 
residues were replaced with non-phosphorylatable alanines, showed decreased myofilament Ca
2+-
sensitivity after 
β-adrenergic stimulation, and a reduction in the lusitropic effect (Pi et al., 2002, Pi et al., 2003). In mice 
expressing mutant cTNI where the Ser residues were replaced by aspartate residues mimicking a constantly 
phosphorylated state, enhanced left ventricular relaxation were observed compared to animals expressing normal 
cTNI, especially noticeable at increased heart rates. Upon isoproterenol treatment, this effect was similar in both 
groups (Takimoto et al., 2004). 
Playing such a crucial role in crossbridge kinetics, it is not surprising that mutations in TNNI3 have been 
implicated in HCM. Many of the cTNI mutations cause an increase in Ca
2+
-sensitivity, which could lead to 
hypercontractility resulting in an increased energy demand. An increase in Ca
2+
-sensitivity could also have an 
effect on slowing the rate of relaxation (Gomes and Potter, 2004).  
PKA-dependent phosphorylation of Ser23/Ser24 in the cardiac-specific N-terminal of cTNI is thus essential for 
normal crossbridge cycling. Specificity of second messenger responses due to β-adrenergic signaling acting on 
cTNI is therefore required for efficient contractility regulation under different stresses, and this is partly achieved 
by anchoring PKA to cTNI via AKAPs (McConnell et al., 2009). However, the specific AKAP/s responsible for 
this targeting has been unknown until now. McConnell et al. have disrupted global PKA-AKAP binding by in 
vivo gene transfer of Ht31, a competing RII-binding peptide, and showed that in order to achieve maximal 
phosphorylation of PKA substrates upon β-adrenergic signaling, a local pool of PKA is needed in close 
proximity to its target (McConnell et al., 2009). Phosphorylation of cTNI in vivo, along with other PKA 
substrates viz. PLB and RyR2, was significantly reduced upon isoproterenol stimulation of Ht31-expressing 
hearts compared with isoproterenol-stimulated controls, leading to increased cardiac contractility (McConnell et 
al., 2009). cTNI is also subjected to increased calpain-dependent proteolysis when Ser23/Ser24 are 
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dephosphorylated, causing truncation of the cardiac-specific N-terminal (Di Lisa et al., 1995). Ht31-mediated 
disruption of PKA-AKAP interaction resulted in an increase of N-terminal truncation, presumably due to 
reduced phosphorylation of the N-terminal Ser sites. It could be speculated that upon phosphorylation, 
conformational changes occur which alters the accessibility of the cleavage site, and therefore protects cTNI 
against cleavage (McConnell et al., 2009).  
The present study therefore identified MMGL as an AKAP that is responsible for creating a local pool of PKA 
close to cTNI, mediating the physiological responses to β-adrenergic signaling as described in this section. It is 
interesting to note how cTNI and cMyBPC phosphorylation overlaps. Both contain phosphorylation sites in their 
N-terminals that is cardiac-specific. Upon phosphorylation, cMyBPC and cTNI together causes increased rates 
of cross-bridge cycling and decreased Ca
2+
 sensitivity of force (Layland et al., 2005), and together with altered  
Ca
2+-
handling, contribute to increased twitch force, decreased twitch duration as well as increased rates of 
relaxation (Katz and Lorell, 2000). Separately, cTNI phosphorylation is mainly responsible for reducing Ca
2+
 
sensitivity, with cMyBPC phosphorylation playing the dominant role in the PKA-mediated modulation of 
crossbridge cycling rate and force development (Stelzer et al., 2007). Phosphorylation of both cTNI and 
cMyBPC also protects each protein against proteolytic cleavage, contributing to a cardioprotective effect 
(McConnell et al., 2009, Sadayappan et al., 2006). Identifying a single AKAP able to anchor PKA, together with 
PDE4D, to both these regulatory proteins, both of which have been implicated in HCM when mutated, could 
therefore be of important clinical relevance for HCM and heart failure in general. 
4.3. MYOMEGALIN ISOFORM 4 IS A NOVEL SARCOMERIC AKAP 
The current AKAP anchoring model incorporates four important concepts. In order for a protein to be classified 
as an AKAP, it has to meet these four requirements being 1.) it must interact with the R-subunit of PKA in cells 
2.) the unique targeting domains within each AKAP should participate in either protein-protein or protein-lipid 
interactions, which will determine the subcellular localization of PKA, 3.) it should be able to coordinate 
multiple signaling pathways by anchoring additional signaling enzymes such as phosphodiesterases, 
phosphatases and other kinases, and 4.) lastly, it should be able to form larger, multiprotein units by binding 
additional anchoring and scaffolding proteins (Colledge and Scott, 1999, Dodge and Scott, 2000, Colledge et al., 
2000, Fraser et al., 2000). 
MMGL isoform 4 meets all four requirements. It interacts with two distinct R-subunits of PKA (PRKAR1A and 
PRKAR2A), thereby displaying dual-specifity. By interacting with other PKA targets, such as cTNI and 
cMyBPC, it demonstrates that the targeting domains contained within MMGL participate in protein-protein 
interactions. MMGL also meets the criterion for being able to coordinate multiple signaling events by anchoring 
additional enzymes by interacting with PDE4D (Verde et al., 2001) and enolase. Moreover, MMGL meets the 
final criterion of binding to other adaptor and scaffolding proteins by binding to COMMD4 (C.Swanepoel, 
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personal communication) and CARP. Our results strongly suggest that MMGL forms part of a larger, 
multiprotein unit, as Y2H screens have shown that cMyBPC also binds to COMMD4 and ENO3, here shown to 
be MMGL interactors, while COMMD4 itself also binds to ENO1 and SNX3 (A. Ramburan, PhD thesis, C. 
Swanepoel, PhD thesis). MMGL isoform 4 may therefore function as a vital link in signaling between upstream 
activators and numerous downstream targets. It is important to note that some of these interactions certainly 
occur within the sarcomere, but that not all interactions necessarily occur within the sarcomere, nor do they 
necessarily all occur concurrently. 
By the beginning of 2006, there were no AKAPs known that were responsible for the phosphorylation of 
sarcomeric proteins (Dodge-Kafka et al., 2006). Currently, several AKAPs have been described in 
cardiomyocytes, yet there are still very few AKAPs known to be responsible for phosphorylation of sarcomeric 
proteins. As example, an intermediate filament protein that functions as an AKAP, localized at the Z-disc, has 
been identified: synemin was speculated to participate in the regulation of myofilament protein phosphorylation 
(Russell et al., 2006). We add to this list by identifying MMGL isoform 4 as a novel dual-specific AKAP that 
interacts with two sarcomeric PKA targets, viz. cMyBPC and cTNI. 
Furthermore, imaging of cardiomyocytes treated with the β-adrenergic agonist isoproterenol showed a higher 
level of colocalization between MMGL and its two sarcomeric PKA targets, cMyBPC and cTNI. This implies 
that under adrenergic stress, and consequential increased intracellular cAMP levels, PKA is dynamically 
recruited by MMGL isoform 4 to distinct sarcomeric locations to mediate cardiac stress responses, leading to 
increased cardiac contraction.  
However, the observed increase in colocalization between MMGL with both cMyBPC and cTNI did not reach 
statistical significance. This observation is most likely due to the small sample sample size (n=3), resulting in 
inadequate statistical power, and not due to an inadequate concentration of isoproterenol, shown by McClellan et 
al. (2001) to be an effective concentration to induce β-adrenergic stimulation of cardiomyocytes. An increase in 
sample size would probably result in statistical significance, and this should be tested by additional experiments. 
 
Moreover, MMGL-bound enolase would also be at the cMyBPC site to provide additional energy via glycolysis 
for the increased workload. Furthermore, MMGL would also act as AKAP in a different sarcomeric region, viz. 
titin’s N2A domain, to enable PKA phosphorylation of CARP, and thereby regulate part of the myocardial 
stress-sense response by allowing CARP to dissociate from N2A and shuttle to the nucleus to upregulate the 
more compliant N2BA titin isoform. Outside the sarcomere, MMGL acts as AKAP by binding to COMMD4, as 
well as enolase, to facilitate control of efficient PKA phosphorylation of these proteins to mediate protein-
protein interactions and enzyme activation in order to effect cMyBPC degradation via the UPS, and to supply 
this system with glycolytic energy. Lastly, the MMGL-bound PDE4D on these sites will terminate the second 
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messenger response by degrading cAMP. The lower levels of cAMP may then cause these multiprotein 
complexes to dissociate again. 
 
4.4. MYOMEGALIN IS AN ESSENTIAL PART OF THE β-ADRENERGIC PATHWAY LEADING TO 
TRISPHOSPHORYLATED cMYBPC 
Our knockdown studies of MMGL isoform 4 (Section 3.5) further suggests that MMGL not only acts as an 
AKAP at the MyBPC motif, but is an important link in adrenergic signaling and the regulation of cardiac 
function. In the presence of MMGL, all phosphorylation isoforms of cMyBPC are expressed well in H9C2 cells, 
and the level of the trisphosphorylated form of cMyBPC increases in such cells when they are treated with CaCl2 
and isoproterenol, i.e. under conditions of β-adrenergic stimulation. 
However, with knockdown of MMGL under the same conditions of adrenergic stimulation, cMyBPC expression 
is dramatically reduced. These results can be interpreted as follows: during β-adrenergic stimulation, increased 
levels of cAMP activate PKA, which is subsequently targeted to the N-terminal of cMyBPC by binding to 
MMGL isoform 4. This ensures optimum phosphorylation of the MyBPC motif, and hence, enhanced cardiac 
contraction. When MMGL is not expressed, cMyBPC phosphorylation would be hindered, rendering the protein 
vulnerable to cleavage by proteases like calpain I (Section 1.2.4) (Decker et al., 2005, Sadayappan et al., 2009), 
leading to reduced cMyBPC levels in the cell, as observed in the knockdown experiment under adrenergic 
conditions. Typically, annulment of the effect of an AKAP is commonly more noticeable on the target protein 
only after adrenergic stimulation: The study of McConnell et al. (2009) showed no significant difference in the 
level of phosphorylation of cTNI, PLB and RyR2 between Ht31-transfected versus control rat hearts. However, 
upon isoproterenol stimulation, dramatically decreased levels of PKA phosphorylation of all three proteins was 
observed in Ht31-transfected hearts compared to isoproterenol-stimulated hearts not expressing Ht31. Fink et al. 
(2001) also observed that isoproterenol stimulation resulted in significantly reduced PKA-dependent 
phosphorylation of cTNI and cMyBPC in cardiomyocytes expressing Ht31 compared to controls, and 
demonstrated that AKAPs regulate phosphorylation of these PKA targets in response to β-adrenergic 
stimulation, although it has been unknown which AKAP/s are responsible for the phosphorylation of these two 
proteins up till now. Thus, it appears that MMGL is an essential part in the β-adrenergic pathway leading to 
trisphosphorylation of cMyBPC and protection of the protein against degradation. The effects of MMGL 
knockdown on cTNI phosphorylation should also be investigated; however, due to time-constraints this was not 
attempted in the present study. Like cMyBPC, increased PKA phosphorylation of cTNI renders the protein 
resistant to N-terminal cleavage by calpain-dependent proteolysis, and it has been shown that disruption of 
cardiac PKA-AKAP binding under β-adrenergic conditions lead to a decrease in cTNI phosphorylation plus an 
increase in cTNI N-terminal cleavage, analogous to what was observed for cMyBPC in the present study 
(McConnell et al., 2009). However, in the McConnel et al. study the disrupted PKA-AKAP interactions were 
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mediated by the non-specific RII binding peptide i.e. Ht31, so the AKAP/s involved in this pathway were not 
identified. MMGL is a good candidate and a study of the effects of MMGL knockdown on cTNI expression and 
phosphorylation could shed light on these findings.  
4.5. A MODEL OF CONTRACTION INCORPORATING MYOMEGALIN AND ITS LIGANDS  
The contractile properties of muscle changes in response to phosphorylation of sarcomeric proteins, thus creating 
a converging point of complex signaling events in the cell (Montgomery et al., 2002). Together with its role in 
maintaining part of the structural arrangement of the sarcomere, cMyBPC phosphorylation plays a crucial role in 
regulating force by facilitating interaction between the thick and thin filaments (Flashman et al., 2004, Tong et 
al., 2008). cMyBPC acts as a link by tethering the myosin heads and the actin filaments, thereby facilitating the 
activation of crossbridge formation (Colson et al., 2008). Phosphorylation of cMyBPC via adrenergic 
stimulation leads to acceleration of crossbridge recruitment and force generation rates to match the stretch 
activation response to increases in chronotropy (Stelzer et al., 2006).  
The C-terminal domains (C8-C10) of cMyBPC interact with the thick filament, by binding to titin and the 
myosin rod (Freiburg and Gautel, 1996). When cMyBPC is unphosphorylated, the N-terminal (C1-C2) interacts 
with myosin S2, thereby inhibiting myosin binding to actin, preventing crossbridge formation (Kunst et al., 
2000, Kulikovskaya et al., 2003). In the unphosphorylated state, part of the N-terminal (C1 and the MyBPC 
motif) also binds to actin (Shaffer et al., 2009, Kulikovskaya et al., 2003) (Figure 4.1A). In addition, domains 
C0-C1 bind actin irrespective of the phosphorylation state of the MyBPC motif. The latter interaction allows for 
tethering of the thick and thin filament, thus cMyBPC structurally couples the thick and thin filaments (Shaffer 
et al., 2009). However, upon maximum phosphorylation of the MyBPC motif by CaMK and PKA, the 
interaction between the N-terminal of cMyBPC and myosin S2 is abolished (Kunst et al., 2000). This frees the 
myosin heads to make contact with actin, thus initiating force generation. Concurrently, the interaction between 
the MyBPC motif and actin is also lost. 
It has been suggested that the MyBPC motif might block myosin S1 binding to actin, limiting crossbridge 
formation; upon phosphorylation, the unbinding of the motif from actin could then enable myosin binding and 
hence crossbridge formation. Alternatively, the unphosphorylated MyBPC motif could be free to bind to other 
ligands such as thin filament regulatory proteins (Shaffer et al., 2009, Razumova et al., 2006). Interestingly, in a 
Y2H library screen conducted in our laboratory, cTNI was found to be one of the most frequent interactors of the 
C1-C2 region of cMyBPC; this interaction was also shown to be affected by the phosphorylation status of the 
MyBPC motif. Specifically, binding of cTNI to C1-C2 involved a trisphosphorylated motif, as opposed to 
myosin S2 and actin that bind to an unphosphorylated motif. This particular study also confirmed the binding of 
the C1-C2 domains to actin and that it involved the unphosphorylated MyBPC motif. It is therefore likely that 
the MyBPC motif shuttles between actin and cTNI, depending on the phosphorylation state of the motif. 
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(A.Ramburan, PhD thesis, Ramburan et al., article in preparation). Therefore, the C1-C2 region is able to 
crosslink thick and thin filaments, possibly by using different surfaces to bind actin, and cTNI vs myosin S2, 
depending on the phosphorylation state of the motif, and thereby improving contractile efficiency. Figure 4.1B 
illustrates these changes described in response to phosphorylation. 
It is therefore plausible that two PKA targets, i.e. cMyBPC and cTNI, which are both implicated in the 
regulation of cardiac contractility by increasing crossbridge cycling rates in response to phosphorylation, should 
have a means of ensuring spatial and temporal control over phosphorylation in response to second messenger 
signaling. The mechanism of PKA anchoring to these proteins have never been described; the findings of the 
present study strongly suggest that MMGL isoform 4 acts as AKAP to anchor PKA to these two sarcomeric 
proteins in response to β-adrenergic signaling, and thereby ensures optimum precision and speed of second 
messenger responses in this specialized area of contraction.  
We, therefore, speculate that the following sequence of events might occur to facilitate cardiac contractility in 
response to stress: Membrane depolarization will cause a release of a small amount of Ca
2+
 via voltage-gated L-
type channels, and this will cause the activation of CaMK, which will phosphorylate the first site (B) of the 
MyBPC motif (McClellan et al., 2001). This in turn will cause the myosin heads to be ordered in a more tight 
structure along the thick filament backbone. The transient Ca
2+ 
concentration, which is not sufficient to directly 
activate the myofilaments, will subsequently serve as trigger to release Ca
2+
 from the sarcoplasmic reticulum via 
ryanodine receptors, and this increased level of Ca
2+ 
will lead to a greater Ca
2+
 affinity in cTNC. Ca
2+ 
activation 
of cTNC will result in a conformational change of the troponin complex, causing the release of the inhibitory 
region of cTNI from actin, and enabling crossbrigde formation (Li et al., 1999, Dong et al., 2003).  
Upon β-adrenergic stimulation, the levels of diffusible cAMP will increase, leading to the activation of PKA. 
This will lead to phosphorylation of a number of sarcomeric and Ca
2+ 
handling proteins, such as L-type Ca
2+ 
channels, RyR2, PLB, cMyBPC and cTNI, of which only cMyBPC and cTNI will be described here. 
Specifically, the binding of adrenaline or noradrenaline to the G-protein-coupled receptor will activate the G-
protein, thereby activating adenylyl cyclase to convert ATP to cAMP, which in turn will activate PKA. cAMP-
activated, MMGL-bound PKA will phosphorylate the remaining two sites (A and C) on the MyBPC motif, 
leading to di- and trisphosphorylation of cMyBPC, which then results in greater order of the myosin heads and a 
looser packing of the myosin backbone (Levine et al., 2001).  
Although MMGL can bind to the C1-C2 region of cMyBPC irrespective of the phosphorylation state 
(A.Ramburan, PhD thesis), the increased levels of colocalization of MMGL with cMyBPC (and cTNI) observed 
upon β-adrenergic stimulation (Section 3.4) suggests that additional MMGL-PKA complexes could be recruited 
from the cytosol during times of physiological/pathological stress. Interestingly, the AKAP Yotiao, which targets 
PKA to the K
+
 channel responsible for Iks (Section 1.3.5.3), is itself also a substrate for PKA: phosphorylation of 
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Yotiao increases the functional response of the phosphorylatable cardiac IKS channel to cAMP, whereas channel 
activation decreased when Yotiao is incapable of being phosphorylated, despite remaining functionally intact as 
an AKAP (Chen et al., 2005). The study by Chen et al. thus showed for the first time that an AKAP itself may 
actively participate in the functional regulation of a target protein, and may play a more important role than 
merely acting as adaptor (Chen et al., 2005). MMGL isoform 4 contains putative phosphorylation sites predicted 
by Phosphomotif Finder (www.hrpd.org/PhosphoMotif_finder), including PKA and CaMK II sites. Considering 
the above, the increased levels of colocalization between MMGL and cMyBPC (and cTNI) might be explained 
by the same principle in that MMGL may first need to be phosphorylated itself in order to recruit PKA to the 
target site, and/or to bind to the target site, or its ability to do so may be enhanced upon its own phosphorylation.  
Therefore, the release of Ca
2+
 upon membrane depolarization will activate CaMK II, which will phosphorylate 
not only the first site (B) on the MyBPC motif, but may also phosphorylate MMGL. Additionally, 
phosphorylated MMGL might be able to bind with a higher affinity to cMyBPC (and cTNI) and recruit PKA to 
phosphorylate the remaining sites on the MyBPC motif (or cTNI). Although binding of PDE4D to isoform 4 of 
MMGL was not investigated in this study, it would be plausible that MMGL-bound PDE4D may also be on site 
to hydrolyze the increased amounts of cAMP, eventually attenuating the cAMP signal. This fits with the finding 
that  MMGL interacts with the C1-C2 region of both unphosphorylated and trisphosphorylated cMyBPC: in the 
unphosphorylated state, MMGL would target PKA to phosphorylate the MyBPC motif, and in the 
trisphosphorylated state, MMGLwould anchor PDE4D to cMyBPC in order to hydrolyze the excess cAMP and 
attenuate the signal.  
Therefore, in addition to increased levels of Ca
2+
 leading to the activation of the molecular switch of contraction 
involving the troponin-tropomyosin complex, MMGL-bound PKA trisphosphorylation of cMyBPC would 
enhance cardiac contractility by initiating the following events: Trisphosphorylation of the MyBPC motif will 
cause the interaction between the motif and myosin S2 to be abolished, enabling the myosin heads to be free to 
make contact with actin (Kunst et al., 2000). The interaction between the MyBPC motif and actin would 
concurrently be abolished (Shaffer et al., 2009), causing the trisphosphorylated motif to switch to bind to cTNI 
(Ramburan et al., article in preparation) and freeing actin to bind to the myosin heads, thereby accelerating 
crossbridge recruitment and force generation rates and matching the stretch activation response to the increased 
heart rate. Additionaly, as described in Section 4.2.2.4, phosphorylation of the N-terminal of cTNI by MMGL-
bound PKA would add to the adaptation of cardiac muscle to the increased stress by reducing myofilament 
sensitivity to Ca
2+
, as well as increasing the crossbridge cycling rate by reducing the binding affinity of cTNC 
for Ca
2+
, all together contributing to β-adrenergic-induced lusitropy (Abbott et al., 2001, Kentish et al., 2001). 
Lastly, PDE4D may be anchored by MMGL in close proximity to cMyBPC and cTNI, which will allow for 
spatio-temporal control of cAMP hydrolysis, thereby attenuating the adrenergic signal. The lower levels of 
cAMP might then cause dissociation of these complexes (Figure 4.1C). 
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A: cMyBPC = unphosphorylated: MyBPC motif 
interacts with myosin S2; C0, C1 and MyBPC motif 
binds actin; crossbridge formation inhibited (see text 
for details) 
B: cMyBPC = phosphorylated: Interaction between 
myosin S2 and MyBPC motif abolished; interaction 
between actin and MyBPC motif is lost; myosin heads 
free to make contact with actin and initiate force 
generation; MyBPC motif switches to bind cTNI; C0-C1 
binds actin irrespective of phosphorylation state, both 
these interactions allow structural coupling of thick and 
thin filaments (see text for details) 
actin   
cMyBPC domain 
MyBPC motif 
cTNT 
cTNC 
cTNI 
 
 
tropomyosin  
myosin S2 
myosin heads 
PDE4D 
PKA-R subunit 
MMGL 
 
 
Figure 4.1. A model of contraction. See text for details 
C: Upon β-adrenergic stimulation, cAMP levels increase and 
activate PKA that is compartmentalized by MMGL in close 
proximity to its targets, cMyBPC and cTNI. MMGL-bound PKA 
phosphorylation abolishes binding of myosin S2 and actin with 
the MyBPC motif, causing the trisphosphorylated motif to switch 
from actin to cTNI; this renders actin free to bind to myosin 
heads, resulting in acceleration of crossbridge recruitment and 
force generating rates. Additionally, MMGL-bound PDE4D 
hydrolyzes PKA, eventually attenuating the cAMP-derived 
adrenergic signal (see text for details) 
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In addition, MMGL might act as AKAP at another sarcomeric location by mediating the spatio-temporal control 
of CARP phosphorylation at the N2A domain of titin. Phosphorylation of CARP might result in weakening of 
the interaction between CARP’s coiled-coil domain with N2A, thereby freeing CARP to shuttle to the nucleus. 
In the nucleus, CARP would act as a transcription regulator (Kojic et al., 2004, Witt et al., 2005) and might take 
part in the upregulating process of N2BA, the more compliant isoform of titin. It could therefore be speculated 
that MMGL is indirectly involved in facilitating the acute myocardial stress-sensing response via 
phosphorylation (Section 4.2.2.1). 
In this study, both the α- and β-isoforms of enolase were shown to interact with MMGL. In addition, β-enolase 
was found to interact with cMyBPC (A. Ramburan, PhD thesis) whereas α-enolase was found to interact with 
COMMD4 (C. Swanepoel, PhD thesis). Given that cMyBPC and COMMD4 also interact with MMGL, we 
deduce that the αβ-heterodimer of enolase forms a three-way interaction between these three proteins. In the 
sarcomere, MMGL might act as scaffold and AKAP to enable optimum spatio-temporal control of αβ-enolase 
phosphorylation by PKA. Phosphorylated αβ-enolase might have an increased binding affinity for cMyBPC; 
thereby binding to and producing energy required for crossbridge formation through glycolysis in this 
subcellular space, as discussed in Section 4.2.2.2. Additionally, or alternatively, when cMyBPC is released form 
the sarcomere for turnover, phosphorylation of αβ-enolase, by MMGL-bound PKA, might increase its binding 
affinity and/or activate the enzyme to enable glycolysis, providing energy required for the degradation process to 
the UPS. Simulateously, phosphorylation of COMMD4, also by MMGL-bound PKA, might result in a higher 
binding affinity of this adaptor protein for its ligands cMyBPC and the E3 ubiquitin ligase. By binding these 
proteins, COMMD4 will thereby act as adaptor protein bringing the E3 ligase in close proximity to cMyBPC to 
enable polyubiquination of cMyBPC to mark it for degradation by the UPS (C. Swanepoel, PhD thesis) (Section 
4.2.2.3).  
4.6. MYOMEGALIN AS A POTENTIAL DRUG TARGET 
4.6.1. Current treatments for heart failure 
Chronic adrenergic signaling is a compensatory mechanism of the failing heart (Bristow 2000). Increased 
adrenergic drive will at first support cardiac performance of a failing heart; however, over time, the activation of 
the sympathetic nervous system causes harmful effects, which are therapeutically typically countered by using β-
blockers (Hunt et al., 2005, Bristow 2000). Current treatment for chronic heart failure (CHF) consists of an array 
of drugs, the most commonly used being β-blockers, ACE-inhibitors and angiotensin II receptor antagonists. 
While there is no cure for CHF, these drugs are available as chronic treatment that aims to postpone further 
development of heart failure, improve heart function and lead to a general improvement of life quality (Hunt et 
al., 2005). Excellent results are obtained by employing β-adrenergic receptor blockade for CHF, and it is 
believed to be the only therapy proven to increase survival after myocardial infarction leading to CHF 
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development, although it is not free of side-effects (Bristow 2000, Lygren and Tasken, 2008). The discovery of 
new targets in the β-adrenergic signaling pathway could open up a new avenue of pharmacotherapy for CHF: by 
employing new antagonists capable of inhibiting the effect of cAMP at the level where its acts, rather than 
reducing total cAMP levels, it may be possible to isolate the favourable effects of β-blockers from its side effects 
(Lygren and Tasken, 2008). 
4.6.2. AKAPs allow for specialized altered cAMP signaling   
By altering PKA signaling, a variety of potential applications may arise in clinical settings where abnormal PKA 
signaling has been observed. By anchoring PKA directly to a target, AKAPs may represent a novel target for 
drugs that could lead to treatment of numerous diseases. Peptides, such as Ht31, have been designed to compete 
with full-length AKAPs for binding PKA-RII, and thereby disrupt the PKA-AKAP interaction, and have been 
successfully used as tools to delineate the specific effects facilitated by PKA isozymes, as described in Section 
1.3.4. However, such peptides are non-specific and disrupt all PKARII-AKAP interactions in the cell. Moreover, 
based on reported X-ray crystal structures, the PKA-AKAP molecular interface is relatively large and covers 
approximately 30 square nm. This interface is also hydrophobic and flat, with very few grooves, making it 
difficult to design a small molecular compound capable of disrupting the interaction (Gold et al., 2006, 
Kinderman et al., 2006). A possible solution that ensures specificity may therefore be to target the interaction 
between the AKAP and the PKA substrate, and not the PKA-AKAP interaction itself (Lygren and Tasken, 
2008). This, however, requires the identification of the specific AKAP plus its PKA substrate, as well as 
additional ligands, as was done in the current study. 
An example of such identification of a specific AKAP plus its ligands, with the aim of possibly employing it as 
drug target for heart failure, is AKAP18δ. This AKAP recruits PKA to PLB (Lygren et al., 2007). 
Phosphorylation of PLB alters the interaction between PLB and SR ATP-dependent Ca
2+
 pump sarcoplasmic 
reticulum Ca
2+ 
-ATPase (SERCA) 2, releasing the Ca
2+ 
pump from inhibition. This causes rapid entering of Ca
2+
 
into the SR, leading to faster cardiac relaxation rates (Bassani et al., 1994). AKAP18δ therefore provides a 
mechanism for precise adrenergic control of Ca
2+ 
cycling and hence, regulation of cardiac relaxation. PKA 
phosphorylation of PLB was reduced upon β-adrenergic stimulation with isoproterenol when a cell-permeable 
adrenergic disruptor-peptide directed against the AKAP18δ-PLB interaction was introduced in an in vivo 
experiment conducted in cardiomyocytes. This altered Ca
2+
 re-uptake into the SR, and demonstrates that such 
peptides could block one specific effect of adrenergic signaling (Lygren et al., 2007). It is speculated that the 
targeting of the compartmentalization of this specific cAMP signaling complex with an AKAP18δ antagonist 
will interfere with adrenergic-induced phosphorylation of PLB, and thereby prevent SERCA2 activation. This 
will block the adrenaline-induced increase of energy expenditure that induces further damage to the post-
infarcted failing heart (Lygren and Tasken, 2008).  
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In the failing heart, an adrenaline-induced increase in contractility could be detrimental, and validates the use of 
β-blockers to reduce chronic adrenergic signaling. However, β-blockers reduce cAMP signaling only by about 
50%, and are non-specific (Lygren and Tasken, 2008); it would therefore be advantageous to develop 
antagonists that interferes with cAMP signaling at specific sites. Such compounds could then be used 
independently or together with β-blockers for a potentially more potent therapeutic effect, with less unwanted 
effects. By identifying a specific AKAP, such as MMGL, together with its sarcomeric ligands cMyBPC and 
cTNI, and PDE4D, it is possible to start developing interrupting molecules capable of producing specific 
alteration of cAMP signaling at a specific subcellular location. Interrupting MMGL-cMyBPC binding may result 
in reduced levels of trisphosphorylated cMyBPC, and therefore decreased inotropy. Blocking this single effector 
of the adrenergic pathway might be advantageous in cases of end-stage CHF where adrenergic signaling is 
constantly elevated and leading to further damage. In the case of cTNI, where phosphorylation leads to an 
overall increase in β-adrenergic lusitropy, a different effect might be obtained by disrupting MMGL-cTNI 
binding. This might be advantageous during other stages of heart failure. It would also be interesting to 
investigate the effect of distruption of both these AKAP bindings simultaneously. By altering cAMP signaling in 
two different, but still interdependent areas of contraction, different signaling outcomes could be achieved and 
this could be manipulated until an optimal desired effect is obtained.  
On the other hand, disrupting the binding between MMGL and PDE4D could lead to increased phosphorylation 
of both cMyBPC and cTNI, thereby obtaining the exact opposite pharmacological effect than described above. 
Different from conventional PDE inhibitors, this would also allow for specificity. PDE inhibitors have been 
shown to be promising clinical agents for improving cardiac performance under critical conditions such as 
ischaemic heart attack (Rao and Xi, 2009). Conversely, by lowering PDE4D levels at the specific sarcomeric 
locations where MMGL binds could improve pathological conditions where increased force of contraction and 
relaxation rates is required in the long run. 
However, our results have shown that MMGL binds additional ligands that are implicated in various cellular 
mechanisms viz. the degradation of proteins via the UPS (COMMD4), glycolysis (αβ-enolase) and the 
regulation of myocardial stress-sensing (CARP). This complicates the idea of developing a disrupting peptide 
that, for instance, is designed to interrupt the binding between MMGL and cMyBPC with the aim of decreasing 
cMyBPC phosphorylation resulting in reduced cardiac contractility upon β-adrenergic stimulation in patients 
with CHF. The MMGL domains involved in these interactions are unknown, and because MMGL isoform 4 is 
such a small protein, the possibility exists that the same domain might be involved in interacting with more than 
one ligand. If this is the case, blocking such a domain would have multiple effects on the cell, which might be 
more harmful than beneficial. For example, blocking the binding between MMGL and COMMD4 might result 
in COMMD4 not being phosphorylated, and therefore unable to anchor cMyBPC and/or E3 ligase, which will 
lead to the build-up of protein destined for degradation by the UPS. The build-up of truncated cMyBPC, and 
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subsequent impairment of the UPS, has been implicated in HCM (Sarikas et al., 2005). However, if it turns out 
that different domains  are involved in these interactions, specific effects can be obtained that might result in a 
beneficial effect, as described in this section. Therefore, the next step in determining whether MMGL isoform 4 
is a possible drug target would be to identify the specific domains of the protein that interacts with each of its 
ligands. 
In conclusion, it should be remembered that the change in phosphorylation status of different individual PKA 
substrates can have a beneficial of harmful effect in the failing heart (Movsesian and Bristow, 2005), and 
therefore it is important to elucidate the effect of manipulating phosphorylation of each individual substrate. The 
different outcomes can then be combined to enable a mutual advantageous effect depending on the disease. 
Identifying specific AKAP-PKA substrate complexes will be the starting point toward developing novel drugs 
targeting AKAPs for the treatment of various human diseases. 
4.7. MYOMEGALIN AND PKA AS MODIFIERS OF CONTRACTILITY  
Concluding from our results discussed up to this point, we believe that MMGL is directly involved in the 
phosphorylation of two key regulatory proteins within the sarcomere, and therefore in the regulation of cardiac 
contractility. By anchoring PKA directly to two proteins implicated in HCM, viz. cMyBPC and cTNI, gene 
polymorphisms in MMGL and the regulatory subunits of PKA may be considered as potential modifiers of the 
development of hypertrophy within the context of HCM, as discussed in Section 1.7. According to our 
knowledge, the role of variants in genes involved with phosphorylation of sarcomeric proteins in cardiac 
hypertrophy has never been evaluated, and this is the first time a multi-SNP approach has been used to 
investigate the modulation of hypertrophy in a South African HCM cohort by the genes PDE4DIP, PRKAR1A 
and PRKAR2A. 
 4.7.1. SNP selection 
The number of SNPs required for an association study depends on the LD pattern in the area of interest (Zhang 
et al., 2004). Only a small number of tag SNPs need to be selected in areas of the genome with high LD regions 
(Johnson et al., 2001, Patil et al., 2001), which will reduce genotyping effort without losing power (Zhang et al., 
2001). PRKAR1A and PRKAR2A are both in regions of high LD, and SNPs were selected using the SNPbrowser 
software to achieve an even spacing of 0.5 LDUs on the metric LD map for the HapMap CEU and YRI 
populations. The LD structure of the CEU and YRI populations were used because previous association studies 
conducted in our laboratory found that it is the best possible estimation of our own South African population’s 
LD structure, which is still uncharacterized. The metric LD map with additive distances in LDUs was developed 
by Maniatis et al. (2002), who concluded that LDU maps have greater power compared to a centi-Morgan/kb 
map in context of association mapping (Maniatis et al., 2004). The LDU method significantly reduces the 
number of SNPs required to cover a gene, which lead to the selection of only 4 SNPs in PRKAR1A and 3 SNPs 
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in PRKAR2A. However, the LDU method could not be used for SNP selection in PDE4DIP, because the gene is 
in a region of low LD. SNPs were therefore selected manually aiming to cover the gene, with SNPs distributed 
every 60000kb on average, as described in Section 2.21.2, and lead to the selection of 9 SNPs in PDE4DIP. 
4.7.2. Genotyping approach 
The high-throughput ABI Validated TaqMan® genotyping system used in the present study was much more 
effective compared to previous PCR-based genotyping approaches (ASREA and SNaPshot® primer extension 
analysis) conducted in our laboratory for the same cohort. Predesigned and validated TaqMan® assays save time 
on assay design, testing and optimization. The system also operates at a low concentration of DNA (5-20ng) 
which spares DNA samples. An automatic liquid handling robot was used to set up 5µl reactions in 384-well 
plates, which allows for quicker genotyping and reduces human error, while the small reaction volumes involved 
reduces costs to some extent. This system also eliminates the need for post-PCR transfer and handling.  
The SDS software used to assign genotypes post-PCR performs automatic allele-calling based on fluorescence 
signals, and all genotypes with a confidence level lower than 95% are marked as undetermined. This ensures that 
doubtful genotypes are not entered into the data analyses. The genotyping results are exported as a text file 
which allows results to be directly imported to the database, which minimizes human typographical errors. We 
further monitored genotyping errors by utilizing the program Pedstats to determine whether all genotypes were 
consistent with expected Mendelian inheritance patterns. Genotypes that were inconsistent were resolved by re-
genotyping. 
Drawbacks of this system are that the use of commercial systems such as Taqman® is more expensive than 
conventional PCR-based genotyping approaches, and that validated TaqMan® assays are not yet available for all 
SNPs. However, it is possible to custom design TaqMan® assays for any SNP, although this will require 
additional optimization and sequencing to confirm accuracy. 
4.7.3. Caveats in association studies 
Three situations may give rise to statistical association between an allele and a phenotypic trait. Firstly, the allele 
itself may be functional and thereby exert a direct effect on the phenotypic expression. Secondly, the allele may 
be in LD with a functional allele and thirdly, it may be that the association exists due to pure chance. It is 
therefore crucial to ensure the reproducibility of such a study, yet there are many factors that influence the 
reproducibility of an association study on complex genetic traits (Cardon and Palmer, 2003).  
4.7.3.1. Population stratification 
Spurious association may result from undetected population substructure in any association study. Population 
stratification might confound association between an allele and a disease trait in a population that consists of a 
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mixture of subpopulations with different allele frequencies and disease risks. This will lead to false positive 
association between a specific genotype and a disease trait (Colhoun et al., 2003). We compensated for this by 
first testing for population stratification and then using the orthogonal QTDT model for SNPs where 
stratification was detected. The orthogonal model protects against population stratification by matching each 
“case-control” pair within a family, making any population-level differences in a given allele frequency 
irrelevant (Cardon and Palmer, 2003). 
4.7.3.2. Phenotypic definition 
Phenotypic definition contributes extensively to the reproducibility of any association study and it is therefore 
important that all measurements taken are relevant to the disease phenotype, and that it is taken with the same 
precision. Phenotypic expression of HCM varies greatly between individuals, predominantly the extent and 
distribution of hypertrophy. Hypertrophy in HCM is mainly asymmetrical and patients rarely exhibit uniform 
concentric hypertrophy, which makes it impossible to quantify the extent of hypertrophy in a whole cohort with 
a single measurement. To compensate for this problem, composite scores that consist of a number of 
hypertrophy measurements describing the extent of hypertrophy can be derived. However, there is still no 
consensus on which composite scores represents the best estimated extent and distribution of hypertrophy in 
HCM. Alternatively, cardiac magnetic resonance imaging (cMRI) can be used to determine LVM accurately; 
however cMRI is not as available as the more conventionally used echocardiography. In addition, not all 
individuals are suited to cMRI investigation (for instance due to implanted pacemakers or ICDs, or due to 
claustrophobia), reducing the number of individuals who may be phenotyped using this more accurate method; 
there is thus a play-off between power and accuracy. 
These issues were addressed in the present study as follows: A single cardiologist characterized all individuals in 
the cohort by 2-D and M-mode echocardiography, thereby ensuring that all measurements were taken the same 
way and with the same precision. A total of 16 wall thickness measurements were taken at three levels of the 
heart to estimate the distribution of hypertrophy. Left ventricular mass (LVM) was determined by 
echocardiography as an indication of the extent of hypertrophy, however, due to left ventricular geometry in the 
presense of HCM-related LVH, a possibility exists that LVM as determined by echocardiography would not be 
an accurate estimate of hypertrophy. This trait is commonly used in similar studies and was therefore also used 
in this study as it would be more familiar to researchers in the field. However, to obtain a more comprehensive 
and possibly less inaccurate indication of the extent of hypertrophy, we made use of a composite score derived 
by principal component analysis (Comp1), which is the weighted average of the 16 cardiac wall thickness 
measurements, as well as two additional composite scores (CWT and Spirito-Maron), in addition to LVM.  
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4.7.3.3. Power 
The definition of statistical power in an association study is the probability that a test statistic reflects a true 
association (or lack thereof) between a genomic variant and a specific disease trait (Gordon and Finch, 2005). 
The power of an association study therefore relies on the disease allele frequency as well as the sample and 
effect size (Colhoun et al., 2003, Donahue and Allen, 2005). Genotyping errors and errors in phenotypic 
classification also significantly impact the power of such a study (Gordon and Finch, 2005).  
There is currently no comprehensive method for calculating the power of an association study in extended 
families such as those used in the present study, and thus no formal calculations were done to estimate the power 
of the present study.  Increasing the number of study subjects was also not possible seeing that every individual 
that gave consent within these 22 families, including all mutation-carriers, had already been included. 
4.7.3.4. Multiple testing 
Multiple testing in any cohort may cause an increased probability of obtaining a false positive (type I error). 
Bonferroni adjustment is a popular solution to this problem, and assumes that all the performed tests are 
independent and that each p-value is subsequently essentially multiplied by the number of tests performed. In the 
present study, the traits being evaluated are not truly independent seeing that they are all derived from the same 
16 cardiac wall thickness measurements. Furthermore, it is commonly considered that the Bonferroni adjustment 
is too strict, and may lead to discarding of relevant associations (Perneger 1998).  
Bayesian methods for correction are also not applicable seeing that prior knowledge of the probability of 
involvement are required, which is currently unknown for most genetic variants (Campbell and Rudan, 2002). 
Therefore, as the current study was conducted as an explorative study, no formal corrections for multiple testing 
were made, although the probability for type I errors were reduced by determining exact p-values for QTDT 
analyses with Monte-Carlo permutations, which provides an overall evaluation of significance (McIntyre et al., 
2000).  
4.7.3.5. Confounding variables 
Ensuring that association between a specific variant and a phenotypic trait is due to the effect of the variant and 
not due to an unrelated covariant or trait is of utmost importance. Blood pressure is an example of a confounding 
variable in that it has an independent effect on hypertrophy. If these aspects are not accounted for in an 
association study, one cannot be sure if the variation in hypertrophy is due to variation in the covariant (eg. 
blood pressure) or the variant. In the current study, all analyses were adjusted for known hypertrophy covariates 
viz. systolic and diastolic blood pressure, sex, age, body surface area and heart rate, as well as the particular 
HCM-causing mutation. 
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4.7.4. Results from the present association study 
The present association study forms part of a larger study conducted by our research group, of which the 
ultimate aim is to identify genes that modify the development of hypertrophy in a South African HCM cohort. 
Initially viewed as a monogenic disease where a single sarcomeric mutation is sufficient to cause the disease, 
HCM was used as a model disease to investigate the modifier effect on cardiac hypertrophy in general. However, 
due to the variable phenotypic expression, it is now accepted that the presentation of HCM is influenced not only 
by the main causal mutation, but also by additional environmental and genetic modifiers. This study identified a 
novel AKAP involved in the phosphorylation of cMyBPC, which lead us to believe that SNP variants in 
PDE4DIP, PRKAR1A and PRKAR2A might contribute to the phenotypic expression of HCM, and possibly also 
modify cardiac hypertrophy in general.  
We found that the G-allele of the PDE4DIP SNP rs1664005 was associated with increased hypertrophy. This 
allele leads to an increase of 1.3mm in mIVST, 3.4mm in Maronscore and 8.1mm in CWTscore in our study 
population. Comp1 is derived from quantile-normalized data; therefore, the effect size following association 
analysis of this trait is not interpretable in terms of the original cardiac measurements. We therefore estimated 
the effect size from an analysis of the mean of the 16 untransformed cardiac wall thickness measurements that 
was originally used to derive Comp1 and found that the effect size was 0.5mm. This SNP is located in an 
intronic region of PDE4DIP, and therefore does not seem to have any obvious functional role. However, an 
intronic SNP may influence gene splicing by affecting a splice donor or acceptor site. In silico analysis of this 
SNP variant in two splice site prediction programs viz. Alternative Splice Site Predictor 
(http://www.es.embnet.org/~mwang/assp.html) and NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/) 
showed that rs1664005 had no effect on either acceptor or donor splice sites, nor  created a cryptic splice site. 
It can therefore be speculated that the association found in this study is due to an effect of a functional variant 
that is in LD with rs1664005, either within PDE4DIP itself or with an adjacent gene that is associated with 
hypertrophy development. Because the LD distribution and and the extent of variation of PDE4DIP is unknown 
in our study population, the LD distribution and genetic variation of the CEU and YRI populations were used as 
best possible representation of our study population. Non-synonymous (i.e. possible functional) SNPs were 
found to be in LD with rs1664005 in both the CEU and the YRI populations (http://www.ncbi.nlm.nih.gov/SNP, 
www.ensembl.org/Homo_sapiens/Transcript/ProtVariations,  SNPbrowser™ v 3.0, Haploview 4.2) which could 
explain the observed association. Rs3010980 is in LD with rs1664005 in the CEU and YRI populations, and 
results in an amino acid coding for either Ser or Asn. Both these amino acids have uncharged polar side chains, 
so it is unlikely that a change in the amino acid sequence will have an effect on the tertiary structure of the 
protein. Rs1324366 is in LD with rs1664005 in the YRI population, and the SNP codes for either Ala or Glu. 
This will result in either an amino acid with a nonpolar side chain (Ala) or a charged polar side chain (Glu), 
which may well affect protein tertiary structure, because Ala is hydrophobic and will most likely occur in the 
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interior of the protein, whereas Glu is hydrophilic and will most likely occur on the outer surface of the protein; 
therefore subsequent protein-protein interactions could be affected. It is therefore likely that this SNP may have 
a functional effect. Rs1628172 and rs2762875 are also in LD with rs1664005 in the YRI population. Both SNPs 
result in either an uncharged polar residue [Cys (rs1628172) or Gln (rs2762875)], or a charged polar residue 
[Arg (both SNPs)], which may also affect protein tertiary structure and interactions, for the same reasons as 
described for rs1324366. However, no reports of any studies of these non-synonymous SNPs in hypertrophy 
development could be found in the literature. Another explanation may be that rs1664005 itself exerts an 
unknown functional effect, however, to explore this option, additional studies in different and bigger cohorts, as 
well as functional work, should be conducted. 
Two intronic SNPs in PRKAR1A were found to have a significant effect on two of the investigated hypertrophy 
traits. The A-allele of rs11651687 leads to an increase of 2.1mm in mIVST, whereas the A-allele of rs3785906 
leads to an increase of 2.2mm in mIVST as well as a 16.3mm increase in CWTscore. It should be noted that 
although an increase of of 16.3mm in CWTscore seems extravagant, this trait represents the sum of all 16 
cardiac wall thickness measurements, and therefore represents an average increase of ~1mm in each of the 16 
measurements. In silico analyses of these SNPs with splice-site prediction programs (Alternative Splice Site 
Predictor and NetGene2) predicted no alternative splice-site acceptor or donor sites. These variants are not in LD 
with any possible functional SNPs known (http://www.ncbi.nlm.nih.gov/SNP, 
www.ensembl.org/Homo_sapiens/Transcript/ProtVariations, SNPbrowser™ v 3.0, Haploview 4.2). It is possible 
that this SNP in PRKAR1A is in LD with a variant(s) on adjacent gene(s) associated with hypertrophy 
development, or that these two SNPs themselves exert a currently unknown functional effect. However, this 
option should be further explored by conducting additional SNP studies in different and bigger cohorts, and by 
doing functional work. 
No association was found between any SNP with mPWT, which is generally more closely associated with LVH 
than mIVST. Association was, however, found between all three positively associated SNPs with mIVST. This 
could be explained due to the extreme variability in extent and distribution of LVH in HCM patients, and it 
could be speculated that in this particular cohort, the distribution of hypertrophy is more localized to the septum 
than the posterior wall, explaining why association was found between both PRKAR1A SNPs, as well as with the 
PDE4DIP SNP, and mIVST, and not with mPWT. However, this should also be further explored by conducting 
additional SNP studies in different and bigger cohorts. 
No association was found between SNPs in PRKAR2A and any hypertrophy trait. This was unexpected seeing 
that the R2A subunit has a high affinity for AKAP binding, and is the predominant PKA subunit expressed in the 
heart (Section 4.1), and also showed the stronger interaction with MMGL of the two regulatory subunits. 
However, only two SNPs were suitable for analysis with the genotyping approach followed in this study; it may 
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be that additional SNP studies should be applied to this gene before it is discarded as a potential modifier of 
hypertrophy in HCM. 
This explorative study therefore identifies MMGL, and, to a lesser extent PRKAR1A, as putative modifiers of 
cardiac hypertrophy. The interaction work done in this study supports a role for these proteins in regulation of 
cardiac contractility, and therefore by extension, a role in cardiac morphology (viz. hypertrophy). However, as 
for any association study, these results need to be verified by independent studies in different populations, with 
bigger cohort sizes and additional functional work. As genetic modifiers appear sufficient to completely prevent 
disease expression in some HCM carriers, these two genes may point to new targets for intervention, especially 
given the interest in PDE4-inhibitors. This finding might lead to an improved understanding of HCM patho-
aetiology and may also improve risk profiling. Such understanding may eventually lead to strategies aimed at 
preventing the development of pathological cardiac hypertrophy in HCM. 
4.7.5. PDE4DIP as a candidate gene for HCM 
The findings of the association of PDE4DIP variants with hypertrophy parameters and the functions derived for 
MMGL by protein interaction as well as knockdown studies, suggest that PDE4DIP should also be investigated 
as a candidate gene for HCM. Variants in PDE4DIP could lead to a translated protein with increased or 
decreased affinity for some of its ligands, perhaps sufficiently so to result in disease. For example, if MMGL is 
unable to bind cMyBPC, cTNI, the regulatory subunit of PKA, or PDE4D, the regulation of second messenger 
signaling would be affected. It is quite plausible that a mutant MMGL unable to bind any one of these interactors 
may have detrimental effects on contractility in general. Many HCM-causing point mutations are found in the 
C1-C2 region of MYBPC3 and the N-terminal of cTNI, of which the pathological mechanisms are still unknown. 
A possible disease mechanism for this may be that MMGL binding is disrupted, and hence PKA cannot be 
brought close to its target site to mediate second messenger responses. Therefore, the opposite scenario is also 
likely to result in a similar effect, where MMGL is mutated and unable to bind cMyBPC and/or cTNI.  
Moreover, mutations causing the regulatory subunits of PKA to be unable to bind to MMGL will render the 
protein useless as an AKAP, and this may also lead to hypertrophy development. Although cMyBPC and cTNI 
are phosphorylated by other kinases as well, only PKA phosphorylation can result in trisphosphorylated 
cMyBPC which is required for β-adrenergic stress responses, whereas PKA-dependent phosphorylation of 
Ser23/Ser24 in the N-terminal of cTNI is essential for normal crossbridge cycling. Incomplete phosphorylation 
of both these proteins will abolish the cardioprotective effect and will lead to increased protease cleavage of both 
of these sarcomeric proteins. Furthermore, if MMGL isoform 4 interacts with PDE4D, and is mutated in such a 
way that it cannot target to the sarcomere, it will also lead to insufficient levels of PDE4D in this region, due to 
lack of appropriate compartmentalization, which will lead to incomplete attenuation of any existing PKA signal. 
Higher levels of cAMP will activate prolonged PKA signaling, which in turn requires higher consumption of 
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ATP; such a scenario would fit with the energy depletion hypothesis that proposes that the unifying dysfunction 
in HCM is an increased energy demand due to increased and inefficient ATP utilizationin the sarcomere (Blair et 
al., 2001, Ashrafian et al., 2003). Over-usage of ATP might compromise the capacity of the cell to maintain 
energy levels in areas where ATP is crucial for normal homeostatic functions such as Ca
2+ 
re-uptake and the 
myosin ATPase. Failure of proper Ca
2+ 
re-uptake at the end of each contractile cycle by the SERCA2 pump, 
which has large energy requirements, will cause a prolonged cytosolic Ca
2+ 
transient which will activate 
downstream mediators and stimulate hypertrophy (Ashrafian et al., 2003). Prolonged elevated cytosolic Ca
2+
 is 
also a trigger for ventricular arrhythmias (Ashrafian et al., 2003) which could lead to SCD.
 
 Further, if lower 
levels of ATP are available for the myosin ATPases, some crossbridges might fail to detach, which will result in 
reduced mechanical efficiency of the crossbridge cycle. 
4.8. FUTURE STUDIES 
Our understanding of the roles that different AKAPs play in physiological and pathological processes is still in 
its infancy. Generating animal models that lack individual AKAP genes will be invaluable towards contributing 
to our current knowledge, as it will not only provide insight into the mechanism of AKAP functioning, but also 
serve as models for the understanding of diseases. 
However, before undertaking such proposed studies, one should first address the obvious questions that resulted 
from this study, which are the following: Does isoform 4, the smallest isoform of MMGL, of which the full-
length isoform is classified as a PDE4D-interacting protein, also interact with PDE4D? To do this, a similar 
approach can be followed that was used to identify MMGL as a PKA R-subunit ligand, as was done in this 
study. Secondly, one should investigate the effect on cTNI phosphorylation upon MMGL knockdown, as was 
done for cMyBPC, to see if what the functional effect of MMGL binding to cTNI. Thirdly, if MMGL is to be 
considered a potential drug target, one should first identify the specific domains on MMGL that interact with its 
ligands identified in this study, as described in Section 4.6. 
This study identified a novel AKAP involved in the regulation of cardiac contractility, and although it proved to 
be essential for the normal phosphorylation of its target protein in an in vivo RNAi setting, it is not clear what 
the physiological effects would be in a mammalian organism deficient or defective in MMGL. Generating a 
MMGL knockout animal model will provide insight into all the speculated roles that it plays in contractility as 
discussed in this chapter. It may also provide further answers for the pathological mechanisms in HCM, 
hypertrophy and heart failure. Generating a transgenic expression of different cMyBPC phosphorylation states 
against a MMGL-null background as well as the expression of wild-type cMyBPC against a MMGL-null 
background will shed light on the mechanism of how cMyBPC is phosphorylated, and the same approach could 
be used to better understand the interplay between cTNI, MMGL and cardiac function and structure.  
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MMGL is also expressed in the Golgi organelles of cells. Considering the fact that the library screen yielded 
three possible ligands that operate in protein trafficking in the Golgi area viz. SNX3, COMMD4 and the 
proteasome 26S subunit, the function of MMGL in this area should also be investigated.  
Furthermore, MMGL should be considered a candidate HCM-causing gene, and should be assessed by mutation 
screening of HCM patients.  
These proposed studies will be of utmost necessity if MMGL is to be considered as a possible target for 
pharmacological intervention, which in the end is the ultimate goal of biomedical research.  
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APPENDIX I 
1.  YEAST TRANSFORMATION REAGENTS       
 1M LiAc           
 LiAC     5.1g       
 Make up to 50ml with sterile water 
 100mM LiAc           
 1M LiAc    5ml       
 Make up to 50ml with sterile water  
 50% PEG 4000          
 PEG 4000    25g       
 Make up to 50ml with sterile water 
2.  YEAST PLASMID PURIFICATION SOLUTIONS      
 Yeast Lysis Buffer          
 SDS     1%       
 Triton X-100    2%       
 NaCl     100mM       
 Tris, pH 8    10mM       
 EDTA, pH 8    1mM 
3.  ELECTROPHORESIS STOCK SOLUTIONS      
 10% Ammonium Persulphate         
 Ammonium Persulphate  10g       
 Sterile water    10ml       
 Mix well and store at 4°C       
 20X SB Stock Solution          
 di-Sodium tetraborate decahydrate 38.14g       
 Sterile water to a final volume of 1litre 
 1X SB Solution          
 20X SB solution   50ml       
 Sterile water to final volume of 1 litre  
 SDS-PAGE Resolving Gel Buffer (4X)        
 Tris base    109.2g       
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 ddH2O     330ml       
 10% SDS    24ml       
 pH to 8.8 using 1M HCl. Make up to 600ml using ddH2O 
 SDS-PAGE Stacking Gel Buffer (4X)        
 Tris base    36.3g       
 ddH2O     330ml       
 10% SDS    24ml       
 pH to 6.8 using 1M HCl. Make up to 600ml using ddH2O   
 10X SDS-PAGE Running Buffer        
 Tris base    30g       
 Glycine     144g       
 10% SDS    100ml       
 Add ddH2O to a final volume of 1litre 
 1X SDS-PAGE Running Buffer        
 10X SDS-PAGE running buffer  100ml       
 Sterile water to a final volume of 1litre     
4.  GELS            
 1% Agarose gel          
 Agarose    1g       
 SB Buffer (1X)    100ml       
 Microwave for 1min on maximum power and add 5µl ethidium bromide (10mg/ml) when temperature of 
 ±55°C is reached    
 2% Agarose gel          
 Agarose    2g       
 SB Buffer (1X)    100ml       
 Microwave for 1min on maximum power and add 5µl ethidium bromide (10mg/ml) when temperature of 
 ±55°C is reached  
 15% SDS-PAGE Stacking Gel         
 Sterile water    2.56ml       
 10% SDS    40µl       
 SDS-PAGE stacking gel buffer (4X) 1ml       
 Acrylamide (40%)   390µl       
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 APS (10%)    30µl       
 TEMED    6µl       
 Makes two gels for the Bio-Rad Mini gel apparatus system (Bio-Rad Laboratories, Hercules, CA, USA) 
 15% SDS-PAGE Resolving Gel        
 Sterile water    4.82ml       
 10% SDS    100µl       
 SDS-PAGE resolving gel buffer(4X) 1.25ml       
 Acrylamide (40%)   3.75ml       
 APS (10%)    80µl       
 TEMED    6µl       
 Makes two gels for the Bio-Rad Mini gel apparatus system (Bio-Rad Laboratories, Hercules, CA,USA) 
5. LOADING DYES          
 Ethidium Bromide Stock (10mg/ml)        
 Ethidium bromide   500mg       
 Sterile water    50ml       
 Stir well on magnetic stirrer for 4h and store in dark container at 4°C 
 Bromophenol Blue Loading Dye        
 Bromophenol Blue   0.1% (w/v)      
 Sterile water to a final volume of 100ml. Store at 4°C 
 SDS Loading Dye          
 1M Tris-HCl (pH6.8)   50mM       
 DTT     100mM       
 SDS     2%       
 Bromophenol Blue   0.1%       
 Glycerol    10% 
6.  CO-IP REAGENTS          
 Co-IP Buffer           
 1M Tris (pH 7.5)   400µl       
 5M NaCl    60µl       
 1M DTT    20µl       
 2ng/ml Aprotinin   50µl       
 50mM PMSF    200µl       
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 Tween 20     20µl       
 Make up to 20ml using sterile water 
 Pre-washed Protein G Agarose        
 A volume of Co-IP buffer (double the volume of protein G agarose) was used to wash the protein G 
agarose (10µl/reaction) by centrifugation for 30sec. Following centrifugation, the supernatant was 
discarded and the pellet resuspended (double the volume of Co-IP buffer) before another round of 
centrifugation. This was repeated five times. After the final centrifugation step, the pellet was 
resuspended in a volume of Co-IP buffer representing the initial volume of protein G aliquoted. 
 TBST (pH 7.6)          
 NaCl     8g       
 1M Tris-HCl (pH7.6)   20ml       
 Tween 20    1ml       
 Make up to 1litre using sterile water 
7. SOLUTIONS USED FOR THE ESTABLISHMENT OF BACTERIAL COMPETENT CELLS
 CAP-Buffer           
 CaCl2     2.21g       
 Glycerol    37.5ml       
 PIPES     0.76g       
 Sterile water to a final volume of 250ml. Adjust pH to 7.0 and store at 4°C 
8. BACTERIAL MEDIA          
 LB media           
 Bacto tryptone    5g       
 Yeast extract    2.5g       
 NaCl     5g       
 Sterile water to final volume of 500ml. Autoclave and add appropriate antibiotic (Ampicillin 25mg/l, 
Kanamycin 5mg/l or Zeocin™ 10mg/l to media when temperature of ±55°C is reached 
  LB agar plates          
 Bacto tryptone    5g       
 Yeast extract    2.5g       
 NaCl     5g       
 Bacto agar    8g       
 Sterile water to final volume of 500ml. Autoclave and add appropriate antibiotic (Ampicillin 25mg/l, 
Kanamycin 5mg/l or Zeocin™ 10mg/l to media when temperature of ±55°C is reached, prior to pouring 
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~20, 90mm plates. These plates were then allowed to set for 2-5 hours and stored at room temperature 
for up to three weeks 
9. YEAST MEDIA         
 YPDA media           
 Difco peptone     10g      
 Yeast extract     10g      
 Glucose     10g      
 L-adenine hemisulphate (0.2%stock solution) 7.5ml      
 Add sterile water to a final volume of 500ml. Autoclave at 121°C for 15min  
  YPDA agar plates          
 Difco peptone     10g      
 Yeast extract     10g      
 Glucose     10g      
 L-adenine hemisulphate (0.2%stock solution) 7.5ml      
 Bacto agar     10g      
 Add sterile water to a final volume of 500ml. Autoclave at 121°C for 15min. Allow to cool to a 
temperature of ±55°C, before pouring ~20, 90mm plates. These plates were then allowed to set for 2-5 
hours and stored at room temperature for up to three weeks 
 SD
-W
 media           
 Glucose     12g      
 Yeast nitrogen base without amino acids 4g      
 SD
-W
 amino acid supplement   0.4g      
 Add sterile water to a final volume of 600ml. Adjust pH to 5.8 and autoclave at 121°C for 15min 
 SD
-W
 agar plates          
 Glucose     12g      
 Yeast nitrogen base without amino acids 4g      
 SD
-W
 amino acid supplement   0.4g      
 Bacto agar     12g      
 Add sterile water to a final volume of 600ml. Adjust pH to 5.8 and autoclave at 121°C for 15min. 
Allow to cool to temperature of ±55°C, before pouring ~20, 90mm plates. Plates were allowed to set for 
2-5h and stored at room temperature for up to 3 weeks 
 SD
-L
 media           
 Glucose     12g      
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 Yeast nitrogen base without amino acids 4g      
 SD
-L
 amino acid supplement   0.4g      
 Add sterile water to a final volume of 600ml. Adjust pH to 5.8 and autoclave at 121°C for 15min 
 SD
-L
 agar plates          
 Glucose     12g      
 Yeast nitrogen base without amino acids 4g      
 SD
-L
 amino acid supplement   0.4g      
 Bacto agar     12g      
 Add sterile water to a final volume of 600ml. Adjust pH to 5.8 and autoclave at 121°C for 15min. 
Allow to cool to temperature of ±55°C, before pouring ~20, 90mm plates. Plates were allowed to set for 
2-5h and stored at room temperature for up to 3 weeks 
 SD
-L-W
 media           
 Glucose     12g      
 Yeast nitrogen base without amino acids 4g      
 SD
-L-W
 amino acid supplement   0.4g      
 Add sterile water to a final volume of 600ml. Adjust pH to 5.8 and autoclave at 121°C for 15min 
 SD
-L-W
 agar plates          
 Glucose     12g      
 Yeast nitrogen base without amino acids 4g      
 SD
-L-W
 amino acid supplement   0.4g      
 Bacto agar     12g      
 Add sterile water to a final volume of 600ml. Adjust pH to 5.8 and autoclave at 121°C for 15min. 
Allow to cool to temperature of ±55°C, before pouring ~20, 90mm plates. Plates were allowed to set for 
2-5h and stored at room temperature for up to 3 weeks 
 TDO media           
 Glucose     12g      
 Yeast nitrogen base without amino acids 4g      
 SD
-L-W-H
 amino acid supplement  0.4g      
 Add sterile water to a final volume of 600ml. Adjust pH to 5.8 and autoclave at 121°C for 15min 
 TDO agar plates          
 Glucose     12g      
 Yeast nitrogen base without amino acids 4g      
 SD
-L-W-H
 amino acid supplement  0.4g      
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 Bacto agar     12g      
 Add sterile water to a final volume of 600ml. Adjust pH to 5.8 and autoclave at 121°C for 15min. 
Allow to cool to temperature of ±55°C, before pouring ~20, 90mm plates. Plates were allowed to set for 
2-5h and stored at room temperature for up to 3 weeks 
 QDO media           
 Glucose     12g      
 Yeast nitrogen base without amino acids 4g      
 SD
-L-W-H-Ade
 amino acid supplement  0.4g      
 Add sterile water to a final volume of 600ml. Adjust pH to 5.8 and autoclave at 121°C for 15min 
 QDO agar plates          
 Glucose     12g      
 Yeast nitrogen base without amino acids 4g      
 SD
-L-W-H-Ade
 amino acid supplement  0.4g      
 Bacto agar     12g      
 Add sterile water to a final volume of 600ml. Adjust pH to 5.8 and autoclave at 121°C for 15min. 
Allow to cool to temperature of ±55°C, before pouring ~20, 90mm plates. Plates were allowed to set for 
2-5h and stored at room temperature for up to 3 weeks 
 X-α-Galactosidase Solution (5mg/ml)        
 X-α-Galactosidase    25mg      
 Dimethylformamide    1ml      
 Make a 25mg/ml stock. Dilute with dimethylformamide to a 5mg/ml working solution 
10. EUKARYOTIC CELL CULTURE MEDIA       
 Complete Growth Media         
 DMEM (4.5g/L glucose, with L-glutamine) 178ml      
 Foetal calf serum    20ml      
 Penstrep     2ml      
 Pre-warm to 37°C before use     
 Serum-free Media         
 DMEM (4.5g/L glucose, with L-glutamine) 100ml      
 Pre-warm to 37°C before use 
 Differentiating Growth Media         
 DMEM (4.5g/L glucose, with L-glutamine) 196ml      
183 
 
 Horse serum     2ml      
 Penstrep     2ml      
 Pre-warm to 37°C before use       
 10X Isoproterenol          
 Isoproterenol     2.48mg      
 Add 100ml sterile water for 1000X stock. Dilute further 1:100 with sterile water for 10X working 
solution. Make up as required as it cannot be stored in solution 
  65mM CaCl2           
 Calcium chloride    478mg      
 Add 50ml sterile water for a 10X working solution   
11. WESTERN BLOT REAGENTS        
 Bradford solution          
 Coomassie Brilliant Blue   100mg      
 Phosphoric acid    100ml      
 95% ethanol     50ml      
 Dilute Coomassie Brilliant Blue in phosphoric acid, add ethanol. Make up to 1litre with ddH2O, stir. 
Filter 2-5X until solution has light brown colour. Store at room temperature in lightproof container 
  Phosphate Buffered Saline (PBS)        
 PBS tablet (Sigma)    one tablet     
 ddH2O      200ml      
 Dissolve tablet in ddH2O. Store solution at 0-5°C 
  Passive Lysis Buffer          
 EDTA      0.5M      
 NaVO4     1M      
 Nappi      1M      
 HEPES     1M      
 NaCl      5M      
 Triton-X-100     1%      
 Add ddH2O to final volume required. Store at 4°C. Prior to use, add 1mM PMSF and dissolve protein 
inhibitor tablet (Roche) (1 tablet/20ml working solution)       
  Transfer Buffer          
 Tris Base (25mM)    3.03g      
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 Glycine (192mM)    14.4g      
 Methanol      200ml      
 Add sterile water to a volume of 1L         
12. DNA EXTRACTION SOLUTIONS        
 Cell lysis buffer          
 Sucrose     0.32M      
 Triton-X-100     1%      
 MgCl2      5mM      
 Tris-HCl     10mM      
 H2O      1L    
  3M NaAc           
 NaAc.3H2O     40.18g      
 ddH2O      50ml      
 Adjust pH to 5.2 with glacial acetic acid and adjust volume to 100ml with ddH2O 
  DNA Extraction Buffer         
 NaCl      0.1M      
 Tris-HCl     0.01M      
 EDTA (pH 8)     0.025M      
 SDS      0.5%      
 Proteinase K     0.1mg/ml   
  TBE Buffer (10X Stock)         
 Tris-HCl     0.89M      
 Boric Acid     0.89M      
 Na2EDTA (pH 8)    20mM      
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APPENDIX II 
CALCULATING YEAST MATING EFFICIENCIES (Calculations based on Clontech Manual) 
Count number of colonies on all plates with 30-300 colonies after 4 days 
 
#colony forming units (cfu)/ml    =    cfu x 1000µl/ml  /  volume plated (µl) x dilution factor 
1. Number of cfu/ml on SD-L plates = viability of prey partner 
2. Number of cfu/ml on SD-W plates = viability of bait partner 
3. Number of cfu/ml on SD-L-W plates = viability of diploids 
4. Lowest number of cfu/ml of SD-L or SD-W plates indicate limiting partner 
5. Mating efficiency   =  #cfu/ml of diploids x 100  /  #cfu/ml of limiting partner 
Library titer 
Count number of colonies on all plates with 30-300 colonies after 4 days 
cfu/ml      =   #colonies  /  plating volume (ml) x dilution factor 
# colonies clones screened = #cfu/ml x final resuspension volume 
Haemocytometric cell count 
A Neubauer haemocytometer (Superior, Berlin, Germany) was used to perform haemocytometric cell counts to 
determine the titer of the bait culture used in the library mating experiment. A glass coverslip was placed over 
the counting surface before aliquoting the sample onto the haemocytometer. About 50µl of a 1 in 10 dilution of 
bait culture was then pipetted into one of the haemocytometer’s V-shaped wells. This allowed for the area under 
the coverslip to fill up with the sample through capillary action. The counting chamber was then placed under a 
microscope (Nikon TMS, Nikon Instruments, New York, USA) and the counting area was brought into focus 
under low magnification. The number of cells in the large central quadrant of the haemocytometer was counted 
and this value was used to calculate the number of cells per milliliter using the following formula:  
number of cells/ml = number of cells x dilution factor x 10
4
 (a constant used because the depth of the 
haemocytometer is 0.1 mm) 
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APPENDIX III 
BACTERIAL STRAIN PHENOTYPES 
E. coli strain DH5α 
Φ 80d lacZΔM15 recA1, endA1, Gry A96 thi-1, hsdR17 supE44, relA1, deoR Δ(lacZYA argF)u169 
YEAST STRAIN PHENOTYPES 
Yeast strain AH109 
MATa, trp1-901, leu2-3, ura3-5, his3-200, gal4Δ, gal80Δ, LYS::GAL1uas-GAL1TATA-HIS3, GAL2UAS-GAL2TATA-
ADE2, URA3::MEL1UAS-MEL1TATA-lacZ (James et al., 1996) 
Yeast strain Y187 
MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4Δ, met-, gal80Δ, URA3::GAL1UAS-GAL1TATA-
lacZ (Harper et al., 1993) 
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APPENDIX IV 
 
Restriction map and multiple cloning site (MCS) of pGBKT7 Y2H bait vector a) The positions of the 
kanamycin resistance gene (Kan), TRP1 and GAL4-BD coding sequences, f1 bacteriophage and pUC plasmid 
origins of replication, the truncated S. cerevisiae ADH1 promoter sequence (PADH1), the T7 RNA polymerase 
promoter, the T7 and c-Myc epitope tag are indicated on the map. b) Nucleotide sequence of the pGBKT7 MCS. 
The positions of all unique restriction enzyme recognition sequences, stop codons in the T7 terminator sequence, 
the GAL4-BD coding sequence, the T7 promoter sequence, c-Myc epitope tag and the positions of pGBKT7-F 
and pGBKT7-R screening primers are indicated on the sequence (Taken from Clontech MATCHMAKER™ 
vectors handbook). 
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Restriction map and multiple cloning site (MCS) of pACT2 Y2H prey vector a) The positions of unique 
restriction sites are indicated in bold. The position of the ampicillin resistance gene (Amp
r
), LEU2 and GAL4-
AD coding sequences, and pBR322 plasmid origins, the S. cerevisiae ADH1 termination sequences, Lox sites 
(Lox 1 and Lox 2), the Haemagglutinin (HA) epitope tag and the MCS are indicated on the map. b) Nucleotide 
sequence of the pACT2 MCS. The positions of all unique restriction sites, stop codons, the position of the final 
codon of GAL4-AD coding sequence, the positions of the pACT2-F and pACT2-R primers and the HA epitope 
tags are all indicated on the map (Taken from Clontech MATCHMAKER™ vectors handbook). 
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Restriction map and multiple cloning site (MCS) of pGFP
2
-C1 vector a) The positions of the zeocin 
resistance gene (Zeo
r
), GFP
2
 coding sequence, f1 bacteriophage and pUC plasmid origins of replication, the 
truncated PCMV promoter sequence, the multiple cloning site, the TK poly (A) signal and the SV40 early poly (A) 
signal are indicated on the map. b) Nucleotide sequence of the pGFP
2
-C1 MCS. The positions of all unique 
restriction enzyme sequences as well as stop codons are indicated on the sequence (Taken from BioSignal 
Packard BRET
2
 ™ technical data sheet). 
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Restriction map and multiple cloning site (MCS) of pDsRed-Monomer-C1 vector a) pDsRed-Monomer-C1 
is a mammalian expression vector that encodes DsRed-Monomer, a monomeric mutant derived from the 
tetrameric Discosoma sp. red fluorescent protein DsRed. The multiple cloning site (MCS) is positioned between 
the DsRed-Monomer coding sequence and the SV40 polyadenylation signal (SV40 poly A). The position of the 
f1 ori, PCMV early promoter, Kan/Neo resistance genes, SV40 origin of replication, pUC plasmid replication 
origin and the Herpes simplex virus (HSV) thymidine kinase (TK) are indicated on the map. b) Nucleotide 
sequence of the pDsRed-Monomer-C1 MCS. The positions of all unique restriction enzyme sequences as well as 
stop codons are indicated on the sequence (Taken from Clontech MATCHMAKER™ vectors handbook). 
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Restriction map and multiple cloning site (MCS) of pdEYFP-C1 vector a) The position of the EYFP tag, 
chloramphenicol resistance gene, ccdA gene, ccdB gene, SV40 early poly A signal, PCMV early promoter, Kan 
resistance gene, SV40 origin of replication, pUC plasmid replication origin, attR1 and attR2 recombination sites 
are indicated on the map. b) Nucleotide sequence of the pdEYFP-C1 MCS. The positions of all unique 
restriction enzyme sequences as well as stop codons are indicated on the sequence (Taken from Clontech 
MATCHMAKER™ vectors handbook). 
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Articles submitted to peer reviewed journals using data generated in the present study 
 
Myomegalin is a novel A-kinase anchoring protein involved in the phosphorylation of cardiac myosin 
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Abstract 
Background 
Cardiac contractility is regulated by dynamic phosphorylation of sarcomeric proteins by kinases such as cAMP-
activated protein kinase A (PKA). Efficient phosphorylation requires that PKA be anchored close to its targets 
by A-kinase anchoring proteins (AKAPs). Cardiac Myosin Binding Protein-C (cMyBPC) and cardiac troponin I 
(cTNI) are hypertrophic cardiomyopathy (HCM)-causing sarcomeric proteins which regulate contractility in 
response to PKA phosphorylation.  
Results 
During a yeast 2-hybrid (Y2H) library screen using a trisphosphorylation mimic of the C1-C2 region of 
cMyBPC, we identified isoform 4 of myomegalin (MMGL) as an interactor of this N-terminal cMyBPC region. 
As MMGL has previously been shown to interact with phosphodiesterase 4D, we speculated that it may be a 
PKA-anchoring protein (AKAP). 
To investigate this possibility, we assessed the ability of MMGL isoform 4 to interact with PKA regulatory 
subunits R1A and R2A using Y2H-based direct protein-protein interaction assays. Additionally, to further 
elucidate the function of MMGL, we used it as bait to screen a cardiac cDNA library. Other PKA targets, viz. 
CARP, COMMD4, ENO1, ENO3 and cTNI were identified as putative interactors, with cTNI being the most 
frequent interactor.  
We further assessed and confirmed these interactions by fluorescent 3D-colocalization in differentiated H9C2 
cells as well as by in vivo co-immunoprecipitation. We also showed that quantitatively more interaction occurs 
between MMGL and cTNI under β-adrenergic stress. Moreover, siRNA-mediated knockdown of MMGL leads 
to reduction of cMyBPC levels under conditions of adrenergic stress, indicating that MMGL-assisted 
phosphorylation is requisite for protection of cMyBPC against proteolytic cleavage. 
Conclusions 
This study ascribes a novel function to MMGL isoform 4: it meets all criteria for classification as an AKAP, and 
we show that is involved in the phosphorylation of cMyBPC as well as cTNI, hence MMGL is an important 
regulator of cardiac contractility. This has further implications for understanding the patho-aetiology of HCM-
causing mutations in the genes encoding cMyBPC and cTNI, and raises the question of whether MMGL might 
itself be considered a candidate HCM-causing or modifying factor.  
 
Key Words: AKAPs, cMyBPC, HCM, phosphorylation, PKA, regulation of contractility 
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Background  
Cardiac contractility is significantly enhanced by the dynamic phosphorylation of a number of sarcomeric proteins, 
including cardiac myosin binding protein C (cMyBPC) [1,2]. This highly modular protein, found in the C-zone of 
the sarcomere, is encoded by a gene which is frequently implicated in hypertrophic cardiomyopathy (HCM) [3], a 
common inherited cardiac disease characterised by hypertrophy of the ventricular muscle [4]. There are multiple 
isoforms of this protein; the cardiac isoform differs from its skeletal counterparts by containing an extra 
immunoglobulin–like (IgI) domain (C0) at the amino terminal, a charged residue-rich insertion in domain C5 and 
three phosphorylation sites in a motif between the second and third IgI domains (C1-C2), known as the MyBPC 
motif or m-domain. Originally thought to have only a structural role, cMyBPC has been shown to play an important 
role in the regulation of cardiac contractility [1], for which the N-terminal region of the protein appears to be 
crucial. Upon β-adrenergic stimulation, three sites within the MyBPC motif are phosphorylated by protein kinase A 
(PKA) and calcium/calmodulin-activated protein kinase (CaMK), the phosphorylation of this region of MyBPC then 
leads to rearrangement of the myosin crossbridges and thick filament structure [1,5,6] such that cardiac contractility 
is increased [7].  
However, since these kinases regulate a broad range of cellular responses, their compartmentalization in close 
proximity to their sarcomeric targets is required to facilitate control over which proteins are phosphorylated in 
response to second messenger signalling [8,9]. At the same time, co-compartmentalization of enzymes or proteins that 
generate or terminate these second messenger metabolites, such as the phosphodiesterases (PDEs) which degrade cAMP 
and cGMP, with the relevant responsive kinases helps to optimise the precision and speed of response to second 
messenger signaling [10]. Compartmentalization of kinases in general is achieved by either direct docking of the kinase 
on the target protein, or by anchoring of the kinase to, or close to, the target via an adaptor protein, named A-kinase 
anchoring proteins or AKAPs in the case of PKA [11]. Although a CaMK has been found to co-purify with cMyBPC 
[1,12], the mechanism of co-compartmentalization of cMyBPC and PKA has never been described and very little is 
knowns about sarcomeric AKAPs in general. 
In this study we identified myomegalin (MMGL) isoform 4, a PDE4D-interacting protein [13], as a binding partner 
of PKA, the cMyBPC N-terminal region, as well as other PKA-targets, and show that MMGL meets all the 
requirements for classification as a novel sarcomeric AKAP, with important implications for regulation of cardiac 
contractility during adrenergic stimulation. 
Results  
Interaction of trisphospho-cMyBPC with MMGL 
As the interactions of the N-terminal region of cMyBPC under its various phosphorylation states appear to be 
integral to the regulatory role of cMyBPC in contracility, we aimed to gain further insight into the interactions of 
the trisphosphorylated form of the N-terminal region of cMyBPC. Thus, we used a construct of C1-C2 in which 
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the serines in the three phosphorylation sites of the MyBPC motif had been replaced by glutamic acids (PPP), 
mimicking the trisphosphorylated state, as bait in a Y2H cardiac library screen.  
During successive rounds of nutritional and colorimetric selection, 19 putative interactors of PPP were 
identified, which were able to activate the HIS3, ADE2 and MEL1 reporter genes in the presence of the PPP bait, 
but not in the presence of heterologous baits (Table 1). Of these, three in-frame prey plasmids encoded isoform 4 
of PDE4D-interacting protein, also known as myomegalin (MMGL) (Table 1). This putative interaction between 
MMGL and the N-terminal of cMyBPC was intriguing, as the former protein is known to anchor PDE4D to 
particulate structures; PDE4D, in turn, is known to hydrolyze cAMP and thus to attenuate PKA-driven 
phosphorylation [13]. Furthermore, it has been shown that some adaptor proteins can anchor both PKA and 
PDE4D [14], raising the possibility that MMGL may be anchoring PKA to at least cMyBPC in the sarcomere as 
an AKAP; hence this interaction was prioritized for further investigation. 
3D-fluorescence microscopy indicated that cMyBPC and MMGL isoform 4 colocalize in the cytoplasmic 
(encompassing the sarcomeric) region of differentiated rat cardiac H9C2 cells. Exposure of the cells to the 
adrenergic agonist isoproterenol led to an increase in colocalization of the two proteins, as evidenced by the 
increased yellow staining during fluorescence microscopy of such cells (Fig. 1A, B).  
Furthermore, in order to verify that it is the C1-C2 region of cMyBPC that interacts with MMGL isoform 4, 
specifically, and does so in the absence of the GAL4 regions of the Y2H bait protein, we used in vitro co-
immunoprecipitation assays. We also used these assays to assess whether trisphosphorylation of the MyBPC 
motif within this region was crucial to the putative interaction. Both the native C1-C2 and a trisphospho-mimic 
of the C1-C2 region interacted with MMGL isoform 4 in the absence of the Y2H GAL4 domains (Fig. 1C), 
suggesting that the interaction can take place whether or not the MyBPC-motif is phosphorylated. 
MMGL binds to PKA regulatory subunits 
As the primary characteristic of an AKAP is the ability to bind at least one PKA regulatory subunit, we 
investigated the possibility that MMGL functions as an AKAP by using Y2H-based direct protein-protein 
interaction assays to determine binding between MMGL and the two cardiac-expressed regulatory subunits of 
PKA. Both regulatory subunits (PRKAR1A and PRKAR2A) interacted with MMGL, as assessed by growth and 
light colour of the colonies on quadruple dropout nutritional selection medium, compared to relevant controls 
(Fig. 2A).  
Further support for this finding was garnered by co-localization studies using 3D-fluorescence microscopy: we 
demonstrated that MMGL isoform 4 occurs in the same 3D-subcellular region as the two PKA regulatory 
isoforms in H9C2 cardiomyocytes (Fig. 2B).  
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To further verify physical interaction between MMGL and these PKA isoforms in a cellular context and in the 
absence of GAL4 domains, we performed pull-down assays in diffentiated H9C2 cardiomyocytes. As 
commercial antibodies against MMGL/PDE4DIP are not able to detect isoform 4, the smallest isoform of this 
protein (results not shown), we used an antibody directed against dsRed to detect a dsRed-tagged version of 
MMGL isoform 4 in these assays. In this way, endogenous PRKAR1A and PRKAR2A were shown to 
immunoprecipitate dsRed-MMGL, and vice versa (Fig. 2C), indicating physical interaction of MMGL with these 
two PKA regulatory isoforms.  
MMGL binds to additional PKA targets 
We further investigated the function of MMGL isoform 4 by using it as Y2H bait to screen a cardiac cDNA 
library in order to identify its additional binding partners. Thirteen in-frame putative MMGL-interactors were 
identified that activated all three nutritional reporter genes in the presence of the MMGL bait, but not in the 
presence of heterologous baits (Table 2). As we were primarily interested in the possibility of MMGL acting as a 
sarcomeric AKAP, proteins with defined vesicular localizations were not considered of primary interest for 
follow-up in this study; these included the mitochondrial protein COX5A, the proteosome 26S subunit and the 
endosomal protein SNX3. Of the remaining ten putative MMGL interactors, six encoded cardiac troponin I 
(cTNI) (Table 2).  
Further support for the validity of these interactions was provided by finding that MMGL occurs in the same 3D-
subcellular region as all five of the putative interactors identified in the Y2H library screen, viz. cardiac ankyrin 
repeat protein (CARP), copper metabolism gene MURR1 domain 4 (COMMD4), α-enolase (ENO1), β-enolase 
(ENO3) (Fig. 3), and cardiac troponin I (cTNI) (Fig. 4A), in differentiated cardiomyocytes.  
cTNI is a known PKA target [15], while the remaining four putative interactors were shown to be likely targets 
using Phosphomotif Finder (www.hprd.org/PhosphoMotif_finder); we therefore investigated the effect of 
isoproterenol stimulation of the H9C2 cells on colocalization, using the most frequent, and sarcomeric-located, 
putative interactor, cTNI, as example. Treating H9C2 cells transfected with dsRed-MMGL/GFP-cTNI with 
isoproterenol resulted in significantly more 3D colocalization between these two proteins, as shown in Fig. 4, 
compared to non-treated cells.  
Moreover, in pull-down assays, exogenous, fluorescently-tagged MMGL and endogenous ENO1, ENO3, CARP 
and cTNI reciprocally co-precipitated each other (Fig. 5i-iv). As COMMD4 had a similar mobility to antibody 
light chains, which interfered with detection of these proteins in Western blots, a GFP-tagged fusion of this 
protein was expressed in H9C2 cells for pull-down assays. In these assays, exogenous GFP-COMMD4 
immunoprecipiated exogenous dsRed-MMGL, and vice versa (Fig. 5v). Thus, Western blot analysis data 
supported the proposed interaction of MMGL with ENO1, ENO3, CARP, cTNI and COMMD4. 
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Thus, our results strongly suggest that MMGL interacts with both PKA regulatory isoforms, as well as with each 
of the prioritized five putative prey interactors identified in the Y2H screen, in a cellular milieu, and in the 
absence of the GAL4 domains. 
Effect of MMGL knockdown  
In order to evaluate the role of MMGL in cMyBPC phosphorylation, we assessed the expression of the different 
phosphorylation isoforms of cMyBPC, in the context of siRNA-mediated MMGL knockdown. Typically, 
interference with AKAP-functioning is commonly more noticeable on the target protein only after adrenergic 
stimulation [16], thus we also tested the effect of MMGL knockdown in the presence of adrenergic stimulation. 
Of four siRNAs tested, Rn_RGD:708410_3_HP siRNA (MMGL 3) (Qiagen) was found to provide optimal 
knockdown of MMGL (80%) in H9C2 cells (Fig. 6A); thus MMGL 3 siRNA was used in subsequent 
experiments to silence MMGL gene expression. 
Using Western blots of 2-dimensional IEF gels, we found that similar amounts of the mono- and 
diphosphorylated forms of cMyBPC were expressed in untreated H9C2 cells, while lesser amounts of the un- 
and trisphosphorylated forms, relative to the other isoforms, were present (Fig. 6Bi, Ci). When these cells were 
exposed to increased CaCl2 and isoproterenol, to activate CaMK and PKA such that maximum phosphorylation 
of the MyBPC-motif is likely [7], the relative amount of the trisphosphorylated form increases markedly, while 
the relative amount of unphosphorylated cMyBPC decreased (Fig 6Bii, Cii). However, adrenergic stimulation in 
the presence of MMGL knockdown resulted in very low expression of all isoforms (Fig. 6Biii, Ciii). This 
finding is compatible with previous findings of an inverse relationship between phosphorylation of cMyBPC and 
its proteolytic degradation, suggesting that phosphorylated cMyBPC is protected against proteolytic cleavage, 
whereas absence of phosphorylation results in increased degradation of the protein and reduced levels of 
cMyBPC in the cell [17,18]. 
Discussion  
Myomegalin has been characterized as a protein with the properties of a scaffold or structural protein that is 
expressed at high levels in skeletal and cardiac tissue, suggesting an important function in muscle, and which 
interacts with a cAMP-specific phosphodiesterase [13]. However, the precise function and interactions of this 
protein, and its five isoforms, have been largely unknown. We here describe how the smallest MMGL isoform, 
isoform 4, binds to known and predicted PKA targets in the cardiac myocyte, including some sarcomeric 
proteins, viz. cMyBPC, cTNI, ENO1, ENO3, CARP and COMMD4 (Tables 1 and 2). Moreover, we show that 
MMGL isoform 4 interacts with two regulatory subunits of PKA (Fig. 2). Together these results describe 
MMGL isoform 4 as a novel sarcomeric AKAP, which, like mAKAP [14], is involved in assembling a 
PKA/PDE cAMP signalling module.  
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In addition to interacting with both types of regulatory subunits, viz. RI and RII, which qualifies MMGL isoform 
4 as a dual-specific AKAP [11,19], MMGL also meets the three other criteria for classification as an AKAP: By 
verifying its interaction with its proposed binding partners, we demonstrate that the targeting domains contained 
within the proposed AKAP participates in protein-protein interactions [11]. Further, it has previously been 
shown that MMGL is a phosphodiesterase 4D-interacting protein [13], thus it meets the criterion for being able 
to coordinate multiple signaling pathways by anchoring additional signaling enzymes [11,20]. Lastly, we have 
shown in other Y2H screens that cMyBPC also binds to COMMD4 (unpublished results), here shown to be a 
MMGL interactor, while COMMD4 itself also binds to ENO1 and SNX3 (unpublished results). This strongly 
suggests that MMGL is part of a larger, multiprotein unit [11,20], and that MMGL isoform 4 may function as a 
vital link in signaling between upstream activators and numerous downstream targets [21]. 
Co-compartmentalization of both PKA and PDE4D is crucial for maintaining specificity of adrenergic signaling, 
and for maintaining contractility in cardiac cells [16]. We here established an important and novel link between 
PKA and PDE4D co-compartmentalization at the sarcomere level, and cMyBPC phosphorylation, and hence, 
regulation of cardiac contraction. The mechanism of docking of PKA to cMyBPC for phosphorylation of the 
MyBPC motif has previously not been elucidated; this study strongly suggests that MMGL isoform 4 anchors 
PKA to the N-terminal region, viz. C1-C2, of cMyBPC. The interaction between MMGL isoform 4, PKA, 
PDE4D and the N-terminal region of cMyBPC therefore sheds light on how second messenger responses are 
regulated in this particular part of the sarcomere.  
We also found that β-adrenergic stimulation led to greater colocalization of myomegalin with both cMyBPC and 
cTNI in live cardiomyocytes, as evidenced by the increase in yellow staining during fluorescence microscopy in 
Figs. 1 & 4. This implies that under adrenergic stimulation, and consequential increased intracellular levels of 
cAMP, PKA is dynamically recruited by MMGL isoform 4 to distinct sarcomeric locations. This translocation of 
MMGL to the sarcomeric region is therefore compatible with a mechanism that would lead to increased 
phosphorylation of cMyBPC and cTNI, which is known to form part of the cardiac cellular stress response that 
leads to increased cardiac contraction [22]. Furthermore, given MMGL’s known interaction with PDE4D [13], 
the mechanism for termination of the second messenger response, by degrading cAMP, would also be on site; 
lower levels of cAMP may then cause this multiprotein complex to dissociate again.  
The knockdown studies of MMGL further suggests that MMGL not only acts as an AKAP at the MyBPC motif, 
but by implication plays a role in cardioprotection during adrenergic signaling. Although, in the presence of 
MMGL, all phosphorylation isoforms of cMyBPC are expressed well in H9C2 cells, and the level of the 
trisphosphorylated cMyBPC is increased in such cells under conditions of β-adrenergic stimulation as is to be 
expected, knockdown of MMGL under the same conditions dramatically reduced cMyBPC expression (Fig. 5). 
The latter finding suggests that when MMGL expression is reduced, cMyBPC phosphorylation is hindered, 
rendering the protein vulnerable to cleavage by proteases and reducing cMyBPC protein levels in the cell, as 
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described by others [17,18,23]. Thus, it appears that MMGL is an essential part in the β-adrenergic pathway 
leading to trisphosphorylation of cMyBPC and protection of the protein against degradation, which in turn is 
essential for normal sarcomeric integrity and cardiac function, as well as cardioprotection during ischemia-
reperfusion injury.[24] 
The subcellular localization and functions of some of the putative PKA targets identified via the Y2H library 
screen suggest that MMGL may act as AKAP in regions outside the sarcomere as well. Although some of the 
identified interactions, such as those with cMyBPC and cTNI, certainly occur within the sarcomere, associations 
with the other identified interactors (Table 2) do not necessarily occur within the sarcomere, nor do they 
necessarily all occur concurrently. In fact, a multiprotein subunit in the sarcomere consisting simultaneously of 
all identified MMGL-ligands would most likely sterically hinder crossbridge formation, and is therefore 
improbable. However, interaction of MMGL with proteins such as COMMD4, CARP, ENO1 and ENO3 may 
facilitate control of efficient PKA phosphorylation of these proteins; the protein-protein interactions and/or 
activation of these proteins may thus be regulated.  
Although this study prioritized investigation of the interaction between the N-terminal of cMyBPC and MMGL, 
the other putative interactions of this region of cMyBPC should be further explored. The absence of cMyBPC as 
a prey in the MMGL Y2H library screen is most likely explained by the known absence of cDNAs representing 
the N-terminals of large proteins in oligo dT-primed libraries, while the absence of PRKAR1A and PRKAR2A 
may relate to the stringency of selection during heterologous bait-matings during this Y2H screen [25]. 
Interaction between myomegalin, PKA and cMyBPC or cTNI is also relevant to understanding of HCM patho-
aetiology, as both of the latter proteins cause HCM when defective. It is known that point mutations in the C1-
C2 region and in the MyBPC motif lead to HCM [3,26]; a potential mechanism for this may be involve 
disruption of binding between MMGL and cMyBPC. Such disruption would have consequences for PKA-
phosphorylation of the cMyBPC motif (with implications for regulation of cardiac contractility), implying a 
poison-peptide mechanism underlying disease, as well as maintenance of sufficient cMyBPC levels within the 
sarcomere, particularly under conditions of adrenergic stress, implying a haplo-insufficiency mechanism. Point 
mutations in cTNI may have a similar patho-aetiology. It could be further speculated that, mutations in MMGL 
could similarly lead to inadequate binding of PKA and/or its sarcomeric partners, which might affect cMyBPC 
or cTNI phosphorylation and hence affect adaptation of cardiac contractility to adrenergic stimulation. Future 
studies could therefore consider MMGL as either a candidate causal gene or a potential modifier gene for HCM.  
Conclusions  
This study shows that myomegalin isoform 4 is a novel sarcomeric AKAP, which forms part of a multiprotein 
complex that functions in cAMP signalling. It is particularly relevant to phosphorylation of cMyBPC and cTNI, 
and therefore, is of significance in the regulation of cardiac contractility in both health and disease. 
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Methods 
Plasmid constructs 
Y2H constructs 
The region of MYBPC3 encoding domains C1-C2 was PCR-amplified from a MYBPC3 cDNA clone (kind gift 
of Prof Hugh Watkins, Oxford University). PCR-based site-directed mutagenesis, as previously described by 
Elliott et al.[27], was then used to generate a PCR fragment representing domains C1-C2 in which the codons 
for serines within all three phosphorylation sites of the cMyBPC motif were mutated to encode glutamic acids to 
mimic the trisphosphorylated state (PPP). The full-length cDNA from MMGL isoform 4 was amplified from a 
commercial construct, in vector pdEYFP-C1 (imaGenes GmbH). These fragments were individually cloned into 
the NdeI and EcoRI restriction sites in-frame with GAL4BD in the Y2H bait yeast expression vector pGBKT7 
(Clontech) for use in the respective Y2H library screens or in Y2H-based direct protein-protein experiments.  
The cDNA of the two PKA regulatory isoforms (PRKAR1A and PRKAR2A) were PCR amplified from a cardiac 
cDNA library (Clontech). These fragments were cloned into the BamHI and XhoI restriction sites or the NcoI 
and BamHI sites, respectively, of the Y2H prey vector pACT2 (Clontech). 
Integrity of insert sequences, reading frame and cloning sites were verified by means of bi-directional 
sequencing, after which pGBKT7-PPP and pGBKT7-MMGL were transformed into S. cerevisiae strain AH109, 
and pACT2-R1A and pACT2-R2A into strain Y187 (Clontech). 
Constructs used for verification analyses 
The cDNAs from the putative interactors of MMGL isoform 4 identified in the Y2H library screen viz. TNNI3, 
CARP, COMMD4, ENO1 and, ENO3, as well as PRKAR1A and PRKAR2A, were PCR amplified and cloned into 
the pGFP2-C1 fluorescent vector (BD Bioscience).  MMGL was further subcloned from the pGBKT7-MMGL 
construct into the pDs-Red-C1 vector (dsRed-MMGL) (BD Bioscience). The integrity of the cloning sites, 
reading frames and all interactor sequences were verified by bi-directional sequencing. These constructs were 
subsequently used in 3D in vivo colocalization and in vivo co-immunoprecipitation analyses. 
Y2H library screening 
A S.cerevisciae Y187 pre-transformed human MATCHMAKER™ cardiac cDNA library constructed in pACT2 
(BD Bioscience) was mated with the AH109 strain transformed with pGBKT7-PPP and the library screen 
performed according to manufacturer’s instructions. Clones that expressed all three reporter genes, HIS3, ADE2, 
and MEL1, were further analyzed. An interaction-specificity test was used to identify preys that did not activate 
reporter genes in the presence of the following heterologous baits: pGBKT7-C5 (encoding Igl domain C5 of 
cMyBPC), pGBKT7-53 (encoding murine p53) and unrecombined pGBKT7. Prey plasmids interacting 
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specifically with PPP were sequenced using a vector specific primer, and in-frame ORF sequences analyzed via 
BLASTN and BLASTP (http://ncbi.nlm.nih.gov/blast) to assign identity. Literature and public database searches 
were used to prioritize putative ligands according to function and subcellular localization. A Y2H library screen 
with pGBKT7-MMGL was subsequently similarly performed. 
Direct Y2H protein-protein interaction assay 
pGBKT7-MMGL in yeast strain AH109 was mated individually with pACT2-R1A and pACT2-R2A in yeast 
strain Y187 to determine whether the PKA regulatory subunits interacts directly with MMGL. A single colony 
of pGBKT7-MMGL in AH109 was taken from appropriate selection plates and suspended with a single colony 
of pACT2-R1A or -R2A in YPDA media overnight. Mating mixes were plated onto solid growth medium 
lacking leucine (Leu) and tryptophan (Trp). Following an incubation period of four days, the colonies on each 
plate were transferred to medium lacking Leu, Trp and histidine (His), and incubated five days. Surviving 
colonies were finally transferred to medium lacking Leu, Trp, His and adenine (Ade) and growth was assessed 
on day 4 and 7. Control matings were included those of pGBKT7-MMGL with pACT2-cTNI(+), pACT2-
TUSC4(-) and empty pACT2(-). 
Antibodies 
Anti-HA, anti-Myc and anti-CARP antibodies were purchased from Santa Cruz Biotechnology. Living 
colours™ anti-dsRed and -JL-8 antibodies were purchased from Clontech and anti-β-actin antibody from Cell 
Signaling Technology. Anti-ENO1, -ENO3, -PRKAR1A, -PRKAR2A and -cTNI antibodies were purchased 
from Abnova. 
Cell culture and transfection 
H9C2 cells were maintained at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium, supplemented with 
10% fetal bovine serum, 100µg/ml penicillin and 100µg/ml streptomycin. For in vivo co-immunoprecipitation, 
approximately 4 million H9C2 cells were seeded per 135mm petri dish, and were transfected once 70-80% 
confluency was reached. Genejuice® (Novagen) was used for transfections according to manufacturer’s 
instructions. For 3D in vivo colocalization, approximately 20 000 – 30 000 H9C2 cells were seeded per well in 
8-well borosilicate coverglass chambers (Nunc), and transfected after 70-80% confluency have been reached 
using Lipofectamine™ (Invitrogen) according to manufacturer’s recommendations. Cells were differentiated 
into myotubes 24h after transfection by changing the growth media to differentiation media (Dulbecco’s 
modified Eagle’s medium, 1% horse serum, 100µg/ml penicillin and 100µg/ml streptomycin). Fresh 
differentiation media was added every 48h until cells were fully differentiated. 
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Three-dimensional in vivo co-localization 
Prior to image acquisition, the differentiation media was removed from the co-transfected, differentiated H9C2 
cells and replaced with culture media containing a 1:200 dilution of Hoechst H-33342 nucleic acid stain 
(Sigma). Cells in three wells co-transfected with GFP-MyBPC/dsRed-MMGL were photographed using an 
Olympus IX 81 motorised inverted microscope (Olympus); after photography, cells were treated with  0.1µM 
isoproterenol in order to stimulate phosphorylation of the MyBPC motif [7] and the same cells photographed 
again, to monitor changes in colocalization upon adrenergic stimulation. CellR software was used to perform 
image analysis. Z-stacks were done in order to co-localize the tagged proteins in three dimensions. Double-
labeled images, utilizing the co-transfected samples, were obtained at different focal planes which were 
processed by the CellR software to determine colocalization. A 60X oil immersion objective was used to collect 
image stacks at 0.26µm intervals in the plane. Subsequently, each co-localized image was created from the 
average of 25 frames. Changes in colocalization of MMGL isoform 4 and cTNI were obtained in a similar 
manner. 
In vitro protein transcription and translation 
The cDNA encoding the native as well as the trisphosphorylated mimic of the C1-C2 region of cMyBPC and the 
full-length MMGL isoform 4 cDNA were PCR amplified to generate fragments that incorporates the T7 
promoter and Myc- or HA-epitope tags, respectively. The TnT Quick Coupled Transcription/Translation System 
(Promega) was then used to transcribe and translate these PCR products into Met-35S-radiolabelled proteins, 
according to manufacturer’s instructions.  
In vitro co-immunoprecipitation 
Five microlitres of the respective 35S-labelled HA-MMGL and Myc-C1-C2 were mixed and incubated for 1h at 
room temperature. One microlitre of anti-HA or anti-Myc antibody (5µg/ml) was added followed by incubation 
of 1h. Ten microlitres of pre-washed protein G agarose (Kirkegaard & Perry Laboratories) were subsequently 
added, together with 135µl Co-IP buffer [5mM phosphate-buffered saline (PBS), 5µg/ml aprotinin, 0.5mM 
PMSF, 100mM DTT, 1% Tween-20]. Incubation of 1h at 4°C followed on a rotating device. Centrifugation 
followed for 30s at 3000g, after which the pellet was washed five times with Tris-buffered saline with Tween-20 
[20mM Tris-HCl, pH7.5, 150mM NaCl, 1% Tween-20]. Samples were electrophoresed on a 20% SDS-
polyacrylamide gel, and protein bands were detected by autoradiography. 
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In vivo co-immunoprecipitation 
H9C2 cells transfected with the appropriate constructs were harvested 48h following transfection, centrifuged at 
3000rpm for 3min and the pellet washed with PBS. Two hundred microlitres of passive lysis buffer (PLB) [0.5M 
EDTA, 1M NaVO4, 10mM Nappi, 1M HEPES, 5M NaCl, 1% TritonX, protease inhibitors and 
phenylmethylsulfonyl fluoride (PMSF)] was added to each sample. Samples were then incubated on ice for 
30min followed by centrifugation at 14000rpm and the supernatants collected. Lysate concentration was 
determined via a Bradford assay, and the volumes equalized to 200µl by adding PLB containing protease 
inhibitors and PMSF with a final concentration of 200µg/µl. Lysates were pre-cleared by adding 20µl Protein G 
agarose beads (KPL) and incubating samples at 4°C for 2h on a rotating device. Fluorescent-tagged or 
endogenous proteins were immunoprecipitated from lysates using 1-2µg of the appropriate antibody, as 
indicated in Fig. 2c and 5. Following overnight incubation, 60µl of protein G agarose beads was added to each 
sample, and incubated at 4°C for 2h on a rotating device. Afterwards, immunoprecipitates were washed 5X in 
cold PLB containing protease inhibitors and PMSF, followed by resuspension in SDS loading buffer, and boiling 
prior to SDS-PAGE and subsequent Western blotting. 
RNA interference 
The effect of siRNA transfection on myomegalin mRNA expression using different PDE4DIP siRNAs (Qiagen) 
was determined and optimized by a 2-step Q-RT-PCR using the Corbett Rotorgene system as follows: 
Approximately 4x10
4
 H9C2 cells were seeded per well of an 8-well chamber slide, and siRNA transfected when 
cells reached 50-60% confluency, using HiPerFect transfection reagent (Qiagen) as per manufacturer’s 
instructions. Total RNA extraction followed after 24 hours using the RNeasy Plus Mini kit (Qiagen) as per 
manufacturer’s instructions. cDNA was subsequently transcribed using the Quantitect Reverse Transcription kit 
(Qiagen) as per manufacturer’s instructions. The Quantifast SYBR green PCR kit (Qiagen) was then used to 
perform a real-time quantification of cDNA transcribed from the extracted RNA with or without non-silencing 
control (NSC) or PDE4DIP siRNAs. PDE4DIP levels were quantified with reference to three rodent reference 
genes (transferring receptor – TRFR, glyceraldehydes-3-phosphate dehydrogenase – GAPDH and heat shock 
protein 1β - Hsp1β) selected from a panel of 6 commonly used housekeeping genes. 
The Genomewide designed non-validated Rn_RGD:708410_3_HP siRNA (Qiagen) resulted in the lowest 
MMGL gene expression quantification levels, and was used in subsequent experiments. Confluent H9C2 cells 
were transfected with GFP-tagged cMyBPC using Genejuice® (Novagen). These cells were then transfected 
after 24h with 10nM PDE4DIP Rn_RGD:708410_3_HP siRNA using HiPerFect Transfection Reagent 
(Qiagen); control cells were not transfected with siRNA. For adrenergic stimulated cells, cells were treated with 
65mM CaCl2 for 10min at 24h post-transfection, followed by a 0.1µM isoproterenol treatment for another 
10min. All cells were then lysed (as done for in vivo co-immunoprecipitation) and concentrations determined via 
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Bradford assays, and all volumes equalized to 200µl by adding PLB containing protease inhibitors and PMSF 
with a final concentration of 200µg/µl. A non-denaturing immunoprecipitation of GFP-cMyBPC from the lysate 
followed using 1µg of the JL-8 antibody with the Dynabeads® Protein G and DynaMag™-2 system (Invitrogen) 
as per manufacturer’s instructions. Isoelectric focusing of the GFP-cMyBPC immunoprecipitates followed to 
separate the four possible phosphorylation isoforms of cMyBPC. 
Isoelectric focusing 
For the first dimension separation, the GFP-tagged cMyBPC immunoprecipitates were suspended in ReadyPrep 
2-D Rehydration buffer 1 (Bio-Rad) containing Bio-lite pH 3-10 buffer (Bio-Rad) to a final volume of 200µl. 
The protein/rehydration buffer mix was then applied to a pH 4-7 (11cm) immobilized pH gradient (IPG) strip 
(Bio-Rad). Rehydration of the strip followed for 12 hours at room temperature. Afterwards, IEF was done under 
the following conditions: 8000V for 20min, 8000V for 2 hours and 8000V for 40 000 V hours at 21°C (Protean 
IEF Cell, Bio-Rad). Strips were stored at -80°C after IEF until required. 
For 2-dimensional gel electrophoresis (2-DE), IPG strips were equilibrated by incubating the strips in 
equilibration buffer (0.375M tris-HCl, 6M urea, 20% glycerol, 2%, SDS) containing DTT (Sigma-Aldrich) for 
15min and then in equilibration buffer containing iodoacetamide (Sigma-Aldrich) for 15min shaking at room 
temperature. Following equilibration, the IPG strips were placed on top of a Criterion XT 12% bis-tris precast 
gel (Bio-Rad) and sealed with 0.5% agarose (Bio-Rad). Electrophoresis of the second dimension separation was 
done under constant voltage (200V) for 1-2 hours in 5% XT-MOPS running buffer (Bio-Rad). Gels were then 
transferred to a nitrocellulose membrane and subsequently western blotted with the JL-8 antibody. 
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Tables 
Table 1 - Interactors of the C1-C2 region of cMyBPC in the trisphospho-mimic state as identified by yeast 
2-hybrid library screening 
Clone # Genomic Hit, 
Accession no (E-
value) 
In-frame ORF Protein 
Hit, Accession no (E-
value) 
Subcellular localization 
P205, P272, P403 PDE4DIP, transcript 
4 
NM_001002810 
(0.0) 
Homo sapiens 
phosphodiesterase 4D 
interacting protein 
(myomegalin) 
NP_055459.3 (1e-70) 
Cytoplasm, Cytoskeleton 
P182, P286, P267 ACTC1 
NM_005159 (0.0) 
Homo sapiens actin, 
alpha, cardiac muscle 1 
NP_005150 (1e-89) 
Thin filament sarcomere 
P259 ACTCB 
NM_001101 (0.0) 
Homo sapiens actin, beta 
AAH23548.1 (8e-34) 
Cytoplasm, cytoskeleton 
P62, P213, P319 MYBPC3 
NM_000256 (0.0) 
Homo sapiens cardiac 
myosin binding protein 
C, NP_000247.2 (2e-26) 
Thick filament; 
Sarcomere 
P2,P81 Gcom1 transcript 12 
NM_001018100 
(0.0) 
Homo sapiens 
GRINL1A combined 
protein 
NP_001018100.1, (2e-
65) 
Unknown 
P80 FLNC 
NM_001458.2 (0.0) 
Homo sapiens filamin C, 
gamma 
NP_001449.3(2e-91) 
Myofibrillar z-disks; actin 
cytoskeleton 
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Clone # Genomic Hit, 
Accession no (E-
value) 
In-frame ORF Protein 
Hit, Accession no (E-
value) 
Subcellular localization 
P175, P465 CNN1 
NM_001299.4 (0.0) 
Homo sapiens calponin 
1, basic, smooth muscle 
NP_001290.2 (1e-104) 
Cytoplasm, cytoskeleton 
P11 PARD3 
NM_019619.2 (3e-
121) 
Homo sapiens par-3 
partitioning defective 3 
homolog NP_062565.2 
(1e-24) 
Plasma membrane; tight 
junctions 
P223 CCT7 
NM_001009570.1 
(0.0) 
Homo sapiens 
chaperonin containing 
TCP1, subunit 7 (eta) 
NP_001009570.1 (1e-
83) 
Cytoplasm 
P238 SVIL 
NM_021738.1 (0.0) 
Homo sapiens 
supervillin NP_003165.1 
(1e-15) 
Actin cytoskeleton, plasma 
membrane, nucleus 
P398 FLJ21347 
NM_022827.2 (0.0) 
FLJ21347 NP_073738.2 
(4e-101) 
Unknown 
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Table 2 - Interactors of MMGL isoform 4 identified by yeast 2-hybrid library screening 
Clone # Genomic Hit, 
Accession no & E-
value 
In-frame ORF 
Protein Hit, 
Accession no & E-
value 
Subcellular 
localization 
128, 137, 148, 149, 
160, 200 
 
TNNI3 
NM 000363, 0.0 
 
Homo sapiens 
troponin I type 3 
(cardiac) 
NP 000354.3, 2e-82 
Thin filament 
192 CARP 
NM 014391, 0.0 
Homo sapiens Cardiac 
ankyrin repeat protein 
NP 055206, 2e-121 
Cytosol, nucleus 
715 COMMD4 
NM 017828, 0.0 
 
Homo sapiens COMM 
domain 
containing 4 
NP 060298.2, 3e-97 
Cytoplasm 
130 ENO1 
NM 001428, 0.0 
 
Homo sapiens Enolase 
1 (alpha) 
NP 001419, 4e-116 
Cytoplasm 
203 ENO3 
NM 053013, 0.0 
 
Homo sapiens Enolase 
3 (beta, muscle) 
NP 001967.1, 000.1 
Cytoplasm 
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Figures 
Figure 1 - MMGL isoform 4 interacts with the C1-C2 region of cMyBPC 
A: Live cell fluorescence imaging showing that colocalization of MMGL isoform 4 and cMyBPC increases 
under adrenergic stress. Each panel represents a single frame of the 25 images that were captured for the Z-stack. 
Each of the first three columns shows a single colour channel, while the image in the last column shows an 
overlay of the four colour channels used. Column iii shows colocalization (yellow fluorescence) between dsRed-
MMGL and GFP-cMyBPC in the absence (-isopro) and presence (+isopro) of the beta-adrenergic agonist, 
isoproterenol. As evidenced by the increased yellow staining, co-localization levels between MMGL and 
cMyBPC increased ten minutes after the addition of isoproterenol. B: Quantification of colocalization shown in 
A demonstrates the noticeable increase in co-localization, although the increase does not reach statistical 
significance. C: In vitro co-immunoprecipitation showing that MMGL interacts with the native as well as the 
trisphospho-mimic of C1-C2 in the absence of Y2H GAL4 domains. Abbreviations: isopro-isoproterenol 
Figure 2 – MMGL acts as a dual-specific AKAP by anchoring PKA regulatory isoforms R1A and R2A 
A: Activation of nutritional reporter genes by PKA-MMGL interaction during direct protein-protein interaction 
assays. Small-scale Y2H matings between pGBKT7-MMGL and pACT2-PRKAR1A (i) and pACT2-PRKAR2A 
(ii) on solid medium lacking Leu, Trp, His and Ade. Growth of yeast yells indicate interaction of MMGL with 
PRKAR1A as well as PRKAR2A B: Live cell fluorescence imaging of co-localization of MMGL with 
PRKAR1A and PRKAR2A in differentiated H9C2 cardiomyocytes. (i) GFP-tagged PRKAR1A and PRKAR2A 
is seen in the cytosol  as green fluorescence. (ii) dsRed-tagged MMGL expression is seen as red fluorescence. 
(iii) Yellow fluorescence indicates the co-localization of PRKAR1A and PRKAR2A with MMGL. (iv) Overlay 
of images A-C with Hoechst H-33342 labeling of the nuclei (blue fluorescence), for orientation purposes. C: 
Western blots of in vivo co-immunoprecipitations of PKA regulatory subunits and MMGL. (i) Endogenous 
PRKAR1A and PRKAR2A immunoprecipitated exogenous dsRed-MMGL in lysates of dsRed-MMGL-
transfected, differentiated H9C2 cardiomyocytes. Conversely, (ii) PRKAR1A and (iii) PRKAR2A also 
immunoprecipitated exogenous dsRed-MMGL in these lysates. The clear protein G control lanes showed that 
these precipitations are not spurious, but are the result of physical association between the relevant proteins. 
Abbreviations: IP-immunoprecipitate; Prot G-protein G control; R1A-PRKAR1A; R2A-PRKAR2A WB-western 
blot 
Figure 3 – 3D co-localization of MMGL and its respective preys identified in the Y2H library screen   
Live cell fluorescence imaging of co-localization of MMGL and the putative interactors identified in the Y2H 
library screen in differentiated H9C2 cardiac myocytes. (i) Individual GFP-tagged putative library screen 
interactors are seen as green fluorescence, as indicated by labels to the left of the row. (ii) dsRed-tagged MMGL 
expression in the same cell(s) are shown are red fluorescence. (iii) Co-localization of interactors and MMGL 
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within these cell(s), generated from 3D Z-stack images, are shown as yellow fluorescence. (iv) Overlay of 
images A-C with Hoechst H-33342 labelling of the nuclei (blue) for orientation purposes. The presence of 
yellow staining in each of the images in (iii) indicates that each of the respective preys colocalize with MMGL 
in differentiated H9C2 cardiomyocytes. 
Figure 4 – Co-localization increases between MMGL and PKA target upon β-adrenergic stimulation  
A: Live cell fluorescence imaging showing that co-localization of MMGL isoform 4 and cTNI increases under 
adrenergic stress. Each panel represents a single frame of the 25 images that were captured for the Z-stack. Each 
of the first three columns shows a single colour channel, while the image in the last column shows an overlay of 
the four colour channels used. Column iii shows colocalization (yellow fluorescence) between dsRed-MMGL 
and GFP-cTNI in the absence (-isopro) and presence (+isopro) of the beta-adrenergic agonist, isoproterenol. The 
increase in intensity of yellow fluorescence in the second row demonstrates that co-localization levels of MMGL 
and cTNI had increased ten minutes after the addition of isoproterenol. B: Quantification of co-localization 
shown in A shows that co-localization increased noticeably, although the increase does not reach statistical 
significance. Abbreviations: isopro-isoproterenol 
Figure 5 – Western blots of in vivo co-immunoprecipitations of MMGL and putative interactors  
A: Western blots showing that endogenous CARP (i), ENO1 (ii), ENO3 (iii) and cTNI (iv) immunoprecipitated 
exogenous dsRed-/YFP-MMGL in vivo in lysates of ds-Red-/YFP-MMGL transfected, differentiated H9C2 
cardiomyocytes. (v) Western blot showing that GFP-COMMD4 immunoprecipitates dsRed-MMGL in 
differentiated H9C2 cardiomyocytes transfected with both GFP-COMMD4 and dsRed-MMGL B: Western blots 
of reciprocal immunoprecipitations indicated that dsRed-/YFP-MMGL immunoprecipitated endogenous CARP 
(i), ENO1 (ii), ENO3 (iii) and cTNI (iv) in lysates of ds-Red-/YFP-MMGL transfected, differentiated H9C2 
cardiomyocytes. (v) Western blot indicating that dsRed-MMGL immunoprecipitates GFP-COMMD4. The 
dsRed antibody is directed against the dsRed-MMGL fusion protein, while the JL-8 antibody is directed against 
the YFP/GFP fusion proteins. The clear protein G control lanes show that these precipitations are not spurious, 
but are the result of physical association between the relevant proteins. Abbreviations: IP-immunoprecipitate; 
Prot G-protein G control; WB-western blot 
Figure 6 - siRNA-mediated knockdown of MMGL leads to reduced levels of cMyBPC phosphorylation 
under adrenergic stimulation.  
A: Graph demonstrating that real-time quantification of MMGL cDNA transcribed from RNA extracted from 
cells transfected with either a non-silencing control or a particular MMGL siRNA. Pde4dip 
Rn_RGD:708410_3_HP (MMGL 3) resulted in optimal knockdown of MMGL (80%). B: Western blots of 2-
dimensional IEF gels showing the expression of the four phosphorylation isoforms of GFP-cMyBPC in H9C2 
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cells (i) under non-stimulated conditions; (ii) under adrenergic stimulation, and (iii) under adrenergic stimulation 
in the absence of MMGL (i.e. with MMGL knock-down). C: Quantification of cMyBPC isoforms in the 
autoradiographs of the 2-dimensional IEF gels shown in (B), graphing the levels of the four phosphorylation 
isoforms (0=unphosphorylated; 1=monophosphorylated, 2=diphosphorylated, 3=trisphosphorylated). B and C(i) 
show that under non-stimulated conditions, levels of the mono- and diphosphorylated forms are similar and 
increased compared to the trisphosphorylated form. B and C(ii) show that under adrenergic stimulation, there is 
a relative increase in the trisphosphorylated form of cMyBPC and reduction of the non-phosphorylated form. B 
and C(iii) show that, upon MMGL knock-down, adrenergic stress leads to a reduction in the levels of all 
cMyBPC phosphorylation forms. 
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